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The maintenance of highly regulated mechanisms to control
intracellular levels of reactive oxygen species (ROS) is
essential for normal cellular homeostasis. Indeed, most
ROS, including free radicals and peroxides, are produced
at low level by normal aerobic metabolism and play an
important role in the redox-dependent regulation of many
signaling processes. In contrast, excessive accumulation of
ROS, resulting from an imbalance between ROS production
and scavenging, leads to a condition of oxidative stress
that can cause extensive oxidative damage to most cellular
components, including proteins, lipids, and DNA, and may
have pathophysiological consequences. Remarkably, oxida-
tive stress has been clearly implicated in aging and the
pathogenesis of several human diseases, including cardio-
vascular, metabolic, inflammatory, and neurodegenerative
diseases and cancer. Thus, ROS may function as friends or
foes of signal transduction depending on specific threshold
levels and cell context.
To highlight the important topics in this evolving field
the Journal of Signal Transduction presents a special issue
on the involvement of ROS in physiological and pathological
signal transduction processes from prokaryotes to low and
high eukaryotes.
In particular, the topics covered in this special issue
include ROS-mediated signaling in bacteria (in the first
paper), the mechanisms by which ROS affect Neurospora
crassa light signal transduction (in the second paper), the
interplay between ROS and mitochondria in the control of
cell death and aging (in the third and fourth papers) and
cancer progression (in the fifth and sixth papers), the role
of ROS in nuclear transport (in the seventh paper), the inter-
play between ROS and Ras GTPases (in the eighth paper), the
role of ROS in the crosstalk between integrins and cadherins
(in the ninth paper), integrin signaling (in the tenth paper),
and skeletal muscle signaling (in the eleventh paper). These
articles describe our current understanding of this field.
Furthermore, this special issue highlights the importance
of gaining a greater understanding of the physiological and
pathological role of ROS in the perspective of defining new
therapeutic strategies based on redox regulation of signal
transduction processes.
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Paolo Pinton
Alexey M. Belkin
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Increased ROS (cellular reactive oxygen species) are characteristic of both fibrosis and tumour development. ROS induce the trans-
differentiation to myofibroblasts, the activated form of fibroblasts able to promote cancer progression. Here, we report the role of
ROS produced in response to dysfunctions of mitochondrial complex I, in fibroblast activation and in tumour progression. We
studied human fibroblasts with mitochondrial dysfunctions of complex I, leading to hyperproduction of ROS. We demonstrated
that ROS level produced by the mutated fibroblasts correlates with their activation. The increase of ROS in these cells provides a
greater ability to remodel the extracellular matrix leading to an increased motility and invasiveness. Furthermore, we evidentiated
that in hypoxic conditions these fibroblasts cause HIF-1α stabilization and promote a proinvasive phenotype of human melanoma
cells through secretion of cytokines. These data suggest a possible role of deregulated mitochondrial ROS production in fibrosis
evolution as well as in cancer progression and invasion.
1. Introduction
Mitochondrial-produced ROS have been recently involved
in metastatic dissemination of cancer cells, as shown by
Ishikawa et al. These authors described how replacing the
endogenous mitochondrial DNA in a weakly metastatic
tumour cell line with mitochondrial DNA from a highly
metastatic cell line enhanced tumour progression through
increased production of ROS and HIF-1α stabilization [1].
Recent studies demonstrate that tumour growth does
not depend only on malignant cancer cells themselves but
also on the surrounding tumour stroma. Indeed, tumour
progression, growth, and spread is strictly dependent on
angiogenesis and on cytokines and growth factors secreted
by microenvironmental cells [2]. In this context, evidence
is increasing that CAFs (cancer-associated fibroblasts) are
key determinants in the malignant progression of can-
cer [3]. These fibroblasts, also commonly referred to as
myofibroblasts, are the differentiated form of fibroblast that
have acquired contractile and secretory characteristics [4].
They have been initially identified during wound healing
[5], but are also present in the reactive tumour stroma,
promoting tumour growth and progression [6]. Their role
is linked to extracellular matrix deposition and secretion of
MMPs (matrix metalloproteinases). Furthermore, activated
fibroblasts influence cancer cells through the secretion of
growth factors and are able to mediate EMT (epithelial mes-
enchymal transition) and stemness of tumor cells themselves,
supporting their progression and the metastatic process.
Transdifferentiation to myofibroblast is dependent on both
exposure to MMPs and increased level of cellular ROS
[7, 8]. Increased cellular ROS are characteristic of both
fibrosis and malignancy. We have recently demonstrated
that CAFs induce EMT of prostate cancer cells through a
proinflammatory pathway involving COX-2 (cycloxygenase-
2), NF-κB (nuclear factor-κB), and HIF-1α [9]. The secretion
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of MMPs by CAFs induces a release of ROS in prostate
carcinoma cells, which is mandatory for EMT, stemness, and
dissemination of metastatic cells.
The aim of the present work is to assess the role of
ROS produced in response to mitochondrial dysfunctions in
fibroblast activation and in tumour progression.
Analysis of human fibroblasts with genetic dysfunctions
of mitochondrial complex I show that ROS level produced
by these fibroblasts correlate with their activation, leading
to enhanced motility and invasiveness. Furthermore, in
hypoxic conditions, we evidentiated that ROS generated by
mitochondrial mutations promote a proinvasive phenotype
of melanoma cells though HIF-1α stabilization and growth
factor secretion.
2. Results
2.1. ROS Produced by Fibroblasts Carrying Mitochondrial
Disfunctions Induce Transdifferentiation to Myofibroblasts.
Our interest is to assess the role of mitochondrial oxidative
stress for stromal fibroblast activation during tumour pro-
gression. To this end we used human fibroblasts carrying
mitochondrial dysfunctions of complex I. In particular,
fibroblasts mutated in the nuclear NDUFS1 gene encoding
for the 75 kDa-FeS protein (NDUFS1 Q522K and NDUFS1
R557X/T595A) of mitochondrial complex I, fibroblasts
mutated in the nuclear NDUFS4 gene encoding for the
18 kDa subunit (NDUFS4 W15X) of mitochondrial complex
I, and fibroblasts mutated in the nuclear PINK1 gene encod-
ing for the PTEN induced Ser/Thr putative kinase1 localized
in mitochondria (PINK W437X), in the same patient this
mutation coexists with two homoplasmic mtDNA missense
mutations in the ND5 and ND6 genes coding for two
subunits of complex I [10, 11]. As control we used neonatal
human dermal fibroblasts (HFY). Previously, it has been
shown that mutation in NDUSF4 gene results in com-
plete suppression of the NADH-ubiquinone oxidoreductase
activity of complex I, without any ROS accumulation [12].
The Q522K mutation in the NDUFS1 gene results in a
marked, but not complete, suppression of complex I activity
with large accumulation of H2O2 and intramitochondrial
superoxide ion [12]. Furthermore, it has been shown that
the coexistence of the ND5 and ND6 mutations with the
PINK1 mutation, contributes to enhanced ROS production
by complex I and to a decrease in the Km for NADH [11, 13].
We first detected the superoxide ion production by flow
cytometer analysis and confocal microscopy analysis using
Mitosox as a redox-sensitive probe. As shown in Figures 1(a)
and 1(b), mutations in NDUFS1 genes and in PINK gene are
associated with superoxide ion accumulation while NDUFS4
gene mutation affects only marginally ROS production in
agreement with previous data [12]. Recently, it has been
demonstrated that the oxidative stress in the tumour stroma
promotes the conversion of fibroblasts into myofibroblasts,
a contractile and secretory form of fibroblasts [7]. To
this purpose we analysed whether also ROS produced by
mitochondrial disfunctions could affect the differentiation
process of fibroblasts. We analysed the expression level
of α-SMA (α-smooth muscle actin), a typical marker of
myofibroblast differentiation, by western blot and confocal
microscopy analyses (Figures 1(c) and 1(d)). The level of α-
SMA in control and mutated fibroblasts correlates with ROS
production, in particular, in fibroblasts carrying mutations
in the NDUFS1 gene (Q522K and R557X/T595A) and in the
nuclear PINK gene (W437X) α-SMA is organized in stress
fibers, thereby conferring to the differentiated myofibroblasts
a strong contractile activity. Altogether, these data show that
ROS produced by fibroblasts carrying mitochondrial genetic
disfunctions correlates with their activation.
2.2. Mitochondrial ROS Production Induces an Increase in the
Migration and Invasion Abilities of Myofibroblasts. During
the conversion of fibroblasts into myofibroblasts, these cells
acquire clear contractile and motile properties. To investigate
whether fibroblasts carrying mitochondrial disfunctions and
showing increased ROS level have modified their behaviour,
we evaluated the migration and invasion abilities of these
cells by Boyden assays. As shown in Figures 2(a) and 2(b),
mutations in NDUFS1 gene (Q522K and R557X/T595A) and
in the nuclear PINK gene (W437X) increase both migration
and invasion of fibroblasts while mutations in NDUFS4 gene
do not affect the contractile properties of cells, in agreement
with their ROS production and α-SMA expression. Hence,
we proposed that high mitochondrial generation of ROS
converts fibroblasts into myofibroblasts, their activated form,
causing an increase in the invasive and migratory abilities of
these cells.
2.3. Hypoxic ROS Production in Mutated Fibroblasts Is Associ-
ated with HIF-1α Stabilization and Growth Factor Expression.
Hypoxic conditions are able to induce a deregulation in
mitochondrial ROS production, which control a variety of
hypoxic responses, including the activation of HIF-1α tran-
scription factor [14–16]. To this end, we analysed ROS pro-
duction after culturing fibroblasts under hypoxic conditions
(1% O2). As shown in Figure 3(a), genetic mitochondrial
disfunctions result in increased ROS production in hypoxic
conditions. This effect is mainly evident for fibroblasts
carrying mutations in nuclear PINK1 gene. Noticeable,
also fibroblasts mutated in NDUFS4 gene show high level
of ROS in hypoxic conditions. In agreement, in hypoxic
conditions, all mutated fibroblasts show an increase of
HIF-1α level (Figure 3(b)). Previous results from other
laboratories indicated that the activated stroma secretes large
amounts of VEGF-A (vascular endothelial growth factor-A),
SDF1 (stromal cell-derived factor-1) and HGF (hepatocyte
growth factor) leading to a significant increase in the invasive
capacity of surrounding tumor cells [17–19]. In order to
verify whether the increased ROS production in mutated
fibroblasts correlates with a raise of these soluble growth
factors and cytokines, we performed a real-time PCR analysis
to quantify VEGF-A, SDF1, and HGF transcripts. As shown
in Figures 4(a) and 4(c) mutated fibroblasts cultured in
hypoxic conditions have higher level of transcripts for VEGF-
A, SDF1, and HGF, acknowledged factors for the modulation
of the response of tumour cells to activated fibroblasts.
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Figure 1: Oxygen superoxide level and α-SMA in fibroblasts carrying mitochondrial dysfunctions of complex I. (a) Flowcytometer analysis
of O2
•− level. Control fibroblasts (HFY) and fibroblasts carrying mutations in NDUFS1 gene (Q522K and R557X/T595A), in NDUFS4 gene
(W15X), and in the nuclear PINK gene (W437X) were cultured for 48 hours in low glucose medium and then incubated with 5 mM Mitosox
for 10 minutes at 37◦C for detection of oxygen superoxide. A flowcytometer analysis is then performed. The results are representative of
five experiments with similar results. ∗P < 0.005 mutated fibroblasts versus control fibroblasts. (b) Fibroblasts seeded on glass coverslips
are treated as in (a) and a confocal microscopy analysis is performed. (c) Analysis of α-SMA expression in control fibroblasts (HFY) and
fibroblasts carrying mutations. Lysates of cells were subjected to α-SMA immunoblot analysis. An antiactin immunoblot was performed for
normalization. (d) Analysis of α-SMA expression in control fibroblasts (HFY) and fibroblasts carrying mutations seeded on glass coverslips
by confocal microscopy analysis.
2.4. The Conditioned Media of Mutated Fibroblasts Promotes
Melanoma Cells Invasiveness. Recently, it has been demon-
strated that high levels of mitochondrial ROS produced by
cancer cells are linked to enhanced metastatic potential [1].
To this end we decided to investigate whether mitochondrial
ROS derived from stromal components could, as well,
influence the behavior of tumor cells. Thus, we analysed
the ability of media from mutated fibroblasts cultured
under hypoxic conditions to promote metastatic potential of
cancer cells, using A375 cells, derived from human primary
melanoma. As shown in Figure 5(a), left, while there are
no differences in A375 human melanoma cells invasiveness
when cultured with media from fibroblasts grown in nor-
moxic condition, media from mutated fibroblasts cultured
in hypoxic conditions cause an increase in A375 human
melanoma cells invasiveness as examined by Boyden cell
invasion assay (Figure 5(a), right).
To verify that the effect exerted by media from mutated
fibroblasts on the invasiveness of melanoma cells are effec-
tively due to their ROS production and HIF-1α stabilization,
we analyzed HIF-1α level and melanoma cell invasion in the
presence of NAC (N-acetyl cysteine), a ROS scavenger. As
shown in Figures 5(b) and 5(c), NAC treatment blocks HIF-
1α accumulation and reverts the increase of invasiveness of
A375 treated with media from mutated fibroblasts cultured
in hypoxic conditions. Hence, this evidence underlines the
4 Journal of Signal Transduction
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(a) Boyden cell migration assays of fibroblasts carrying mitochondrial
dysfunctions of complex I. 15× 103 fibroblasts, after 24 hours of
serum starvation, were seeded into the upper compartment of Boyden
chamber. Cells were allowed to migrate through the filter toward the
lower compartment filled with complete medium. Cell invasion was
evaluated after Diff-Quick staining by counting cell in six randomly
chosen fields. The results are representative of four experiments with
similar results
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(b) Boyden cell invasion assays of fibroblasts carrying mitochon-
drial dysfunctions of complex I. Cells were treated as in (a). Cells
were allowed to migrate through the filter coated with Matrigel
toward the lower compartment filled with complete medium. Cell
invasion was evaluated after Diff-Quick staining by counting cell
in six randomly chosen fields. The results are representative of four
experiments with similar results. ∗P < 0.005 mutated fibroblasts
versus control fibroblasts
Figure 2: Mutations in NDUFS1 genes (Q522K and R557X/T595A) and in the nuclear PINK gene (W437X) increase fibroblasts migration
and invasion.
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(a) Fibroblasts were cultured in low glucose serum-free medium for 24
hours in normoxic or hypoxic condition (1% O2) and then incubated
with 5 μM Mitosox for 10 minutes at 37◦C for detection of oxygen
superoxide. A flowcytometer analysis was then performed. The results
are representative of three experiments with similar results. ∗P < 0.005
hypoxic fibroblasts versus normoxic fibroblasts
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Figure 3: Mutated fibroblasts induce HIF-1α stabilization in hypoxic conditions.
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Figure 4: mRNA levels of VEGF-A, SDF-1, and HGF secreted by fibroblasts cultured in hypoxic condition. (a–c) Quantitative real-time
reverse transcription PCR of RNA extracted from fibroblasts cultured for 24 hours in low glucose serum-free medium in hypoxic conditions
using primers for human VEGF-A (a), SDF-1 (b), and HGF (c) and GAPDH gene. Results were normalized first to GADPH expression levels
and then displayed relative to level in HFY cells. Data are representative of three independent experiments. ∗P < 0.005 mutated fibroblasts
versus control fibroblasts.
involvement of mitochondrial ROS production in regulating
the aggressiveness of melanoma cells, likely modulating the
delivery of key cytokines able to affect cancer cell invasive-
ness.
3. Discussion
Data reported in this study clearly underscore the central role
of mitochondrial ROS in the transdifferentiation of fibrob-
lasts and in the stimulation of a pro-invasive phenotype of
melanoma tumour cells.
Recent data unlighted that tumour microenvironment
has a key role for the development of a variety of cancers
promoting both tumour growth and metastatic dissemina-
tion. CAFs are the most common type of cells found in
the reactive stroma of several human carcinomas. These
activated fibroblasts express α-SMA, leading to the term
“myofibroblasts,” influence ECM turnover synthesizing both
components of ECM itself and ECM-degrading enzymes,
release a large amount of cytokines affecting cancer cells
progress towards an aggressive phenotype. The origin of
myofibroblasts are not fully understood. In culture the
transdifferentiation of fibroblasts to myofibroblasts can be
achieved by treatment with TGFβ (transforming growth
factor β) [20], suggesting that similar pathways might be
responsible for generation of myofibroblasts in tumours.
Besides, emerging evidence indicates that also EMT, involv-
ing normal epithelial cells adjacent to the tumour, is a
source of myofibroblasts in both fibrosis and cancer [21].
Furthermore, CAFs may arise directly from carcinoma
cells through EMT [3, 7], allowing cancer cells to adopt
a mesenchymal cell phenotype, with enhanced migratory
capacity and invasiveness [22]. Indeed, mainly in breast
cancers, have been reported CAF somatic mutations in TP53
and PTEN, as well as gene copy number alteration at other
loci in tumour stroma, [23, 24]. Actually, more recently,
Radisky et al. [25], demonstrated that treatment of mouse
mammary epithelial cells with MMP3 cause EMT through a
pathways involving elevated ROS production and increased
levels of Rac1b. The ROS increase in cells treated with MMP-
3 was caused by mitochondrial activation and was found to
be required for the induction of the mesenchymal vimentin
as well as other myofibroblast genes. Thus, a new role for
ROS in tumour progression is emerging, in addition to their
well-known action in the oxidative damage to DNA. We
have recently demonstrated that CAFs secrete MMPs which
in turn stimulate ROS production in prostate carcinoma
cells via a Rac1b/Cox2/HIF-1α pathway, finally leading to
tumour growth and metastatic spreading [9]. Furthermore,
Toullec et al., using a model of junD-deficient fibroblasts,
demonstrated that the constitutive oxidative stress generated
by inactivation of the junD-gene promotes the conversion
of fibroblasts into myofibroblasts in a HIF1α and CXCL12-
dependent pathway [19].
Mitochondria are the major site of ROS generation,
which occurs mainly at complexes I and III of the respiratory
chain. It is well known that mitochondrial disfunctions
and increased ROS levels are present in many cancer cells.
Pelicano et al. evidentiated a more invasive behavior of
breast cancer cells in which oxidative stress is induced by
inhibition of the electron transport complex I with rotenone
[26]. A correlation between mutations in mitochondrial
genes of complex I and cancer has been observed in
various laboratories [1, 27, 28]. Recently, the group of G.
Romeo reported, in the thyroid oncocytic cell line XTC.UC1,
a dramatically decreased activity of complex I and III
associated with ROS increase. Indeed, these defects are due
to two mtDNA mutations: a frameshift mutation in the
gene encoding ND1 subunit of complex I and a missense
substitution in the cytochrome b gene, which affects the
catalytic site involved in the electron transfer of complex
III [29, 30]. Furthermore, mitochondria dysfunctions in
a tumour cell line contribute to tumour progression by
enhancing the metastatic potential of tumour cells [1].
Indeed, Ishikawa et al. demonstrated, by replacing the
6 Journal of Signal Transduction
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(a) Boyden cell invasion assay. Control and mutated fibroblasts were incubated in low glucose serum-free media in normoxic or hypoxic conditions
(1% O2) for 24 hours. Media are then collected, and monolayers of A375 human melanoma cells were incubated in these conditioned media for 24
hours. 15× 103A375 melanoma cells were seeded into the upper compartment of Boyden chambers. Cells were allowed to migrate through the filter
toward the lower compartment filled with complete medium for 24 hours. Cell invasion was evaluated after Diff-Quick staining by counting cell in six
randomly chosen fields. The results are representative of three experiments with similar results ±P < 0.05 media from mutated fibroblasts versus media
from control fibroblasts, ∗P < 0.005 media from mutated fibroblasts versus media from control fibroblasts
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subjected to HIF-1α and α-SMA immunoblot analysis
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(c) Fibroblasts were cultured as in (b) A375 melanoma cells were then
incubated for 24 hours with media collected from fibroblasts. 15 ×
103A375 melanoma cells were seeded into the upper compartment of
Boyden chambers coated with Matrigel. Cells were allowed to migrate
through the filter toward the lower compartment filled with complete
medium for 24 hours. Cell invasion was evaluated after Diff-Quick
staining by counting cell in six randomly chosen fields. The results
are representative of four experiments with similar results. ∗P < 0.005
media from mutated fibroblasts versus media from control fibroblasts
Figure 5: Conditioned media from mutated fibroblasts promotes melanoma cells invasiveness; NAC treatment blocks HIF-1α stabilization
and reverts the increase of melanoma cells invasiveness.
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endogenous mtDNA in a mouse tumour cell line that was
poorly metastatic with mtDNA from a cell line that was
highly metastatic and viceversa, that the recipient tumour
cells acquired the metastatic potential of the transferred
mtDNA. Really, mtDNA containing mutations in the ND6
(NADH dehydrogenase subunit 6) gene and hence a defi-
ciency in respiratory complex I activity triggers an increase
of ROS and higher expression levels of two genes associated
with neoangiogenesis, namely, HIF-1α and VEGF. As already
mentioned, mitochondrial alterations in cancer cells have
been intensively studied to understand their role in tumour
development and progression [31, 32], but, at least to our
knowledge, this manuscript, for the first time, evidenced
that mitochondrial dysfunctions in stromal cells affect the
invasiveness of cancer cells. Indeed, our data show that ROS
produced by mitochondrial dysfunction affect not only the
migratory and invasive abilities of fibroblasts themselves but
also the aggressiveness of melanoma cancer cells. In order
to investigate the involvement of mitochondrial ROS derived
from stromal cells in modulating the invasiveness of tumour
cells, we used fibroblasts producing elevated mitochondrial
ROS due to defects in NADH: ubiquinone oxidoreductase,
or complex I. Dysfunctions of this complex cover more than
30% of hereditary mitochondrial encephalopathies [33–35];
furthermore, complex I defects have been also found in
familiar Parkinson disease [11, 13], hereditary spastic para-
plegia [36], Friedreich ataxia [37], and aging [38, 39]. We
used fibroblasts from a baby diagnosed for Leigh syndrome
(NDUFS4 W15X), from a baby diagnosed for leukodystro-
phy (NDUFS1 Q522K), from a child with complex I deficit
(NDUFS1 R557X/T595A), and from a patient with familiar
Parkinsons disease (PINK W437X) in which mutations in the
ND5 and ND6 mitochondrial genes of complex I coexist with
mutation in the nuclear phosphatase and tensin homolog-
(PTEN-) induced serine/threonine putative kinase-1 (PINK-
1) gene. We showed that in normoxic conditions all muta-
tions present in these fibroblasts, with the exception of
the mutation in the gene NDUFS4, produce an increase
in ROS level, which correlates with the levels of α-SMA
and hence with the degree of differentiation towards the
myofibroblast-activated form. This differentiation represents
also a key event during wound healing and tissue repair [4].
The deregulation of normal healing and continued exposure
to chronic injury results in tissue fibrosis, massive deposition
of ECM, scar formation, and organ failure. Indeed, oxidative
stress, caused by increase in ROS is closely associated with
fibrosis [40] and inhibitors of ROS have shown promise
in clinical trials targeting this disease [41–43]. Herein, we
demonstrate that mutated fibroblasts have a great ability
to increase their motility and invasiveness. Overall, these
findings indicate that increased mitochondrial ROS induce
the transdifferentiation of fibroblasts to their activated form
suggesting a possible involvement of these mutated fibroblast
also in fibrogenic events.
The inappropriate induction of myofibroblasts that leads
to organ fibrosis greatly enhances the risk of subsequent can-
cer development, by creating a stimulating microenviron-
ment for epithelial tumor cells. Really, we show that exposure
of melanoma cells to media of fibroblasts with mitochon-
drial dysfunctions cultured in hypoxic conditions promotes
invasiveness of tumour cells. It is well known that in hypoxic
condition, the low oxygen tension increases the generation
of mitochondrial ROS that prevent hydroxylation of HIF1α
protein, thus resulting in stabilization and activation of its
transcriptional activity [14, 15, 44]. Recently, for instance,
Klimova et al. demonstrated that ROS generated by mito-
chondrial complex III are required for the hypoxic activation
of HIF1α [16]. Furthermore, Brunelle et al. showed that
fibroblasts from a patient with Leigh’s syndrome, which
display residual levels of electron transport activity, stabilize
HIF1α during hypoxia [45]. Really, we evidentiated in
hypoxic conditions an extra ROS production in fibroblasts
carrying mutations in mitochondrial complex I; this increase
in ROS production is also evident in fibroblasts mutated
in the NDUFS4 gene that, conversely, have a low level of
ROS in normoxic condition. The extra ROS production in
hypoxic condition is associated with HIF1α stabilization.
This stabilization is really dependent on mitochondrial
mutations since it is absent in control fibroblasts and finally
leads to the transcriptional activation of genes that allow
cells to adapt to and survive in the hypoxic environment.
We believe that this extra ROS production acts synergistically
with the hypoxic condition in the promotion of a pro-
invasive behavior of melanoma cancer cells. Neutralizing
this extra ROS production with antioxidants allows the
degradation of HIF1α and abolishes the aggressive behavior
of melanoma cancer cells. Altogether we evidentiated that
mitochondrial ROS produced by complex I defects of stromal
components, namely, activated fibroblasts, are key molecules
able to modulate the behavior of surrounding cancer cells,
increasing their aggressiveness.
These data underline once again the close loop between
tumor cells and stromal counterparts. It is well known
that activated fibroblasts influence, through the secretion
of soluble factors, the adhesive and migratory properties of
cancer cells, which then in turn release cytokines influencing
the behavior of stromal cells. Thus, to deeply explore the
effect of mutated fibroblasts on surrounding tumour cells
we investigated the transcriptional levels of some HIF1α
target genes in fibroblasts cultured in hypoxic conditions. We
observed an increase in VEGF-A, HGF, and SDF1 transcripts.
These data are in keeping with those obtained by Orimo
et al. [46], demonstrating that the coinjection of tumour cells
with CAFs into nude mice generates larger xenografts with
respect to those generated with normal fibroblasts. This event
correlates with an increase in both cancer-cell proliferation
and angiogenesis through the SDF-1 secretion. In agree-
ment, Toullec et al. demonstrated that the same cytokine
causes the conversion of fibroblasts into highly migrating
myofibroblasts and subsequently promotes migration and
dissemination of neoplastic cells [19]. Furthermore, Cat et
al. showed that myofibroblasts secrete large amounts of HGF
and VEGF resulting in a significant increase in the invasive
capacity of surrounding tumor cells [17]. Besides, clinical
studies show that the abundance of stromal myofibroblast
is associated with disease recurrence, as shown for human
colorectal cancers [47]. Really, our data, showing an increase
in fibroblast secreted VEGF-A, HGF, and SDF1, are in
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keeping with others emphasizing that tumour dissemination
could be facilitated by the myofibroblastic component of the
stroma through the secretion of invasion associated-secreted
factors.
Altogether our findings suggest a possible role of ROS
production, due to mitochondrial complex I dysfunctions of
stroma, in fibroblast activation as well as in cancer progres-
sion and invasion.
4. Materials and Methods
4.1. Materials. Unless specified, all reagents were obtained
from Sigma. Antibodies anti-HIF-1α were from BD Trans-
duction Laboratories; antibodies anti-α-SMA were from
Sigma; antibodies anti-actin were from Santa Cruz Biotech-
nology; MitoSOX Red mitochondrial superoxide indicator
was from Molecular Probes.
4.2. Cell Culture. Control fibroblasts (neonatal human der-
mal fibroblasts) were from Cambrex. Fibroblasts carrying
mitochondrial mutations in the nuclear NDUFS4 gene-
W15X and in the NDUFS1 gene-Q522K (from M. Zeviani,
C. Besta Neurological Institute Foundation, Milan) were cul-
tivated and characterized by S. Scacco. Fibroblasts carrying
mutation in the nuclear PINK1 gene-W437X (from G. De
Michele, Department of Neurological Sciences, Federico II
University, Naples) were cultivated and characterized by A.
M. Sardanelli. Fibroblasts carrying mitochondrial mutations
in the nuclear NDUFS1 gene (NDUFS1 R557X/T595A)
were a generous gift from Fondazione Giuseppe Tomasello
O.N.L.U.S. A375 human melanoma cells were from ATCC.
Cells were cultured in DMEM supplemented with 10%
fetal bovine serum and maintained in 5% CO2 humidified
atmosphere.
4.3. Mitochondrial Superoxide Detection. 25× 103 cells were
cultured for 48 hours in low glucose DMEM medium
(5 mM glucose). Cells were then incubated for 10 minutes
at 37◦C with 5 μM MitoSox in PBS. Cells are trypsinized,
centrifuged, washed with PBS, and resuspended in 300 μL
PBS. A flowcytometer analysis was then performed (MitoSox
excitation/emission: 510/580 nm). For the confocal micro-
scope analysis of O2
•− level, cells were seeded onto coverslips,
incubated for 10 minutes at 37◦C with 5 μM MitoSox in
PBS, washed with PBS, and analysed with a laser scanning
confocal microscope (model LEICA TCS SP2 with Acusto-
Optic Beam Splitter) equipped with a five-lines Ar laser and
two He/Ne lasers (lines 543 and 633 nm).
4.4. Western Blot Analysis. 1 × 106 cells were lysed for 20
minutes on ice in 500 μL of complete radioimmunoprecipi-
tation assay (RIPA) lysis buffer (50 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1% NP40, 2 mM EGTA, 1 mM sodium ortho-
vanadate, 1 mM phenylmethylsulfonyl fluoride, 10 μg/mL
aprotinin, 10 μg/mL leupeptin). Lysates were clarified by
centrifuging, separated by SDS-PAGE, and transferred onto
nitrocellulose. The immunoblots were incubated in 3%
bovine serum albumin, 10 mM Tris-HCl (pH 7.5), 1 mM
EDTA, and 0.1% Tween 20 for 1 hour at room temperature
and were probed first with specific antibodies and then with
secondary antibodies.
4.5. Immunohistochemistry. Fibroblasts were seeded onto
coverslips, washed with PBS, and fixed in 3% paraformalde-
hyde for 20 minutes at 4◦C. Fixed cells were permeabilized
with three washes with TBST (50 mM Tris/HCl pH 7.4,
150 mM NaCl, 0.1% Triton X-100) and then blocked with
5.5% horse serum in TBST for 1 hour at room temperature.
Cells were incubated with primary antibody, 1 : 100 dilution
in TBS (50 mM Tris/HCl pH 7.4, 150 mM NaCl) containing
3% BSA overnight at 4◦C. After extensive washes in TBST,
cells were incubated with secondary antibodies for 1 hour
at room temperature, washed, and mounted with glycerol
plastine. Finally, cells were observed under a laser scanning
confocal microscope (model LEICA TCS SP2 with Acusto-
Optic Beam Splitter) equipped with a five-lines Ar laser and
two He/Ne lasers (lines 543 and 633 nm).
4.6. Preparation of Conditioned Media. Conditioned media
were obtained from fibroblasts as follow: fibroblasts were
incubated in low glucose (5 mM glucose) serum-free media
in normoxic or hypoxic conditions (1% O2) for 24 hours.
Media are then collected and monolayers of A375 human
melanoma cells were incubated in these conditioned media
for 24 hours.
4.7. In Vitro Boyden Migration and Invasion Assay. Fibrob-
lasts were serum starved for 24 hours and then 15× 103
cells were seeded onto Boyden chamber (8 mm pore size,
6.5 mm diameter) for the migration assay. For the invasion
assay Boyden chambers are precoated with Matrigel (12.5 μg
Matrigel/filter). In the lower chamber, complete medium was
added as chemoattractant. Following 24 hours of incubation,
the inserts were removed and the noninvading cells on the
upper surface were removed with a cotton swab. The filters
were then stained using the Diff-Quik kit (BD Biosciences)
and photographs of randomly chosen fields are taken.
4.8. Real-Time PCR. Total RNA from fibroblasts was ex-
tracted using RNeasy (Qiagen) according to the manufac-
turer instructions. Strands of cDNA were synthesized using
a high-capacity cDNA reverse transcription kit (Applied
Biosystem) using 1 μg of total RNA. For quantification of
VEGF-A, SDF-1, and HGF mRNA, real-time PCR, using
Power SYBR green dye (Applied Biosystem) was done on
a 7500 fast real-time PCR system (Applied Biosystem).
The primers for VEGF-A were 5′TTCTGCTGTCTTGGG
TGCAT-3′ (forward) and 5′TGTCCACCAGGGTCTCGATT-
3′ (reverse). The primers for SDF-1 were 5′GTGTCACTG
GCGACACGTAG-3′ (forward) and 5′TCCCATCCCACA
GAGAGAAG-3′ (reverse). The primers for HGF were 5′CAT
CAAATGTCAGCCCTGGAGTT-3′ (forward) and 5′CCT
GTAGGTCTTTACCCCGATAGC-3′ (reverse). Data are nor-
malised to those obtained with glyceraldehyde-3-phosphate
dehydrogenase primers. Results (mean ± SD) are the mean
of three different experiments.
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On the basis of our findings reporting that cell adhesion induces the generation of reactive oxygen species (ROS) after integrin
engagement, we were interested in identifying redox-regulated proteins during this process. Mass spectrometry analysis led us
to identify nonmuscle myosin heavy chain (nmMHC) as a target of ROS. Our results show that, while nmMHC is reduced in
detached/rounded cells, it turns towards an oxidized state in adherent/spread cells due to the integrin-engaged ROS machinery.
The functional role of nmMHC redox regulation is suggested by the redox sensitivity of its association with actin, suggesting a role
of nmMHC oxidation in cytoskeleton movement. Analysis of muscle MHC (mMHC) redox state during muscle differentiation,
a process linked to a great and stable decrease of ROS content, shows that the protein does not undergo a redox control.
Hence, we propose that the redox regulation of MHC in nonprofessional muscle cells is mandatory for actin binding during
dynamic cytoskeleton rearrangement, but it is dispensable for static and highly organized cytoskeletal contractile architecture in
differentiating myotubes.
1. Introduction
Studies over the past years have shown that reactive oxygen
species (ROS) are involved in a diverse array of biological
processes, including normal cell growth, induction and
maintenance of cell transformation, programmed cell death,
and cellular senescence. ROS are able to trigger such
divergent responses probably through differences in the
level and duration of the oxidant burst or in the cellular
context accompanying oxidative stress. ROS include a variety
of partially reduced oxygen metabolites (e.g., superoxide
anions, hydrogen peroxide, and hydroxyl radicals) with a
higher reactivity with respect to molecular oxygen. Oxidants
can either be produced within cells by dysfunction of
mitochondrial respiratory chain complexes or by cytosolic
or membrane recruited enzymes such as NADPH oxidase,
cyclooxygenases, lipoxygenases, and the NO synthase [1].
Oxidants have been proposed as intracellular messengers
of a variety of physiological stimuli acting on cytosolic
oxidases. Considerable progress has been made in identifying
intracellular targets of ROS. Several findings support the
idea that exogenous ROS or oxidants produced by activation
of growth factors receptors or integrins can reversibly oxi-
dize and hence inactivate redox-sensitive proteins. Proteins
with low-pKa cysteine residues, which are vulnerable to
oxidation by hydrogen peroxide, include several transcrip-
tion factors, such as the nuclear factor κ-B [2], activator
protein 1 [3], hypoxia-inducible factor [4], p53 [5], the
p21Ras family of proto-oncogenes [6], phosphotyrosine
phosphatases (PTPs) [7], and src kinase family [8]. Our
findings provide evidence that intracellular ROS are gener-
ated following integrin engagement and that these oxidant
intermediates are necessary for integrin signalling during
fibroblasts adhesion and spreading [9]. ROS production
in response to integrin engagement represents signalling
integration point between extracellular matrix (ECM) and
growth factor signalling, and they are produced in Rac1
and 5- lipoxygenase- (5-LOX-) dependent manner [9]. A
key role in the cytoskeleton redox regulation is played by a
low molecular weight-phosphotyrosine phosphatase (LMW-
PTP), which is oxidised/inhibited in response to ECM
contact. Its inactivation prevents the dephosphorylation
of two key regulators of cytoskeleton dynamics: the focal
adhesion kinase (FAK) [9] and a GTPase activating protein
for the GTPase RhoA (p190RhoGAP) [10]. Accordingly, the
redox-dependent activation of FAK and p190RhoGAP leads
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to focal adhesion formation, membrane ruffles development,
and cell spreading [9, 11, 12]. Hence, both the small GTPases
Rac1 and RhoA are critical regulators of redox-mediated
actin cytoskeleton remodelling during cell spreading and
migration.
Significantly, the key role of ROS in integrin signalling
suggests that they may contribute to malignant growth and
invasiveness through a deregulation of cell/matrix interac-
tion and cell motility. We are now interested in identifying,
among cytoskeleton proteins, the molecular targets of ROS
in anchorage-dependent growth. To date, specific targets of
integrin-generated ROS are LMW-PTP and SH2-PTP [9, 13],
the tyrosine kinase Src [8, 9] and actin [9, 14, 15]. Oxidation
of these proteins produces differential effects: (i) LMW-
PTP and SH-PTP2 are inactivated through formation of an
intramolecular disulfide [9, 13]; (ii) Src family kinases are
conversely activated through a disulfide which blocks the
protein in active state [8]; (iii) β-actin is oxidized through
glutathionylation in a single sensitive cysteine, thus leading
to increased polymerization and stress fiber formation [15].
We report herein that nonmuscle myosin heavy chain
(nmMHC) is oxidized in the early stage of integrin-mediated
adhesion in human fibroblasts. This redox control retains a
functional role during cytoskeleton dynamic rearrangements
in response to ECM contact, strongly affecting nmMHC
binding of β-actin. Conversely, during stable and static
cytoskeletal organization in contractile myotubes, the asso-
ciation of muscle MHC (mMHC) with actin is redox
independent, suggesting a selective role of redox regulation
of these proteins only during dynamic rearrangements of
cytoskeleton.
2. Materials and Methods
2.1. Materials. Unless specified, all reagents were obtained
from Sigma-Aldrich. Human fibroblasts were obtained
as already described [16]. Anti-pan-actin and antimuscle
Myosin Heavy Chain antibodies were from Santa Cruz
Biotechnology, Nonmuscle myosin heavy chain antibod-
ies were from Biomedical Technologies Inc. Anti-GSH
antibodies were obtained from Virogen. N-(biotinoyl)-N′-
(iodoacetyl)ethylene diamine (BIAM) was obtained from
Molecular Probes. The streptavidin-horseradish (Strp-HRP)
conjugate was from Biorad. Immunopure immobilized
streptavidin was from Pierce Biotechnology. Blotting grade
blocker nonfat dry milk was from Biorad. Secondary anti-
bodies were from Amersham Bioscience. Sequencing grade
modified trypsin was from Promega.
2.2. Cell Culture. Human fibroblasts were obtained as
previously described [17]. Human fibroblasts and murine
myoblasts C2C12 were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% calf
serum at 37◦C in a 5% CO2 humidified atmosphere. To
induce myogenic differentiation, C2C12 cells were grown
until subconfluence and then cultured for six days in
differentiating medium containing DMEM supplemented
with 2% horse serum.
2.3. Cell Adhesion Assay. Human fibroblasts were serum
deprived for 24 h and then detached with 0.25% trypsin
for 1′. Trypsin digestion was then blocked by the use of
0.5 mg/mL soybean trypsin inhibitor. Cells were then cen-
trifuged and diluted in fresh culture media and incubated for
30 minutes in gentle agitation at 37◦C. The adherent/spread
sample was obtained plated the cells on fibronectin-coated
dishes for 45 minutes while the detached/cell rounded
sample was plated for the same time on polylysine-coated
plates. Nordihydroguaiaretic acid (NDGA) was added to the
cells at the beginning of the suspension phase at a final
concentration of 10 μM.
2.4. Intracellular H2O2 Assay. For the measure of ROS
generation during adhesion, cells were serum deprived for
24 h, detached and incubated in gentle agitation for 30
minutes. Cells were then plated on fibronectin-coated dishes
in serum-free medium, with or without NDGA 10 μM, and
ROS assay was performed at different times of adhesion.
Three minutes before the end, 5 μM DCF-DA was added.
Cells were lysed in 1 mL of RIPA buffer containing 1% Triton
X-100 and fluorescence was analysed immediately using a
Perkin Elmer Fluorescence Spectrophotometer (excitation
wavelength 488 nm, emission wavelength 510 nm). The val-
ues of fluorescence were normalized on the proteins content.
The assay of ROS production in myoblasts and in six days
differentiating myotubes were performed using the same
protocol.
2.5. In Vivo BIAM Labelling of Proteins. Cells from adher-
ent/spread and detached/rounded conditions are lysates in
RIPA buffer (50 mM Tris-HCl, pH 7,5, 150 mM NaCl, 1%
Triton, 2 mM EGTA) supplemented with BIAM (100 μM
final concentration) and protease inhibitors cocktail (1 mM
AEBSF, 8 μM aprotinin, 20 μM leupeptin, 40 μM bestatin,
15 μM pepstatin A, and 14 μM E-64). Lysates were then
maintained on ice for 15 minutes and then centrifuge
at 13000 rpm for 15′. For the binding of BIAM-labelled
proteins with immobilized streptavidin, 30 μL of resin were
added to the clarified samples and maintained overnight at
4◦C in gentle agitation [12]. The resin was firstly washed four
times with RIPA buffer and then resuspended in Laemmli
sample buffer. The pattern of BIAM-labelled proteins were
visualized by a Western blot analysis using horseradish
peroxidase-streptavidin conjugate, washed and developed
with the enhanced chemiluminescence kit.
2.6. Matrix Assisted Laser Desorption Ionization-Time of Light
(MALDI-TOF) Sample Preparation. BIAM-labelled lysates
from spread and rounded cells were run on SDS-PAGE. The
gel was then stained by Coomassie blue solution, subjected
to destaining solution for 24 h, and finally washed in water
until completely equilibrated. The bands of interest were
excised, transferred to an Eppendorf tube, and then washed
twice with 50 mM NH4HCO3/acetonitrile (1 : 1), and they
were shrunk with acetonitrile. After drying, samples were
subjected to a reduction reaction in a buffer containing
10 mM dithiothreitol, 25 mM NH4HCO3 for 45 minutes at
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56◦C followed by an alkylation step in a buffer containing
55 mM Iodoacetic acid, 25 mM NH4HCO3 for 30 minutes
at room temperature in the dark. After a final washing
step, samples were dried up and trypsin digested for 24 h at
37◦C. The peptides were then extracted from gel bands by
sonification and by supplementing 50% acetonitrile and 1%
trifluoroacetic acid (1 : 1 proportion with sample), and the
supernatants were recovered and then dried.
2.7. MALDI-TOF Analysis. Spectrometric analysis were
conducted on an Ultraflex MALDI-TOF (Bruker Dalton-
ics) using a Scout ion source and operating in posi-
tive reflector mode. Samples were mixed with a-Cyano-4-
hydroxycinnamic acid (1 : 1). 0.8 pmol/uL of sample were
deposed with the dry droplet technique on an AnchorChip
target. Peptides were identified within an error of 120 part
per million. Mascot search algorithm parameters was set
as following: carboxylation of cysteine and oxidation of
methionine.
2.8. Immunoprecipitation and Western Blot Analysis. Immu-
noprecipitation was performed overnight using 2 μg/mL of
specific antibodies. Immunocomplexes were collected on
protein A-Sepharose, separated by SDS-poly-acrylamide gel
electrophoresis, and transferred onto PVDF membrane. Im-
munoblots were probed firstly with specific antibodies in
2% nonfat dry milk, 0,05% Tween 20 in phosphate buffered
saline buffer, and then with secondary antibodies conjugated
with horseradish peroxidase, washed, and developed with the
enhanced chemiluminescence kit.
2.9. Statistical Analysis. Data are presented as means ± S.D
from at least three experiments. Analysis of densitometry
was performed using Quantity One Software (Bio-Rad).
Statistical analysis of the data was performed by Student’s t-
test. P values ≤0.05 were considered statistically significant.
3. Results and Discussion
3.1. Redox Regulation of Nonmuscle MHC during Cell Adhe-
sion. Firstly, we found that the engagement of integrin
during cell adhesion induces in human fibroblasts a transient
burst of ROS production (with a peak 40 minutes after
fibronectin attachment) in keeping with what observed dur-
ing spreading and adhesion of NIH-3T3 murine fibroblasts
[9]. ROS burst was significantly inhibited by the use of
NDGA which affects the activity of 5-LOX, thus confirming
5-LOX as the source of ROS production (Figure 1(a)) [9].
To study redox-regulated proteins during integrin-mediated
cell adhesion, we used the BIAM-labelling technique. BIAM
is a sulfhydryl-modifying reagent that selectively probes the
thiolate form of cysteine residues, as already reported by
Kim et al. [18]. Human fibroblasts were serum deprived
for 24 h, detached, and maintained in suspension for 30
minutes to eliminate integrin signalling. For adherent/spread
conditions, cells were left to adhere for 45 minutes on
fibronectin-coated plates, while detached/rounded cells were
seeded on polylysine-coated dishes. The analysis of redox-
regulated proteins during integrin engagement shows the
presence of a major band of about 200 KDa, differently
labelled with BIAM in rounded and spread cells, suggesting
a redox regulation of this protein during cell adhesion
(Figure 1(b)). We repeated the experiment described above,
performing a Coomassie staining of the SDS-PAGE gel, and
the BIAM labelled band was excised and used for MALDI-
TOF analysis. After trypsin digestion, the peptide fragments
were probed on a MALDI-TOF mass spectrometer, and the
fingerprint data were then submitted to the Mascot search
algorithm. Figure 1(c) shows the analysis of the spectrum
of the digested peptides that identify the protein as non-
muscle myosin heavy chain (nmMHC) with a score of 107
(Figure 1(d)).
3.2. The Redox State of nmMHC Affects β-Actin Association.
Firstly, we confirmed the data obtained by MALDI-TOF
analysis by nmMHC immunoprecipitation. Results indi-
cated that nmMHC is reduced in rounded cells and turns
towards the oxidized form in spread cells. Furthermore, the
treatment of the cells with NDGA, which abrogates ROS
production by 5-LOX, rescues the reduced form of nmMHC
(Figure 2(a)). In the same experimental setting, we found a
redox regulation of β-actin, which became oxidised in spread
cells through the binding with glutathione (Figure 2(b)).
Myosin is the main motor protein of the cell and carries
on this function through its binding with β-actin. The role
of this association is the generation of the force responsible
for cellular dynamic functions such as locomotion, cell
division, and cytoplasmic contraction [19]. Therefore, we
investigated whether the nmMHC oxidation, upon complete
cell spreading, influences its association with β-actin. Results
clearly show a redox sensitivity of the binding of nmMHC to
β-actin. Indeed, treatment of spread fibroblasts with the 5-
LOX inhibitor NDGA rescues the lack of binding between
β-actin and nmMHC observed upon completion of the
spreading process (Figure 2(c)).
In addition to other redox-regulated proteins of
cytoskeleton, such as actin and profilin [15, 20, 21], our data
add nmMHC as a new cytoskeletal protein undergoing redox
regulation during spreading of human fibroblasts.
3.3. Redox State and mMHC/Actin Association in Differen-
tiating Myotubes. In agreement with previous results [22],
we observed that differentiation of murine myoblasts C2C12
is associated with a decrease of ROS content (Figure 3(a)).
On the basis of these results, we speculated that muscle
MHC (mMHC) might not be redox regulated in resting
conditions, that is, when cytoskeleton does not undergo
rearrangements due to the movement or spreading onto
ECM. Therefore, we compared MHC redox state in spread
or rounded fibroblasts and in differentiating myotubes. The
results clearly showed that MHC in differentiating myotubes
is mainly in its reduced form, while in spread fibroblasts
MHC undergoes redox control (Figure 3(b)).
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Figure 1: Identification of nmMHC as a redox-sensitive protein during cell adhesion. (a) Content of H2O2 in human fibroblasts during
adhesion on fibronectin. Hydrogen peroxide production was assayed used DCF-DA. ∗P < 0.001 versus time 0. (b) Cell lysates from rounded
and spread human fibroblasts were labelled with BIAM and then added to immobilized streptavidin. The pattern of proteins were visualized
by a treatment with HRP conjugate streptavidin. (c) Nonredundant (nrNCBI) database was scanned using MASCOT search algorithm. The
nonmuscle myosin heavy chain IX of mus musculus (gi/20137006) was identified with a significant score of 115 at 120 ppm mass tolerance.
The spectrum shows the matched peaks. (d) The primary structure of nmMHC is shown.
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Figure 2: Analysis of nmMHC redox state and β-actin association in human fibroblasts. Cells lysates from detached and spread cells,
treated with or without NDGA, were labelled with BIAM and nmMHC was immunoprecipitated with specific antibodies. (a) BIAM labelled
pattern of nmMHC was revealed by western blot using HRP-streptavidin conjugate; amount of immunoprecipitated nmMHC was obtained
probing the membrane with anti-nmMHC antibodies; the histogram shows the ratio between two corresponding samples after densitometric
evaluation. ∗P < 0.001 versus rounded. (b) Representative immunoblot showing actin glutathionylation in rounded and spread human
fibroblasts. The histogram corresponds to the ratio between GSH-actin and total actin. P < 0, 001 versus rounded. (c) Analysis of nmMHC-
actin association. An anti-nmMHC immunoprecipitation was performed from rounded and spread cells treated with or without NDGA.
The detection of actin associated with nmMHC was obtained with antiactin immunoblot, while anti-nmMHC immunoblot was used for
normalization. The histogram corresponds to the ratio between the values obtained by densitometric analysis of two corresponding samples
of the blots. ΦP < 0.005 versus rounded. Similar results were obtained in four independent experiments. a.u.: arbitrary units.
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Figure 3: Continued.
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Figure 3: Analysis of the redox state of muscle MHC and actin in differentiating myotubes. (a) Analysis of H2O2 content in myoblasts
and in differentiating myotubes after six days of differentiation. Hydrogen peroxide assay was performed with DCF-DA. ∗P < 0.005
versus myoblasts. (b) Analysis of the redox state of MHC on rounded or spread human fibroblasts and in differentiating myotubes.
BIAM labelled pattern of MHC was revealed by a Western blot using HRP-streptavidin conjugate after immunoprecipitation of nmMHC
in human fibroblasts and mMHC in differentiating myotubes; MHC normalization was performed probing the membrane with specific
anti-MHC antibodies; the histogram corresponds to the ratio between two corresponding values obtained by densitometric analysis.
ΨP < 0.001. (c) Analysis of MHC-actin association in myoblasts and in differentiating myotubes. An anti-nmMHC immunoprecipitation
was performed from myoblasts and from differentiating myotubes. The amount of actin associated with MHC was obtained with antiactin
immunoblot, while the normalization was performed using anti-MHC antibodies. The histogram reports the ratio between the values
obtained by densitometric analysis of the two corresponding values of the blots. P < 0.0015 versus myotubes. (d) and (e) Analysis of actin
glutathionylation. Actin glutathionylation was assayed on growing C2C12 myoblasts, differentiating myotubes, human fibroblasts, and in
murine skeletal muscle, liver, and kidney using anti-GSH antibodies. ΦP < 0.001 versus myotubes. a.u.: arbitrary units.
It is well known that muscle differentiation is accompa-
nied with a dramatic and stable rearrangement of cytoskele-
ton architecture accompanied with the formation of con-
tractile fibers. It is likely that binding of myosin to actin
behaves as a cyclic event, and it is not under redox control.
As expected, the results show that MHC/actin association
is greatly improved in differentiating myotubes with respect
to myoblasts (Figure 3(c)). Again, when ROS are high (as
in spread fibroblasts or in undifferentiated myoblasts), β-
actin is not bound to MHC. Conversely, when ROS are
low (as in rounded/detached fibroblasts or in differentiating
myotubes), actin strictly binds MHC, thereby underscoring
the key importance of the redox control of the two proteins
for their regulated interaction.
We have previously demonstrated that the ROS burst
produced by ECM-integrin binding induces oxidation of β-
actin, through glutathionylation of cysteine 374, which is
an essential step for actomyosin disassembly [15]. Whether
glutathionylation is important for its binding to myosin, we
expected that in differentiating myotubes, where the associ-
ation between these two proteins is essential for contraction,
actin should be less glutathionylated. As expected, we found
that actin glutathionylation is greater in myoblasts with
respect to differentiating myotubes, in agreement with their
ROS content in differentiated cells (Figure 3(d)). Further-
more, analysis of several murine tissues reveals that skeletal
muscle fibres contains reduced actin, while in liver, kidney,
and skin fibroblasts β-actin is oxidised/glutathionylated
(Figure 3(e)). This suggests that both actin and MHC in
skeletal muscle must be reduced to allow their continuous
association for muscle contraction.
Although acute production of ROS have positive effects
in skeletal muscle (such as for glucose uptake), ROS accumu-
lation can provoke serious consequences for skeletal muscle
physiology [23]. Beyond serious skeletal muscle pathologies
(such as Duchenne muscular dystrophy and mitochondrial
myopathies), in which an increased/uncontrolled production
of ROS has been reported [24], oxidative molecules alter the
physiology also in healthy muscle. Indeed, high amount of
ROS induce an acute decrease in force production during
repeated contractions, accompanied with a lower Ca2+
sensitivity of myofibrils [25]. In addition, several studies
reported slower fatigue development in the presence of ROS
scavengers [26]. In agreement with these observations and
with our results, a decreased muscle contraction in oxidative
conditions has been reported, suggesting that molecules
involved in these process should not meet oxidation [27,
28].
The different behaviour of MHC in growing fibrob-
lasts and in differentiating myotubes could be explained
considering the function and architecture of cytoskeleton
in these two situations. In undifferentiated growing cells,
cytoskeleton is a dynamic structure which is subjected to
continuous remodelling in response to extracellular signals
to allow cell-shape changes associated with directed move-
ment, secretion, or cell division (Figure 4(a)). Conversely,
muscle differentiation is associated to a great cytoskeletal
rearrangements that culminate with the formation of a static
structure. In this view, it is possible that the actin/MHC
binding does not need any further (i.e., transient) regulatory
mechanism, as they are already associated to form stable
structures (Figure 4(b)). On the contrary, in nonmuscle
cells this association may be finely regulated, since both β-
actin and MHC can be rapidly assembled and disassembled
in response to extracellular signals. This control may be
obtained through ROS generated by integrins during cell
8 Journal of Signal Transduction
nmMHC-S     OH
Actin-SG
nmMHC-actin
dissociation
nmMHC-SH
ECM
ECM
ROS
Actin-SH
Rounded cell
Integrin 
receptor
(a) Moving cell: dynamic cytoskeletal architecture
Actin filament-SH
Actin filament-SH
Actin filament-SH
mMHC-SH
mMHC-SH
mMHC-SH
Decreased
ROS content
Contraction
(b) Myotube: static cytoskeletal architecture
Figure 4: Proposed model for the MHC oxidation during fibroblasts adhesion and muscle differentiation. In a rounded cell, where level
of ROS are low, both nmMHC and actin are reduced and associated ((a), left). In the early stage of fibroblast adhesion, the engagement of
integrin receptors generates a burst of ROS leading to oxidation of nmMHC and decreased its binding with actin ((a), right). It is likely that
the redox-dependent nmMHC/actin association is functional to the cytoskeleton dynamics during cell motility. Myotubes, where a stable and
static cytoskeletal structure has been formed, are characterized by a low ROS content. In this environment, nmMHC is not redox-regulated
and the increased nmMHC/actin association is a redox-independent mechanism that guarantees contraction (b).
adhesion, where oxidants might act as second messengers for
actin/MHC cytoskeleton remodelling (Figure 4).
Taken together, these findings demonstrate that also
proteins forming the cytoskeletal architecture could be ROS-
regulated and that this control might be important for the
cytoskeleton rearrangement during some cellular functions.
Furthermore, these results open new perspectives for future
investigations, such as the evaluation of ROS sensitivity of
cytoskeletal proteins in cancer cells, a phenomenon linked
both to a great ROS increase and a strong cytoskeleton
rearrangements.
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The coordinate modulation of the cellular functions of cadherins and integrins plays an essential role in fundamental physiological
and pathological processes, including morphogenesis, tissue differentiation and renewal, wound healing, immune surveillance,
inflammatory response, tumor progression, and metastasis. However, the molecular mechanisms underlying the fine-tuned
functional communication between cadherins and integrins are still elusive. This paper focuses on recent findings towards the
involvement of reactive oxygen species (ROS) in the regulation of cell adhesion and signal transduction functions of integrins and
cadherins, pointing to ROS as emerging strong candidates for modulating the molecular crosstalk between cell-matrix and cell-cell
adhesion receptors.
1. Introduction
The communication between signaling pathways, the so-
called molecular crosstalk, plays a central role in cell biology,
enabling the cell to couple the molecular functions of either
near neighbors or distant cell components, with resulting
synergistic or antagonistic effects and eventually appropriate
biological outcomes.
Among the most important cellular crosstalk events is
the signaling network that couples the molecular functions
of adhesion receptors of the integrin and cadherin families.
Indeed, acting in concert with growth factor receptor
signaling pathways, this regulatory network is fundamentally
important during the entire life of all metazoans, whereas its
dysfunction almost invariably leads to developmental defects
and/or diseases, including genetic diseases and cancer [1].
Integrins and cadherins are the major cell-extracellular
matrix (ECM) and cell-cell adhesion receptors, respectively,
and represent critical determinants of tissue architecture and
function both in developing and adult organisms [2, 3].
Integrins are heterodimeric transmembrane glycopro-
teins composed of noncovalently linked α and β subunits,
which are endowed with both structural and regulatory
functions. They link the ECM to several distinct cytoplasmic
proteins and the actin cytoskeleton at focal adhesions, thus
serving as organizing centers for the assembly of structural
and regulatory protein complexes at discrete cell-matrix
adhesion sites and providing a mechanically sensitive system
for mechanotransduction [4]. Furthermore, often acting in
concert with growth factor receptors, they provide both
outside-in and inside-out transmission of signals across the
plasma membrane that control a number of critical cellu-
lar processes, including adhesion, cytoskeleton remodeling,
migration, proliferation, differentiation, apoptosis, and gene
expression [2, 5]. Specifically, integrin-mediated outside-in
signaling stimulates tyrosine phosphorylation and activation
of several proteins, including major components of focal
adhesions, such as Src and FAK nonreceptor tyrosine kinases
(PTK), and paxillin, as well as receptor tyrosine kinases
(RPTK). In turn, these proteins are antagonized by nonre-
ceptor (PTP) and receptor tyrosine phosphatases (RPTP),
and entwined in a dynamic interplay with small GTPases
and components of specialized plasma membrane and en-
dosome microdomains, including caveolin-1, to form com-
partmentalized signaling platforms that allow for temporal
and spatial coordination of specific downstream signaling
events [6, 7].
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Cadherins are single-pass transmembrane glycoproteins
that support calcium-dependent, homophilic cell-cell adhe-
sion. Together with their cytoplasmic domain interactors,
such as β-catenin and p120ctn, they constitute the core
components of adherens junctions (AJs). These specialized
adhesive structures link the cadherin homophilic adhesion
to the actin cytoskeleton and are required for formation and
maintenance of stable cell-cell adhesion and differentiated
phenotype in all solid tissues [3, 8, 9]. Cadherin endocytosis
and endosome-mediated trafficking has emerged as a major
mechanism for controlling AJ remodeling [10–17]. More-
over, growing evidence demonstrates that cadherins can
modulate the signaling activity of several proteins, including
β-catenin, Ras and Rho family GTPases, PTK, RPTK, PTP,
and RPTP, as well as mechanotransduction pathways that
affect membrane and actin cytoskeleton dynamics [3, 18–
21].
Although there is a large body of evidence supporting
the existence of a fine-tuned crosstalk between members of
these two adhesive receptor families, which influences their
expression, turnover, positioning, and/or functions, and may
enhance or suppress adhesion depending on the cellular
and environmental context [1, 10, 17, 22–41], the molecules
and molecular mechanisms involved in such important
phenomenon are not completely defined. To clarify how
this crosstalk is regulated remains therefore a fundamental
challenge for basic and translational research, including
research on tumor and vascular disease progression.
Multiple molecules and regulatory mechanisms have
been placed at the heart of the molecular crosstalk between
integrins and cadherins, including small GTPases of the Ras
and the Rho families [10, 17, 42–45], nonreceptor kinases
such as Src, FAK, Fer, and PI3K [27, 34, 46, 47], cell
surface receptor-mediated pathways [48–50], and adhesion-
dependent actomyosin traction forces [26, 34, 51].
Previously, we reported the pivotal role of the small
GTPase Rap1 in regulating the crosstalk between cadherins
and integrins, suggesting a model where Rap1 acts as a
turnabout for endosome signaling andmembrane trafficking
pathways to orchestrate the delivery of cadherins and
integrins to specific cell-cell and cell-matrix landmarks at the
plasma membrane, respectively [10, 17].
Intriguingly, recent growing evidence suggests that reac-
tive oxygen species (ROS) play an important role in both
integrins, small GTPases, and cadherins functions, raising
the possibility that ROS may contribute to the modulation
of the molecular crosstalk between integrins and cadherins.
In this paper, we discuss the most recent advances on the
role of ROS in outside-in and inside-out signal transduction
events implicating integrins and cadherins, providing build-
ing bloks for the hypothesis that ROS constitute important
players in themolecular crosstalk between these cell adhesion
receptors.
2. ROS Metabolism and Signaling
ROS are a highly reactive group of oxygen-containing
molecules, including free radicals and peroxides, such as
superoxide anion (O2
•−) and hydrogen peroxide (H2O2),
which are generated constitutively, as common by-products
of oxidative metabolism, or in response to the activation of
several oxidative enzyme complexes [52–55].
The superoxide anion (O2
•−) is the key determinant
of the overall effects of ROS. Indeed, even though it has
a short half-life, O2
•− is the precursor of all other major
reactive oxygen species found in biological systems, includ-
ing the powerful oxidants hydroxyl radical (•OH), hydrogen
peroxide (H2O2), and peroxynitrite (OONO
−) [52–55]. It is
generated by a number of sources located throughout the
cell via the incomplete, one-electron reduction of molecular
oxygen (O2). Specifically, under physiological conditions the
redox complexes I (NADH/ubiquinone oxidoreductase) and
III (ubiquinol/cytochrome c oxidoreductase) of the mito-
chondrial electron transport chain are the major constitutive
source, converting up to 5% of molecular O2 to O2
•− [56]. In
addition, O2
•− is produced by the activity of NAD(P)H oxi-
dases, xanthine oxidases, cytochrome P450monooxygenases,
uncoupled NO synthase (NOS), myeloperoxidases, lipoxyge-
nases, and cyclooxygenases [52–55], which can be induced by
a variety of chemical and physical stimuli, including integrin
ligands, growth factors, G-protein coupled receptor agonists,
cytokines, neurotransmitters, metabolic factors, shear stress,
ischemia/reperfusion, chemotherapeutics, and ionizing radi-
ations, as well as aging [52–54, 57, 58]. Conversely, O2
•−
is rapidly removed by distinct superoxide dismutase (SOD)
isoenzymes, located in the mitochondria (SOD2), cytoplasm
(SOD1), and extracellular (SOD3) compartments, which
catalyze the dismutation of O2
•− into H2O2 and O2. In turn,
H2O2 is reduced to H2O by the catalase and glutathione
peroxidase enzymes. In addition, O2
•− can be converted
to hydroxyl radical (•OH) by the Fenton or Haber-Weiss
reactions, or to peroxynitrite (OONO−) by reacting with
nitric oxide (NO) [59] (Figure 1).
It is now well established that physiologic concentrations
of ROS are endowed with essential signaling properties,
which are mainly due to the reversible oxidation of redox-
sensitive molecular targets, thereby functioning as signaling
molecules. Accordingly, it has been clearly demonstrated
that ROS are involved in the redox-dependent regulation of
multiple signal transduction pathways to fulfill a wide range
of essential biological processes, including cell adhesion,
migration, proliferation, differentiation, and survival [52–
55]. However, at high levels, ROS are known to exert very
damaging effects through oxidative stress. This is caused
by an imbalance between the production of ROS and
the ability of cellular antioxidant mechanisms to readily
detoxify the reactive intermediates. Importantly, because
O2
•− can spontaneously react with NO to form OONO−
at a rate 3 times faster than O2
•− dismutation by SOD,
modest increases of O2
•− can result in a great reduction of
NO bioavailability and increased formation of OONO−, a
very strong oxidant with the potential to produce multiple
cytotoxic effects [60, 61]. In addition, OONO− can also
trigger feedforward mechanisms that further amplify O2
•−
generation and oxidative stress, including the uncoupling
of NO synthase (NOS) which produces O2
•− instead of
NO, thus amplifying the risk of cellular dysfunction and
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Figure 1: Schematic representation of ROS metabolism and signaling. The superoxide anion (O2
•−) is a key determinant of oxidative
effects as well as the precursor of all other major reactive oxygen species, including hydroxyl radical (•OH), hydrogen peroxide (H2O2), and
peroxynitrite (OONO−). It is generated constitutively as by-product of oxidative metabolism, as well as upon stimuli triggering the activation
of oxidative enzymes, including NADPH oxidases, xanthine oxidases, cytochrome P450 monooxygenases, uncoupled NO synthase (NOS),
myeloperoxidases, lipoxygenases (LOX), and cyclooxygenases (COX). Conversely, O2
•− is removed by superoxide dismutase (SOD) enzymes,
which catalyze the dismutation of O2
•− into H2O2 and O2. In turn, H2O2 is reduced to H2O by the catalase (CAT) and glutathione peroxidase
(GPX) enzymes. At physiologic concentrations, ROS are endowed with essential signaling properties, being involved in the redox-dependent
regulation of multiple signal transduction pathways to fulfill a wide range of essential biological processes, including cell adhesion, migration,
proliferation, differentiation, and survival. However, at high levels, ROS exert very damaging effects through oxidative stress. H-W: Haber-
Weiss reaction; NO: nitric oxide.
oxidative injury [52]. The maintenance of highly regulated
mechanisms to control ROS levels and functional specificity
is therefore essential for normal cellular homeostasis and
proper response to environmental stimuli.
Among the major source of ROS, NADPH oxidases
have been demonstrated to play a fundamental role in
the compartmentalization of ROS production and redox
signaling [7].
The NADPH oxidase (NOX) complex was originally
identified in phagocytic leukocytes as an enzymatic defense
system against infections required for the oxidative burst-
dependent microbial killing [62, 63]. It is composed of
membrane-associated and cytosolic components, which
assembly to form the active NOX enzymatic complex in
response to appropriate stimuli. Specifically, this complex
consists of membrane-associated cytochrome b558, com-
prising the catalytic gp91phox (also known as NOX2) and
regulatory p22phox subunits, and four cytosolic regulatory
components, including p40phox, p47phox, p67phox, and the
small GTPase Rac1 [63]. Subsequently, NADPH oxidase
complexes were also found in nonphagocytic cells, where
several isoforms of the catalytic NOX2 protein were identi-
fied, including NOX1, NOX3, NOX4, and NOX5, and shown
to localize in proximity of specific redox-sensitive molecular
targets within discrete subcellular compartments, thereby
facilitating the compartmentalization of redox signaling [7].
Indeed, NADPH oxidases can be targeted and activated
within caveolae/lipid rafts, focal adhesions, cell-cell contacts,
lamellipodial leading edges and membrane ruffles, endo-
somes, and the nucleus, allowing spatiotemporally confined
ROS production and activation of specific redox signaling
events [7].
Besides NADPH oxidase, an important role in the spatio-
temporal regulation of ROS production is also played by
enzymes involved in arachidonic acid (AA) metabolism,
such as phospholipase A2(PLA2), lipooxygenases (LOX),
and cyclooxygenases (COX), suggesting that a complex
regulatory network may take place for proper modulation of
redox signaling [64].
Accumulating evidence points to PTPs as the major
redox-sensitive molecular targets of ROS [65]. This protein
family is indeed characterized by the presence in the active
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site of a highly conserved sequence motif containing a Cys
residue that is essential for catalysis and very susceptible to
reversible inactivating oxidation by ROS. In turn, oxidative
inactivation of PTPs promotes phosphorylation-dependent
downstream signaling events. In addition to PTPs, other
important signaling proteins have been shown to act as
endogenous redox sensors for mediating ROS signaling,
including RPTKs, cytoplasmic kinases, small GTPases of the
Ras and Rho families, and transcription factors [7, 65, 66]
(Figure 1). Conversely, protein oxidation can be reversed by
thiol donors such as glutathione [67].
Remarkably, the activation of redox signaling com-
plexes at integrin-mediated cell-matrix adhesion sites and
cadherin-mediated cell-cell junctions induces opposite ef-
fects, leading to the assembly of focal adhesions and the dis-
assembly of adherens junctions, respectively [7].
3. ROS and Integrins
It is now well established that ROS are implicated in regu-
lating many integrin-mediated cellular responses, including
adhesion, cytoskeleton organization, migration, prolifera-
tion, differentiation, and survival. Indeed, a large body
of evidence demonstrates that integrin activation triggers
a transient and localized burst of ROS, either indepen-
dently or in cooperation with growth factor receptors,
which is essential to the proper transduction of outside-
in signaling pathways [7, 47, 68]. Specifically, although the
underlying molecular mechanisms remain to be precisely
defined, there is clear evidence that integrin engagement
with antibodies or extracellular matrix proteins triggers
ROS production by promoting changes in mitochondrial
metabolic/redox function [69–71], and activation of distinct
oxidases, including NADPH-oxidases [47, 72, 73], and the
AA-metabolizing enzymes 5-lipoxygenase (5-LOX) [70, 72]
and cyclooxygenase-2 (COX-2) [74]. Conversely, there is
evidence that ROS can also influence integrin-mediated
inside-out signaling by inducing the conformational change
required for integrin activation [64]. Remarkably, the small
GTPase Rac1 has emerged as a crucial, common upstream
mediator of ROS production in integrin-mediated outside-
in signaling [64, 69–72]. Consistently, Rac1 acts upstream
of both NADPH oxidase [7] and AA-metabolizing enzymes,
such as PLA2 [75, 76], 5-LOX [70, 72, 76], and COX-2 [77],
whereas many reports show that AA metabolism modulates
NADPH oxidase and mitochondrial ROS production, as
well as the existence of a bidirectional signaling crosstalk
betweenmitochondria, and NADPH oxidase, suggesting that
Rac1 can orchestrate a complex web of regulation for ROS
production [64, 78] (Figure 2). In addition, it is becoming
evident that the formation of focal adhesions promotes the
assembly of redox signaling platforms, involving integrins,
growth factor receptors, and NADPH oxidases, which are
essential for localized ROS production and activation of
specific redox signaling pathways that mediate adhesion-
dependent cell functions [7]. Furthermore, there is evidence
that fine-tuned sequential compartmentalization and kinet-
ics of ROS production can account for the modulation
of distinct subsets of redox-sensitive signaling molecules
involved in early and late phases of cell adhesion, leading to
distinct outcomes [70, 79].
The signaling properties of integrin-induced ROS are
largely due to the reversible oxidation of target proteins, and
especially of PTPs, as the activity of these proteins is depen-
dent on reactive cysteine residues (Cys-SH) at their active site
that are readily susceptible to reversible oxidation [7, 65].
Indeed, ROS produced locally by the synergistic action of
integrins and growth factor receptors on NADPH oxidase,
as well as on mitochondria and 5-LOX, have been shown to
induce oxidative inactivation of distinct PTPs, including the
low-molecular-weight protein tyrosine phosphatase (LMW-
PTP), PTP1B, PTEN, and SHP2, preventing these enzymes
from dephosphorylating and inactivating specific targets,
and thereby promoting downstream adhesion-related sig-
naling events (Figure 2). Consistently, integrin-mediated
adhesive and signaling functions are significantly mimicked
by PTP inhibition [80]. However, ROS generated by integrin
activation can also activate PTKs and RPTKs through
either direct oxidation of susceptible cysteine residues or
indirect inhibition of negative regulatory PTPs [68], whereas
the synergistic cooperation between integrins and growth
factor receptors expands enormously the plethora of ROS-
regulated target proteins to include redox-sensitive small
GTPases of the Ras superfamily and transcription factors
such as AP-1 and NF-κB [7, 81–83] (Figure 2).
Remarkably, ROS production has often a dual role in
small GTPase regulation, leading to either inhibition or
activation under different conditions [83–88]. In partic-
ular, the inactivation of RhoA has been shown to occur
indirectly through a signaling cascade involving the Rac-
stimulated release of O2
•− from NADPH oxidase, which
in turn inhibits LMW-PTP. Because p190Rho-GTPase-
activating protein (p190RhoGAP) is a substrate of LMW-
PTP, inactivation of LMW-PTP results in accumulation of
the active phosphorylated form of p190RhoGAP, which
stimulates the hydrolysis of bound GTP to produce inactive
GDP-bound RhoA, thereby determining well-characterized
readouts, including decreased cell contractility and stabiliza-
tion of cell-cell junctions [85, 88]. Conversely, RhoA can
be directly activated by ROS-mediated reversible oxidation
of two critical cysteine residues located in a unique redox-
sensitive motif within the phosphoryl binding loop, leading
to characteristic outcomes, including stress fiber and focal
adhesion formation and cell-cell junction weakening [84,
89, 90]. On the other hand, there is evidence that ROS can
activate Rap1 [91], whose signaling is in turn required for
suppression of Ras-generated ROS and protection against
oxidative stress and consequent cell dysfunctions [92–94].
4. ROS and Cadherins
Growing evidence demonstrates that ROS play a major
role in either stabilization or destabilization of cell-cell
junctions mediated by distinct cadherins, including E-, N-,
and VE-cadherin [81, 95–99]. In particular, it has been
reported that Rac1-mediated ROS production is an essential
component in signaling cascades that promote p190RhoGAP
translocation to the AJs and the consequent inhibition of
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Figure 2: ROS mediate integrin outside-in signaling. Integrin engagement with extracellular matrix (ECM) proteins triggers a transient
and localized burst of ROS, either independently or in cooperation with growth factor receptors (GFR), which is essential to the proper
transduction of outside-in signaling pathways. The small GTPase Rac1 acts as a crucial upstream regulator of ROS production, orchestrating
integrin outside-in signaling-mediated changes in mitochondrial metabolic/redox function, and activation of distinct oxidases, including
NADPH-oxidases (NOX), 5-lipoxygenase (5-LOX), and cyclooxygenase-2 (COX-2). The signaling properties of integrin-induced ROS are
largely due to the reversible oxidation of specific subsets of redox-sensitive proteins, including oxidative inhibition of PTPs, and activation
of PTKs, RPTKs, small GTPases of the Ras and Rho families, and transcription factors (TF) such as AP-1 and NF-κB.
local RhoA activity, thus favoring the stabilization of cell-cell
contacts [99]. Conversely, clear evidence shows that Rac1-
induced ROS function as signaling molecules to disrupt
VE-cadherin-based cell-cell adhesion leading to various
biological responses, including endothelial barrier dysfunc-
tion, enhanced microvascular permeability, and endothelial
migration and proliferation involved in angiogenesis [7, 96,
98, 100, 101] (Figure 3). Intriguingly, the apparent contrast
between the positive and negative roles of ROS in the main-
tenance of cadherin-mediated cell-cell junctions correlates
with similar features of small GTPases involved in this
process, including Rac1, RhoA, and Rap1. Indeed, depending
on the extracellular and intracellular context, the activities
of Rac1, RhoA, and Rap1 may be not only involved in
regulating AJs and endothelial barrier maintenance, but also
in active enforcement or disruption of AJs and endothelial
barrier integrity, suggesting that the location and duration
of the activities of these small GTPases affect the choice of
downstream targets, thereby determining distinct biological
outcomes [81]. Indeed, while under basal conditions Rac1
enforces the junctions that form the endothelial barrier by
promoting ROS-mediated p190RhoGAP recruitment to AJs
and the consequent inhibition of local RhoA activity, upon
certain growth factor stimuli, including VEGF, it becomes
part of a barrier-disturbing mechanism by inducing ROS-
mediated phosphorylation of VE-cadherin at Tyr658 and
Tyr731, and β-catenin at Tyr654, which lead to the disassembly
of AJs [81, 96]. Whether ROS act directly on growth factor
receptor kinase activity or, more likely, inhibit VE-cadherin-
associated tyrosine phosphatases has still to be clarified.
In addition, there is evidence for the involvement of the
Pyk2 and Src redox-sensitive kinases in the phosphorylation
of AJ proteins, including β-catenin and p120ctn, and the
resulting loss of cell-cell adhesion mediated by the Rac1-
ROS signaling pathway [95, 100, 102] (Figure 3). Notably, it
has been reported that antioxidant compounds can inhibit
VEGF-induced angiogenesis through disruption of ROS-
dependent Src kinase activation and the subsequent VE-
cadherin tyrosine phosphorylation, resulting in the retention
of VE-cadherin at cell-cell contacts [100]. Conversely, the
cell-cell contact-dependent inhibition of cell growth and
stimulation of PTP activity [103] have been associated with
a decrease in the steady-state levels of intracellular ROS and
the consequent impairment of redox signaling mediated by
growth factor receptors [104].
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Figure 3: ROSmodulate cadherin-mediated cell-cell junctions. Rac1-induced ROSmay function as signaling molecules to disrupt cadherin-
based cell-cell adhesion through either inhibition or activation of regulatory tyrosine phosphatases and kinases, respectively, as well as by
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Another component of the Rac1-ROS signaling pathway
that plays an important role in the regulation of cadherin
adhesive functions is IQGAP, a scaffold protein involved
in cellular motility and morphogenesis [105]. IQGAP has
been shown to be required for the establishment of VE-
cadherin-based cell-cell contacts, and to colocalize and form
a complex with VE-cadherin at cell-cell contact sites in
quiescent endothelial cells [105]. It may act as a downstream
effector of Rac1, as well as an inhibitor of its GTPase activity
through a RasGAP-related domain [106–108]. Furthermore,
it can facilitate localized ROS production through com-
partmentalization of Nox2 [109]. Indeed, there is evidence
that IQGAP1 plays an essential role in VEGF-stimulated
ROS production and VEGFR2-mediated endothelial cell
migration and proliferation, suggesting that IQGAP1 may
function as a scaffold protein to link VEGFR2 to the
VE-cadherin/β-catenin complex at AJs, thereby promoting
VEGF-stimulated ROS-dependent tyrosine phosphorylation
of VE-cadherin, which may contribute to AJ weakening and
angiogenesis [105, 110] (Figure 3).
Besides biochemical modification of AJ molecules, the
ROS-dependent regulation of cadherins may be also driven
by epigenetic events, as a ROS-induced hypermethylation
of E-cadherin promoter, due to the upregulation of the
transcriptional factor Snail and the recruitment of the DNA
methyltransferase-1, and the consequent downregulation of
cadherin expression have been reported [111].
5. ROS as Potential Pivotal Players in the
Crosstalk between Integrins and Cadherins
A number of experimental reports have shown that the
engagement of integrins with ECM proteins can affect
cadherin-containing adherens junctions via multiple mech-
anisms, including the activation of signaling pathways
mediated by small GTPases [10, 17, 42–45], cell surface
receptors [48–50], and nonreceptor kinases [22, 27, 34, 47,
112], and the modulation of the actin network [26, 34, 51,
112]. Conversely, there are relatively fewer examples where
cadherins have been shown to regulate integrin function
[40, 113], but this may be due to the fact that crosstalk
in this direction has been explored less extensively. In this
context, we have previously reported that the small GTPase
Rap1 plays a pivotal role in regulating the crosstalk between
cadherins and integrins, suggesting a model where Rap1
acts as a turnabout for endosome signaling and membrane
trafficking pathways to orchestrate the control of cadherin
and integrin adhesive and signaling functions [10, 17].
Intriguingly, despite the lack of direct experimental
evidence, the large number of studies implicating ROS as
major modulators of integrin and cadherin adhesive and sig-
naling functions strikingly supports the thought-provoking
hypothesis that ROS play a crucial role in the crosstalk
between integrins and cadherins (Figure 4). In particular,
there is clear evidence that the assembly of integrin-mediated
focal adhesions and the disassembly of cadherin-mediated
adherens junctions require the activation of redox signaling
complexes involving common regulatory proteins andmech-
anisms, including redox-sensitive small GTPases and the
oxidative inactivation of PTPs [7]. Consistently, both focal
adhesions assembly and adherens junctions disassembly are
significantly mimicked by oxidative inhibitors of PTPs [10,
80], and prevented by ROS scavengers [95, 96].
Remarkably, both integrin- and cadherin-related redox
signaling pathways involve Rac1 as a key mediator, which
is in turn implicated in intimately intertwined functional
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Figure 4: ROS in the crosstalk between integrins and cadherins. ROS generated by integrin activation may influence cadherin adhesive
functions by various mechanisms, including inhibition of PTPs and/or activation of PTKs, RPTKs, and IQGAP acting at adherens junctions,
as well as spatiotemporal modulation of the activity of redox-sensitive small GTPases and signaling endosomes.
relationships with other small GTPases, including Ras, RhoA,
and Rap1 [7, 64, 69–72, 96, 98, 100, 101, 114].
Furthermore and importantly, recent evidence shows
that Rap1 activation by Epac1, a Rap1-GEF involved in the
Rap1-dependent regulation of cadherins, may be stimulated
by ROS and inhibited by ROS scavengers, indicating that
ROS production can trigger Rap1 activation [91]. Con-
versely, Rap1 signaling has been shown to be required for
suppression of Ras-generated ROS and protection against
oxidative stress and consequent cell dysfunctions [92–94].
Taking together, these data suggest that the role of Rap1
as pivotal regulator in the crosstalk between cadherins
and integrins [10, 17] may underlie feedback mechanisms
involving spatially and temporally regulated ROS production
and scavenging. Consistently, KRIT1, a Rap1 effector whose
loss-of-functionmutations are implicated in endothelial cell-
cell junction dysfunction and enhanced microvascular per-
meability underlying the Cerebral Cavernous Malformation
disease, has been recently shown to play a role in molecular
mechanisms involved in the maintenance of the intracellular
ROS homeostasis to prevent oxidative cellular damage [115].
Finally, ROS generated by integrin activation could
influence cadherin adhesive functions through the activation
of either PTKs and RPTKs, including Src and growth
factor receptors [68], or IQGAP, a component of the Rac1-
ROS signaling pathway implicated in the modulation of AJ
dynamics [105, 110] as well as in signaling downstream
from both integrins and RPTKs [116], suggesting a further
crosstalk mechanisms (Figure 4).
6. Concluding Remarks
It is well established that, besides their structural roles,
both integrins and cadherins can provide bidirectional trans-
mission of signals across topographically discrete regions
of the plasma membrane. In addition, there is growing
evidence supporting the existence of a fine-tuned, bidirec-
tional crosstalk between these adhesion molecules, which
may enhance or suppress their adhesive and signaling func-
tions depending on the cellular and environmental context.
Indeed, the integrin-cadherin crosstalk is involved in the
epithelial-mesenchymal transition (EMT) underlying funda-
mental physiological and pathological processes, including
embryonic development and cancer [22, 25–27, 33, 39].
This paper highlights recent growing evidence sup-
porting a major role of reactive oxygen species (ROS) in
both outside-in and inside-out signaling of integrins and
cadherins, raising the possibility that ROS constitute master
regulators of the crosstalk between these fundamental cell
adhesion receptors.
Indeed, over the past few years, it has clearly emerged
that outside-in integrin signaling triggers ROS production
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by several distinct mechanisms, such as changes in mito-
chondrial metabolic/redox function [69–71] and activation
of distinct oxidases, including NADPH oxidase [47, 70, 72–
74]. On the other hand, growing evidence demonstrates
that ROS play a major role in the regulation of cadherin
adhesive and signaling functions by mechanisms involving
either biochemical modifications (e.g., phosphorylation) of
AJ proteins, including cadherins and catenins, epigenetic
modifications of the cadherin promoter, or modulation
of small GTPases regulating cadherin-dependent cell-cell
adhesion [7, 81, 95–101].
Remarkably, whereas emerging data show that integrin
and cadherin redox signaling involves shared regulatory
proteins, accumulating evidence suggests that discrete sub-
cellular compartmentalization of ROS constitutes a major
mechanism of localizing activation of downstream redox
signaling events, thereby playing a critical role in trans-
mitting cell signals in response to various environmental
stimuli to regulate distinct cell functions, including cell-
matrix and cell-cell adhesion [7, 117]. In particular, ROS
productionmay be localized through interactions of NADPH
oxidase with signaling platforms associated with lipid rafts
and caveolae, as well as with endosomes [7, 118]. Fur-
thermore, there is evidence that growth factor receptors
mediate signaling through a subset of signaling endosomes
termed redoxosomes (redox-active endosomes), which are
uniquely equipped with redox-processing proteins capable
of transmitting ROS signals from the endosome interior to
redox-sensitive effectors on the endosomal surface, thereby
controlling redox-dependent effector functions through the
spatial and temporal regulation of ROS as secondmessengers
[117].
Taken together with the well-established roles of growth
factor receptors, small GTPases and endosome signaling in
the functional relationship between integrins and cadherins
[17], the experimental evidence and observation discussed in
this paper point to a novel hypothetical mechanism whereby
the spatial and temporal regulation of ROS may contribute
significantly to the modulation of the molecular crosstalk
between these cell adhesion receptors, thus opening a novel
research avenue.
Furthermore, as the impairment of the integrin-cadherin
crosstalk is involved in the development of serious patho-
logical processes, including abnormal angiogenesis, tumor
invasion, and metastasis, strategies aimed at controlling
ROS homeostasis to preserve the coordinated adhesive and
signaling functions of integrins and cadherins might harbor
important therapeutic potential for human health.
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Generation of reactive oxygen species (ROS) is a ubiquitous phenomenon in eukaryotic cells’ life. Up to the 1990s of the past
century, ROS have been solely considered as toxic species resulting in oxidative stress, pathogenesis and aging. However, there is
now clear evidence that ROS are not merely toxic species but also—within certain concentrations—useful signaling molecules
regulating physiological processes. During intense skeletal muscle contractile activity myotubes’ mitochondria generate high ROS
flows: this renders skeletal muscle a tissue where ROS hold a particular relevance. According to their hormetic nature, in muscles
ROS may trigger different signaling pathways leading to diverging responses, from adaptation to cell death. Whether a “positive”
or “negative” response will prevail depends on many variables such as, among others, the site of ROS production, the persistence
of ROS flow or target cells’ antioxidant status. In this light, a specific threshold of physiological ROS concentrations above which
ROS exert negative, toxic effects is hard to determine, and the concept of “physiologically compatible” levels of ROS would better
fit with such a dynamic scenario. In this review these concepts will be discussed along with the most relevant signaling pathways
triggered and/or affected by ROS in skeletal muscle.
1. Introduction
Oxidative stressors, such as reactive oxygen species (ROS),
have been initially and long considered as merely delete-
rious species to skeletal muscle tissue. Indeed, since the
1980s abundant evidence clearly indicated that ROS play
a pathogenic role in inherited muscular dystrophies [1]
and have then been identified as concausal factors in
various muscular diseases [2–5]. However, and thereafter,
accumulating evidence indicated that ROS, at least within
concentrations emerging from physiological conditions,
could also play a positive role in physiologically relevant
processes in muscle cells. As an example, inflammation-
derived ROS play a contradictory role in muscle repair [2]:
in combination with other actors such as growth factors
and chemokines, ROS participate in a cascade of events
leading to muscle regeneration and repair; on the contrary,
the local persistence of ROS sustained by infiltrated neu-
trophils may cause further injury by oxidatively damaging
differentiating myoblasts and myotubes thus delaying the
restitutio ad integrum. Similarly, ROS generated during
exercise promote mitochondriogenesis (a key factor in mus-
cle differentiation) via peroxisome proliferator-activated-
receptor-gamma-coactivator-1α-(PGC-1α) activated signal
transduction pathway [3] but, at higher and persistent levels,
they might target mitochondria and mitochondrial DNA
(mtDNA) turning into blockers of myogenic differentiation
[4, 5]. Other examples of such diverging capacities—which
strengthen the generally accepted notion that ROS act
in a hormetic fashion—will be discussed thereafter. The
prevalence of each of the two actions, that is, beneficial or
detrimental, depends on the coincidence of various intrinsic
and extrinsic factors among which the most prominent
is the level and the duration of ROS targeting muscle
cells; other variables are the source or the site of ROS
generation, the antioxidant status of target cells, and their
DNA repair capacity. The differentiation stage of muscle cells
(satellite cell, differentiating myoblast or mature myotube)
is also capable of redirecting the cell through different
signaling pathways and of further modulating the ensuing
cell response. Today ROS are known to trigger and/or affect
many signaling pathways relevant to skeletal muscle cells’
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Figure 1: Major signaling pathways triggered and/or affected by ROS in skeletal muscle. Low levels of ROS activate specific key signaling
molecules such as PGC-1α, AMPK, and MAPK, which control cellular mechanisms for muscle adaptation (oxidative metabolism,
mitochondrial biogenesis, and mitochondrial functionality) as well as antioxidant enzymes that function as backregulators of intracellular
ROS levels. Slight ROS accumulation also inhibits PPases and promotes the phosphorylation state of many proteins involved in the muscle
signaling responses. Moreover, low levels of ROS play an important role in inducing upregulation of growth factors such as IGF-1, which
has beneficial effects in muscle protein balance, supports oxidative metabolism, and contributes to the development of an oxidant-resistant
phenotype, therefore preventing oxidative damage and chronic diseases. Thus, low levels of ROS elicit positive effects on physiological muscle
responses. By contrast high levels of ROS cause functional oxidative damages of proteins, lipids, nucleic acids and cell components, induce a
significant rise of intracellular [Ca2+], and promote signaling cascades for apoptosis or autophagy via NF-κB or FoxO paths. For these reasons
high ROS levels are reputed to act as etiological, or at least exacerbating factors in muscle atrophy, sarcopenia, wasting, and chronic-/aging-
related muscle diseases and myopathies. Depending on their level/persistence, ROS may also turn the same process from “physiologic” into
“pathologic”, as in the case of inflammation.
homeostasis and adaptation: here we will illustrate some of
the signaling pathways triggered/affected by ROS in muscle
tissue and their physiopathological implications (see Figure 1
for a visual summary).
2. Generation of ROS in Skeletal Muscle Cells
Mitochondria are commonly considered as the predominant
source of ROS in skeletal muscle cells [6, 7]. Increased
mitochondrial ROS generation occurs during various and
different situations, such as in the course of intense con-
tractile activity [8] or in response to cytokines such as
tumor necrosis factor-α (TNF-α) [9]. Early reports assumed
that 2–5% of the total oxygen consumed by mitochondria
may undergo one electron reduction with the generation
of superoxide [10, 11]. More recent studies indicated that
complexes I and III of the electron transport chain are
the main sites of mitochondrial superoxide production [12,
13]. During exercise, it is assumed that the increased ROS
generation in the course of contractile activity is due to the
high oxygen consumption that takes place during increased
mitochondrial activity. Indeed superoxide generation in
skeletal muscle increases to about a 50- or 100-fold during
aerobic contractions [14, 15].
However, recent evidence demonstrates that mitochon-
dria may not be the prevalent source of ROS during exercise
[8], and future studies are required to better elucidate the
mitochondrial role in contraction-induced production of
ROS in skeletal muscle. In 2002 St. Pierre and colleagues
[16] reexamined the rate of mitochondrial ROS production
and concluded that the total fraction of oxygen converted
into superoxide was equal to 0.15%; this value is significantly
lower than that (2–5%) estimated by other authors (see for
example [17]). This lower rate of superoxide production
takes account of the uncoupling proteins role (specifically
UCP3 in skeletal muscle) as regulators of mitochondrial
ROS production [18, 19] acting to prevent oxidative damage
to mitochondria. In addition, growing evidence highlights
that mitochondria produce more ROS during the basal
state 4 of respiration as compared to state 3 (maximal
ADP-stimulated respiration) [20–23]. Thus, since skeletal
muscle mitochondria, during aerobic contractile activity,
are predominantly in state 3, this limits their capacity of
generating ROS during contractions [21–23].
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Mitochondria are not the main and only source of ROS
production in skeletal muscle during exercise. Indeed, other
relevant sources of ROS production within muscle cells
are nicotinamide adenine dinucleotide phosphate (NADPH)
oxidases (NOXs) located within the sarcoplasmic reticulum,
transverse tubules, and the sarcolemma [24, 25].
Phospholipase A2 (PLA2) is another known source of
intracellular ROS production [17]. Arachidonic acid released
from cell membranes by PLA2 is a substrate for ROS-
generating enzyme systems such as the lipoxygenases [26].
Activation of PLA2 can stimulate NOXs [27] and increased
PLA2 activity can promote ROS production in muscle
mitochondria [28] and cytosol [29] and release ROS into
the extracellular space [26]. Both calcium-dependent and
-independent forms of PLA2 exist in skeletal muscle and both
contribute to muscle ROS generation [17]. In particular,
the calcium-independent isoforms are likely to be involved
in cytosolic oxidant activity in skeletal muscle cells [29],
whereas a 14-kDa calcium-dependent isoform located within
mitochondria is reputed to stimulate mitochondrial ROS
generation during contractile activity [30]. In this light it has
been proposed [29] that the calcium-independent PLA2 is a
major determinant of ROS activity under resting conditions,
whereas during processes or stress elevating intracellular cal-
cium concentration (contraction, inflammation, heat stress,
etc.) the calcium-dependent PLA2 is activated to promote
ROS production.
Finally, superoxide anion is known to be generated by
xanthine oxidase (XO) in the cytosol of contracting rat
skeletal muscles cells [31]. However, human skeletal muscles
contain lower levels of XO than rat muscle cells, and the
question whether XO plays an important role in superoxide
production in human skeletal muscle is still open [31, 32].
More ROS-generating mechanisms may be operative at the
same time, as in the case of prolonged muscle ischemia where
mitochondrial and cytoplasmic (via XO) ROS production
has been simultaneously scored [33].
ROS can be generated through the above mechanisms
not only within muscle cells but also in their proximity. For
instance, during inflammation (a pathophysiological state
that substantially alters cellular oxidative/antioxidant home-
ostasis) infiltrated polymorphoneutrophils activate NOX
producing ROS via the respiratory burst and many cytokines,
which amplify in a feedforward cycle ROS production,
are secreted within muscles [34]. For instance, during
the early phase of muscle injury, inflammatory cytokines
can bind to membrane receptors and activate specific
ROS-generating enzymes, such as cyclooxygenase-2, NOX,
and XO [35]. Endothelial cells from injured muscle are
known to secrete TNF-α, interleukine (IL)-1, IL-6, and IL-
8, providing a positive feedforward cycle [36]. Whereas a
transient oxidative stress is necessary in inflamed muscle
cells to exert an antiseptic function and to activate various
signal transduction pathways relevant to the restitutio ad
integrum, prolonged severe oxidative stress may imbalance
intracellular antioxidant homeostasis and hence long-term
muscle welfare.
The oxygen-centered species that mostly arises from
the processes described so far is superoxide anion, but its
significance in ROS signaling pathways seems to be limited
to a role as a precursor signaling molecule. Indeed superoxide
undergoes enzymatic or spontaneous dismutation, a process
generating H2O2. H2O2 is a nonradical, is a weak oxidant
with a relatively long half-life allowing its diffusion within
cells and across cell membranes [37], reacts with many
different cellular molecules, and activates a wide number of
signaling pathways. These properties render H2O2 the most
relevant ROS signaling molecule in cells [38]. In contrast,
H2O2 undergoing Fenton chemistry in the presence of redox
active free iron ions or other transition metals can give
rise to hydroxyl radicals, which react immediately with any
surrounding biomolecules exerting most of the deleterious
effects associated with oxidative stress. In this light, iron
homeostasis can be considered as a comodulator of ROS
signaling and effects. In particular, since skeletal muscle
contains 10 to 15% of body iron—mainly in myoglobin
and mitochondria—it could be particularly sensitive to alter-
ations of iron homeostasis: accordingly it has been recently
reported that levels of muscle nonheme iron and the iron
transport protein, transferrin were elevated in senescence,
suggesting that iron load is a significant component of
sarcopenia [39].
3. Antioxidants and Modulation of
Muscle Cells’ Sensitivity to ROS
As it will be discussed throughout this review, the net effect
of ROS on cells’ signaling pathways and fate depends also
on the cellular antioxidant capacity. The antioxidant network
consists of enzymes, such as catalase, glutathione peroxidase
(GPx), thioredoxin reductases (TRxs), superoxide dismu-
tases (SODs), and soluble antioxidants such as glutathione
(GSH) and vitamin E. Depending on its efficacy, the antiox-
idant cellular network plays a primary role in maintaining
ROS below a physiologically compatible threshold level, thus
allowing ROS to serve, theoretically, as signaling molecules
and avoiding them to exert direct toxic effects. Many
antioxidant enzymes are known to be induced in response to
increased ROS generation. The increased ROS flux occurring
in the course of strenuous exercise, through redox-sensitive
mechanisms, induces the expression of γ-glutamylcysteinyl
synthetase, the rate-limiting enzyme of GSH synthesis, of
GPx, and of MnSOD [40]. Nuclear Factor KappaB (NF-κB),
activator protein 1 (AP-1), and mitogen-activated protein
kinases (MAPKs) have been identified as the major signaling
pathways that can be activated by exercise-derived ROS and
directly involved in the induction of the above antioxidant
enzymes [40]. For instance, in the signaling path of MnSOD
gene expression, NF-κB and AP-1 play an important role
[41]: both NF-κB and AP-1 binding sites are present in the
promoter of the mammalian MnSOD gene, and ROS have
been shown to activate their binding.
The above responses, whose extent might be genetically
predetermined, represent a fundamental adaptive counter-
measure to conditions potentially resulting in frank oxidative
stress. A specific modulator of ROS activity, working in an
“antioxidant-like” fashion in ROS-mediated autophagy and
apoptosis (see also “ROS mediate autophagy and apoptosis”),
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is the p53-inducible glycolysis and apoptosis regulator
(TIGAR), a p53-target gene. Indeed, TIGAR can reduce ROS
levels in response to nutrient starvation or metabolic stress,
thus inhibiting autophagy and apoptosis independently of
mammalian target of rapamycin (mTOR) or p53 modu-
lation [42]. The TIGAR protein functions as a fructose-
2,6-bisphosphatase and contributes to the regulation of
intracellular ROS levels by modulation of the glycolytic
pathway [43]. By decreasing glycolytic rate and redirecting
glycolytic intermediates to the oxidative branch of the
pentose phosphate pathway, TIGAR causes an increase in
NADPH production, which favours ROS scavenging through
GPx/glutathione reductase and GSH cycle. In this manner,
TIGAR lowers the sensitivity of cells to ROS-induced p53-
dependent apoptosis [43].
As to the influence of physical exercise, it caused an acti-
vation of MAP kinases in gastrocnemius muscle from rats;
this in turn activated the NF-κB pathway and consequently
the expression of SOD and adaptation to exercise through
increased expression of endothelial and inducible nitric oxide
synthase [40]. All these responses were silenced when ROS
production was prevented by allopurinol [40]. Thus ROS
act as signals in exercise because their scavenging prevents
activation of important signaling pathways promoting useful
adaptations in cells. Because these signals result in an
upregulation of powerful antioxidant enzymes, exercise itself
can be considered an antioxidant.
Besides the established soluble cellular antioxidants,
creatine (Cr) is emerging as a pleiotropic molecule capable
of influencing muscle cell’s trophism, differentiation, and
sensitivity to ROS [44, 45]. Cr has a high tropism for
skeletal muscles, where most of body Cr is stored and
has been shown to exert direct and indirect antioxidant
activity in proliferating and differentiating C2C12 myoblasts
[44]. A recent article by Young et al. [46] showed that
two TRxs situated in the mitochondria and cytoplasm,
respectively, were increased in Cr-treated C2C12 myoblasts:
peroxiredoxin-4, a type 2 peroxiredoxin, and thioredoxin-
dependent peroxide reductase.
As it will be discussed below, the 5′-adenosine mono-
phosphate-activated protein kinase (AMPK) signaling is
critical in regulating mitochondrial content and function in
a PGC-1α -dependent pathway in different tissues and in
response to various stimuli [47]; furthermore AMPK signal-
ing is important in preventing the mitochondrial dysfunc-
tion/impairment increasing ROS leakage and accompanying
sarcopenia, disuse muscle atrophy, and other degenerative
muscle disorders, in such a way that it can be considered
as an indirect antioxidant cellular setting. Ceddia and
Sweeney [48] firstly demonstrated that Cr supplementation
may improve cellular bioenergetics by activating AMPK to
improve overall mitochondrial content and/or function. It
is currently unknown whether Cr supplementation exerts
similar AMPK effects in oxidatively injured muscle tissue.
At this regard, we recently observed in either control or
oxidatively challenged differentiating myoblasts that a 24 h
Cr preloading [0.3 mM] is an adequate stimulus to activate
the AMPK pathway (unpublished observation).
This observation, along with others showing that Cr
also acts as a direct antioxidant [5, 44, 49, 50] and protects
differentiating myoblasts from H2O2-dependent differentia-
tive arrest [5], suggests that in oxidative stressing conditions
Cr treatment might confer myoblasts an enhanced adaptive
capacity resulting in increased mitochondrial functionality
and biogenesis and reduction of oxidative damage during
myogenesis. Thus, besides established antioxidants, Cr might
represent a skeletal-muscle-directed endogenous molecule
capable of exerting multiple, pleiotropic actions which
collectively help counteracting excessive ROS pressure. Con-
sistently, beneficial effects of Cr supplementation have been
reported for a large number of muscular, neurological, and
cardiovascular diseases as well as in sarcopenia and aging
[44, 51–56]. On the contrary, although great attention has
been—and is still—paid to the administration of established
antioxidants including polyphenols and vitamins in order
to reduce the potential risk of the sustained and persistent
action of ROS on skeletal muscle, there is no clear con-
sensus on the benefits of these supplements [40, 57–59].
Thus, exploiting the efficacy of “atypical” and pleiotropic
antioxidants such as Cr deserves consideration.
The integrity of the antioxidant network is particularly
important in aging. Indeed, it is well-established that aging
is associated with increased free radical generation and the
resulting oxidative damage accumulated in organisms are
likely to be involved, at least at a concausal level, in the
progression of numerous diseases [60, 61]. It has long been
suspected that senescent skeletal muscle may progressively
loose its ability to adapt to oxidative stress [62, 63]. However,
at the present, there is no clear consensus about how and
whether senescent skeletal muscle becomes more susceptible
to ROS pressure. For example, although in skeletal muscle
antioxidant enzyme activities are increased with old age
[64, 65], protein and mRNA levels of CuZnSOD, MnSOD,
and GPx were found to be decreased or unaltered in the aged
muscle [66, 67]. More importantly, aged muscle exhibited
reduced antioxidant adaptation compared to training young
muscle [62]. The reduced ability to rapidly activate an
antioxidant adaptation program may render the senescent
muscle more prone to oxidative damage. Notably, it has
been hypothesized that the lack of adaptive capacity in
aging muscle may depend on the impairment of signal
transduction of antioxidant gene expression in response to
oxidative stress [68]. At this regard, as discussed above,
NF-κB and AP-1 are known to play an important role
in MnSOD gene expression [41]. The decreased binding
of these nuclear factors, despite increased ROS generation
found in aged muscles, would suggest that aging slows
down molecular signaling of antioxidant gene expression.
Thus aging seems to decrease the ability of aged muscle to
express at least MnSOD as demonstrated by lower nuclear
protein binding, mRNA levels, and unaltered enzyme protein
[62]. The observed increase in MnSOD activity in the same
setting might depend on a posttranslational modification
(activation) of the enzyme molecules in aged muscle. In
contrast to MnSOD, CuZnSOD showed increased protein
content and activity with age in type II muscle in the
absence of mRNA changes [66]. On the whole, these data
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suggest that the widely reported increase in antioxidant
enzyme activities in aging skeletal muscle do not depend
on enhanced gene transcription, but can rather derive from
translational and/or posttranslational mechanisms. Since
aged skeletal muscles are affected by augmented levels of lipid
peroxidation, protein oxidation, and DNA damage, these
compensatory increases in antioxidant enzyme activity are
ineffective in counteracting increased ROS generation.
4. ROS, Mitochondrial Biogenesis and Function
It is well known that oxidative signals affect mitochondrial
biogenesis, morphology, and function in skeletal muscle cells
[69–71]: again, the effect of ROS seems to be bifaceted
and controversial. Indeed, ROS may be important either
in eliciting pathological effects leading to mitochondrial
dysfunction and cell death ([72, 73], see also below
“Mitochondrial ROS Mediate Autophagy and Apoptosis”),
or play physiological roles promoting positive responses in
mitochondrial biogenesis and function. Mitochondrial bio-
genesis is dependent on the expression of the mitochondrial
genome and the nuclear genes that encode mitochondrial
proteins [74]. An important pathway triggered by ROS
is that leading to the upregulation of the mitochondrial
biogenesis master gene PGC-1α. The PGC-1α transcriptional
coactivator is a major regulator of energy metabolism
[75]. It controls many aspects of oxidative metabolism,
including mitochondrial adaptations, insulin-sensitizing via
the upregulation of selected genes involved in fatty acid β-
oxidation, glucose transport, and oxidative phosphorilation
[76–79]. The mitochondrial biogenesis signaling activated
by PGC-1 members family involves the transcription factors
that regulate expression of nuclear genes such as nuclear
respiratory factor (NRF) 1/2 and estrogen-related receptor-
α (ERR-α). These three latter genes control the expression of
nuclear genes encoding mitochondrial proteins and induce
expression of mitochondrial transcription factor A (T-
fam), which regulates mtDNA replication and transcription,
thus activating the coordinated expression of mitochondrial
proteins [80, 81].
Several signaling kinases have been involved in medi-
ating PGC-1α transcriptional activation in response to a
variety of stimuli among which the most important are
calcium/calmodulin-dependent protein kinase (CaMK) type
IV [82], AMPK [83], and p38 mitogen-activated protein
kinase [84]. Their activation induces the PGC-1α promoter
transcriptional regulation [69]. Recently, it has been demon-
strated that mitochondrial biogenesis in skeletal muscle is
controlled, at least in part, by a redox-sensitive mechanism
and that physical exercise, increasing the ROS production
over the physiological level, stimulates the muscle PGC-
1α/NRF-1/T-fam signaling [85]. Irrcher and colleagues have
evaluated the link between ROS levels and PGC-1α gene
expression [69] in C2C12 cells. They found that endoge-
nously produced ROS, at least within skeletal muscle cells, are
important for the maintenance of PGC-1α expression levels
within a normal physiological range. Indeed, quenching
basal endogenous ROS with N-acetylcysteine (NAC) results
in reduced PGC-1α mRNA expression, an effect which is
unrelated to any inhibition of PGC-1α promoter activity,
but probably dependent on the enhanced instability of
PGC-1α mRNA occurring in a low ROS environment. On
the contrary, increasing ROS levels with exogenous H2O2
augments PGC-1α transcription indirectly via the AMPK
activation caused by the oxidatively-induced ATP depletion.
This stimulates the binding of USF-1 to an Ebox within
the PGC-1α promoter, increases transcription and results in
the induction of PGC-1α mRNA expression, whose stability
would also be restored in a more ROS-rich environment. The
interplay of PGC-1α and ROS is further strengthened by the
fact that, besides being a key modulator of mitochondrial
biogenesis, it is important in regulating the expression
level of protective enzymes acting against ROS generation
and damage [86]. Indeed, experiments with either genetic
knockouts (KOs) or using RNA interference for PGC1α
show that the ability of ROS to induce a ROS-scavenging
program depends largely on PGC-1α activity [86]. This
response includes genes encoding for antioxidant enzymes
localized either within mitochondria (MnSOD) or cytosol
(catalase and GPxs). Indeed, cells lacking PGC-1α are more
susceptible to the toxicity induced by oxidative stress caused
by H2O2 [86]. These latter effects of PGC-1α are likely to
represent a compensatory response where it plays a central
role in the adaptation of cellular energy metabolism, mito-
chondrial biogenesis and antioxidant capacity in response to
oxidative challenge. At this regard and extending previous
research from our group [5], we have recently addressed
the problem of the role of PGC-1α in C2C12 myoblasts
subjected to oxidative stress during the early stages of
differentiation. In particular, we examined the effect of
a mildly toxic concentration of exogenously added H2O2
[0.3 mM] on the regulation of PGC-1α expression and its
relationship with AMPK activation (unpublished observa-
tions). According to Kang and Irrcher [69, 85], we found
that 1 h treatment with H2O2 markedly increased PGC-1α
mRNA expression. It is of worth that, concurrently, we also
found an increased phosphorylation of AMPK as compared
to untreated cells, suggesting that oxidative stress induces
PGC-1α through the AMPK signaling pathway. However,
despite the fact that challenged C2C12 myoblasts rapidly
activate a defense-oriented signaling cascade, they displayed
a 30–40% reduction of their viability as well as a survivors’
reduced differentiative efficiency during the post-challenge
incubation stage (up to 7 days of culture). This observation
would imply that, besides probably being an obligatory
and physiological response to ROS, activation of AMPK
and of PGC-1α may not be sufficient to afford a complete
protection to cells against an overwhelming oxidative stress.
Accumulating or excessive oxidative stress is known to be
detrimental for mitochondria: for instance mtDNA repre-
sents a critical target for oxidative damage [49]. Indeed,
mtDNA mutations are known as being an etiological factor
in oxidative stress-related disorders including cardiovascular
diseases and inherited or acquired neurodegenerative dis-
orders, mitochondrial myopathies, and the normal aging
process.
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5. ROS Mediate Autophagy and Apoptosis
ROS may trigger either autophagy or apoptosis: whether
these two pathways will be activated depends on the cell
context and on the availability of specific modulators of
ROS activity [87]. Autophagy is one of the cellular defense
mechanisms activated in response to an excessive ROS
production. Indeed, ROS act as signaling molecules in the
early events of autophagy induction [87]. Phosphoinositide
3 kinase (PI3K) is known to mediate, at least in part, ROS
effects. If the prosurvival effort fails, ROS induce cell death
which may involve either the autophagic or the apoptotic
pathway, or both [72, 88].
ROS signaling pathways play an important role in the
induction of autophagy under physio- and pathological
conditions. In healthy cells, autophagy is routinely involved
in organelles and proteins turnover as well as in cellular
energetic balance [89]. One of its strongest and better-
characterized stimuli is starvation, where mitochondrial
ROS production is enhanced and autophagy increased [87].
Increased ROS generation in the mitochondria under starva-
tion is known to depend, at least in part, by class III PI3K: this
event is essential for the induction of autophagy [90]. Indeed,
upon starvation, ROS, and in particular H2O2, oxidize
and inhibit Atg4, a protease responsible for microtubule-
associated protein (MAP) light chain 3 (LC3) delipidation,
that is, a condition resulting in the stabilization of the
lipidated forms of LC3 and promoting the autophagosome
maturation [87]. Notably, the same authors reported that
addition of antioxidants inhibits these effects, preventing
autophagosome biogenesis [91].
Thus, autophagy induced by starvation, where ROS
participate in a feedforward manner, plays a prosurvival role
since it contributes to the mobilization and reutilization of
diverse cellular energy stores [89].
In a different direction, it is also known that when
autophagy is prolonged, it could lead to cell death indepen-
dently from apoptosis [92]. Indeed in nonmuscle tissues and
in specific pathological conditions, ROS-induced autophagy
was often linked to cell demise and death. As to skeletal
muscle, ROS have been implicated in the induction of
autophagy in muscle atrophy, disuse, and aging [72, 93].
Important new evidence on the wasting effect induced
by increased oxidative stress on muscle phenotype was
obtained by targeting a mutant SOD variant found in human
amyotrophic lateral sclerosis myopathy [93, 94]. Indeed,
these authors created a mouse model with a G93A mutation
of SOD1 restricted to skeletal muscle [93]: accumulation
of ROS in the muscles of these mice induced progressive
atrophy associated with increased autophagy and forkhead
transcription factors O (FoxO3) expression, a transcription
factor which controls the transcription of autophagy-related
genes and is required for the induction of autophagy through
the lysosomal pathway in skeletal muscle in the absence
of AKT repression [95–97]. In addition, NF-κB signaling
has been proposed as an alternative pathway linked to
ROS-mediated skeletal muscle atrophy [98]: indeed NF-κB
was found to induce muscle atrophy and wasting via the
lysosomal enzyme cathepsin L [93, 99] upregulation. Since
cathepsin L is typically upregulated by FoxO3, it might be
speculated that ROS-induced NF-κB converges on the FoxO3
autophagic pathway.
Increasing evidence suggests that autophagy of mito-
chondria is a selective and defense-oriented response against
ROS, mitochondrial dysfunction and the accumulation of
somatic mutations of mtDNA with aging [72, 100]. For this
reason it has been recently proposed the term “mitophagy”
to emphasize the nonrandom nature of this process [100].
Damaged mitochondria are removed by mitophagy by
Binp3, a BH3 proapoptotic member of the Bcl-2 family
and fis 1, a pro-fission mitochondrial protein that induces
mitochondrial fragmentation and enhances the extent of
mitophagy. Notably, inhibition/alteration of mitophagy can
contribute to myofiber degeneration and weakness in muscle
disorders characterized by accumulation of abnormal mito-
chondria and inclusions [101, 102].
ROS may have various and important roles in apoptotic
cell death: direct actions such as oxidation of cellular
proteins and lipids, damage of nucleic acids and functional
alteration of organelles; ROS may also modulate cell death
processes affecting various signaling cascades [103]. Indeed,
ROS participate in early and late steps of the regulation of
apoptosis, affecting different apoptotic signaling cascades in
both intrinsic or extrinsic pathways.
The extrinsic path, which involves stimulation of recept-
or-mediated apoptotic pathways, can be initiated by ligand-
induced (e.g., TNFα and Fas-L and TNF-related apoptosis-
inducing ligand, TRAIL) binding, which promotes the
activation of caspase-3 and subsequent degradation of
genomic DNA [103]. Recent evidence suggests possible direct
roles for ROS in mediating death receptors activation and
subsequent induction of apoptosis [104]. Indeed, apoptotic
signaling is induced by NOX-derived ROS at the plasma
membrane level, which lead to lipid raft formation and death
receptor clustering activation [104]. The physiological rele-
vance and significance of ROS-dependent receptor-mediated
apoptosis as compared to the classical receptor/ligand-
induced apoptotic signaling is, at present, incompletely un-
derstood and warrants further investigation.
ROS may act as intracellular intermediates directly
dysregulating the sarcoplasmic reticulum Ca++ flux and
handling, which results in caspase-7 and calpain activa-
tion. Furthermore, ROS may cause mitochondrial swelling
and fragmentation, and/or alter the conformation of the
mitochondrial permeability transition pores (MPTPs), thus
facilitating their opening and the release of proapoptotic
proteins such as cytochrome c (Cyt C). Independently of
caspase activity, apoptosis may follow the intrinsic path,
where ROS may directly cause the release of mitochondrial
endonuclease G (Endo G), and/or of apoptosis inducing fac-
tor (AIF), which is capable of promoting DNA fragmentation
in skeletal muscle myonuclei [105].
Another protein coupled with ROS-induced apoptosis
is the voltage-dependent anion selective channel protein 1
(VDAC1). This transmembrane protein has been defined a
ROS sensor [106] that triggers opening of the MPTP complex
under conditions of oxidative stress. Indeed VDAC1 is the
main channel within the mitochondrial outer membrane and
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upon ROS accumulation exhibits an increased conductance
associated with MPTP opening and dissipation of ΔΨ,
thus favouring the efflux of apoptotic proteins located
in the intermembrane space and finally cell death [107].
Notably, the pro- and antiapoptotic Bcl2-family proteins
are released via VDAC1 action and ROS may further affect
these responses as they are known, in nonmuscle cells, to
down-regulate the endogenous levels of the antiapoptotic
protein Bcl-2 [108]. The mechanism through which Bcl-2
levels are affected by ROS has been studied by Azad et al.
in nonmuscle cell types and seems to depend on superoxide
anion-related degradation of Bcl-2 protein through the
ubiquitin-proteasomal pathway [109].
Furthermore, under oxidative stressing conditions, ROS
activate a signaling cascade involving the protein kinase
C (PKC) b-dependent phosphorylation of the Shc adaptor
protein p66shc and its translocation to the mitochondrial
matrix. In particular, the mitochondrially translocated frac-
tion of p66shc behaves as redox enzyme that utilizes reducing
equivalents derived from the mitochondrial electron trans-
port chain to produce H2O2 in the intermembrane space, an
event which is known to trigger apoptosis [110, 111].
The accumulation of ROS within the mitochondrial
matrix, as well as their capacity of triggering apopto-
sis, is counteracted/regulated by mitochondrial antioxidant
enzymes, namely, phospholipids hydroperoxide glutathione
peroxidase, GPx, and Mn-SOD [3, 112].
Thus increased mitochondrial production of ROS is
involved at multiple levels in promoting apoptosis in skeletal
muscle cells, an event which participates in the aetiology and
progression of numerous pathologies including sarcopenia
and disuse muscle atrophy as well as in aging [71, 113].
Physical training and exercise are known to increase
mitochondrial biogenesis and density as well as mitochon-
drial ROS production especially during repeated contrac-
tions [85]. Therefore and unless other determinants are
considered, it might appear paradoxical that although a
routine of regular exercise is associated with numerous
health benefits, physical exercise might potentially promote
oxidative stress and ROS-associated apoptosis of skeletal
muscle cells [17]. Indeed, chronic contractile activity (CCA)
and endurance training induce an adaptive response in
skeletal muscle cells leading to increased mitochondrial
biogenesis [114] and—theoretically—an obligatory increase
in a number of proapoptotic mitochondrial proteins and
byproducts such as ROS. However, as a matter of fact
recent evidence indicates that mitochondria isolated from rat
skeletal muscle subjected to CCA seem to acquire an anti-
apoptotic, rather than proapoptotic, behaviour [114]. The
study also addressed the problem of the relative antiapoptotic
role acquired by different mitochondrial subpopulations
from CCA-trained muscles, namely, the intramyofibrillar
(IMF) and the subsarcolemmal (SS) mitochondria. The
release of both Cyt C and AIF caused by exogenous H2O2
from CCA-isolated IMF and SS mitochondria was decreased;
CCA augmented the expression of antiapoptotic HSP70 and
caspase recruitment domain protein in either SS or IMF and
caused a decreased ROS generation in IMF mitochondria.
On the contrary, states III and IV respiring SS mitochondria
showed a modestly increased rate of ROS generation as well
as an increased resilience of MPTP opening. It was then
hypothesized that these effects might collectively reflect the
overall reduced apoptogenic capacity acquired by mitochon-
dria following CCA training of skeletal muscles and that, in
particular, the slight increase of ROS generated by SS would
contribute to the activation of redox-sensitive transcription
factors promoting muscle fiber plasticity and adaptation,
rather than to function as proapoptotic triggers. Again, such
a scenario is indicative of the diverging effects that ROS may
assume depending on specific situations of cells’ life, rather
than on their net concentration and site of generation.
6. ROS Signaling and Myogenic Differentiation
Increasing evidence indicates that ROS are capable of
affecting—mostly reducing—the efficiency of myogenic dif-
ferentiation. The integrity/alteration of myogenic differ-
entiation is central to many physiological and pathologi-
cal processes. Successful differentiation of satellite-derived
myoblasts into functioning and integrated myotubes is a
fundamental prerequisite for muscle regeneration, a repair
process which is of primary importance in maintaining
muscle function [115]. Notably, oxidative stress is known
to play a concausal and detrimental role in a variety of
multifactorial muscular pathologies characterized by prolif-
eration/differentiation imbalance such as Duchenne dystro-
phy [116], myotonic dystrophy [117], sarcopenia [118], and
cachexia [119].
The role of ROS in this context has been extensively
documented. Ardite et al. [120] showed that ROS induced
a strong depletion of the intracellular GSH pool: notably
depletion of GSH causes further intracellular accumulation
of ROS which favors NF-κB activation, thus contributing to
the lower expression of MyoD and impaired myogenesis (see
below).
According to Ardite et al. [120], data from our group
[5] indicate that a mildly toxic H2O2 treatment during the
early stages of C2C12 myoblast differentiation results in GSH
depletion and strongly impairs the differentiative outcome.
This effect is unlikely to be a mere result of ROS-induced
cell demise: indeed, the cells surviving H2O2, although
exhibiting a partial and late recovery of protein synthesis
and of viability, were unable to continue and execute the
differentiative task. These cells also displayed a strong and
long-lasting reduction of the mRNA levels of MyoD, which
is involved in early stem cell commitment, and of myogenin
and MRF4, both recruited at later differentiation times [121,
122]. Whether the transcription of these muscle regulatory
factors (MRFs) is a result of a specific signaling promoted
by ROS or of a cell suffering is still to be understood.
Under the same conditions depressing these MRFs, insulin-
like growth factor 1 (IGF-1) which plays a pivotal role
in controlling muscle growth [123], was inhibited to an
even greater extent (see also “ROS and IGF-1 signaling”).
Interestingly, H2O2-injured cells showed signs of extensive
mitochondrial degeneration (swelling and disruption) and
lower mitochondrial density, suggesting that these organelles
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are specifically targeted by—or particularly sensitive to—
exogenous ROS. Loss of mitochondria is a clearly detrimental
event in a process typically requiring active mitochondrio-
genesis such as muscle differentiation [4, 124].
ROS generated by the inflammatory cytokine TNFα
are known to inhibit myogenesis, and this effect is widely
attributed to oxidative activation of NF-κB and subsequent
gene expression [125–127]. However, the effect of TNFα is
likely to be more complex since Langen et al. [9] showed that
TNFα causes loss of myogenic capacity of C2C12 cells via
NF-κB-dependent and-independent and oxidative-sensitive
and-insensitive pathways. In particular they hypothesized
that an oxidative-sensitive, NF-κB-independent mechanism
might involve the blockage of the formation of functional
catenin-adherin complexes proximate to the cell membrane
[128]. Potentially, disruption of these complexes and the
resulting alteration of cell-matrix and cell-cell interactions,
might be responsible for the inhibition of myotube forma-
tion independently of NF-κB.
The redox regulation of the NF-κB family of tran-
scriptional activators plays a central role in differentia-
tion, adaptation, and death of muscle cells. This role is
extremely complex: indeed the effects promoted by NF-κB
are sometimes contradicting. As an example, although ROS
can directly stimulate NF-κB, oxidized NF-κB has a dimin-
ished DNA-binding activity [17]. NF-κB has been mostly
associated with a negative regulation of skeletal muscle
differentiation [119, 129, 130]. NF-κB is constitutively active
in proliferating myoblasts and can inhibit myogenesis by
promoting a mitogenic activity via cyclin D1 or by inhibiting
the synthesis of MyoD, a muscle-specific helix-loop-helix
transcription factor operating in muscle development and
repair [131–133]. More recently, NF-κB was shown to sup-
press myofibrillar gene expression through the regulation of
the myogenic transcriptional repressor Yin Yiang 1 [134].
Moreover, treatment of primary myoblasts with the NF-
κB inhibitor curcumin stimulates myoblast fusion thereby
enhancing myogenesis and repair [125]. In line with these
in vitro findings, activation of the TNFα pathway by muscle
gene transfer inhibits regeneration in vivo, while muscle-
specific deletion of the heteromeric kinase complex IKK
was recently described to promote secondary myogenesis
in response to acute injury signals [126, 127]. Activation
of NF-κB downstream ROS formation is also capable of
stimulating the activity of inducible nitric oxide synthase
(iNOS), whose role in myogenic process is controversial [24].
Some authors found that iNOS activity suppresses muscle
differentiation, whereas others reported that stimulation of
iNOS via NF-κB represents a positive and necessary stimulus
for muscle differentiation, that iNOS activity paralleled
myogenesis from the early to later stages in H9C cells and
that ROS formed by NOX 2 were the basic trigger leading
to iNOS stimulation via NF-κB recruitment [24, 135, 136].
Blockage of this pathway, or inhibition of iNOS with specific
inhibitors, led to differentiative arrest. Also, a recent article by
Lee et al. [137] indicates that complex-I-derived superoxide
anions, produced through reverse electron transport, were
dismutated into H2O2 by MnSOD induced via NF-κB
activation and that H2O2 stimulated muscle differentiation
as a signaling messenger. Thus the scenario arising from
these results would indicate that ROS negatively or positively
regulate muscle differentiation via the signaling pathways
involving NF-κB activation.
Another evidence which lends support to the detrimental
role of ROS in muscle differentiation comes from the studies
on the role of p66Shc in skeletal muscle ischemic injury.
p66Shc, along with its isoforms p46 and p52, constitutes the
mammalian Shc adaptor protein group. The three isoforms
share a common structure, but p66ShcA has the unique
feature of an additional domain at the N terminus which
contains a serine residue at position 36 (Ser-36) that is
phosphorylated in response to several stimuli, including
H2O2. Due to this feature p66 isoform regulates ROS
metabolism and apoptosis [138, 139]; indeed, a fraction of
p66ShcA is localized in the mitochondria where, as discussed
above, it produces mitochondrial ROS as signaling molecules
for apoptosis [110, 111]. Interestingly, both p66ShcA KO
cells and mice display lower levels of intracellular ROS [139–
141] and are less prone to apoptosis induced by an array
of different stimuli. Also, p66Shc KO mice are resistant
to ischemia-induced apoptosis and show decreased muscle
damage in response to hind limb ischemia [142]. More
recently, Zaccagnini et al. [143] unravelled the role of p66Shc
and ROS in muscular damage and regeneration following
acute hind limb ischemia in both WT and p66Shc KO
mice. WT mice showed detectable levels of oxidative stress
markers during the postischemic and regenerative stages;
on the contrary, the same markers were undetectable in
KO mice. More interestingly, although the initial ischemic
damage was identical and no advantage in terms of muscle
vascularization and perfusion was observed in KO mice, their
regenerative capacity was significantly higher as compared to
WT. Satellite cell populations were similar in both groups,
but those from KO mice showed a higher proliferation rate
at first and spontaneous differentiation when cultured under
prodifferentiative conditions. Finally, p66Shc KO satellite
cells were resistant to the myogenic inhibition induced by
H2O2 acute challenge or hypoxia. The authors proposed
different and possible explanations for the above effects.
The first one involves the different availability of NO—
whose promyogenic role has been discussed above—in
KO mice: since active p66Shc generates superoxide anions,
which consume available NO forming the toxic species
peroxynitrite, p66Shc KO mice would benefit of higher NO
availability and would not suffer of peroxynitrite toxicity,
two effects favouring myogenesis and muscle regeneration.
Another plausible mechanism involves the NAD+-dependent
histone deacetylase Sir2. Sir2 deacetylase activity is depen-
dent on the fluctuation of cytosolic NAD+/NADH ratio,
that is, the cellular redox state [144]. Under conditions of
high ROS concentrations, NAD levels increase and promote
Sir2 activation, which in turn inhibits MyoD-dependent
transcription. p66Shc KO mice are characterized by lower
levels of ROS and, as a result, decreased Sir2 activity, that is a
condition which affects MyoD functions to a lesser extent.
Finally, since oxidative DNA damage may trigger a differ-
entiation checkpoint and cause a reversible inhibition of
myogenic differentiation targeting MyoD phosphorylation,
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such a checkpoint activation may be attenuated by p66ShcA
deletion, which results in decreased intracellular ROS levels.
With regard to prodifferentiative effects induced by ROS
in this context, in addition to the already cited report by
Lee et al. [137], it has been recently demonstrated that in
a non skeletal-muscle cell, that is, vascular smooth mus-
cle cells (VSMC), ROS increase their differentiation rate
after quiescence through a p38 MAPK-dependent pathway
[145]. Similarly, other studies focusing on ROS and muscle
metabolism, differentiation, and growth unravelled some
positive interactions with IGF-1 signaling (see below).
Again, the most likely explanation for these opposite
effects is that cell fate may depend on the intracellular ROS
type (i.e., which is the prevailing reactive species) and level.
In fact, it is well known that ROS elicit a wide spectrum
of cellular responses, depending on their intracellular level
[146]. A low dose of ROS controls normal cellular signaling
pathways while an intermediate dose results in either tem-
porary or permanent growth arrest [147]. Obviously, a high
dose of ROS causes cell death via either apoptotic or necrotic
mechanisms [142].
7. ROS and IGF-1 Signaling
Growing evidence suggests that oxidative stress is responsi-
ble, as a causal or a concausal factor, for the pathogenesis
of many muscle diseases and muscle wasting [148, 149].
In muscle cells, IGF-1 is known to promote muscle welfare
inducing muscle hypertrophy and stimulate muscle-cell pro-
liferation, differentiation, and survival [123]. IGF-1 has also
been found to contribute to oxidative balance and to mediate
protective responses against iron-induced-lipid oxidative
stress in vivo [150]. Accordingly, Yang and colleagues [151]
demonstrated that IGF-1 displayed protective effects on
muscle cells after oxidative stress: indeed, pretreatment with
IGF-1 protected muscle cells from H2O2-induced cell death
and enhanced their survival through promotion of the
antiapoptotic protein Bcl2. The same authors showed that
protection was via an IGF-1 subpathway: PI3K/Akt and
ERK1/2 MAPK pathways [151].
IGF-1 is a peptide hormone with a complex post-tra-
scriptional regulation, generating distinct isoforms, namely,
IGF-1Ea, IGF-1Eb, and IGF-1Ec (this latter also known
as mechano growth factor, MGF) [152]. Mouse models
have provided insights into the tissue-specific functions and
responses to ROS of the different IGF-1 isoforms [152–155].
For example, in murine models, the local muscle isoform of
IGF-1 (mIGF-1, the orthologue of human MGF) has been
shown not only to activate proliferation of myoblasts [156],
but also to protect cardiomyocytes from oxidative stress via
the Sirtuin 1 deacetylase activity [157].
As to physical activity, although its role in regulating
the expression of specific IGF-1 isoforms has been widely
studied, data in the literature regarding humans are often
contradictory and are affected by many uncontrolled vari-
ables such as the lack of dietary control, heterogeneity
of subjects, their physical fitness, differences in proposed
physical exercise, and time course of sampling [158–160].
Similarly to other pathways, ROS may regulate either
positively or negatively IGF-1 signaling [161]. Low levels
of endogenous ROS—due to their reversible oxidative inhi-
bition of protein tyrosine phosphatases (see also “ROS as
multipurpose local regulators of muscle cell functions”)—
induce the phosphorylation on specific tyrosine residues of
insulin receptor (IR) and IR substrates (IRS) protein(s),
thus facilitating the IGF-1 signaling. Indeed, the IRβ chain
contains multiple sites for the phosphorylation of tyrosine
that are sensitive targets of ROS such as H2O2 [162]. By
contrast, higher ROS levels inhibit IGF-1 signaling cascades
and recent evidence implicates ROS as downregulators of
IGF-1 signaling and inducers of insulin resistance and its
pathological sequelae [162].
However, ROS may be also involved in the activation
of “insulin-like” metabolic effects by activating other non-
insulin-initiated signaling pathways: one of the most impor-
tant examples is the stimulation of glucose transport in
skeletal muscle during exercise [163, 164]. Skeletal muscle
contraction stimulates, as well as insulin, glucose transport
by up to 50-fold during maximal exercise in humans [165].
Adding exogenous ROS to skeletal muscle in vitro stimulates
glucose transport [166] whereas NAC, a potent antioxidant,
reduces contraction-mediated glucose uptake by about 50%
[167]. This effect of NAC was associated with a similar
degree of inhibition of contraction-induced activation of
AMPK. This kinase is a fundamental signaling kinase
which, besides being involved in mitochondrial biogenesis
(see “ROS signaling and myogenic differentiation”), is also
known to upregulate the glucose uptake in muscle under
conditions of high AMP/ATP ratio, like hypoxia and muscle
contraction, forming a non-insulin-dependent pathway to
increase muscle glucose utilization [158, 168–172]. Thus the
proposed role of ROS in mediating the stimulation of glucose
transport is related to skeletal muscle contraction, that
increases superoxide anion production via mitochondrial
respiration. Superoxide anion is rapidly converted to H2O2
by SOD, resulting in direct activation of AMPK, Glucose
transporter 4 (Glut4) translocation to the plasma membrane,
and an increase in glucose transport [173]. Moreover, in
muscle cells, NAC antagonized ROS-mediated increase in
glucose uptake in response to contraction, but not to
insulin. Activation of AMPK in aerobic-exercise-induced
glucose uptake is paradigmatic of ROS participation in
physiologically-oriented signaling pathways relevant to the
homeostasis of the entire organism.
It has also been demonstrated that ROS regulate IGF-
1-induced myotube hypertrophy in vitro. It is well known
that exercise-induced muscle hypertrophy mostly depends
on the increased local production of IGF-1 via activation of
the PI3K/Akt pathway [174, 175]; interestingly ROS, which
are being overproduced during exercise, contribute in a
feedforward manner to stimulate IGF1 net accumulation.
Previous reports show that there are positive and negative
interactions between ROS and IGF-1 synthesis in both
skeletal and VSMCs [176–178]. Treating VSMCs with H2O2
or XO augments both IGF-1 mRNA and IGF-1 protein
secreted into the cultured medium, indicating that ROS
enhance the IGF-1 autocrine system in VSMCs [176]. By
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contrast, we and others [5, 178] found that toxicologically
relevant concentrations of H2O2 negatively regulate the
IGF-1 mRNA levels in differentiating C2C12 myoblasts. In
our experience, oxidative insult significantly decreased IGF-
1 mRNA expression levels [5]. Cr, notably, prevented its
inhibition: moreover Cr is known to induce hypertrophy of
differentiating myoblasts via IGF-1 pathway [123].
Taken collectively, these results suggest that—although
ROS enhance IGF-1 signaling—there is a negative feedback
regulation of IGF-1 mRNA levels occurring with mildly toxic
ROS levels in C2C12 cells. Thus, ROS regulate IGF-1 action
via a variety of mechanisms, and the effects are likely, again,
to be cell type and dose dependent.
Thus, ROS play a crucial role in the IGF-1 signaling
regulation and its biological action in muscle cells. However,
additional studies are necessary to better explain the phys-
iological significance of these interactions in humans, with
particular regard to the identification of the distinct actions
on the IGF-1 propeptide isoforms.
8. ROS as Multipurpose Local Regulators of
Muscle Cell Functions
Similarly to other noninflammatory cells, skeletal muscle
cells produce transient fluxes of ROS in response to an
array of diverse stimuli, such as intense contractile activity
[179, 180], heat stress [181], short-term disuse atrophy
[182], acute hypoxia [143, 183], acute osmotic stress [184],
and stretch [185]. Furthermore, locally produced waves of
ROS are also released by skeletal muscle in response to cell
surface receptor activation via cytokines, hormones, growth
factors [186–188], or nuclear receptor activation [189, 190].
Considering the large variety of different stimuli converging
to ROS production along with their lack of chemical
specificity, it is hard to formulate a unitary explanation
of the physiological significance of ROS in the responses
triggered by such divergent signals [188]. At this regard,
data published by Wright et al. [191] prompted these
authors to draw an attractive hypothesis which involves the
regulation of the protein phosphatases (PPases) “tone” in
muscle cells and tissue. PPases belong to two broad families,
the protein tyrosine PPases (about 112 human proteins)
and the serine/threonine PPases (about 31 proteins). These
two families are divided into further subclasses according
to their specificity (only tyrosine targets or tyrosine plus
serine/threonine targets) or, with regard to the second family,
the subclasses characterized by a Zn2+/Fe2+ complex at the
catalytic site or by the Mn2+/Mg2+ dependence [191].
The redox sensitivity of the protein tyrosine PPases and
its potential biological importance is well documented in
vitro and in cell culture systems since the early 1990s [192,
193]. As to Ser/Thr PPases, their sensitivity to oxidants is
more controversial: calcineurin is the first whose sensitivity
to oxidants has been clearly identified [194–196].
Interestingly, Wright et al. [191] found that not only
protein tyrosine PPases, but also Ser/Threo PPases are inhib-
ited by exposure to ROS or ROS generating agents (namely,
H2O2 and DMNQ, resp.). The relative sensitivity of different
PPases to oxidation in the above scenario has not yet been
addressed. The mechanism by which PPases are oxidized is
likely to involve the vulnerability of their ubiquitous and
conserved cysteine-based active site; more surprising and still
unexplained is the observed inhibition of ser/threo PPases
which—with the exception of calcineurin—are best known
in literature as “relatively immune to oxidation”.
Indeed, the same study by Wright et al. [191] shows
that in muscle tissue even minimal, physiologically relevant
concentrations of oxidants, lead to an overall inhibition of
PPases’ activity. Notably, the concentrations used neither
affected contractile function nor resulted in clear oxidative
stress. Consistently, the level of net phosphorylation of a wide
range of functionally diverging proteins was correspondingly
higher in treated muscle preparations. This latter data
suggests that oxidants are capable of affecting a broad range
of PPases. Interestingly the majority of kinases are equally
sensitive to oxidants but, contrary to PPases, oxidants pro-
mote their activation. Since kinases operate sequentially as
amplification chains, it is likely that the observed increase
in the net protein phosphorylation level under low-oxidative
stressing conditions is the result of a lower PPases activity
along with an increased kinases activity. These two combined
events promoted by ROS would obviously trigger and/or
affect many different signaling pathways, contributing to
orchestrate the final cellular responses.
In summary, oxidants could function to regulate in vivo
global “phosphatase and kinase tone” and thus influence the
kinetics and amplification of many kinase signaling path-
ways. With respect to skeletal muscle, such a scenario would
be of great biological and physiopathological relevance, since
muscle cells typically and continually produce ROS fluxes
of different duration, intensity, and localization, depending
on either intrinsic and extrinsic variables. Notably, such a
hypothesis fits well with the hormetic nature of ROS.
9. Conclusion
The picture arising from this review indicates that ROS
activate and/or participate in many signaling pathways
promoting complex and diverging effects in skeletal muscle
cells, ranging from positive to detrimental. As an example,
many studies have concluded that inactivity-induced ROS
production in skeletal muscle contributes to disuse muscle
atrophy [197, 198]. On the contrary, growing evidence also
suggests that intracellular ROS production is a required
signal for the normal remodelling that occurs in skeletal
muscle in response to repeated bouts of endurance exercise
[40, 199, 200]. How can the same trigger promote such
opposite effects? Based upon current knowledge, it appears
that the mode and the situation characterizing skeletal
muscle cells exposure to ROS may account, at least in part,
for this apparent paradox. Transiently increased, moderate
levels of oxidative stress might represent a potentially health-
promoting process, whereas its uncontrolled persistence
and/or propagation might result in overwhelming cell dam-
age thus turning into a pathological event: for instance,
the role of ROS in inflammation fits well with this model.
In addition, the complexity, the variety, the interplay, and
the functionally diverging roles of the signaling pathways
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activated or modulated by ROS contribute to further com-
plicate this scenario. Thus, a gradual and variable, rather
than a sharp, boundary is likely to characterize the transition
between the two types of ROS actions. Such a variable
“greyscaling” of ROS effects may depend on extrinsic and
intrinsic situations such as, at least, (i) the concentration
of ROS, (ii) the type of reactive species involved, (iii) the
persistence of ROS activity, (iv) the localization of ROS
source, (v) the antioxidant capacity and the energy status
of muscle cells, (vi) their ability to adapt to oxidative stress
(which in vivo also depends on ageing and/or physical train-
ing), (vii) the differentiative status, for example, myoblasts
versus integrated myotubes, (viii) the absence/presence of
an inflammatory process, and (ix) the plasticity of the
signaling pathways triggered/affected by ROS. The balance
between these factors will ultimately determine which type
of signal(s) and effect(s) will prevail within the cell. Again,
the hormetic nature of ROS emerges as the key feature
of these species in many tissues, including skeletal muscle.
Careful titration of ROS levels within skeletal muscle cell
may therefore lie at the cross between the initiation and
progression of disease and cell death, the induction of
mitochondrial biogenesis, repair, and more generally cellular
metabolic health. Supplementation with exogenous antioxi-
dants is being widely studied to attain and maintain an “ideal
titration” of ROS within skeletal muscle: unfortunately, at
the present, no clear indication of the benefits arising from
supplemental antioxidant intake emerges from literature.
This reflects the need for further studies aimed at clarifying
how to regulate ROS levels to exploit their physiological
effects and avoid their damages.
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The members of the RasGTPase superfamily are involved in various signaling networks responsible for fundamental cellular
processes. Their activity is determined by their guanine nucleotide-bound state. Recent evidence indicates that some of these
proteins may be regulated by redox agents. Reactive oxygen species (ROSs) and reactive nitrogen species (RNSs) have been
historically considered pathological agents which can react with and damage many biological macromolecules including DNA,
proteins, and lipids. However, a growing number of reports have suggested that the intracellular production of ROS is tightly
regulated and that these redox agents serve as signaling molecules being involved in a variety of cell signaling pathways. Numerous
observations have suggested that some Ras GTPases appear to regulate ROS production and that oxidants function as effector
molecules for the small GTPases, thus contributing to their overall biological function. Thus, redox agents may act both as
upstream regulators and as downstream effectors of Ras GTPases. Here we discuss current understanding concerning mechanisms
and physiopathological implications of the interplay between GTPases and redox agents.
1. Introduction
The Ras GTPase superfamily includes low molecular weight
GTP-binding and hydrolyzing (GTPases) proteins that act
as molecular switches by coupling extracellular signals to
different cellular responses, thus controlling cellular signal-
ing pathways responsible for growth, migration, adhesion,
cytoskeletal integrity, survival, and differentiation. The three
human Ras proteins, H-Ras, N-Ras, and K-Ras, are the
founding members of this large superfamily of small GTPases
comprising over 150 human members with evolutionarily
conserved orthologs found in Drosophila, C. elegans, S. cere-
visiae, S. pombe, Dictyostelium, and plants. This superfamily
is divided into families and subfamilies on the basis of
sequence and functional similarities (Table 1). The five major
families are Ras, Rho, Rab, Arf, and Ran [1]. In addition
to the different Ras isoforms, the Ras family includes Rap,
R-Ras, Ral, and Rheb proteins, also regulating signaling
networks. Rho GTPase family includes the well-characterized
family members Rac1, RhoA, and Cdc42, each of which
is associated with unique phenotypes and functions [2–4].
Rab proteins comprise the largest branch of superfamily
and regulate intracellular vesicular transport and trafficking
of proteins. Like the Rab proteins, Arf family proteins are
involved in regulation of vesicular transport. The Ran protein
is the most abundant small GTPase in the cell and is best
known for its function in nucleocytoplasmic transport of
both RNA and proteins [1].
Although being similar to the heterotrimeric G protein
α subunit in biochemical mechanism and function, Ras
GTPases function as monomeric GTP-binding proteins. The
functional diversity of these proteins is based on variations
in structure, posttranslational modifications that dictate spe-
cific subcellular localizations, and proteins that act as reg-
ulators and effectors [1, 5].
Signal transduction through Ras proteins occurs by re-
versible binding of GTP, while the inactive form is bound
to GDP. Switching between these two states is regulated by
three distinct types of protein modulator agents: Guanine
nucleotide Exchange Factors (GEFs) catalyze the exchange of
GDP with GTP to promote Ras activation, whereas GTPase-
Activating Proteins (GAPs) deactivate the Ras protein by
2 Journal of Signal Transduction
Table 1: The Ras superfamily of small GTPases. The RasGTPase superfamily is divided into 9 families of small GTP-binding proteins on the
basis of sequence and functional similarities (modified from [7]).
Ras Rab Rho Sec Arf Rad Ran RheS Rit
H-Ras Rab1A RhoA N-Sec1 Arf1 Rad Ran/TC4 Rhes Rit
K-Ras Rab1B RhoB S-Sec1 Arf2 Gem Dexras1 Others Rin
N-Ras Rab2 RhoC Sec4 Arf3 Kir Others Ric
E-Ras Rab3A RhoD Sly1p Arf4 Rem1 Others
TC21 Rab3B RhoE Others Arf5 Rem2
R-Ras Rab4 Rnd1 Arf6 Others
M-Ras Rab5A Rnd2 Arf7
Rap1A Rab5B RhoG Others
Rap1B Rab6 Rac1
Rap2A Rab7 Rac2
Rap2B Rab8 Rac3
RalA Rab9 Cdc42
RalB Rab10 TC10
Others Others TTF
Others
stimulating hydrolysis of bound GTP to GDP. Deactivation
can also be achieved by association with Guanine Nucleotide
Dissociation Inhibitors (GDIs), which prevent membrane
association, and GDP dissociation. All of these regulatory
proteins are themselves affected by diverse upstream signals,
which serve to activate or inactivate Ras GTPase signaling
pathways. The transition of Ras proteins between the GDP-
and GTP-bound states is accompanied by a conformational
change that greatly enhances their affinity for downstream
effectors [6]. The interaction between the active GTP-bound
GTPase and the effector molecule leads to activation of
downstream signal transduction pathways.
In addition to these protein regulatory factors, many of
the Ras superfamily small GTPases have been shown to be
redox sensitive, and their known conserved redox-sensitive
sequences have been termed the NKCD, GXXXXGK(S/T)C,
and CGNKXD motifs. The action of redox agents on these
redox-sensitive GTPases is similar to that of guanine nu-
cleotide exchange factors in that they perturb GTPase nu-
cleotide-binding interactions that result in the enhancement
of the guanine nucleotide exchange of small GTPases [7].
For many years, the generation of intracellular redox
agents such as reactive oxygen species (ROS) and reactive ni-
trogen species (RNS) was viewed solely as the unregulated
by-product of aerobic metabolism and other enzymatic
processes, and redox agents have been historically considered
pathological agents which can react with and damage many
biological macromolecules including DNA, proteins, and
lipids. However, over the last years a growing number of
reports have suggested that mammalian cells can rapidly
respond to ligand stimulation with a change in intracellular
ROS thus indicating that the production of intracellular
ROS is tightly regulated and that these redox agents serve as
intracellular signaling molecules being involved in a variety
of cell signaling pathways, including growth factor signaling
[8, 9], inflammation [10], engagement of integrins [11,
12], and adhesion to extracellular matrix [13]. The precise
means of regulation is not completely understood. However,
numerous observations have suggested that the Ras GTPases
appear to regulate ROS production and that oxidants func-
tion as effector molecules for the small GTPases, thus con-
tributing to their overall biological function [14].
Here we discuss current understanding concerning the
interplay between GTPases and redox agents. The discussion
also takes into account pathological implications of alter-
ations of both ROS regulation by small GTPases and small
GTPases regulation by ROS.
2. ROS Regulation by RasGTPases
Among the major source of ROS, NADPH oxidases have
been demonstrated to play a fundamental role in the com-
partmentalization of ROS production and redox signaling
[15]. Besides NADPH oxidase, an important role in the
spatio-temporal regulation of ROS production is also played
by enzymes involved in arachidonic acid (AA) metabolism,
such as phospholipase A2 (PLA2), lipooxygenases (LOXs),
and cyclooxygenases (COXs), suggesting that a complex reg-
ulatory network may take place for proper modulation of re-
dox signaling [16].
The NADPH oxidase (NOX) complex was originally
identified in phagocytic leukocytes as an enzymatic defense
system against infections required for the oxidative burst-
dependent microbial killing [17–19]. It is composed of
membrane-associated and cytosolic components, which
assembly to form the active NOX enzymatic complex in
response to appropriate stimuli. Specifically, this complex
consists of membrane-associated cytochrome b558, com-
prising the catalytic gp91phox (also known as NOX2) and
regulatory p22phox subunits, and four cytosolic regulatory
components, including p40phox, p47phox, p67phox, and the
small GTPase Rac1 [17]. The neutrophil expresses two
different Rac isoforms, including the phagocyte-specific
Rac2 and the more ubiquitously expressed Rac1. Detailed
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molecular analysis has revealed that Rac proteins function as
a necessary switch for ROS generation and that the protein
is recruited to the membrane following neutrophil activation
where it can bind to both p67phox and gp91phox [20].
Many evidences suggest that certain aspects of neutrophil
biology appear to be conserved in the ROS signaling of non-
phagocytic cells. In particular, homologues of the NADPH
oxidase were found in vascular endothelial cells and smooth
muscle cells, as well as in other normal or transformed cells
such as colon cancer or melanoma [21]. Several isoforms of
the catalytic NOX2 protein were identified, including NOX1,
NOX3, NOX4, and NOX5, and shown to localize in prox-
imity of specific redox-sensitive molecular targets within dis-
crete subcellular compartments, thereby facilitating the com-
partmentalization of redox signaling [15]. In addition, the
expression of a constitutively activated form of Rac1 was
noted to increase the basal level of hydrogen peroxide in
immortalized fibroblasts [22] as well as in certain trans-
formed cell lines [23], while the expression of a dominant
negative form of Rac1 was shown to inhibit the production
of ROS following addition of various ligands [22]. These data
suggest that a Rac-regulated oxidase exists in a wide range of
cell types and participates in normal signal transduction.
It has been shown that NOX1 constitutively binds the
RacGEF βPIX, and the interaction is caused by growth factor
stimulation [24]. This and previous studies [25] also support
a pathway where ligand addition results in the sequential
activation of phosphatidylinositol 3-kinase (PI3K), which in
turn generates lipid products that can activate GEFs through
the PH (pleckstin homology) domain present within the
exchange factors. Activation of the GEF leads to increased
Rac activity that is presumed to directly stimulate NOX [14].
The hypothesis that ROS generation is regulated by Rac
and the role of ROS as specific effector molecules that act
downstream of Rac is supported by several evidences. In a
recent paper there has been shown a role of Rac-regulated
ROS in the crosstalk between G-protein-coupled receptors
(GPCRs) and the JAK/STAT pathway [26], while different
studies support a role of Rac1 as a crucial, common upstream
mediator of ROS production in integrin-mediated outside-in
signaling [11–13, 16, 27].
Several evidences have implicated ROS in the integration
of signals from VEGF and Rac to regulate the integrity of
the endothelial barrier [22, 28–32]. Further studies demon-
strated that the VEGF-dependent phosphorylation of VE-
cadherin and β-catenin are dependent on Rac and ROS
and result in decreased junctional integrity and enhanced
vascular permeability [33, 34].
In addition to NADPH oxidase, Rac1 has been demon-
strated to act upstream of AA-metabolizing enzymes, such as
PLA2 [35, 36], 5-LOX [13, 26, 27], and COX-2 [37], whereas
many reports show that AA metabolism modulates NADPH
oxidase and mitochondrial ROS production [16].
Another aspect of oxidant signaling derived from the
initial observation that Rac proteins regulate ROS levels is
the demonstration of redox-dependent crosstalk between
different small GTPase family members.
ROS production is apparently an essential component in
signaling cascades that mediate Rac1/p190RhoGAP-induced
downregulation of RhoA and concomitant formation of
membrane ruffles and integrin-mediated cell spreading. The
pathway linking generation of ROS to downregulation of
Rho involves inhibition of the low-molecular-weight pro-
tein tyrosine phosphatase (LMW-PTP) and a consequent
increase in the activation by phosphorylation of the Rho
inhibitor p190Rho-GAP [38]. It has been shown that
ROS production causes p190RhoGAP translocation to the
adherens junctions (AJs), where it binds p120ctn, and sub-
sequently inhibits local Rho activity [39]. It thus plays a role
in the stabilization of cell-cell contacts [34].
These findings suggest that Rac1 downregulates Rho and
stress fiber formation in a redox-dependent manner and
define a mechanism for the coupling of changes in cellular re-
dox state to the control of actin cytoskeleton rearrangements
by Rho GTPases.
In addition to Rac, the production of ROS by nonphago-
cytic cell types stimulated by growth factors or cytokines
includes the participation of p21Ras [22]. Fibroblasts ex-
pressing constitutively active mutants of both Rac and Ras
produce high levels of ROS associated with a high rate of
proliferation. In the same study experimental evidence was
provided suggesting that Rac is positioned downstream to
Ras. Similar overexpression of Ras in other cell types such as
keratinocytes [40] and epithelial cells [41] also demonstrated
an increase in basal ROS levels. The pathway by which Ras
regulates the levels of ROS remains incompletely understood.
It has been shown that in some cells it proceeds through
a PI3K and Rac-dependent pathway [25] leading to the
regulation of a NOX-dependent oxidase. In other cell types
the source of Ras-induced ROS appears to be linked to the
mitochondria [42].
Mitochondria have the highest levels of antioxidants in
the cell and play an important role in the maintenance of
cellular redox status, thereby acting as a ROS and redox sink
and limiting NADPH oxidase activity. However, mitochon-
dria are not only a target for ROS produced by NADPH
oxidase but also a significant source of ROS, which under
certain conditions may stimulate NADPH oxidases. Many
findings indicate the existence of a bidirectional signaling
crosstalk between mitochondria and NADPH oxidase, where
small GTPases can orchestrate a complex web of regulation
for ROS production [43–45].
Indeed, in integrin signaling, the regulation of mitochon-
dria by both Rac and RhoA appears to be related to their
ability to alter intracellular ROS [12].
It has been shown that Nerve Growth Factor- (NGF-)
induced differentiation of PC12 cells is mediated by signif-
icant alteration of mitochondrial metabolism by reducing
mitochondrial-produced ROS and stabilizing the electro-
chemical gradient. This is accomplished by stimulation of
mitochondrial manganese superoxide dismutase (MnSOD)
via Ki-Ras and ERK1/2 [46].
Thus ROS produced by small GTPases could regulate
mitochondrial properties, including the overall metabolic
rate and the generation of mitochondrial oxidants with im-
portant signaling functions within the cell [14].
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3. RasGTPase Regulation by ROS
Although several studies implicate RasGTPases in the pro-
duction and regulation of intracellular ROS, many evidences
indicate that Ras proteins can also be direct targets of ROS.
Similar to the action of GEFs, various redox agents, including
both ROS and RNS, have been shown to stimulate Ras
guanine nucleotide dissociation in vitro and upregulate Ras
function in vivo.
Lander and coworkers showed for the first time that NO
is able to activate Ras by promoting RasGDP dissociation
in vitro, GTP binding to Ras in vivo, and stimulation of
pathways downstream to Ras [47–54]. The target site of
NO-mediated guanine nucleotide dissociation on Ras is
Cys118, which is located in the nucleotide-binding NKCD
motif [49, 50, 54, 55]. Further studies indicated that •NO2,
a reaction product of NO with O2, reacts with the Ras
Cys118 thiol to induce a radical-based process leading to
stimulation of nucleotide exchange on Ras [56, 57]. In
addition to NO, O2
•− showed to be able to facilitate
guanine nucleotide dissociation from Ras as well as the Ras-
related GTPase Rap1A. The molecular mechanism of O2
•−-
mediated guanine nucleotide dissociation is similar to that of
the NO/O2-mediated guanine nucleotide dissociation [58].
The redox-sensitive NKCD motif has been found within the
Ras subfamily of GTPases such as H, N, K, and E-Ras as well
as in Rap1A [7].
Redox-active motifs were afterwards found to be present
in other Ras superfamily GTPases, suggesting that redox reg-
ulation of GTPase signaling is more widespread that previ-
ously envisioned [59].
The GXXXXGK(S/T)C redox-sensitive motif, located in
the phosphoryl-binding loop important for redox-mediated
regulation of guanine nucleotide exchange activity in vitro,
was identified and characterized in the Rho family GTPases.
This motif contains a redox-sensitive cysteine (Cys18, Rac1
numbering) at the C-terminus and it is conserved in almost
half of Rho family GTPases such as Rac1 (and its isoforms
Rac2 and 3), Cdc42, and RhoA (and its isoforms RhoB
and C) [59, 60]. The radical-based molecular mechanism of
Rho GTPase guanine nucleotide exchange appears similar in
nature to the mechanism characterized for Ras GTPases.
An in vivo study aimed to analyze the effect of exogenous
and endogenous ROS on the activation of RhoA in fibroblasts
was performed by Aghajanian and coworkers [61]. This study
showed that RhoA can be directly activated by ROS in cells
by oxidative modification of critical Cys residues within the
redox-active motif, and that ROS-mediated activation of
RhoA can induce cytoskeletal rearrangement, thus support-
ing the existence of a novel mechanism of regulating GTPase
signaling cascades, independent to classical regulation by
GEFs and GAPs, that can affect cytoskeletal dynamics [61].
A number of Rab proteins also have the
GXXXXGK(S/T)C motif (Rab1B, Rab2A/B, Rab4A/B,
Rab14, Rab15, Rab19, and Sec4). Intriguingly, many Rab
GTPases (Rab1A, Rab8A/B, Rab10, and RAb13) possess both
the NKCD and GXXXXGK(S/T)C motifs, whereas some Rab
proteins (Rab3A/B/C/D, Rab 7, Rab22, and Rab38) possess
only the NKCD motif [7].
A CGNKXD redox-sensitive motif was found in Ran pro-
tein [62]; this motif contains a redox-sensitive cysteine,
Cys120, at the N-terminal. In addition to this CGNKXD
motif, Ran possesses an additional redox-sensitive cysteine
Cys85 (Ran numbering). This type of redox center is also
conserved in Dexras1 and Rhe proteins as well as in some
Rab GTPases [62].
Although redox regulation of the members of Rab and
Ran families has been recently discovered, its physiological
relevance and pathological consequences linked to the mis-
regulation of redox signaling associated with these redox
sensitive small GTPases have not yet been explored [7].
4. Pathological Implications of the Interplay
between Small GTPases and ROS
Over the past several years, it has become clear that ROSs
play an important role in physiological processes like cell
differentiation, proliferation, migration, and vasodilatation.
On the other hand, production of ROS “in the wrong place at
the wrong time” results in oxidative stress leading to cellular
dysfunction and apoptosis, which contributes to different
pathologies like atherosclerosis, heart failure, hypertension,
ischemia/reperfusion injury, cancer, aging, and neurodegen-
eration [40].
There is a vast body of literature that links vascular
ROS production to cardiovascular disease [63]. Vascular ROS
production as well as Rac1 activation has been associated
with hypertrophy and smooth muscle cell proliferation,
endothelial dysfunction as well as endothelial cell migration,
hypertension inflammation, and atherosclerosis [64–67].
Vascular hypertrophy has been ascribed to the effects of
various receptor agonists, including Angiotensin II (Ang
II), which induces ROS production in VSMCs in a Rac1-
dependent fashion [68]. Recent studies showed that this
Ang II-induced ROS production also requires the membrane
adapter caveolin, which is involved in Rac1 activation [69,
70], and the lipid kinase PI3K-γ [68, 71].
Ischemia/reperfusion (I/R) injury is also associated with
ROS production. This is a clinically relevant problem oc-
curring as damage to the myocardium following blood res-
toration after a critical period of coronary occlusion. It is
well known that immediately following the reinstitution of
oxygenated blood into ischemic tissue, there is a rapid burst
of ROS, but the molecular basis and source of this process
are not yet convincingly identified [14, 72]. However, both
in vitro and in vivo experiments [73, 74] have suggested that
Rac1 plays a dominant role in ROS generation after I/R, and
it activates the nuclear factor NF-κB and stimulates mRNA
expression of several inflammatory genes, such as TNF-α and
iNOS in the liver, leading to massive hepatocyte necrosis.
Thus, efforts aimed at inhibiting Rac protein function could
be useful therapeutic strategies in a variety of clinical settings
in which there is concern about the potential harmful effects
of I/R injury [73, 74].
Data from the literature suggest that ROS and RhoA
activation are associated to airway smooth muscle contrac-
tility [75–77]; it has been shown that oxidative stress with
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H2O2 leads to airway smooth muscle contraction mediated
by increases in intracellular Ca2+ concentration and the
Rho/Rho kinase pathway [77].
Both ROS and Rho/Rho kinase have been suggested to
play important roles in vasoconstriction and may contribute
to the pathogenesis of hypertension in experimental animals
and humans. Jin and coworkers demonstrated the direct
activation of the Rho/Rho kinase signaling pathway by ROS
in rat aorta, suggesting an important role for ROS-mediated
Rho/Rho kinase activation in vasoconstriction [78].
As previously discussed, Aghajanian and coworkers pro-
posed a novel mechanism for the regulation of RhoA in cells
by ROS that allows predicting that ROS may directly activate
Rho signaling in smooth muscle and in the endothelium thus
affecting vascular permeability. This mechanism of regula-
tion, which is independent of classical regulatory proteins,
may be particularly relevant in pathological conditions where
ROSs are generated and the cellular redox-balance altered,
such as in asthma and I/R injury [62].
It is well known that activated Ras signaling contributes
to oncogenic transformation by providing molecular signals
that promote cell proliferation, obstruct cell death, inhibit
cellular differentiation, and induce angiogenesis [79]. Sig-
naling pathways starting from activated Ras and resulting in
mitochondrial ROS production and downstream signaling
regulation have been the subject of several recent interesting
studies, and different mechanisms have been proposed to
elucidate the role of mitochondrial respiration in cancer.
It has been shown that the activation of K-Ras(G12V)
causes modifications in mitochondrial metabolism finalized
to support growth under hypoxic conditions, and leading
to increased generation of ROS [80]. The major source
of ROS generation required for KRas-induced anchorage-
independent growth is the Qo site of mitochondrial complex
III [81]. Thus mitochondrial dysfunction appears to be an
important mechanism by which K-Ras(G12V) causes met-
abolic changes and ROS stress in cancer cells and promotes
tumor development [80].
Mitochondrial dysfunction and ROS production medi-
ated by activation of Ras, Myc, and p53 produce downstream
signaling (e.g., NFκB, STAT3, etc.) that are crucial in cancer-
related inflammation. Different inflammation-associated
cancers resulting from signaling pathways coordinated at
the mitochondrial level have been identified that may prove
useful for developing innovative strategies for both cancer
prevention and cancer treatment [82].
Several studies suggest that autophagy may be important
in the regulation of cancer development and progression and
in determining the response of tumor cells to anticancer
therapy [83]. A recent paper shows that autophagy is
associated with the malignant transformation of mammalian
cells induced by K-Ras and that ROSs are involved as sig-
naling molecules in K-Ras(G12V)-induced autophagy. The
increase in intracellular ROS produced in response to on-
cogenic K-Ras involves p38 MAPK signaling and leads to
JNK activation. JNK acts downstream of ROS and plays a
causal role in autophagy induction through upregulation of
autophagy-specific genes 5 and 7 (ATG5 and ATG7) [84].
As mitochondria sustain viability of Ras-expressing cells in
starvation, autophagy is required to maintain the pool of
functional mitochondria necessary to support growth of Ras-
driven tumors [85]. These findings provide new insights
into the relationship between autophagy and oncogenesis
and suggest that targeting autophagy and mitochondrial
metabolism are valuable new approaches to treat cancers
with Ras mutations.
Oncogenic activation of the H-Ras gene has been found
in more than 35% of patients with urothelial carcinomas
[86]. It has been recently shown that in addition to tu-
morigenic ability, oncogenic H-Ras possesses a novel proap-
optotic activity to facilitate the induction of apoptosis by
histone deacetilase inhibitors (HDACIs), a new class of an-
ticancer agents characterized by high cytotoxicity toward
transformed cells [87]. Expression of oncogenic H-Ras in
human bladder tumor J82 cells and treatment of cells with
the HDACI, FK228, sinergistically induce the ERK pathway,
resulting in differentially increased NOX-1 elevation and
ROS production, leading to differential activation of caspases
and cell death [88–90]. Thus, in addition to its well-known
role in mediating mitogenic signals for cell proliferation
and transformation, the ERK pathway plays an essential
role in mediating apoptotic signals induced by HDACIs
through induction of NOX-1 elevation to ROS production
and caspase activation for inducing cell death. In addition,
expression of oncogenic H-Ras in J82 cells also results in an
increased susceptibility to exogenous H2O2 for inducing cas-
pase activation and apoptosis [88]. Further studies revealed
that FK228 combined with exogenous H2O2 cooperatively
induces activation of MEK1/2 and ERK1/2 to increase NOX-
1 elevation, intracellular ROS production, caspase activa-
tion, and cell death. Expression of oncogenic H-Ras sig-
nificantly increases these FK288- and exogenous H2O2-
induced effects. Oncogenic H-Ras-increased susceptibility to
FK228 could be alternatively achieved by additional treat-
ment with exogenous H2O2. These findings have important
and useful implications as combined use of HDACIs with
ROS-generating agents may apply to therapeutic strategies to
preferentially kill malignant cells with or without oncogenic
H-Ras activation [91].
Due to the crucial role played by Ras in many cellular
signaling cascades, diseases relevant to dysregulation of redox
signaling often result in deregulation of Ras-dependent cel-
lular signaling events. Since the first identification of the
redox-sensitive NKCD motif of Ras [51], considerable patho-
physiological data are available, including some bearing
directly on the relevance of redox-mediated misregulation of
the Ras NKCD motif to certain diseases [7]. Rap1A, another
reprehensive protein that possesses the NKCD-motif, is a reg-
ulator of NAD(P)H oxidase. However, a pathophysiological
outcome associated with the misregulation of Rap1A redox
signaling has not been clearly investigated [7].
Cancer is one of the most prevalent disorders caused by
misregulation of Ras activity by a redox agent. Numerous
studies show that cancers, to a large extent, are induced
by misregulation of Ras redox signaling combined with an
alteration of Ras downstream cellular transduction cascades.
As with cancers, many cardiovascular and neuronal disorders
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appear to be the result of dysregulation of various cellular
signaling events via the redox-sensitive Ras (for a deeper
investigation see [7]).
The misregulation of the redox signaling of Ras with
its downstream cascades also has been linked to various
disorders linked with immune and embryo developments.
The Ras-dependent activation of Raf also leads to stimulation
of a phosphorylation of Ets-like protein-1 and tumor necro-
sis factor-α messenger RNA induction; both actions suggest
that NO, through the Ras-dependent Raf-MEK1/2-ERK1/2
pathway, modulates a host’s defenses and the inflammation
of T lymphocytes [92]. ROS-mediated signaling via Ras, NF-
κB, and related transducers may link to embryopathies [93].
5. Concluding Remarks
Although, for many years, the generation of intracellular
redox agents was viewed solely as the unregulated by-product
of aerobic metabolism and other enzymatic processes, over
the last years a growing number of reports have suggested
that the production of intracellular ROS is tightly regulated
and that these redox agents serve as intracellular signaling
molecules being involved in a variety of cell signaling path-
ways. Here we have reviewed studies reporting that mem-
bers of the RasGTPase superfamily are able to regulate in-
tracellular ROS production, and that the production of
ROS by small GTPases is an important aspect of the
function of these monomeric G-proteins. In addition, the
functional cross-talk between some different RasGTPase
family members (see Rac1 and RhoA) appears strictly related
to redox signaling. Finally, due to the presence of conserved
redox-sensitive sequences, many of the Ras superfamily small
GTPases have been shown to be targets of ROS regulation.
Thus, redox agents, as upstream regulators and/or down-
stream effectors of redox-sensitive RasGTPases, strongly con-
tribute to their overall biological function playing a key role
in various cellular signaling events. Dysregulation of small
GTPases by redox agents or dysregulation of redox signaling
by small GTPases may significantly alter cellular signaling
pathways and lead to the pathological state.
Given the prominent role the RasGTPase family mem-
bers play in regulating fundamental cell processes like
growth, migration, adhesion, cytoskeletal integrity, survival,
and differentiation, the comprehension of molecular mech-
anisms of the interplay between small GTPases and ROS
may strongly help to clarify how redox agents contribute to
physiological and pathological cellular events and provide
novel strategies for treatment of many pathological condi-
tions where both RasGTPases and oxidative stress play a role.
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Reactive oxygen species (ROS) are highly reactive molecules, mainly generated inside mitochondria that can oxidize DNA, proteins,
and lipids. At physiological levels, ROS function as “redox messengers” in intracellular signalling and regulation, whereas excess
ROS induce cell death by promoting the intrinsic apoptotic pathway. Recent work has pointed to a further role of ROS in activation
of autophagy and their importance in the regulation of aging. This review will focus on mitochondria as producers and targets
of ROS and will summarize different proteins that modulate the redox state of the cell. Moreover, the involvement of ROS and
mitochondria in different molecular pathways controlling lifespan will be reported, pointing out the role of ROS as a “balance of
power,” directing the cell towards life or death.
1. Introduction
From the first observation of the real mitochondrial structure
in 1950 [1], it was clear that this particular composition
reflected the different functions of this organelle. Mito-
chondria are delimitated by double-membrane architecture,
an outer membrane of eukaryotic origin and an inner
membrane characterized by the absence of cholesterol and
the presence of cardiolipin, typical elements of bacterial
membranes. The inner membrane is organized in character-
istic folds, termed cristae, which protrude into the matrix
and accommodate the respiratory chain complexes. In
healthy cells, the inner membrane is impermeable to ions
[2], which allows the electrons transport chain (ETC) to
actively build up the proton gradient. The mitochondrial
membrane potential (ΔΨm) results from the difference in
electrical potential generated by the electrochemical gradient
across the inner membrane. Through oxidative phospho-
rylation, mitochondria play their essential role to supply
the cell with metabolic energy in the form of ATP. As a
consequence, they are also the primary source of cellular
reactive oxygen species (ROS), especially at level of the
respiratory chain complexes I and III, where electrons
derived from NADH and ubiquinone can directly react with
oxygen or other electron acceptors and generate free radicals
[3, 4]. Therefore, ROS are a normal side product of the
respiration process, and they react with lipids, protein, and
DNA, generating oxidative damage. Indeed, mitochondria
are the major site of ROS production, but also the major
targets of their detrimental effects, representing the trigger
for several mitochondrial dysfunctions. In this review, we
will focus on this deadly liaison, with particular attention on
ROS production, mitochondrial ROS targets, and their role
in apoptosis, autophagy, and aging.
2. Mitochondrial ROS Production
Mitochondria are responsible for 90% of the energy that
cells, and thus tissues, organs, and the body as a whole need
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Figure 1: Mitochondrial sources of ROS and mitochondrial ROS targets. ROS generators (red) and ROS targets (yellow) are shown in
their precise localizations inside mitochondria. Dotted yellow trace encloses the permeability transition pore components. See text, in
particular sections 2 and 3, for further details. Abbreviations: OMM: outer mitochondrial membrane; IMS: intermembrane space; IMM:
inner mitochondrial membrane; MAO A/B: monoamine oxidases A and B; Cyt. b5 reduct.: cytochrome b5 reductase; DHOH: dihydroorotate
dehydrogenase; mGPDH: glycerol-3-phosphate dehydrogenase; I, II, III, and IV: Complex I to IV of the respiratory chain; Q: coenzyme Q;
Cyt. c: cytochrome c; KGDHC: α-ketoglutarate dehydrogenase complex; PGDH: pyruvate dehydrogenase complex; e−: electrons; VDAC,
voltage-dependent anion channel, Cycl. D: cyclophilin D; ANT: adenine nucleotide translocase; Pol. Γ: polymerase γ; mtDNA: mitochondrial
DNA.
to function. Hence, they are known as the “cells power-
house,” the core of cellular energy metabolism, being the
site of most ATP generation through mitochondrial oxidative
phosphorylation (OXPHOS) [5].
In this process, electrons liberated from reducing sub-
strates are delivered to O2 establishing an electrochemical
gradient used to drive ATP synthesis. During the OXPHOS,
the reduction of oxygen by one electron at a time (O2 →
O2−• → H2O2 → •OH → H2O) produces ROS, relatively
stable intermediates with one unpaired electron [6–8].
Although Brown and Borutaite in their recent review have
presented a number of examples supporting the point of
view that mitochondria are not a major source of ROS in
the cell [9], the fact that oxidative phosphorylation accounts
for 90% to 95% of cellular oxygen consumption and that
3% from that pool can be converted to superoxide is a
very strong argument in favour of mitochondria as a main
source of this oxygen radical. Hence, it is a firm paradigm
that mitochondria are also the major source of ROS in
mammalian cells (Figure 1).
The primary ROS generated by mitochondria, as a result
of monoelectronic reduction of O2, is superoxide anion
(O2−•) that is the precursor of most ROS and a mediator
in oxidative chain reactions. In vivo, O2−• is produced
both enzymatically by NADPH oxidase, cytochrome P450-
dependent oxygenases, and xanthine oxidase and non-
enzymatically, when a single electron is directly transferred
to O2 [8]. In addition, O2−• may react with other radicals
including nitric oxide (NO•) producing reactive nitrogen
species (RNS) [10]. Dismutation of O2−•, either sponta-
neously [11], or through a reaction catalyzed by superox-
ide dismutases (SODs) [12], produces hydrogen peroxide
(H2O2) [13]. H2O2 generated in mitochondria has many
possible fates. Because H2O2 is relatively stable and mem-
brane permeable, it can diffuse within the cell and be
eliminated by cytosolic or mitochondrial antioxidant systems
Journal of Signal Transduction 3
such as catalase, glutathione peroxidase, and thioredoxin
peroxidase [14]. Mitochondrially generated H2O2 can also
act as a signaling molecule in the cytosol, affecting multiple
networks that control, for example, cell cycle, stress response,
energy metabolism, and redox balance [15–17].
When not metabolized, H2O2 can be further transformed
to hydroxyl radical (•OH), in the presence of metal ions, by
Fenton reaction [18]. •OH is one of the strongest oxidants
in nature, is highly reactive, and generally acts essentially
as a damaging molecule. For this reason, mitochondria are
believed to have developed efficient H2O2 removal systems,
as well as metal-chelating mechanisms, such as chaperone
proteins, preventing the formation of this radical.
At least, ten mammalian mitochondrial enzymes con-
tribute to ROS production [17, 19] even if their capacity
of ROS producing greatly differ in a tissues-specific manner
[20]. In vitro experiments demonstrate that mitochondria
isolated from mouse heart, brain, and kidney have selective
substrate and inhibitor preferences for H2O2 generation and
that the apparent sites of H2O2 generation are both substrate
and organ specific [21].
The major bulk of mitochondrial ROS generation occurs
at the electron transport chain, as a byproduct of respiration
[7, 8, 22]. Cytochrome c, oxidase (Complex IV) is the
terminal component of the ETC, receives four electrons from
cytochrome c and reduces one O2 molecule to two H2O. It
retains all partially reduced intermediates until full reduction
is achieved and does not seem to release these intermediates
in measurable quantities [6].
Historically, the first mitochondrial site producing ROS
was identified at the Complex III located at the inner side of
inner mitochondrial membrane (bc1 complex, ubiquinone:
cytochrome c reductase). The primary ROS produced at this
site is O2−•, through the referred Q-cycle [23]. Despite the
recent advances in understanding the structure of the bc1
complex, a mechanism of O2−• production is not yet known
[24–26].
Succinate dehydrogenase (Complex II, SDH) is a flavo-
protein located at the inner surface of inner mitochondrial
membrane. Although oxidation of succinate can theoretically
produce ROS with a high rate, significant O2−• formation
from this enzyme has not been measured so it is still
unclear whether SDH produces ROS in situ, in mitochondria.
Despite the lack of ROS formation by Complex II itself, suc-
cinate is an important source of ROS in many tissues through
a mechanism involving reverse electron transfer. This par-
ticular phenomenon may result from high mitochondrial
membrane potential, which thermodynamically favourites
electron donor from Complex II to I. Because of this, suc-
cinate may promote ROS generation at Complex I level [6, 7].
Mitochondrial Complex I, “NADH dehydrogenase,” in
the inner face of inner membrane provides a major entry
point for electrons into respiratory chain. It is a significant
source of ROS [27] in particular O2−• [28] and H2O2
although whether or not Complex I is the major site of ROS
production in intact mitochondria in vivo is a complicated
issue. Indeed all the evidence on ROS production by
Complex I was obtained in vitro with isolated mitochondria
[29].
There are other mitochondrial nonrespiratory chain
enzymes that produce ROS although pinpointing their
specific contribution to total mitochondrial ROS production
remains unclear.
Mitochondrial cytochrome b5 reductase is located in the
outer mitochondrial membrane [30]. The enzyme is widely
distributed in mammalian tissues and may be involved in
O2−• generation with a very high rate ∼300 nmoL per min
per mg protein [31].
Monoamine oxidases (MAO-A and MAO-B) are also
located in the outer mitochondrial membrane and ubiq-
uitously expressed in various mammalian tissues. These
enzymes catalyze the oxidation of biogenic amines accom-
panied by the release of H2O2 [32].
Dihydroorotate dehydrogenase (DHOH) is located at the
outer surface of inner mitochondrial membrane. It catalyzes
the conversion of dihydroorotate to the pyrimidine base,
orotate, which is a step in the de novo synthesis of uridine
monophosphate. The DHOH is ubiquitously distributed in
mammalian tissues, and it is considered a mitochondrial
source of O2−• and H2O2 although the capacity of DHOH to
produce O2−• requires further clarification [33].
Mitochondrial dehydrogenase of α-glycerophosphate
(Glycerol-3-Phosphate Dehydrogenase, mGPDH) is located
at the outer surface of inner mitochondrial membrane. The
mGPDH is involved in lipid metabolism and in the so-called
glycerol phosphate shuttle capable of regenerating cytosolic
NAD+ from the NADH formed in glycolysis. It is ubiq-
uitously but unequally expressed in various mouse tissues
and mediate the production of H2O2 [34, 35].
Mitochondrial aconitase is an enzyme localized to the
matrix space of mitochondria; it participates in tricarboxylic
acid cycle catalyzing a conversion of citrate to isocitrate. The
enzyme contains an iron-sulfur cluster that can be oxidized
by O2−• or H2O2 producing •OH [36].
Ketoglutarate dehydrogenase complex (KGDHC, 2-
oxoglutarate dehydrogenase) is an integral mitochondrial
enzyme tightly bound to the inner mitochondrial membrane
on the matrix side [37]. It catalyzes the oxidation of α-
ketoglutarate to succinyl-CoA in the tricarboxylic acid cycle.
Structurally, KGDHC is composed of three enzymes: α-
ketoglutarate dehydrogenase (E1 subunit), dihydrolipoam-
ide succinyltransferase (E2 subunit), and lipoamide dehydro-
genase (E3 subunit). The E3 component appears to be the
principal ROS source generating O2−• and H2O2 [38, 39].
Pyruvate dehydrogenase complex (PGDH) localized into
mitochondrial matrix contains flavoenzyme dihydrolipoyl
dehydrogenase subunits like KGDHC, which are very impor-
tant ROS sources [38].
3. Mitochondrial Targets of ROS
A wide range of mitochondrial ROS-induced damages
has been described, including protein carbonylation, lipid
peroxidation, or mtDNA damage. These damages, either
individually or collectively can lead to a cellular energetic
catastrophe. In this section, we are going to treat the most
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important mitochondrial targets of ROS action, also sum-
marized, with their mitochondrial localization, in Figure 1.
3.1. Oxidative Damage of mtDNA. The sequence and orga-
nization of the human mitochondrial genome has been
presented for the first time by Anderson et al. in the landmark
paper in 1981 [40]. Mitochondrial DNA (mtDNA) was iden-
tified as a 16.5 kb circular molecule encoding 13 polypep-
tides, 22 tRNAs, and 2 rRNAs. All of the above mentioned
are components of mitochondrial respiratory machinery.
MtDNA is attached to the IMM on the matrix side, rendering
it particularly prone to oxidative damage, as the aforesaid
localization is in immediate proximity to the cells’ major
source of ROS, that is to the mitochondrial respiratory
chain. ROS accumulating within the matrix are in such a
case explicitly deleterious. Additionally, the lack of introns,
histones, and other DNA-protecting proteins as well as DNA
repair systems inferior to those observed in nDNA allows
increased deterioration [41, 42]. However, mitochondria
possess a number of DNA repair enzymes such as MYH (2-
OH-A/adenine DNA glycosylase) and OGG1 (8-oxoG DNA
glycosylase) [43]. In nucleic acids, both the bases as well as
the sugar are prone to ROS attacks. This may lead to modifi-
cations of base and abasic sites and result in strand breaks
[44]. A good example that may be the addition of the
hydroxyl radical to the double bonds may occur. In this case
the reaction rate-limiting factor is diffusion of approximately
4.5 × 109 to 9 × 109 M−1 s−1 [45]. The main outcome of
the above-mentioned attacks is the hydroxylation of pyrim-
idines at C5 and C6 as well as purines at C4, C5, and C8.
So far over 80 different oxidized bases in DNA exposed to
oxidant factors, such as H2O2 and singlet oxygen, have been
identified [45, 46]. Experiments from the mid 1980s led
to the establishment of a dependable marker of these
alterations—8-hydroxy-deoxyguanosine (8-OHDG) [47–
51]. An increase in 8-OHDG is a sign of mtDNA fragmenta-
tion and is observed in events involving oxidative stress [52].
Alterations in the mitochondrial genome are reflected
in a number of disorders, most of which involve impaired
respiration and oxidative phosphorylation. As a matter of
fact, over 150 pathogenic mutations have been identified in
the mtDNA, which cause human diseases [53]. The scope of
these disorders has been positively correlated with increasing
age and tissues with high-energy demands [54–58]. Individ-
uals may develop a number of symptoms including ataxia,
dystonia, epilepsy, dementia, peripheral neuropathy, optic
atrophy, and deafness [59]. A number of authors report
associations between mtDNA point mutations and neurode-
generative diseases [60–63]. However, some of the mutations
are yet to be confirmed and therefore are under dispute.
On the other hand, in some cases, such as Parkinson’s
disease (PD), there seems to be a consistent PD-associated
haplogroup [64–66]. Brains of aged individuals as well
as those with neurodegenerative diseases exhibit increased
levels of mutated mtDNA, particularly in substantia nigra
neurons, as compared to hippocampal neurons [67]. It is
not clear, whether these mutations are an effect of oxidative
stress. Nevertheless, such explanation seems reasonable.
3.2. Oxidative Damage of Mitochondrial Proteins. Oxidative
modification of proteins (oxidation of arginine, lysine,
threonine, and proline residues) induces the formation
of protein carbonyls, commonly detected under oxidative
conditions, in aged cells and in aged animal tissues. On
the other hand, peroxynitrite oxidizes tryptophan, cysteine,
and tyrosine protein residues as well as unsaturated fatty
acids and low molecular mass components of the antioxidant
defense system like glutathione, α-tocopherol, and ascorbate.
Additionally, oxidative damage can affect carbohydrates,
which, when oxidized, may be used in glycation process
causing the formation of glycation end products. It has
been repeatedly shown that the accumulation rate of such
oxidatively modified proteins (under oxidative stress or in
aging) is tissue specific and depends on protein type [68].
3.2.1. Mitochondrial Respiratory Chain. The mitochondrial
respiratory chain, due to its natural imperfections, can be
considered a peculiar superoxide generator. In such a case,
complexes of the respiratory chain are in the firsthand
exposition to oxidative modification because they are present
at the sites of ROS production. The high sensitivity of the res-
piratory chain complexes to oxidizing agents results from the
fact that they contain iron-sulfur clusters (Complexes I, II,
and III), heme groups (Complexes II, III, and IV) and copper
centers in complex IV, all of which can be a site of direct
ROS attack, and their oxidative modifications can manifest
with a decrease of their enzymatic activity and dysfunction
of the whole respiratory chain [69–71]. Interestingly, three
mechanisms have been reported in the NO• inhibition of
Complex I: S-nitrosation, tyrosine nitration and damage to
FeS centres [72]. The inhibition of mitochondrial Complex
I activity is consistently detected in Parkinson’s disease pa-
tients as well as in mitochondrial toxin models of the disorder
[73].
Cytochrome c (a component of OXPHOS) can be mod-
ified by nitration of its tyrosine residues, which also affects
electron flow through the respiratory chain [74]. Nitration
of a single tyrosine residue in cytochrome c by a relatively
low dose of peroxynitrite resulted in the upregulation of its
peroxidase activity for H2O2 and in the impairment of the
membrane potential formation [75]. Oxidative damage of
individual respiratory chain complexes results not only in a
decreased efficiency of ATP production but can also increase
ROS production by oxidatively affected OXPHOS subunits,
contributing in this way to the intensification of oxidative
stress.
3.2.2. Mitochondrial Carriers. The effect of oxidative stress
(i.e., caused by site-specific metal-catalyzed oxidation) on
mitochondrial carriers was studied intensively in a model
exploiting components of the mitochondrial permeability
pore: the adenine nucleotide translocase (ANT), porin
(VDAC), and creatine kinase. ANT contains many pro-
line, arginine, and lysine residues, which are very sensible
for such type oxidation (systems: vanadyl/H2O2-generating
hydroxyl free radicals or Cu2+/tert-butyl hydroperoxide).
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Moreover, ANT is localized in the IMM in cardiolipin-
rich (containing unsaturated fatty acids) domains. This can
explain its sensibility to oxidation also by lipid peroxidation
products. In 1998, interesting studies of Sohal’s group
revealed that ANT in mitochondria of flight muscles is sig-
nificantly carbonylated in senescent flies. Surprisingly, ANT
was the only mitochondrial protein demonstrating age-
related increase of carbonylation in this experimental model.
In vitro experiments basing on the exposure of isolated mito-
chondria to the hydroxyl free radicals showed an increased
level of carbonylated ANT exhibiting lower nucleotide
exchange activity [76].
In addition to controlling the release of superoxide from
mitochondria [77], VDAC, which accounts for about 10% of
outer mitochondrial membrane (OMM) proteins, can also
be a target for intracellular O2−•. Madesh and Hajnoczky
observed that VDAC-dependent permeabilization of the
OMM and cytochrome c release can be caused by superoxide
but not by H2O2. Moreover, the observed effect of superoxide
does not require the contribution of the proapoptotic
proteins like Bak or Bax [78]. On the other hand, another
component of the mitochondrial permeability transition
pore (mPTP), mitochondrial creatine kinase, present in the
intermembrane space (IMS) is affected by H2O2 and perox-
ynitrite. The drop in the creatine kinase activity is caused
by oxidative modifications of its sulfhydryl groups and
aromatic aminoacids [79, 80].
3.2.3. Permeability Transition Pore as a Ros Target. Based on
the literature, permeability transition pore (mPTP) seems to
be a multiprotein complex with variable composition. The
main core of mPTP consists of the voltage-dependent anion
channel (VDAC), ANT, and cyclophilin D localized in the
outer-, inner mitochondrial membrane, and mitochondrial
matrix, respectively [81–83]. Still there is no consensus
concerning exact composition of mPTP. Recent studies with
the use of transgenic VDAC1 or ANT1 knockout mice seem
to contradict the stereotype model of PTP. To find more
about the presence of VDAC, ANT, or cyclophilin D in
the mPTP, refer to [84–86]. The other components, such
as hexokinase, benzodiazepine receptor, and creatine kinase
seem to play a regulatory role rather than being structural
components of the mPTP. However, regardless of the
composition of mPTP, it has been repeatedly described
already in 90ties that oxidation of critical thiol residues of
ANT induces opening of the mPTP and collapse of mito-
chondrial membrane potential, mitochondrial swelling, and
cytochrome c release. When the thiol groups of ANT are in
reduced state, probability of mPTP opening is much lower
than when they are oxidised and cross-linkage of ANT thiol
groups can occur. Especially oxidation of the Cys160 and
Cys257 of ANT promotes PTP opening [87]. Moreover, Cys56
oxidation alters the conformation of ANT inducing it to
become a nonspecific pore, thus mimicking the effect of Ca2+
which converts ANT into a large channel [88]. Sensitivity of
ANT to the oxidizing agents makes mPTP one of the direct
sites of ROS action in mitochondria.
3.2.4. Aconitase. In Section 2, we have argued m-aconitase as
a source of ROS, but, at the same time, it can be considered
a well-established example of oxidative damage targeting a
mitochondrial enzyme. In fact, its susceptibility to oxidative
damage mainly from superoxide is related to the iron-sulfur
cluster present in the active site of the enzyme [89].
3.2.5. Polymerase γ. Nearly 10 years ago, the studies of
Copeland’s group confirmed that polymerase γ present in
the mitochondrial matrix responsible for mtDNA replication
can also be considered as an intrinsic target for ROS. The
group found that the catalytic subunit of polymerase γ is
one of the proteins most abundantly oxidized in the mito-
chondrial matrix and correlated oxidative modification of
polymerase γ with the drop of its enzymatic activity. This
in turn can result in the reduction of mtDNA repair and
replication [90].
3.3. Peroxidation of Mitochondrial Lipids. In mitochondrial
membranes, unsaturated fatty acids, being components of
phospholipids, are very susceptible to oxidation by the
hydroxyl radical. Lipid peroxidation products, lipid hydrop-
eroxides, generate very reactive unsaturated aldehydes like
4-hydroxy 2-nonenal (4-HNE), malondialdehyde (MDA),
and acrolein. Moreover, the generation of lipid radicals can
induce a chain reaction leading to the generation of new
radicals which intensifies lipid peroxidation. Lipid peroxides
cause various effects in the cell. It has been reported that
oxidatively modified lipids affect membrane fluidity; this is
the case of lipid peroxidation at inner mitochondrial mem-
brane level, leading to increased permeability to protons and
uncoupling of oxidative phosphorylation [91]. Moreover,
lipid radicals diffuse easily in the membranes and can
covalently modify membrane proteins [92], as well as cause
“lipoxidative” damage to the mtDNA. For example, 4-HNE
inhibits ANT activity in isolated mitochondria due to the
modification of critical sulfhydryl groups in ANT [93]. It has
also been suggested that the protein carbonylation process
is more often related to the lipid-protein oxidation than the
direct protein oxidation by reactive oxygen species [94, 95].
4. Mitochondrial ROS Measurements
Direct imaging of ROS in biological samples has proven to
be extremely challenging. A large amount of methods for
ROS monitoring has been developed in the last years, includ-
ing fluorimetric, spectrophotometric, and chemiluminescent
assays [96].
Among different fluorescent assays, MitoSOX is largely
used to visualize superoxide ions inside mitochondria [97].
This reagent is a cell permeant dye that once in mito-
chondria is oxidized by superoxide and trapped inside
organelle, becoming weakly fluorescent. Subsequent binding
with nucleic acid permit to the dye to show high fluores-
cence, with excitation at 510 nm and emission at 580 nm.
It can be considered a superoxide-specific probe, because
its reactivity for hydrogen peroxide or reactive nitrogen
6 Journal of Signal Transduction
species is relatively low. However, several caveats exist
in using MitoSOX probe [98, 99]; one of the mostly frequent
is, without doubts, the photochemical oxidation of the dye,
an aspect which has to be taken into consideration for proper
interpretation of results.
One of the widespread methods to detect H2O2 produc-
tion by mitochondria is based on 2′,7′ dichlorofluorescein
(DCF-H2) oxidation. This dye is commercialized as a diac-
etate chemical probe, in order to be cell permeant, and, once
deacetylated from cellular diesterases, it becomes imperme-
able and weakly fluorescent. DCF-H2, when oxidized by
H2O2, is converted into 2′,7′-dichlorofluorescein (DCF),
a high fluorescent component (λex 500 nm −λem 520 nm)
[100]. DCF formation is directly proportional to H2O2
production; therefore, for data analysis is preferable to
calculate variation in fluorophore accumulation speed. One
of the most relevant limitations of DCF is that it cannot
be used to measure H2O2 production exclusively inside
mitochondria. Mitochondria peroxy yellow 1 (MitoPY1), a
new type of fluorophore for imaging mitochondrial H2O2
in living cells with ROS and spatial specificity [101], may
represent the answer to this problem, but further studies have
to be performed to clarify its real efficacy.
Recently, a new highly specific fluorescent probe has
been introduced in methods for ROS measurements. HyPer
(distribuited by Evrogen) is a genetically encoded fluores-
cent sensor specific for H2O2 and consists in a circularly
permuted yellow fluorescent protein (cpYFP), inserted into
the regulatory domain of OxyR, a hydrogen peroxide-
sensitive transcription factor isolated from E. coli. HyPer is a
ratiometric indicator; the excitation wavelength in normal
condition is 420 nm, and, in the presence of H2O2, a red-
shift moving excitation to 500 nm occurs. Emission spectrum
has a maximum at 516 nm, independently from oxidants
activity. The most palatable feature is the possibility to
direct HyPer to mitochondrial matrix using COX-targeting
sequence, permitting directing fast measurements of mito-
chondrial ROS production [102]. HyPer is not the first
ratiometric probe used for ROS assessment. In 2004,
Tsien and coworkers developed ratiometric redox-sensitive
versions of GFP, termed redox-sensitive green fluorescent
proteins (roGFPs) [103, 104]. When a population of roGFP
is oxidized, excitation increases at the 400 nm peak while
diminishing at the 480 nm peak; the emission is measured
at 510 nm. Because the indicator is genetically encoded, it
can be targeted to specific proteins or organelles of interest
and expressed in a wide variety of cells and organisms (for
an exhaustive discussion of the biophysical properties and
development of these probes, see [105]).
Fluorescent dyes show the high advantage to be easy to
use, fast, and weakly invasive, leading to a quite accurate
calibration using peroxide (or nitric oxide) donors. However,
they are fast degradable and easily produce artefacts; in fact,
as cited above, high light intensity could induce the activa-
tion of the dye, with consequent artefactual ROS generation,
resulting in nonspecific signal amplification.
5. Deadly Liaisons: ROS and Mitochondria in
the Control of Cell Death
As mentioned in the introduction, mitochondria are often
targets of high ROS exposure with deleterious consequences,
such as oxidative damage to mitochondrial DNA. This is
certainly true, but recent evidence has suggested a deep in-
volvement of ROS also in the extrinsic pathway of apoptosis.
The extrinsic receptor-mediated death pathway requires
effective engagement between the death receptors found on
the surface of the cell membranes and their respective ligands
[106]. The receptor-mediated pathway involves death recep-
tors from the tumor necrosis factor (TNF) superfamily such
as TNF, CD95 (Fas), and TNF-related apoptosis-inducing
ligand (TRAIL) receptors. Fas and TNFR1 activation is
known to generate ROS in response to stimulation, which has
been hypothesized to be due to the production of superoxide
(O2•−) because of the formation of lipid raft-derived
NADPH oxidase platforms. This lipid raft-associated ROS
downstream generation may be of high importance in
induction of apoptosis or necrosis [107, 108]. Moreover, ROS
are required for apoptosis induction by Fas ligand (FasL) in
primary lung epithelial cells. ROS mediate the downregula-
tion of FLIP (FLICE inhibitory protein, a strong inhibitor
of apoptosis) by ubiquitination and subsequent degradation
by proteasome or through nitric oxide (NO) scavenging that
prevents FLIP S-nitrosation and cytoprotection [109].
Other evidences underline how ROS generation may
influence the intracellular milieu, favouring the effective exe-
cution of the downstream events leading to extrinsic apopto-
sis. ROS has been shown to sensitize cancer cells to TRAIL-
induced apoptosis [110], and massive upregulation of CD95
and TRAIL death receptors have also been observed in
response to hydrogen peroxide, through a mechanism
involving the activation of NF-kappaB [111]. Interestingly,
the ability of H2O2 to promote apoptosis, through the activa-
tion of JNK, seems inhibited in lung fibroblasts from TNFR1-
deficient mice [112]. ROS activation of JNK can induce
extrinsic or intrinsic apoptotic signaling. TNFα is a potent
activator of the MAPK cascade, and TNFα-induced ROS
cause oxidation and inhibition of JNK-inactivating phos-
phatases, by converting their catalytic cysteine to sulfenic
acid, with a consequent prolonged JNK activation, which is
required for cytochrome c release and caspase 3 cleavage, as
well as necrotic cell death [113].
Upstream of JNK is the redox-sensitive MAPK kinase
kinase, ASK1. Under non-oxidizing conditions, reduced
thioredoxin1 (Trx1) binds ASK1; the resultant Trx1/ASK1
complex, called “ASK1 signalosome,” functions as a perfect
redox switch. Robust and sustained cellular ROS induce
the dissociation of oxidized Trx1 from the complex and let
to complete the activation of ASK1, also through the
recruitment of TRAF2/6 [114]. Moreover, ASK2, another
member of the ASK family, binds and stabilizes ASK1 not
only in the cytosol, but also in nucleus and mitochondria.
Recently, Saxena et al. have shown how the thioredoxin-
interacting protein TXNIP, a ubiquitously expressed redox
protein that promotes apoptosis, could shuttle from nucleus
to mitochondria under oxidative stress, forming a complex
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with mitochondrial Trx2 and removing it from ASK1. This
alleviation of Trx2-mediated inhibition results in phospho-
rylation of ASK1 and consequent induction of the mito-
chondrial pathway of apoptosis, with cytochrome c release
and caspase-3 cleavage [115].
The major ROS target inside mitochondria is undoubt-
edly the permeability transition pore (see Section 3). Oxida-
tive modifications of mPTP proteins will significantly impact
mitochondrial anion fluxes [116]. In response to proapop-
totic stimuli, including ROS and Ca2+ overload, the mPTP
assumes a high-conductance state that allows the deregulated
entry of small solutes into the mitochondrial matrix along
their electrochemical gradient. This phenomenon, which
is known as mitochondrial permeability transition (MPT),
results in immediate dissipation of the mitochondrial mem-
brane potential and osmotic swelling of the mitochondrial
matrix [2]. Mitochondrial swelling is defined as an “increase
in the volume of mitochondria due to an influx of fluid.”
The mechanism concerns an early phase of mitochondrial
swelling, which involves movement of water from the inter-
cristal spaces into the matrix; when this water movement
continues, the pressure applied to the outer membrane from
the increased matrix volume leads to the opening of mPTP
and/or rupture of the mitochondrial outer membrane, allow-
ing further matrix expansion [117]. This leads to the release
of cytochrome c and the subsequent engagement of the
Apaf-1-pro-caspase 9 apoptosome complex, which activates
downstream effector caspases. Cytochrome c is present as
loosely and tightly bound pools attached to the inner mem-
brane by its association with cardiolipin; this interaction
must first be disrupted to generate a soluble pool of this
protein. In 2002, the group of Orrenius elegantly showed
how oxidative modification of mitochondrial lipids, specif-
ically cardiolipin, is fundamental for tightly bound pool of
cytochrome c mobilization, that is so detached because of
disturbances in membrane structure [118]. The cardiolipin-
bound cytochrome c assumes the role of a membrane-bound
peroxidase that can effectively catalyze oxidative stress and
cause oxidation of cardiolipin if a source of oxidizing
equivalents, such as H2O2, is activated. This can lead to
a putative “oxidative wave propagation:” membrane-bound
cytochrome c may be seen as a mitochondrial death receptor
transducing proapoptotic signals into executing oxidative
cascades, with a consequent overload of oxidized cardiolipin
species, detachment of cytochrome c from the membrane
and formation of mPTP (reviewed in [119]). In this regard,
it has been recently shown that overexpression of human
telomerase reverse transcriptase (hTERT), the catalytic sub-
unit of the telomerase holoenzyme, alleviates cellular ROS
levels also through its mitochondrial localization, improving
activity of cytochrome c oxidase, blocking cytochrome c
release, mitochondrial membrane permeabilization, and
inhibiting apoptosis in cancer cells [120].
The pathophysiological importance of intracellular redox
balance and apoptosis regulation was also taken in to
consideration during the study of cerebral cavernous malfor-
mations (CCMs) [121]. Ablation of Krit1, a protein whose
loss of function has been associated to this particular
pathogenesis, leads to a significant increase in intracellular
ROS levels, due to the modulation of the expression of the
antioxidant protein SOD2 and to a drastic decrease of mito-
chondrial energy metabolism, with consequent increased
susceptibility to oxidative damage [121]. In the same
way, MUC1, an oncoprotein aberrantly expressed in acute
myeloid leukemia (AML) cells, regulates ROS levels and the
differentiation of hematopoietic cells [122]. MUC1 expres-
sion is associated with attenuation of endogenous and H2O2-
induced intracellular levels of reactive oxygen species [123],
and, inhibition of MUC1 results in the disruption of redox
balance and thereby AML cell death [122].
Redox regulation of proteins by moderate levels of ROS is
observed in various signaling pathways, including autophagy,
a catabolic pathway for degradation of intracellular proteins
and organelles via the lysosome [124]. Autophagy is activated
mainly by nutrient starvation, and it plays a dual role; it is
primarily a surviving mechanism, but it also leads to cell
death (called type III cell death) thus possibly acting as an
alternative to apoptosis. It is generally accepted that ROS
induce autophagy [125, 126], and that autophagy, in turn,
serves to reduce oxidative damage [124]. Given that, antiox-
idants may represent natural inhibitors of this process. As
a matter of fact, the p53-target gene TIGAR contributes
to the regulation of intracellular ROS levels by modulation
of the glycolytic pathway, increasing NADPH production
(with a consequent decrease in intracellular ROS levels) and
lowering the sensitivity of cells to p53-dependent apoptosis
induced by oxidative stress [127]. In this manner, TIGAR
inhibits autophagy induced by nutrient starvation and
metabolic stress, in a p53-indipendent way [128]. Moreover,
a mutant form of SOD1 (SOD1G93A, associated with one-
fifth of familial amyotrophic lateral sclerosis cases [129]) pro-
motes ROS accumulation and autophagy [130, 131], despite
its role in muscular atrophy induction has not been fully
understood. In transgenic mice spinal cord, SOD1G93A inter-
acts with p62, an LC3-binding partner known to target pro-
tein aggregates for autophagic degradation, suggesting that
p62 may direct mutant SOD1 aggregates to autophagy [132].
Because mitochondria are, at the same time, primary
source and target of ROS, they play a fundamental role
in ROS-mediated autophagy regulation. Indeed, cells use a
specialized form of autophagy, called mitophagy, to selec-
tively eliminate defective mitochondria. The term, coined by
Lemasters in 2007 [133], indicates a selective degradating
process to maintain a healthy population of mitochondria.
Increases in cellular ROS lead to loss of mitochondrial
membrane potential (ΔΨm), which is considered a trigger
for mitophagy [133]. Under serum deprivation, a typical
decrease in mitochondrial membrane potential is observed
in hepatocytes prior to engulfment by autophagosomes,
whereas Cyclosporin A (CsA), a mPTP inhibitor, prevented
this depolarization and the autophagosomal proliferation
[134, 135]. However, in different setups represented by rat
pituitary GH3 cells [136] and muscles [137], Cyclosporin
A works as a strong autophagy-inducer: in particular, CsA
treatment in skeletal muscles of collagen VI knockout mice
(Col6a1 −/−), characterized by impaired autophagy, pres-
ence of abnormal mitochondria, and myofiber degeneration,
promotes autophagy with a concomitant block of apoptotic
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Figure 2: ROS levels control cell fate. Low production of ROS works as trigger of autophagic/mitophagic process, with consequent removal
of damaged mitochondria and in turn cellular survival (upper panel). On the other hand, high levels of ROS lead to cell death promoting
the apoptotic pathway when prosurvival attempt fails (lower panel).
degeneration and recovery of muscle strength [137]. This
discrepancy suggests that mitochondrial depolarization is
not general, leading event to rage the mitophagic process.
Abnormalities in mitochondrial respiration and in-
creased oxidative stress are observed in cells and tissues from
parkinsonian patients [138], which also exhibit increased
mitochondrial autophagy [139]. Two genes, which encode
the OMM kinase PINK1 and the E3 ubiquitin ligase parkin,
are mutated in autosomal recessive Parkinson’s disease [140].
Parkin is able to induce mitophagy through translocation
from cytosol to mitochondria in many different cellular
settings, after stress induction by mitochondrial uncouplers,
which mimic damage by decreasing the mitochondrial mem-
brane potential [141], or by the administration of oxidative
stress inducers, such as Paraquat [142]. Moreover, Parkin
may signal the selective removal of defective mitochondria
within the cell. Overexpression of Parkin can eliminate
mitochondria with deleterious COXI mutations in hetero-
plasmic cybrid cells, thereby enriching cells for wildtype
mtDNA and restoring cytochrome c oxidase activity [143].
PINK1 (PTEN-induced kinase 1) mediates recruitment of
parkin to the damaged mitochondria and activates parkin’s
ligase activity [144], thereby promoting autophagy. Recently,
it has been shown that knockdown of PINK1 expression
also leads to mitophagy in SH-SY 5Y cells, due to mito-
chondrial fragmentation and mitochondrial ROS production
[145]. PINK1 knockdown led to decreased transmembrane
potential, which was ameliorated by antioxidant MnTBAP
treatment, suggesting that ROS production is upstream of
mitochondrial depolarization [146].
Based on these observations, ROS act as signaling
molecules influencing cell fate. Undoubtedly, redox regula-
tion can promote both survival, during starvation for exam-
ple, as well as cell death, during oxidative stress. ROS play
the role of trigger in the early phase of autophagic process,
inducing cytoprotection by eliminating potential sources of
proapoptotic stimuli. On the other hand, if the prosurvival
attempt fails, ROS cause cell death which involves either the
autophagic or the apoptotic pathway, or both (Figure 2).
6. ROS as Key Regulators of Aging
The decline associated with aging is caused by the accumu-
lation of ROS, as supported by cellular and biological data
from different model systems and organisms [147]. Indeed
defects in antioxidant defense mechanisms fail to protect
against oxidative damage, reducing lifespan [148, 149] and
causing cardiomyophaty, neurodegeneration [150], and can-
cer [151].
The relationship between mitochondria dysfunctions
observed during aging and ROS production is still debated.
However, it is clear that the decline of the integrity of mito-
chondria as a function of age is implicated in aging and age-
related diseases [147].
Given this wide scientific evidence, many studies were
aimed to identify the molecular mechanisms responsible for
ROS deleterious effects on the aging process. Genes that
extend lifespan partially included those involved in oxidative
stress response, while partially were clustered in the IGF-
1/insulin-like signaling pathway [152, 153].
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A key mitochondrial effector is the adapter protein
p66shc, which directly mediate, the production of ROS
within the mitochondria [154], participating in intracellular
pathways that control oxidative stress, apoptosis, and lifespan
determination [155, 156]. Accordingly, p66shc knockout
mice are one of the best characterized genetic model of
longevity, is being more resistant to oxidative stress [157]
and protected against age-dependent, ROS-mediated cardio-
vascular complications induced by diabetes [158–160]. On
the contrary, overexpression of p66shc causes alterations of
mitochondrial Ca2+ responses (which is an early event of
mitochondrial damage) and fragmentation of mitochondrial
network [161], leading to cytochrome c release and apoptosis
[162]. Orsini and coworkers showed, for the first time,
that oxidative stress promotes a translocation of part of the
cytosolic pool of p66Shc to mitochondria, binding mtHsp70
in mitochondrial matrix [163]. The same group in 2005
claimed that p66Shc is rather present in the intermembrane
space, where it interacts with cytochrome c. This interaction,
which results in H2O2 production [162], can be supported by
an earlier report showing that p66Shc has internally located
mitochondrial targeting sequence [164]. In order to explain
its activity, p66Shc has to be phosphorylated at serine 36 by
PKCβ, and this event leads to a consequent recognition by the
prolyl isomerase Pin1, allowing p66Shc entrance into mito-
chondria [156]. Our recent data have indicated that p66Shc is
also present in MAM (mitochondria-associate membranes)
fraction, which consists in membranes interacting with
mitochondria [165, 166]. Interestingly, the level of p66Shc
in MAM fraction changes in an age-dependent manner
(MAM fraction isolated from livers of old animals contained
more p66Shc than MAM isolated from young individuals)
[167]. In response to the oxidative stress, high p66Shc Ser36-
phosphorylation status promotes both an additional intra-
cellular ROS generation and reduction of the antioxidant
defence system efficiency. The disturbance of the antioxidant
enzymes level is connected with the recruitment of Akt to the
p66Shc-FOXO3a complex, resulting in a direct inactivation
of FOXO transcription factors by their phosphorylation
[168, 169]. In this way, genes encoding antioxidant enzymes
controlled by FOXO transcription factors are downregulated,
with consequent increased ROS production and oxidative
stress. Accordingly, decrease of phosphorylated p66Shc is
accompanied by positive modulation of the antioxidant
defence system [170].
Many alterations that extend lifespan affect not only
stress response proteins, such as p66shc, but also nutrient
sensors, such as insulin growth factor (IGF-1), target of
rapamycin (TOR) protein kinase, AMP kinase (AMPK),
sirtuins, and PGC-1α [171]. Caloric restriction (CR) is
the best example of signals that modulate the activity of
nutrients sensors, and it is the most robust intervention to
extend lifespan and ameliorate various diseases in mammals,
reducing oxidative stress and damage [172, 173]. Despite CR
was historically considered a nongenetic process regulating
lifespan, many recent lines of evidence have suggested its role
in several signaling pathways, causing ROS reduction and
mitochondrial biogenesis [174].
Nutrient sensor IGF-1 signaling pathway was the first
to be associated to CR-mediated regulation of lifespan in
animals. Indeed, heterozygous knockout mice for the IGF-
1 receptor (Igfr +/−) live longer, show a delay in the onset of
pathologies, and display greater resistance to oxidative stress
[175, 176], suggesting that the effects of the IGF-1 pathway
on longevity are closely related to mitochondrial protection
from oxidative damage. Accordingly in C. elegans, mutations
of downstream components of this pathway, such as age-1
(the homologue of PI3K) and akt-1 and akt-2 (the homo-
logue of AKT1 and AKT2), result in extension of lifespan
[153].
The most important targets regulated by IGF-1-signaling
pathway are the transcription factors FoxO [177] and TOR
protein kinase [178]. FoxO is required for the antiaging
effects of the IGF-1 pathway [179, 180], once downregulated
by CR, since it induces the expression of several antioxidative
enzymes [181, 182], mediating the production of secondary
signals that regulates lifespan.
TOR is highly conserved during evolution and functions
as the major amino acid and nutrient sensor in the cell [183].
Much evidence points out the central role of this kinase in
lifespan extension by CR. In yeast, C. elegans, and Drosophila,
TOR is required for the effects of dietary restriction, and,
importantly, its downregulation extends lifespan of all these
models [184] and in mice too [185].
Recently, other signaling proteins have been shown to
converge and regulate the FoxO transcription factors and
thus oxidative stress and aging. Specifically, the proteins
known as sirtuins, NAD-dependent histone deacetylases
[186], are activated during CR, when the NAD/NADH ratio
is elevated [187]. This group of proteins increases lifespan
in yeast, C. elegans, and Drosophila, and it is thought to act
similarly in mammals [188]. In this respect, aging is often
associated with reduced sirtuins levels. Sirtuins are mainly
antiaging genes via the promotion of mitochondrial function
and autophagy and inhibition of apoptosis. They also have
an inhibitory activity on ROS. Sirtuin function may be
enhanced by restricting caloric intake or increasing physical
activity, thereby, extending lifespan. Importantly, three of
seven mammalian sirtuins (SIRT3, 4, and 5) are targeted
to mitochondria, and SIRT1 is a regulator of mitochondrial
biogenesis [189]. SIRT3 is required for the maintenance of
mitochondrial integrity and metabolism during stress [190].
The protective effects of CR on oxidative stress and damage
are diminished in mice lacking SIRT3. SIRT3 reduces cellular
ROS levels dependent on SOD2. SIRT3 deacetylates two
critical lysine residues on SOD2 (Lys53/89) and promotes its
antioxidative activity. Importantly, the ability of SOD2 to
reduce cellular ROS and promote oxidative stress resistance
is greatly enhanced by SIRT3 [191]. In a very recent paper,
Chen et al. have reported that SOD2 is also acetylated at Lys68
and that this acetylation decreases its activity. SIRT3 binds
to, deacetylates, and activates SOD2. Increase of ROS levels
stimulates SIRT3 transcription, leading to SOD2 deacetyla-
tion and activation [192].
Other studies confirmed that SIRT1 is part of the insulin/
IGF-1 pathway, being able to deacetylate and, thus, activate
FoxO transcription factors [193]. Moreover, SIRT1 can
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activate PGC-1α (peroxisome-proliferator-activated receptor
γ coactivator-1α). Several data linked PGC-1α and aging.
First, PGC-1α is progressively downregulated during aging,
and this event is prevented by CR [194]. Furthermore,
oxidative stress is known to induce the expression of this
gene [195]. In general, PGC-1α improves mitochondrial
dysfunction, the major phenotype of aging and age-related
diseases, in a tissue-dependent fashion [196] and during CR
promotes mitochondrial biogenesis [197], thereby lowering
ROS production [198]. PGC-1α is also directly activated by
phosphorylation by AMPK that is the master nutrient sensor
in the cell [199]. The same kinase is able to phosphorylate
FoxO factors too [200].
Recently another protein, named Bmi1, has demon-
strated to increase the expression of a collection of gene
products involved in mitochondrial function and ROS
production in aging. Cells defective in Bmi1 have significant
mitochondrial dysfunction with a sustained increase in
ROS that is sufficient to cause a marked increase in the
intracellular levels of reactive oxygen species and subsequent
engagement of the DNA damage response pathway. Also
mice Bmi1 −/− present numerous abnormalities including
a severe defect in stem cell self-renewal, alterations in
thymocyte maturation, and a shortened lifespan [201].
Aging is characterized also by the decline of the
autophagic pathway [202]. As described in the previous sec-
tion, autophagy is required in order to remove compromised
mitochondria suffering from oxidative stress. Moreover,
autophagy modulation in different model organisms has
yielded very promising results suggesting that the mainte-
nance of a proper autophagic activity contributes to extend
longevity [203]. During aging, the number of mitochondria
suffering from oxidative stress may increase, while their
cleanup by the autophagic system may become limiting,
leading to the accumulation of damaged mitochondria [204].
It is important to point out that a greater pool of functional
mitochondria could ameliorate tissue damage by opposing
cells against the gradual energetic decline occurring in cells
as mitochondria become damaged during aging [171].
In this respect, the efficient and selective removal of
damaged mitochondria by autophagy is a crucial element in
the maintenance of cellular health since the accumulation
of ROS from dysfunctional mitochondria and eventual cell
death via apoptosis is avoided [204]. At the level of the
organism, apoptosis will be the ultimate resort to remove
seriously damaged cells. This will particularly affect the
lifespan of nondividing cells, like neurons, thereby, affecting
the lifespan of the whole organism. Indeed, the degenerative
processes that arise in old organisms are partly caused by
increased cell death of nondividing cells [205]. In any
case, the accumulation of damaged mitochondria and their
impaired removal is a hallmark of aging and will contribute
to decreased cell viability. Interestingly, autophagy is regu-
lated by the same signaling pathways that determine lifespan,
acting as one of the downstream effectors of these signaling
cascades. Autophagy is essential for the effects of the IGF-
1/insulin pathway on longevity. The insulin/IGF-1 pathway
regulates autophagy through TOR and FoxO, with opposite
effects; TOR was shown to inhibit autophagy [206, 207],
while FoxO induces autophagy [208, 209]. Moreover, SIRT1
seems to be, at least in part, responsible for the direct
induction of autophagy [210], as it forms complexes with
several autophagy-related genes (ATG) proteins, causing
their deacetylation and activation [211]. Autophagy is sug-
gested to be crucial also for the onset of age-related diseases
since knockout animals for ATG5 and ATG7 in the nervous
system show the accumulation of abnormal proteins and
massive neuronal loss leading to neurodegeneration with
decreased lifespan [212, 213]. Altogether, these data suggest
the presence in the cell of a redundant control of autophagy
that allows to finely tune this process under a wide array of
physiological and pathological conditions.
7. Concluding Remarks
Mitochondria and ROS signalling tightly control cellular
homeostasis by regulating fundamental cell-death and cell-
survival processes like apoptosis and autophagy. Therefore,
ROS production may be considered a “balance of power,”
directing the cell towards life or death. It is clear that many
proteins that mediate apoptosis and autophagy directly affect
ROS signalling, through translocation to the mitochondrial
compartment and/or modulation of pro/antioxidant pro-
teins. Although correlation between mitochondrial ROS and
aging has been the subject of debate for over forty years,
recent discoveries about the role of autophagy in cleaning up
damaged mitochondria, prolonging lifespan, underline the
importance of studying ROS dynamics and show that they
continue to be extremely fashionable research targets.
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In the ascomycete fungus Neurospora crassa blue-violet light controls the expression of genes responsible for differentiation
of reproductive structures, synthesis of secondary metabolites, and the circadian oscillator activity. A major photoreceptor in
Neurospora cells is WCC, a heterodimeric complex formed by the PAS-domain-containing polypeptides WC-1 and WC-2, the
products of genes white collar-1 and white collar-2. The photosignal transduction is started by photochemical activity of an excited
FAD molecule noncovalently bound by the LOV domain (a specialized variant of the PAS domain). The presence of zinc fingers
(the GATA-recognizing sequences) in both WC-1 and WC-2 proteins suggests that they might function as transcription factors.
However, a critical analysis of the phototransduction mechanism considers the existence of residual light responses upon absence
of WCC or its homologs in fungi. The data presented point at endogenous ROS generated by a photon stimulus as an alternative
input to pass on light signals to downstream targets.
1. Introduction
The light perception of fungi is a part of the complex sensory
system responding also to changes in the concentrations of
nutrient substrates, hormones, temperature shifts, mechan-
ical damage, and so forth, which allows the fungus to adapt
its vital functions to environmental changes [1–3]. Fungi use
light as a source of information but not as a source of energy.
Light, as all stress agents, increases intracellular con-
centration of reactive oxygen species (ROS) in fungi [1,
4]. Experimentally detected relationship of developmental
processes with the action of factors increasing intracellular
ROS concentration indicated that ROS act as signaling
molecules regulating physiological responses and develop-
mental processes in fungi [3, 5–7].
Considerable recent attention is focused to molecular
mechanisms of ROS signal reception and transduction and
modification of gene activity in response to stress factors.
Absence of biological motility and lack of behavioral
responses in fungi led to induction of the synthesis of com-
pounds (especially carotenoids and melanins in the case of
light action) that ensure increased resistance to detrimental
effects. Another adaptive response is the differentiation of
survival structures such as sclerotia and, of course, spores—
the copies of genetic material of the organism, well protected
from damaging environmental influences.
Neurospora crassa has served as a model organism to
study light responses in eukaryotic cells for several decades
[2, 8–11]. In this organism, various processes of differen-
tiation such as the induction of carotenoid production in
mycelia [12], protoperithecial formation [13], phototropism
of perithecial beaks [14], perithecial polarity [15, 16], and
circadian rhythm [17, 18] are controlled by blue light, which
is associated with the generation of ROS [4, 19–21]. Under-
lying these biological phenomena is the regulation of many
Neurospora genes by light. Recently, of the 5600 detected
genes on a whole genome microarray, approximately 5.6%
or 314 responded to a light stimulus by a relatively rapid
increase in transcript amount [22].
Neurospora crassa uses blue light (350–500 nm) as the
primary signal for photoreception. The primary photorecep-
tor system for blue light in the fungus is the white collar
(WCC) complex, a protein complex formed by two proteins
WC-1 and WC-2. WC-1 is a protein with a flavin-binding
domain and a zinc-finger domain and interacts with WC-
2, another zinc-finger domain protein. The WCC complex
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operates as a photoreceptor and a transcription factor for
blue-light responses in Neurospora. It represents also a key
transcription factor for circadian oscillator [10, 23].
On the other hand it has been shown that manipulation
of ROS was a strategy to regulate cell differentiation in Neu-
rospora crassa [5, 7, 24, 25]. In order to take a step closer to
understanding ROS functions in Neurospora differentiation,
the present review considers participance of ROS in blue light
signal transduction through N. crassa WCC complex.
2. Light in Neurospora Development and
Differentiation
After the classic studies performed by Beadle and Tatum in
the 1940s, Neurospora became a recognized model in genetic
and biochemical studies. Neurospora is multicellular and
produces at least 28 morphologically distinct cell types, many
of which are derived from hyphae [26, 27]. The mycelium
of N. crassa is composed of multinuclear branched hyphae
which show apical polar growth. The hyphae are divided
into compartments (100–200 μm) by septa, each having a
central pore up to 0.5 μm in diameter. The pore is permeable
to cytoplasm, nuclei, and mitochondria. The septal pores
of N. crassa are considered to be functional analogues of
gap junctions of animal cells, plasmodesmata of plants, and
microplasmodesmata of filamentous cyanobacteria [28]. The
diffusional and electric relationships between hyphal cells are
local, as it is in other organisms, and involve three or four
compartments along the hypha. These relationships appear
to be genetically determined and controlled by the gradient
of membrane potential between hyphal compartments. They
are also controlled by light of the blue-violet spectral area
[1, 28].
Frequent fusion among hyphal filaments produces a
complex hyphal network (the mycelium) [29] and promotes
the formation of heterokaryons in which multiple genomes
can contribute to the metabolism of a single mycelium.
Specialized aerial hyphae are differentiated from vegetative
hyphae in response to nutrient deprivation, desiccation,
or various stresses, and these form chains of asexual
spores (the multinucleate macroconidia) for dispersal [30]
(Figure 1). The timing of macroconidiation is controlled
by a circadian rhythm, which in turn is modulated by
exposure to blue light. Another type of asexual spore, the
uninucleate microconidium, is differentiated from micro-
conidiophores or directly from the vegetative hypha [27, 30–
32]. Limiting nitrogen induces a type of hyphal aggregation
that leads to generation of multicellular female sexual
organs (protoperithecia) [32, 33]. Mating is accomplished
by chemotropic growth of a specialized female hypha from
the protoperithecium toward the male cell (typically a
conidium) in a process involving pheromones [34]. Once
fertilized, protoperithecia increase in size, darken, and
transform into perithecia. The sexual process is followed
by a short-term diploid phase. In the perithecia, a fruiting
body, black (melanin-containing) ascospores (haploid spores
of the sexual cycle) mature for several days after meiosis. Each
perithecium comprises 200–400 asci, each containing eight
Perithecium
Ascospore
Ascus
Conidia
Vegetative
mycelium
Blue light
Sexual cycle
Asexual cycle
Carotenoid
synthesis
Protoperithecium
Conidium
Figure 1: Life cycle of Neurospora crassa. Depending on environ-
mental conditions, the vegetative mycelium can undergo the asexual
sporulation processes (macroconidiation and microconidiation).
It can enter the sexual cycle by forming protoperithecia. Upon
fertilization, they initiate development leading to the production
of meiotically derived ascospores. Blue light inputs are shown by
arrows.
oval mononuclear haploid ascospores. During germination
of ascospores, hyphae of vegetative mycelium develop, as in
the case of conidia (Figure 1).
The genome of Neurospora, comprising 42.9 million
bp, has been decoded [35]. The network of the fungus
chromosomes includes 527 multigene families containing
approximately 10,000 genes. Consistent with the greater
biological complexity of filamentous fungi compared to both
fission and budding yeast, Neurospora possesses nearly twice
as many genes as Schizosaccharomyces pombe (4,800) and S.
cerevisiae (6,300). Neurospora contains almost as many genes
as Drosophila melanogaster (14,300), despite the relative
developmental complexity of the latter [35]. The Neurospora
gene complement also displays greater structure complexity
than that of the two yeasts.
Neurospora can be easily cultured on media of a specific
chemical composition. Its development cycle takes one to
two weeks. A change of morphologically distinct develop-
ment phases is easily induced by a change in the composition
of the culture medium or other related factors. Quiescent
spores germinate to form a haploid vegetative mycelium
with hyphae spreading over the substrate at a rate of up to
10 cm/day. Filamentous branching hyphae of the mycelium
are approximately 10–20 μm in diameter.
The effect of light is manifested at different stages of
the Neurospora life cycle (Figures 1 and 2). Light promotes
changes in the electrophysiological parameters of hyphae: the
input resistance increases, followed by hyperpolarization of
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the cytoplasmic membrane [36]. The last phenomenon may
be accounted for by regulation of activity of H+-ATPase, a
plasma membrane proton pump [37].
Changes in these parameters are transient, and their
values subsequently return to the initial level. Illumination
also affects the intercellular communication mechanism
(electric-bond coefficient) or, in other words, the rate of
diffusion of ions between interseptal hyphal areas. It can be
assumed that light-dependent changes in electrophysiolog-
ical parameters are part of the energy cooperation system
in interseptal hyphal areas, which allows the fungus to
more effectively supply energy in the form of membrane
potential for membrane transport in the apical compartment
of growing hyphae [28]. The photoreceptor mutant white
collar 1 (wc-1) has a lower constitutive membrane potential,
disrupted intrahyphal communication mechanisms, and it
lost all the blue-light induced electrical reactions: a transitive
increase of input resistance and membrane potential [28].
Thus changes in the electrical properties of the N. crassa
plasma membranes upon the light action appear to be
controlled via WCC complex (Figure 2).
Light induces the expression of genes albino (al-1, al-
2, and al-3) involved in carotenogenesis in hyphae and,
as a result, the accumulation of neurosporaxanthine and
other pigments imparting orange color to the mycelium
(Figure 3) [38, 39]. Carotenogenesis in conidia, in contrast
to mycelium, has a constitutive nature. The synthesis of
carotenoids—the quenchers of oxygen-excited states and the
inhibitors of free radical processes—is regarded as a means
of cell defense against light-induced damage.
Two light-regulated phenomena, the electrogenic trans-
port function of membrane and accumulation of carotenoids
in the cell, are apparently physiologically related. In the nap
mutant, damage of the proton pump which consumes as
much as 50% of intracellular ATP caused an increase in
the content of ATP and utilization of its energy in other
metabolic processes (including the synthesis of precursors of
carotenoids); as a result, the synthesis of pigments increased
[40].
Light also affects some mycelial enzymes. For example,
illumination increases the degree of phosphorylation of
nucleoside diphosphate kinase [16], activates cAMP phos-
phodiesterase [41], and changes the activity of molecular
forms of NAD+-kinase [42]. In addition, light changes the
inactive (reduced) form of nitrate reductase into the active
(oxidized) state [43]. Photoreactivation with near ultraviolet
light (UV-A) of DNA molecules damaged by more shortwave
radiation occupies a special place. This phenomenon is
based on DNA photolyase-catalyzed cleavage of C–C bonds
between neighboring pyrimidine bases [44].
As mentioned above, differentiation of reproductive
structures is controlled by a complex of external signals
whose effect is regulated by the cell, with light playing a
key role in this mechanism [45]. Exhaustion of a nutritive
substrate is a necessary condition of differentiation. Some
effects (e.g., carbon starvation or mycelium drying) promote
rapid conidiation, with light additionally stimulating this
process [45]. Nitrogen starvation induces the formation of
protoperithecia and simultaneous (yet less active than in
carbon starvation) conidiation. Unlike carbon starvation, in
nitrogen starvation light inhibits conidiation and simultane-
ously stimulates the formation of protoperithecia [46]. In
other words, under these conditions light determines the
selection of either the sexual or asexual development pathway
(Figure 1). Perithecia occurring during the sexual cycle are
also sensitive to light, which induces their polarity (i.e.,
formation of a so-called beak at one end of the perithe-
cium, which, in turns, exhibits positive phototropism) [14]
(Figure 2).
Light also affects the circadian rhythm endogenous sen-
sor function. Conidia are formed with a certain periodicity
on the mycelium that spreads over the substrate surface,
which leads to the occurrence of spatially separated sporu-
lation zones. Pulse illumination changes rhythm parameters,
and constant illumination suppresses manifestations of
rhythmicity [11].
3. Light Effects Are Accompanied by
Formation of ROS
All of the environmental stresses triggering N. crassa differ-
entiation are apparently sources of ROS [24, 25, 47]. Among
these factors are ionizing radiation (alpha, beta, gamma, and
X-ray beams), UV radiation (far 200–290 nm, medium 290–
320 nm, and near 320–420 nm), and visible light. ROS appear
to mediate blue light effects in cells, but the sources of ROS
and their respective roles in the cellular response to blue
light are not completely understood. Direct evidence of ROS
formation under light on various objects is given hereinafter.
High-fluence blue light can induce H2O2 generation at
both the plasma membrane and the chloroplast of Arabidop-
sis. The high-fluence blue light-induced H2O2 generation
can be abolished by the administration of the H2O2-
specific scavenger catalase and other antioxidants or by
the addition of diphenyleneiodonium, which is an NADPH
oxidase inhibitor, and the blocker of electron transport
chain dichlorophenyl dimethylurea [48]. The generation of
O2
−•—(by the coleoptile tip of Sorghum bicolor and wheat
(Triticum vulgare) was augmented upon illumination with
blue light. Various thiol blockers caused powerful inhibition
of blue light induced O2
−• generation [49]. Blue light
increased intracellular ROS equally in both normal human
epidermal keratinocytes and oral squamous cell carcinoma.
Blue light-generated ROS suppress cellular mitochondrial
activity. However, the identity of blue light targets that
mediate these changes remains unclear [21]. In addition, it
was found that acute exposure of keratinocytes to both UVA
and UVB results in activation of NOX and generation of
ROS [50–52]. These studies suggest that a rapid activation
of NOX by UV irradiation in these cells may have a distinct
physiological importance. How irradiation activates NOX is
not totally understood [47]. Thus UV-blue light effects on
various organisms provide ROS formation inside the cells.
4. Intracellular Sources of ROS in Fungi
ROS are formed in fungi in the course of metabolic activity.
The involvement of oxygen in metabolic processes in fungi is
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Figure 2: Blue light reception through WCC complex. (a) WCC-mediated gene expression and various light responses in Neurospora crassa.
(b) Photoreceptor proteins in Neurospora crassa. The figure shows two multidomain proteins WC-1 and WC-2 forming photoresponsive
WCC complex. WC-1 interacts with WC-2 through PAS (protein-protein interaction) domains. LOV-domain (a specialized variant of the
PAS domain) in photoreceptor WC-1 noncovalently binds FAD. The two proteins contain activation domains (ADs), DNA-binding Zn-
finger domains, and nuclear localization domains (NLSs).
coupled to its activation and formation of number of highly
reactive compounds such as (O2
−•), hydrogen peroxide
(H2O2), and OH
•. In addition to the respiratory chain, as
an intermediate product ROS are generated in reactions with
involvement of xanthine oxidase, microsomal monooxyge-
nases, lipoxygenase, and, as a result, of autooxidation of
thiols, flavins, quinones, and catecholamines, as well as the
reduction of xenobiotics [53].
Certain intracellular enzymes producing ROS cannot
be ruled out. These include, first of all, NADPH-oxidases
(NOX), specifically producing ROS and playing a significant
role in growth and differentiation of Neurospora crassa
[54–56]. It is known that specific enzymes, such as NOX,
produce ROS to regulate different cellular functions, includ-
ing growth, cell differentiation, development, and redox-
dependent signaling [47, 54–56]. The fact that NOX regulate
developmental processes in different microbial eukaryotes
suggests that ROS regulate cell differentiation, and that this
is a ROS ancestral role conserved throughout the eukaryotes
[47]. Enzymes belonging to the NOX family produce O2
−•
in a regulated manner. It has been shown in N. crassa that
NOX-1 and NOX-2 are both involved in different aspects of
growth and development; a single regulatory subunit, NOR-
1, an ortholog of the mammalian NOX-2 regulatory subunit
gp67 (phox), is regarded for the function of both NOX.
N. crassa NOX-1 elimination results in complete female
sterility, decreased asexual development, and reduction of
hyphal growth. The lack of NOX-2 did not affect any of
these processes but led instead to the production of sexual
spores that failed to germinate, even in the presence of
exogenous oxidants. These results indicate a link between
NOX-generated ROS and the regulation of growth [55].
It was revealed that NO• synthase participated in asexual
spore development of N. crassa and in differentiation of
other fungi [57]. Glyoxal oxidase appeared to be involved in
differentiation of phytopathogenic fungi [58, 59].
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Figure 3: The enzyme pathway of carotenoid biosynthesis in Neurospora crassa. NCU numbers of light-regulated genes are shown. The
figure is modified from Uspekhi Biologicheskoi Khimii [1].
5. ROS in Neurospora Development and
Differentiation
5.1. Changes in ROS Concentration and Differentiation in
Fungi. High reactivity of ROS is responsible for oxidation
of proteins, lipids, and nucleic acids. Consequently, systems
defending against ROS by repair or resynthesis of damaged
molecules are present in the cell. Nevertheless, impairment
of intracellular redox status, as a result of an increase in
generation of oxygen radicals exceeding the cellular capacity
to neutralize them, can generate a hyperoxidation state
(oxidative stress). As distinct from growth and differentiation
state, oxidative stress is an unstable one, and elimination
or partial inhibition of intracellular antioxidant systems
may cause cell death [5, 7]. Intracellular ROS increase is
accompanied by the cessation of growth, and it provokes
morphological changes leading to cell adaptation to changes
in life conditions as well as the decrease in intracellular oxi-
dants. Numerous experimental data support the relationship
of differentiation triggering processes with an increase in
intracellular ROS [5, 60–63]. Just so, in the myxomycete
D. discoideum an increase in intracellular O2
−• as well as
extracellular one provoked aggregation of myxamoebae and
subsequent differentiation, and the aggregation process was
6 Journal of Signal Transduction
prevented by O2
−• scavengers together with an increase in
expression of genes controlling antioxidant defense systems
(ADS) [62].
H2O2 is considered as one of the most important
metabolites in all respiring cells. H2O2 provoked global
changes of gene transcription, including the ADS genes,
in A. nidulans [60], as well as sclerotial differentiation
in Sclerotium rolfsii [63], increased expression of genes of
carotenogenesis in N. crassa [64], and promoted transition
to filamentous growth in U. maydis and development of its
pathogenicity [59]. It is known that sclerotial differentiation
in S. rolfsii is coupled to H2O2 generation inside the cell. Its
concentration increased under the action of light and iron
ions [63].
OH• formed on the interaction of transition metals
with H2O2 was inhibited by such scavengers as dimethylsul-
foxide, phenylthiourea, p-nitrosodimethylaniline, ethanol,
and benzoate, which suppress sclerotial differentiation in S.
rolfsii [65]. Sclerotial differentiation was similarly inhibited
by antioxidants (ascorbic acid, β carotene) [66, 67]. It was
shown that O2
−• increased cleistothecium differentiation in
A. nidulans [68], while NO• promoted fruit body develop-
ment in F. velutipes [69].
At the onset of different stages of N. crassa macroconidia
differentiation (aggregation of hyphae, aerial hyphae forma-
tion, differentiation of macroconidium), a spontaneous, low-
level chemiluminescence was detected enhanced by lucigenin
and/or luminol, indicative of an increase in level of intra-
cellular oxygen radicals. Antioxidants abolished chemilumi-
nescence and stopped differentiation, which supports the
formation of ROS ahead of every stage of fungal development
[70]. Thus ROS formation is essential for differentiation of
N. crassa as well as development of other fungi.
5.2. Changes in Fungal Cell Metabolism under ROS Action.
An increase of oxidant level inside the cell inevitably causes
the oxidation of organic molecules. It has been shown that
differentiation of sclerotia on the mycelium of S. rolfsii
was accompanied by lipid peroxidation [70]. Light and
Fe2+ enhanced lipid peroxidation as well as the intensity of
sclerotium formation [63], and lipid peroxides and aldehyde
degradation products inhibited many proteins, affected
cell differentiation and proliferation, and might promote
apoptosis [71].
Oxidation of sulfhydryl groups in proteins upon ROS
action promotes a change in activity of some enzymes. As
an example, decrease in glycolytic enzymes and decline of
protein synthesis enzymes have been observed, coupled to
cessation of growth [72, 73].
Oxidative stress was accompanied by cessation of growth
and severe metabolic changes directed towards decrease
in primary metabolites (acetate, glucose) and synthesis of
compounds participating in cell protection, for example,
carotenoids, melanins, proline, and polyols [3]. Trehalose
is of fundamental importance in defending yeast cells in
oxidative stress [74]. At the start of separate steps of
macroconidium differentiation in N. crassa, mass protein
oxidation and their subsequent degradation [75], release
of iron ions upon oxidation of [Fe-S] clusters of enzymes,
oxidation of intracellular NADP and NADPH, glutathione
oxidation, glutathione disulfide excretion to the extracel-
lular medium [76], synthesis of antioxidant enzymes [7,
77], and ROS-dependent chemiluminescence [24] were the
experimental evidence of hyperoxidant state. An increase in
protein carbonylation by ROS has been observed in different
species of mycelial fungi: Mucor racemosus, Humicola lutea,
F. oxisporum, A. solani, Cladosporium elatum, Penicillium
chrysogenum, P. brevicompactum, P. claviforme, P. roquefortii,
A. niger, A. argilacceum, A. oryzae, and N. crassa [78].
A comparative study of the changes in the components
of the ADS, the activity of superoxide dismutase (SOD) and
catalase and the level of extractable SH-groups, during the
growth of wild-type and N. crassa mutants (white collar-1
and white colar-2) showed that oxidative stress developing
during spore germination and upon the transition to a
stationary growth phase was accompanied by an increase
in the level of extractable SH-groups and SOD activity in
all the strains, whereas the total catalase activity decreased
during growth. However, in contrast to the wild-type strain,
the activity of the catalase in the mutant strains wc-1
and wc-2 slightly increased upon the transition to the
stationary phase. In the wc-2 mutant, SOD activity and the
level of extractable SH-groups in the exponential growth
phase were always lower than those in the wild-type and
wc-1 strains [79]. As in previous works [5, 7, 75, 76],
our data pointed to formation of ROS upon transition
to interchangeable phases of development. Moreover, the
data revealed that mechanisms of inactivation of increased
intracellular ROS, developing during spore germination and
entry into the stationary growth phase, distinguished wc-
1 and wc-2 mutants from the wild strain [79]. These data
prompted us to pay a closer attention to mechanisms of blue
light signal transduction through WCC and to the role of
ROS in this process.
6. Photoreceptor Complex, Other
Photoreceptors, and Other Signal
Transduction Pathways
6.1. Photoreceptor Complex WCC. The main blue-light
responses in Neurospora include induction of sporulation
and sexual development, induction of carotenoid synthesis
in mycelium, and the regulation of circadian clock. All
of the mentioned processes require the products of white
collar 1 (wc-1) and white collar 2 (wc-2) genes-GATA zink
finger family members [80]. WC-1 is the product of the
wc-1 gene, a protein with a Zn-finger, two PAS domains
involved in protein-protein interactions, a putative tran-
scriptional activation domain, a nuclear localization signal,
and a chromophore-binding domain [81] (Figure 2). The
chromophore binding domain binds the flavin chromophore
FAD allowing WC-1 to act as a photoreceptor [82, 83].
The WC-1 flavin-binding domain (LOV-light, oxygen, volt-
age) has been described in other photoreceptor proteins,
most notably in plant phototropins [84]. The primary
photochemical event in phototropins is the formation of
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a flavin-cysteinyl adduct at a cysteine of the LOV domain
[85], suggesting that WC-1 activation occurs through the
formation of a light-dependent flavin-cysteinyl adduct [86].
WC-2 is the product of the wc-2 gene, a protein with a
zink finger, a single PAS domain, a putative transcriptional
activation domain, and a nuclear localization signal [87]
(Figure 2). WC-1 and WC-2 interact through the PAS
domains to form a WCC complex [88–93]. In the WCC
complex, WC-1 is the limiting factor while WC-2 is in excess
[89, 93]. WCC binds the promoter of light inducible genes
[81, 82, 94–96]. Light causes a decrease in the mobility of
the WCC complex bound to the promoter, suggesting a light-
dependent aggregation of WCC complexes [82, 96].
The WCC proteins are present in the dark [92, 93, 97]
and are preferentially located in the nucleus although WC-
2 is also observed in the cytoplasm and is more abundant
than WC-1 [92, 95, 97, 98]. Nuclear localization of either
WC-1 or WC-2 is not affected by light and is not altered
by mutations in wc-2 or wc-1, respectively, indicating that
nuclear localization does not require a complete WCC
complex [97].
Microarray analysis showed that the expression of 314
genes responded to the light stimulus by increasing transcript
levels [22]. Most of the identified genes (92%) were either
early (45%), with peak expression between 15 and 45
minutes, or late (55%), with the induced expression peaking
between 45 and 90 minutes after lights on [1, 99]. Genes
related to the synthesis of photoprotective pigments (7.1%),
vitamins, cofactors, and prosthetic groups (4.7%), secondary
metabolism (4.7%), DNA processing (6.3%), cellular signal-
ing (5.5%), and environmental sensing and response (1.6%)
were found enriched in the early light response. In contrast,
genes involved in carbohydrate metabolism (20%), oxidation
of fatty acids (1.9%), and oxygen detoxification reaction
(2.5%) were found enriched in the late light response. Within
the early group were several transcription factors most of
which show mutant phenotypes during development. Tran-
scription factor SUB1 is required for efficient transduction of
light signals to the most of late light response genes [22, 99].
Gene photoactivation is transient. After further light
exposure, WC-1 is phosphorylated [93, 96, 97, 100] leading
to exclusion of the WCC complex from the promoter and the
end of gene transcription.
The protein VIVID, an additional N. crassa photore-
ceptor, is a flavoprotein and serves as a fungal blue light
photoreceptor for photoadaptation [22]. VIVID (VVD) is a
small protein (186 amino acids) with a single LOV domain
functioning downstream of the WCC to regulate negatively
the light responses initiated by the WCC [22, 86, 101–104].
The induced VVD protein accumulates in the nucleus and
physically interacts with WCC to regulate photoadaptation
by repressing WCC activity in constant light. The kinetics of
photoadaptation is predominantly regulated by the amount
of VVD protein in the system [105].
The excluded WCC complex is dephosphorylated and
partially degraded, probably through an interaction with
the protein kinase C (PKC). Since protein phosphatase
2A participates in the dephosphorylation and activation
of the WCC complex in vivo [95], it is possible that this
enzyme is also involved in the dephosphorylation of the
WCC complex after light exposure. After a certain period
in the dark the WCC complex, probably with the addition
of newly synthesized WC-1 and WC-2, is ready for gene
photoactivation again.
The amount of WC-1 and the kinetics of the light-
dependent phosphorylation is altered by the presence of a
mutant form of WC-2 suggesting that WC-2 is necessary to
sustain the transiency and magnitude of WC-1 phosphoryla-
tion [93, 97, 106].
In Neurospora, the photoreceptor complex WCC serves
as an exogenous regulator of the circadian clock which
is an important recipient of light information (Figure 2).
The circadian clock controls the program of Neurospora
development [107, 108]. When cultured in the dark in the
absence of external signals, the fungus periodically (with
an approximately 21.5-hour period in the case of wild-
type cells) switches from mycelial growth to conidiation.
VVD has been shown to take part in regulating various
circadian clock properties, most likely through its effects on
the WCC, including gating of light input to the clock [101],
maintenance of the clock during the light phase [102, 103],
and temperature compensation of the circadian phase [104].
Thus, the first fungal photosensor identified was White
collar-1 (WC-1) of N. crassa [108], and this system has been
extensively studied with emphasis on the circadian clock of
this fungus and how it is regulated by the WC-1 and WC-2
proteins, the clock protein FRQ and interacting factors [109,
110]. More recently, WC-1 homologues have been identified
in basidiomycetes [111, 112] and zygomycetes [113, 114]
as well as other ascomycetes [115, 116]. This information
extends the function of WC-1 homologues in photosensing
across the fungal kingdom.
6.2. Other Photoreceptors. The Neurospora genome contains
genes for additional photoreceptors, including a cryp-
tochrome gene (cry), an opsin gene (nop 1), and two
phytochrome genes (phy 1 and phy 2), but their function in
Neurospora photobiology remains mostly unknown [26, 35].
It has been shown recently that the activity of the WCC
is negatively regulated by the photoreceptors CRY-1, NOP-1,
and PHY-2, presumably through the light-dependent activa-
tion of a putative repressor of the WCC. It is possible that
each photoreceptor may activate an independent repressor
of the WCC [117].
The regulation by secondary photoreceptors of the WCC
may modify the activity of some genes, as it was observed
for con-6, al-1, and vvd. It has been suggested that a light-
dependent repressor of the WCC may be a general feature of
light reception in N. crassa [117].
A major regulator of conidiation in Aspergillus nidulans
is the product of the gene veA. VeA is preferentially
located in the nucleus in cells grown in the dark, which
is consistent with the role of VeA as a repressor of light-
dependent processes [118], and the VeA protein interacts
in a complex with other regulatory proteins for the regu-
lation by light of development and secondary metabolism
[119]. The Neurospora ortolog ve-1 encodes a protein Ve-1.
A pronounced reduction in light-dependent carotenoid
8 Journal of Signal Transduction
accumulation (threefold) was observed in the ve-1 strain
suggesting that the putative regulatory Ve-1 protein is
required for full photocarotenogenesis in Neurospora [117].
6.3. The Complexity of Neurospora Light Sensing Cascade.
It cannot be ruled out that there are possibly multiple
intertwined pathways in the mechanism of photosignal
transduction. The analysis of promoters of approximately
20 light-inducible genes did not reveal any common cis-
acting elements (i.e., DNA sequences that are recognized
by light-dependent transcription factors). The situation is
additionally complicated by the fact that there are light-
dependent genes whose expression is not mediated by the
functional proteins WC-1 and WC-2 [87, 120].
An additional complicating factor may be chemical
modification (enzymatic methylation) of these sequences.
Although the genome of Neurospora is methylated fairly
weakly, it is known that the level of methylation may undergo
changes in the course of ontogeny [121]. It should be noted
that methylation plays an important role in ontogenetic
photoregulation. There are grounds to believe that the WCC
complex is involved in the regulation of DNA methylation,
the level of which determines the light-dependent selection
of either sexual or asexual development by the fungus.
It was shown that 5-azacitidine, an inhibitor of DNA
methylation, suppressed photoinduced formation of sexual
structures (protoperithecia) and simultaneously abolished
the inhibitory effect of light on conidiogenesis [46, 122].
It should be noted that illumination induced a rapid
and transient (30–600 s) decrease in the cAMP content in
Neurospora mycelium [123, 124] as a result of increase in
the activity of cAMP phosphodiesterase [41]. The treatment
with 3-isobutyl-1-methylxanthine, an inhibitor of phospho-
diesterase, as well as addition of exogenous cAMP, inhibited
the cell response to illumination (expressed as the synthesis
of carotenoids), whereas a decrease in the cAMP level,
observed in some mutants, was accompanied by induction
of carotenogenesis in the dark. Exogenous cAMP completely
inhibited photoinduction of expression of the genes al-
1, al-2, bli-3, bli-4, ccg-2, con-8, and con-10. It can be
assumed that the effect of cAMP may be implemented at
the transcriptional level via the cyclic AMP response element
(CRE) in the promoters of photoinducible genes [125].
In addition, it cannot be excluded that photoregulation
influences the change in phosphorylation of WC proteins
that is catalyzed by cAMP-dependent protein kinase. The
involvement of cAMP pathway in blue light signal trans-
duction, possibly with the involvement of RAS protein, was
mentioned in several investigations on N. crassa [22, 126,
127] and Trichoderma atroviride [128]. Possibility of ROS
participation in blue-light signal transduction makes the
regulatory networks of the Neurospora light-sensing cascade
far more complicated.
7. ROS Affected WCC Signal Transduction
According to previous studies with various fungi an assump-
tion was produced that intracellular redox state and light-
induced carotenogenesis were related processes [129, 130].
Sure enough, some experimental data consider partic-
ipance of ROS in blue light signal transduction through
WCC complex in N. crassa. It was shown that illumination
of Neurospora mycelium under O2-enriched air increased
transcript level of al-1 encoding phytoene dehydrogenase. It
also highly enhanced carotenoid production in the mycelium
[131]. These results suggest that increased ROS, under
oxygen enriched air, could increase light-induced carotenoid
production and might act as a controlling factor in the WCC-
signaling cascade, because the light-induced expression of
al-1 mRNA depends on WCC complex function [64].
This assumption was supported by the fact that sod-1
mutant, with a defective Cu, Zn-SOD showed accelerated
light-dependent induction of carotenoid biosynthesis in the
mycelium compared to the wild type [131]. In N. crassa,
catalase-3-deficient mutants showed increased carotenoid
production in colonies under illumination [25]. It was
found that menadione treatment of Neurospora wc mutants
restored circadian conidiation in N. crassa [127].
Thus intracellular ROS apparently enhance several light-
induced responses in N. crassa. They increase the blue-light
action but apparently do not trigger WCC-induced blue-light
responses.
It is well known at present that increase in intracellular
ROS is accompanied by activation of intracellular ADS
specific to developing ROS [132]. Antioxidant enzymes
(SOD and catalase) in wild type and wc-1 and wc-2 mutants
of N. crassa responded differently to various stress factors
(oxygen, light, temperature increase) which rise intracellular
ROS in cells. Menadione treatment provided SOD increase in
the wild type. The enzyme activity did not change in WCC-
mutants (wc-1 and wc-2) [133]. Protein carbonyls (oxidative
stress marker) showed a double increase in the wild type
(but not in the mutants) as a result of menadione treatment
[133]. No increase in SOD activity as well as no rise in protein
carbonyls was revealed in WCC mutants thus demonstrating
high resistance of the mutant strains to menadione.
It should be noted that a high increase in catalase
activity was found only in WCC mutants (wc-1 and wc-
2) upon action of stress agents increasing intracellular
ROS [134]. Increase in catalase activity in the mutants
upon H2O2 treatment points to H2O2 signal transduction
independent of WCC. Thus WCC apparently participates in
environment signal transduction forming intracellular O2
−•
in the wild type. Lack of SOD activity increase upon stress
agents, including light, and high resistance of WCC mutants
to menadione, points apparently to some other systems
preventing intracellular O2
−• formation in wc-1 and wc-2
[134].
As it has been mentioned before, each morpho-
genetic step of N. crassa conidiation was preceded by
NAD(P)(H)/NAD(P) and GSH/GSSG redox imbalance [76].
Generation of singlet oxygen was observed during germina-
tion of N. crassa conidia [135]. Exposure of fungal cells to
oxidative stress results in the modulation of various signaling
pathways. Oxidation and reduction of protein thiols are
thought to be the major mechanisms of ROS integration
into cellular signaling pathways. It has been shown that
incubation in air (increased intracellular ROS) provided
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a significant protein disulfide increase only in the N. crassa
wild type mycelium particularly under light treatment. A
decrease in the formation of disulfide bonds in the proteins
of wc-1 and wc-2 mutants (as compared with the wild type
strain) was recorded [134]. It can be assumed that at least
one ROS signal transduction pathway may be controlled by
the WCC.
The main intracellular source of ROS is the mitochondria
respiratory chain. Comparative analysis of respiratory activ-
ity in the N. crassa wild type and its photorecepror complex
mutants (wc-1 and wc-2) revealed high cyanide-resistant
respiration in the mutant strains under glucose oxidation
pointing to the increased activity of alternative oxidase in
the mutant strains. This fact was confirmed by inhibitory
analysis [136]. Transfer of electrons through alternative
oxidase is not coupled with ATP synthesis. Alternative
oxidase prevents autooxidation of electron carriers under
ROS increase [137]. It can be assumed that antioxidant
defence in WCC mutants is performed using catalase and
alternative oxidase.
The data presented show that signal transduction via
WCC complex enhances oxidative stress in Neurospora cells.
In the WCC mutants—wc-1 and wc-2—no experimental
evidence of oxidative stress was revealed. On the other
hand, alternative signal transduction pathways apparently
functioned. The fact is confirmed by increase in catalase
and alternative oxidase levels in wc-1 and wc-2 mutants. It
can be assumed that accomplishment of blue-light responses
through WCC-complex in Neurospora cells is coupled to
oxidative stress.
8. Conclusion
Light signaling pathways and circadian clock have profound
effects on behavior in most organisms. N. crassa is eukaryotic
model for light responses and circadian clock. Sequence and
functional orthologs of WC-1 and WC-2 and most of the
other light signaling components are widespread among the
fungal kingdom. Recent studies have demonstrated that WC-
1- and WC-2-like molecules in various fungal species play an
essential role in mediating light signals from the Ascomycota,
Basidiomycota, and Zygomycota phyla [8–10, 138, 139].
Successful work on the WCC in Neurospora has led
to fundamental breakthroughs in understanding photo-
biology in other fungi. While many of the downstream
genes regulated by the WCC are not well studied or are
uncharacterized, most of them have homologs in plants and
mammals. Unfortunately even after extensive research, little
is known about mechanisms that directly link photoreceptor
activation to signaling pathways eliciting light responses.
Proteomic analysis across human, yeast, and bacterium has
raised that the cellular stress response can be characterized
by the induction of a limited number (300) of highly
conserved proteins [140]. It is noteworthy that among the 44
proteins with known functions, 40% of them are related to
regulation of the intracellular redox status. It is noticed that
increased reactive oxygen species (ROS) generation seems
to be a common response in fungal organisms exposed to
stresses; thus, redox regulation in fungal cells may represent
a second messenger system that is upstream of the fungal
stress signaling network. It cannot be excluded that reactive
oxygen species generated by a photon stimulus might provide
a transcriptional response through redox signaling pathways
or serve as an input pass on some extra signal transduction
systems to downstream targets correcting for the complexity
of Neurospora light sensing cascade.
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Imbalances in the formation and clearance of reactive oxygen species (ROS) can lead to oxidative stress and subsequent changes
that affect all aspects of physiology. To limit and repair the damage generated by ROS, cells have developed a multitude of responses.
A hallmark of these responses is the activation of signaling pathways that modulate the function of downstream targets in different
cellular locations. To this end, critical steps of the stress response that occur in the nucleus and cytoplasm have to be coordinated,
which makes the proper communication between both compartments mandatory. Here, we discuss the interdependence of ROS-
mediated signaling and the transport of macromolecules across the nuclear envelope. We highlight examples of oxidant-dependent
nuclear trafficking and describe the impact of oxidative stress on the transport apparatus. Our paper concludes by proposing a
cellular circuit of ROS-induced signaling, nuclear transport and repair.
1. Introduction
1.1. Reactive Oxygen Species. Oxidative stress is generated
by an increase in reactive oxygen species (ROS), either in
the form of free radicals or nonradical oxidants [1, 2].
Although elevated levels of ROS can damage a wide variety
of molecules, ROS production is essential to normal cell
physiology [3–12]. As such, ROS participate in cell-signaling
events and can function as second messengers. Moreover,
ROS are generated at sites of inflammation, where they fend
off microbial infections [13–16]. On the other hand, ROS are
believed to contribute to aging [3–9, 12]; they are also pro-
duced in response to environmental insults, such as X-rays,
UV light, ultrasound, or microwave radiation [17–19]. At the
cellular level, ROS are generated as metabolic byproducts of
normal biological processes, with oxidative phosphorylation
in mitochondria as the primary source in eukaryotic cells
[20]. Aside from the mitochondrial electron transport chain,
NADPH oxidases, cyclooxygenases, lipoxygenases, xanthine
oxidase, and other cellular enzymes make also important
contributions to cellular ROS production [21–25].
The different types of ROS and their mode of action
have been discussed in detail [1, 11, 26–30]. ROS that
are particularly important to cell physiology include the
hydroxyl radical •OH, superoxide anion •O2−, the nonrad-
ical hydrogen peroxide (H2O2), alkoxy and peroxy radicals,
hypochlorous acid or peroxynitrite, and reactive sulfur
species [1, 29, 31, 32]. Here, we recapitulate the properties of
those ROS only that are relevant to the experiments discussed
in this review.
The hydroxyl radical •OH is highly reactive and causes
damage to nucleic acids and proteins, this radical also
promotes lipid peroxidation [2, 12, 33]. Due to their high
reactivity, hydroxyl radicals are especially harmful and con-
sidered a major cause of oxidant-induced damage [34]. The
superoxide free radical •O2− can interfere with the proper
function of enzymes by damaging their active sites, with
cysteine residues being particularly susceptible [32]. In an
experimental setting, superoxide radicals can be generated by
providing xanthine oxidase with the appropriate substrates
[35].
There is some debate about the impact of H2O2 on
the cellular redox homeostasis. On one hand, H2O2 is not
deemed a major direct threat for the cellular redox homeo-
stasis due to its poor reactivity towards biomolecules [36].
However, H2O2 rapidly translocates through lipid bilayers
2 Journal of Signal Transduction
and is a potential precursor for •OH radicals [32, 37]. Thus,
high concentrations of H2O2 can release iron from heme
proteins and catalyze the conversion of H2O2 to hydroxyl
radicals [37]. It was also proposed that the nonradical
oxidant H2O2 may have profound effects on redox signaling
in living cells, where it alters the function of redox circuits
that are composed of redox-sensitive building blocks [1].
Despite these different views on how H2O2 contributes
to oxidant-induced damage, we and others [38–42] have
used this compound extensively to examine the impact of
oxidative stress on nuclear transport (see below).
1.2. Oxidative Stress and Cellular Defense Mechanisms. The
appropriate response to stress is fundamental to cell survival
and the recovery from disease-related or environmental
damage [3, 5, 6, 9, 11]. Thus, in order to maintain redox
homeostasis, the balance between production and clearance
of ROS is essential. Imbalances in ROS concentration, if
left without proper intervention, can interfere with a wide
variety of cellular processes, leading to serious injuries and
possibly cell death, either by apoptosis or necrosis [28, 43].
Upon accumulation, ROS can interact inappropriately
with a large number of biomolecules, including lipids, pro-
teins, and DNA, thereby interfering with numerous cellular
functions [28, 37]. For instance, ROS may induce damage
to various enzymes, leading to the partial or complete loss
of their function. Notably, ROS-damaged proteins can form
toxic aggregates that cause cell injury and ultimately cell
death [16]. Furthermore, ROS-induced lipid peroxidation
may alter the permeability of cellular membranes, potentially
destroying the membrane integrity and triggering cell death
[33, 44]. In addition, ROS-induced modifications of DNA
can be mutagenic, possibly initiating cell transformation and
promoting cancer [45].
In line with the complex pattern of damage triggered
by oxidative stress, ROS accumulation contributes to the
pathophysiologies of many human diseases and syndromes.
In particular, oxidative stress plays a critical role in the onset
and the progression of neurodegenerative disorders, diabetes,
cardiovascular diseases, and nephropathy [27, 46–58].
To counteract the potential damage of elevated ROS
concentrations, cells have developed different strategies that
limit the action of reactive compounds and prevent their
accumulation. To this end, eukaryotic cells are equipped
with multiple defense mechanisms that promote the removal
and inactivation of ROS in different cellular compartments
[59–62]. These mechanisms rely on the coordinated action
of several enzymatic systems that are able to react with
and neutralize different ROS. For example, the superoxide
dismutase (SOD) system is essential to redox homeostasis
[11, 63–65], as it catalyzes the conversion of •O2− to H2O2.
H2O2 produced by SOD can then be eliminated by the
enzymatic action of catalases.
The glutathione/glutathione disulfide system (GSH/
GSSG) is one of the major contributors to redox homeostasis
and of particular importance to the intracellular redox
state. Accordingly, glutathione is believed to be the primary
defense when cells are injured by oxidative stress during
ischemia/reperfusion [66, 67]. Moreover, changes in the
GSH/GSSG ratio affect the intracellular redox state, and
depletion of intracellular glutathione generates oxidative
stress [61]. Owing to its pivotal importance to redox
homeostasis, imbalance of the GSH/GSSG system has been
linked to many human diseases, pathologies, and aging
[11, 66, 68]. The GSH/GSSG system can be modulated
experimentally, and diethyl maleate is one of compounds
that deplete glutathione, thereby causing oxidative stress [38,
69]. Furthermore, the cellular redox homeostasis can also be
altered by changing the activity of glutathione peroxidase,
glutathione, or thioredoxin reductase.
2. Oxidative Stress and
Nucleocytoplasmic Transport
2.1. Nuclear Transport of Macromolecules. Nucleocytoplas-
mic transport is central to the cellular homeostasis, as the
proper and timely response to endogenous and environ-
mental stimuli relies on the communication between the
nucleus and cytoplasm. This applies in particular to kinases
and phosphatases, many of which move in and out of
the nucleus in response to oxidants or other stressors (see
below). The nuclear envelope provides the barrier between
these two compartments [70, 71], and macromolecules
traverse the nuclear envelope via nuclear pore complexes
(NPCs). Trafficking in and out of the nucleus controls signal
transduction, gene expression, cell-cycle progression, and
apoptosis; regulated nuclear transport is also essential for
development and required for the proper response to stress
[72–75]. The separation of nucleus and cytoplasm is ideal
to divide signaling and other events. However, this compart-
mentalization can impede the intracellular communication
if components of the nuclear transport apparatus are affected
by ROS. This is indeed the case, as nuclear transport factors
are primary cellular targets for oxidants. Before describing
the impact of oxidative stress on nuclear transport, we briefly
summarize those mechanisms of nuclear trafficking that are
relevant to our review (Figure 1).
Although diffusion across the NPC is not simply a
function of the molecular mass, most proteins that are
larger than 40 kD do not efficiently diffuse across the nuclear
envelope. Nevertheless, molecules exceeding the diffusion
channel of the NPC can move in or out of the nucleus if
they carry specialized transport signals. Nuclear localization
(NLS), nuclear export (NES), or shuttling sequences serve
as permanent signals that mediate targeting to the proper
location. Classical NLSs are characterized by clusters of basic
amino acid residues, whereas NESs are frequently enriched
for leucine or isoleucine residues. However, the final destina-
tion of a macromolecule not only depends on such transport
signals; the steady-state distribution is also controlled by its
retention in the nuclear or cytoplasmic compartment.
Nuclear Carriers. Nuclear transport of most proteins de-
pends on transporters of the importin-β group (also called
karyopherin-β). Importin-β family members interact with
their cargo either directly or through an adaptor. The latter
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Figure 1: Simplified model for classical nuclear import and Crm1-
mediated export, two essential transport pathways. Classical nuclear
import depends on the carrier importin-β and the adaptor protein
importin-α. Together, importin-α/β move NLS-containing cargos
to the nucleus. The absence of RanGTP from the cytoplasm permits
the assembly of import complexes in the cytoplasm. Conversely,
the high RanGTP concentration in the nucleus promotes the
dissociation of classical import complexes after they translocate
across the NPC. RanGTP in the nucleus is also necessary to generate
export complexes that contain Crm1 and NES-containing cargo.
The function of Crm1 is inhibited by leptomycin B (LMB).
applies to classical nuclear import, which relies on the
carrier importin-β1 and its adaptor importin-α (Figure 1).
Multiple isoforms of importin-α exist in higher eukary-
otes, where they recognize classical NLSs in endogenous
and fluorescent cargos such as NLS-mCherry (Figure 2(a)).
Crm1/exportin-1 [76], another importin-β family member,
moves NES-containing proteins like mCit-NES to the cyto-
plasm (Figure 2(b)). This transport route can be inhibited
specifically with leptomycin B, a compound that covalently
modifies a cysteine residue of Crm1 [77].
The RanGTPase System. Carriers of the importin-β family
require the small GTPase Ran and factors that mod-
ulate Ran activity. These factors include in the cyto-
plasm RanBP1 (Ran-binding protein 1) and the GTPase
activating protein RanGAP1, with RanGAP1 binding to
Nup358 at the cytoplasmic side of the NPC. By contrast,
the RanGTP-binding protein RanBP3 and the guanine
nucleotide exchange factor RCC1 (RanGEF) are located in
the nucleus, where RCC1 binds to chromatin. The asym-
metric distribution of Ran modulators generates a gradient
across the nuclear envelope, with RanGTP in nuclei and
RanGDP in the cytoplasm (Figure 1). This gradient provides
the driving force for all importin-β dependent transport
[70, 71].
Regulation of Nuclear Transport. Control of nuclear traffick-
ing is crucial under normal, stress, and disease conditions,
and it occurs on multiple levels [72, 73]. For instance,
phosphorylation and other posttranslational modifications
can change the transport of individual cargos [73, 78].
A more general regulation that affects multiple transport
cargos is achieved by targeting components of the nuclear
transport machinery. This can be accomplished by altering
the localization or posttranslational modification of trans-
port factors, and such changes are observed in response to
oxidative stress [72].
The following sections summarize the effects of oxidative
stress on specific cargos that are relevant to human health,
the nucleocytoplasmic transport apparatus, and important
signaling components. We will then build on this informa-
tion to propose that the interdependence of oxidative stress,
nucleocytoplasmic transport, and signaling provides a circuit
that controls cell survival.
2.2. Oxidative Stress Impinges on Multiple Nuclear Cargos.
As discussed above, oxidative stress causes the modification
of targets in the nucleus and cytoplasm. Together, ROS-
dependent modifications of cargos and the nuclear transport
apparatus regulate the intracellular distribution of many
of these targets. Among the oxidant-sensitive targets that
translocate through NPCs are transcription factors, some of
which are also implicated in the stress response. Prominent
examples of transcription factors that relocate in response
to oxidative stress are NF-κB and Nrf2 (NF-E2-related
factor 2). The ROS-mediated redistribution of NF-κB and
Nrf2 has been described extensively [80–83] and the relevant
data will only be summarized here. Our discussion will
focus on high-mobility group box 1 protein (HMGB1) and
glycerolaldehyde-3-phosphate dehydrogenase (GAPDH) to
illustrate the link between ROS, nuclear trafficking and
signalling.
The role of NF-κB in immunity and inflammation is
well established; however, this transcription factor is also
critical for the synthesis of antioxidant proteins [80, 81]. The
genes upregulated by NF-κB include MnSOD, Cu,ZnSOD,
and HO-1 (heme oxygenase 1), all of which participate in
antioxidant defense processes. ROS and numerous other
stimuli control the intracellular distribution of NF-κB. In the
absence of these stimuli, NF-κB is retained in the cytoplasm
due to its association with I-κB. ROS trigger the degradation
of I-κB, thereby promoting the nuclear accumulation of NF-
κB and the subsequent transcription of genes that contain
NF-κB response elements [81].
Nrf2 is another key player in the antioxidant response
that relocates upon oxidant exposure. Under nonstress
conditions, concentrations of the transcription factor Nrf2
are low, and the protein is retained in the cytoplasm owing to
its association with Keap1 [82, 83]. In response to oxidative
stress, a complex series of events leads to the stabilization of
Nrf2 and its translocation into the nucleus. In the nucleus,
Nrf2 upregulates the expression of several genes that are
implicated in the antioxidant response [84]. The oxidant-
induced nuclear accumulation of Nrf2 can be mediated by
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Figure 2: Oxidative stress inhibits classical nuclear import and
Crm1-mediated export. (a) Nuclear import. HeLa cells transiently
synthesizing the import substrates NLS-mCherry or GFP-tagged
glucocorticoid receptor (GR-GFP) were incubated under nonstress
conditions (control) or with DEM as described [69]. Note that
a significant amount of the reporter proteins relocated to the
cytoplasm upon oxidant treatment, indicating that classical nuclear
import was inhibited. (b) Nuclear export. HeLa cells synthesizing
the fluorescent reporter protein mCit-NES, a Crm1 cargo, were
exposed to DEM and processed as in part a. The Crm1 export
cargo was excluded from the nucleus under control conditions, but
relocated to nuclei upon oxidative stress. Size bar is 20 μm.
importin-α5/importin-β1 [85], whereas Nrf2 nuclear export
is promoted by Crm1 [86]. Phosphorylation of Nrf2 likely
plays a role in its nuclear import and export, with PI3 kinase
possibly stimulating Nrf2 nuclear accumulation [83, 84].
More recent studies identified HMGB1 and GAPDH
as redox sensitive proteins whose nucleocytoplasmic distri-
bution is regulated by ROS and signaling [87, 88]. Like
Keap1/Nrf2, HMGB1 functions as a redox sensor [87]. In
nuclei, HMGB1 serves as a DNA chaperone and partici-
pates in replication, transcription, as well as DNA repair.
However, HMGB1 also contributes to a variety of signaling
processes, which involve HMGB1 export to the cytoplasm
and its subsequent secretion. At steady-state HMGB1 shuttles
between the nucleus and cytoplasm, but hyperacetylation
triggers its relocation to the cytosol [89]. It was speculated
that lysine acetylation reduces the number of positive charges
and thus interferes with nuclear import of the protein
[89]. Karyopherin-α1, a member of the importin-α family,
was identified as a binding partner that supports in vitro
nuclear import of HMGB1, most likely in conjunction
with importin-β1 [90]. The interaction of HMGB1 with
karyopherin-α1 can be abrogated by phosphorylation, and
modification of two NLS segments is necessary to relocate
HMGB1 to the cytoplasm [90]. Taken together, a combina-
tion of acetylation and phosphorylation controls HMBG1
nuclear accumulation. These posttranslational modifications
likely prevent the recognition of HMBG1 by the classical
import apparatus.
Nuclear export of HMGB1 is at least in part mediated
by Crm1, as leptomycin B drastically reduced HMGB1 exit
from the nucleus [89]. Treatment with H2O2 upregulated
the interaction Crm1/HMBG1 and relocated HMBG1 to
the cytoplasm for secretion [91]. This oxidant-dependent
secretion was sensitive to JNK and MEK inhibitors, in line
with the idea that several members of the MAP kinase
families control HMBG1 movement from the nucleus to the
cytoplasm and its subsequent release. In other studies, IL-1β-
dependent ERK1/2 activation increased the concentration of
Crm1 and led to HMBG1 accumulation in the cytoplasm
[92]. Whether H2O2 treatment, which activates ERK1/2, has
the same effect on Crm1 levels is an exciting question that
has to be answered in the future.
In recent years GAPDH has emerged as an enzyme that is
involved in diverse cellular processes [88, 93]. Thus, GAPDH
not only functions in glycolysis in the cytoplasm, but also
plays additional important roles in other compartments of
the cell, including the nucleus [88, 94–101]. The nuclear
accumulation of GAPDH is controlled by posttranslational
modifications and the interaction with different binding
partners in the cytoplasm and nucleus. In response to
oxidative stress, GAPDH undergoes S-nitrosylation and
subsequent association with Siah. The GAPDH-Siah com-
plex then moves into the nucleus, where it participates
in the regulation of gene expression and apoptosis [88].
GAPDH nuclear accumulation depends on the acetylation
of three lysine residues by the acetyltransferase p300 [101].
Furthermore, O-GlcNAc glycosylation of GAPDH occurs
close to the Siah-binding site, and this modification pro-
motes GAPDH nuclear accumulation [100]. Although not
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tested by the authors, O-GlcNAc modifications rise in
response to oxidative stress [102] and could therefore assist
in the stress-induced nuclear accumulation of GAPDH.
Interestingly, the nucleocytoplasmic trafficking of GAPDH
has been linked to several signaling pathways. In particular,
activation of AMPK promoted the nuclear accumulation of
GAPDH, whereas signaling through the PI3 kinase→Akt
module is required for Crm1-dependent nuclear export [96].
The intracellular location of GAPDH is directly relevant
to human health (see below). For example, when in the
nucleus GAPDH might contribute to the initiation of
apoptosis in brain cells. Moreover, the oxidant-induced
changes in GAPDH subcellular localization probably play a
role in the pathology of Alzheimer disease [93]. GAPDH is
also critical to the development of diabetic complications,
and changes in its nuclear accumulation might aggravate
diabetic retinopathy [97].
Taken together, there is a growing list of proteins whose
nucleocytoplasmic distribution is controlled by the intra-
cellular redox homeostasis. This regulation frequently relies
on posttranslational modifications, which can alter the
interaction of a particular cargo with its carrier or the
retention in nuclear and cytoplasmic compartments.
2.3. Oxidative Stress as a Key Player in Human Health. The
cellular damage caused by oxidative stress promotes the onset
as well as progression of several diseases and pathophysiolo-
gies. Thus, oxidative stress plays a critical role in neurode-
generative disorders, cardiovascular and metabolic diseases,
as well as the complications associated with diabetes. Here,
we focus on some examples that highlight the adverse effects
of oxidative stress on human health.
Oxidative Stress and Neurodegenerative Diseases. The human
brain is particularly vulnerable to oxidant-induced damage
owing to high oxygen consumption, lipids rich in polyun-
saturated fatty acids, high amounts of redox-active transi-
tion metals, and relatively poor defense against oxidative
stress [30, 48, 103]. Several lines of evidence implicate
oxidative stress in the neuronal damage that accompanies
neurodegenerative disorders [25, 30, 34, 103, 104]. For
instance, analysis of cerebrospinal fluid, plasma, and urine
samples or postmortem brain specimens demonstrated the
increase in oxidative damage in patients suffering from
amyotrophic lateral sclerosis [105], Friedreich ataxia, Parkin-
son, Alzheimer, and Huntington diseases [30, 48, 103].
Oxidant-induced injury is elevated in the brain at early
stages of these diseases, supporting the model that oxidative
stress contributes to the etiology of neurodegeneration. In
line with this hypothesis, mitochondrial dysfunction and
oxidative damage to mitochondrial proteins are shared
features of different neurodegenerative diseases [25, 30,
34, 103]. Animal models further support this idea, as
inhibitors of mitochondrial function can induce some of
the pathologies associated with Parkinson disease [34]. In
addition, proteomics identified a large number of proteins
that show increased oxidative damage in patients suffering
from various forms of neurodegeneration. These proteins
include several enzymes that are critical to oxidative phos-
phorylation and glycolysis. Notably, when compared to con-
trol subjects GAPDH oxidation was increased in Alzheimer
and Parkinson patients; GAPDH was also affected in ALS
mouse models [103]. This is significant, because GAPDH
and its subcellular trafficking are of particular importance
to human metabolism and the pathologies associated with
neurodegenerative diseases. As such, oxidative damage not
only reduces the enzymatic activity of GAPDH in Alzheimer
disease, but also supports the association with Siah and the
subsequent translocation of the GAPDH-Siah complex to
the nucleus (see above). In Alzheimer disease, both GAPDH
expression and nitrosylation are increased, probably leading
to elevated concentrations of GAPDH-Siah in the nucleus,
which in turn promotes apoptosis [93]. Taken together, the
oxidant-induced changes in GAPDH enzyme activity and
intracellular distribution will reduce the energy supply and
advance apoptosis in the brain of Alzheimer patients. Since
GAPDH is an established target of oxidative damage in
several neurodegenerative diseases [103], it is possible that its
oxidant-dependent change in nuclear transport and the sub-
sequent increase in cell death are common to multiple forms
of neurodegeneration. Interestingly, GAPDH also plays a
critical role in the development of diabetic complications.
Oxidative Stress and Diabetes. Oxidative stress is crucial to
the etiology of diabetes mellitus and the ensuing damage
to different tissues and organs [27, 49, 55, 106, 107]. Thus,
oxidative stress can alter insulin signaling by targeting insulin
receptor and insulin receptor substrates or through the
activation of ser/thr kinases that regulate insulin signaling
[55]. In this scenario, the ROS-induced changes to the insulin
signaling pathway will advance insulin resistance and the
subsequent development of diabetes. PI3 kinase and the
MAP kinases ERK1/2 are major components of insulin-
mediated signaling. Interestingly, signaling through these
kinases is also modulated by oxidative stress and regulates
nuclear trafficking (see below).
Oxidative stress not only promotes the development of
diabetes, but diabetes also triggers the increase in oxidative
stress due to elevated blood glucose and free fatty acids.
Such disease-induced ROS production further exacerbates
cellular damage and contributes to diabetic complications.
In the following, we discuss some of the routes that generate
oxidative stress in the diabetic patient [49, 55, 106–108].
Hyperglycemia rises intracellular glucose concentrations
and the subsequent production of pyruvate, which is
ultimately metabolized via the tricarboxylic acid cycle. As
a result of the high abundance of pyruvate, increased
amounts of NADH and FADH2 are generated by the
tricarboxylic acid cycle. Both NADH and FADH2 enter
into the mitochondrial electron transport chain, but their
excess interferes eventually with the proper transfer of
electrons. As a consequence of this overload, superoxide
production by mitochondria increases and promotes cellular
damage, especially in the diabetic vasculature [109, 110].
The importance of mitochondria in hyperglycemia-induced
injuries was demonstrated experimentally, as inhibitors of
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Figure 3: Oxidative stress interferes with importin-α1-dependent
import of endogenous cargos. The import of two endogenous
proteins, the RNA-binding protein HuR and galectin-3, was moni-
tored in HeLa cells under the conditions described for Figure 2(a).
Importin-α1 promotes nuclear import of both proteins. HuR and
galectin-3 were visualized by indirect immunofluorescence and
nuclei were stained with DAPI [69]. HuR was nuclear in control
cells and redistributed to the cytoplasm of stressed cells, where
it accumulated in stress granules (SGs). Similarly, galectin-3 was
more concentrated in the nuclei of control cells and relocated to
the cytoplasm upon DEM treatment. Arrows indicate the position
of some of the SGs.
the electron transport chain, upregulation of the uncoupling
protein UCP1, or mitochondrial SOD ameliorated some of
the damage [49, 106].
The excess of mitochondrial superoxide, combined
with other hyperglycemia-induced changes, culminates in
secondary diabetic complications. In particular, diabetic
nephropathy, retinopathy, neuropathy, and cardiomyopathy
arise from the modulation of multiple biochemical pathways,
some of which alter the cellular redox homeostasis [27,
49, 107]. For example, upon diabetes, the abundance of
intracellular glucose and glycolytic metabolites leads to the
increased production of sorbitol and other sugar alcohols
by the polyol pathway. This generation of sugar alcohols
mediated by members of the aldo-keto reductase family relies
on the conversion of NADPH to NADP+ [49]. Since NADPH
is necessary to generate GSH from GSSG, excessive NADPH
consumption will compromise the antioxidant defense and
promote ROS-induced damage.
Moreover, ROS concentrations can also be elevated by
hyperglycemia-dependent changes in cell signaling. As de-
scribed above, GAPDH is sensitive to oxidative stress, and
the inhibition of GAPDH by ROS increases intracellular
concentrations of triose phosphate, a precursor of the
PKC activator diacylglycerol. Hence, hyperglycemia triggers
PKC activation, thereby changing the signaling events in
the diabetic retina, heart, and endothelial cells [49, 106].
Moreover, this hyperglycemia-induced PKC activation is
particularly detrimental to the kidney, as it stimulates ROS
production by NAD(P)H oxidases and advances diabetic
nephropathy [106, 111].
Like other forms of stress, diabetes modulates the nucleo-
cytoplasmic distribution of transcription factors, with NF-κB
as a prominent example [112]. Similarly, high glucose con-
centrations accumulated GAPDH in the nucleus of bovine
retinal endothelial cells [97], where it could contribute to the
progression of diabetic retinopathy.
The downstream effects of hyperglycemia further include
changes in the posttranslational modification of proteins.
Thus, elevated glucose concentrations raise the amount of
fructose-6-phosphate that enters the hexosamine pathway
[27, 106], which in turn increases the production of UDP-
N-Acetylglucosamine and the subsequent O-GlcNAc modi-
fication of proteins. These changes are important to nuclear
transport, because nucleoporins are well established targets
for O-GlcNAc-glycosylation.
In summary, oxidative stress is implicated in different
pathophysiological conditions, some of which alter the
proper coordination of nuclear and cytoplasmic events. As
discussed in the following section, ROS impinge on the
nuclear transport apparatus and thereby modify the commu-
nication between nucleus and cytoplasm.
2.4. Nuclear Transport and Redox Homeostasis. Changes in
cell physiology affect nucleocytoplasmic trafficking in a wide
variety of eukaryotes, and the effects of oxidative stress on
the nuclear transport apparatus have been analyzed during
the past years. We have shown for the yeast S. cerevisiae
and mammalian culture cells that different forms of stress,
including oxidants, heat, and nutrient deprivation inhibit
classical nuclear import and export [38, 39, 69, 72, 79, 113–
121]. Our previous studies examined the impact of severe
and mild oxidative stress. While severe oxidative stress was
produced with high concentrations of H2O2 [39], mild
oxidative stress was generated by the oxidant diethyl maleate,
DEM [69]. Under severe stress conditions, cells underwent
apoptosis, but a large fraction of cells survived the milder
stress inflicted with DEM [69]. Nevertheless, Figures 2 and
3 show that DEM treatment diminished nuclear transport
of both fluorescent reporter proteins and endogenous cargos
[69, 79, 117]. This is not simply a consequence of stress-
induced permeabilization of nuclear envelopes, because the
barrier function of nuclear membranes was preserved under
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Figure 4: Mild and severe oxidative stress have different effects on nuclear transport factors. The effects of mild (2 mM DEM) and severe
oxidative stress (10 mM H2O2) on the subcellular distribution of importin-α1, Ran, and HuR were analyzed in HeLa cells. Proteins were
located by indirect immunofluorescence [39, 69, 79]. DEM treatment accumulated importin-α1 in nuclei but did not drastically affect the
distribution of Ran. By contrast, severe oxidative stress induced by H2O2 caused a pronounced nuclear accumulation of importin-α1 and
collapsed the nucleocytoplasmic Ran gradient. Both treatments relocated HuR to the cytoplasm. However, DEM triggered the assembly of
HuR-containing SGs, which were rare or absent upon incubation with H2O2.
these conditions [122]. Since fluorescent reporter proteins
like NLS-mCherry or mCit-NES do not contain nuclear or
cytoplasmic retention signals, it was reasonable to assume
that their stress-induced redistribution reflected changes to
the transport apparatus. As described below, such changes
were indeed reported by different laboratories, both for
severe and mild forms of oxidative stress.
A common consequence of H2O2-induced severe oxida-
tive stress is the collapse of the nucleocytoplasmic Ran
GTPase gradient in growing cells (Figure 4); this collapse
contributes to classical import inhibition [35, 38, 39, 121].
In addition, three key components of the transport appa-
ratus, nucleoporin Nup153, the carrier importin-β1, and
importin-α1 (Figure 4), redistributed when cells were treated
with H2O2 [39]. Aside from transport factor redistribution,
H2O2 also caused the degradation of Ran, Nup153 and
importin-β1, both by proteasome and caspase-dependent
mechanisms. In addition to growing cells, the consequences
of H2O2 incubation were also examined in vitro. In these
experiments, oxidant treatment led to a significant reduction
of the docking step of nuclear import, as it diminished the
binding of importin-α1/β1/cargo complexes at the nuclear
envelope [39].
Our more recent studies investigated how nonlethal
oxidative stress affects the transport apparatus. To this
end, intracellular glutathione concentrations were depleted
with DEM. Unlike severe oxidative stress, DEM incubation
caused neither a dissipation of the Ran gradient (Figure 4)
nor the degradation of transport receptors. However,
DEM treatment mislocalized several transport components,
including importin-α1, its nuclear exporter CAS as well
as nucleoporins Nup153, Nup88, and Nup50 [69]. Nuclear
retention was one of the mechanisms that contributed to
the oxidant-induced nuclear accumulation of these proteins.
Concomitant with nuclear retention, high molecular mass
complexes were formed in nuclei that contained importin-
α1, Nup153, and Nup88. A second mechanism promoting
the redistribution of transport factors was the increase in
nuclear import for importin-α1 and CAS [69]. Notably,
the subcellular redistribution of importin-α1, CAS, Nup153,
and Nup88 was accompanied by changes in their posttrans-
lational modification. For example, DEM augmented the
phosphorylation for each factor and increased the O-GlcNAc
modification of Nup153 [117]. All of these events are pos-
sibly linked to oxidant-induced signaling, as the relocation
of importin-α1, CAS, Nup153 and Nup88 was modulated by
MEK→ERK1/2 and PI3K→Akt pathways [117].
Oxidative stress not only inhibits nuclear import, the
Crm1 export pathway is sensitive to oxidants as well [79],
and our group demonstrated that Crm1-mediated export
was inhibited by DEM. Consequently, mCit-NES, a Crm1
cargo predominantly in the cytoplasm of unstressed cells,
relocated to nuclei in DEM-treated samples (Figure 2).
Several mechanisms participated in the oxidant-induced
inhibition of Crm1-dependent export [79]. First, oxidative
stress changed the association of Nup358, Nup214, Nup62,
and Crm1 with the nuclear envelope and redistributed
Nup98. Second, the interaction among these nucleoporins
was altered. Third, oxidant treatment impaired Crm1 exit
from the nucleus and increased its binding to Ran.
Taken together, these studies revealed that oxidative stress
alters several steps of classical nuclear import and export
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and substantiated the hypothesis that the nuclear transport
apparatus is an important target for oxidants. Some of
the oxidant-sensitive components are shared by import and
export pathways, which might explain why both transport
routes are affected in stressed cells.
Work by other groups identified additional transport
factors that are likely controlled by ROS homeostasis [72].
For instance, ceramide inhibited nuclear import through a
pathway that relied on the MAPK p38 [123]. As ceramide
is believed to cause oxidative stress [124, 125], these exper-
iments provide another link between ROS imbalance and
changes in nuclear trafficking. This idea is further supported
by experiments in smooth muscle cells, where lysophos-
phatidylcholine modulated RanGAP1 activity [126]. Since
lysophosphatidylcholine can induce ROS production [127],
RanGAP1 and thereby the generation of RanGDP in the
cytoplasm are potential candidates for ROS-dependent regu-
lation. The role of RanGAP1 as an oxidant-sensitive target in
the cytoplasm is significant, because RanGAP1 promotes the
termination of protein export for all importin-β like carriers.
Furthermore, RanGAP1 has emerged as target for several
MAP kinases [128], emphasizing its potential to serve as a
redox-sensitive transport regulator at the NPC.
The idea of redox-dependent control at the nuclear pore
is consistent with a recent publication that detected the MAP
kinases ERK, p38, and JNK at the NPC [129]. Importantly,
all of these kinases are activated and/or redistributed by
ROS (Table 1). Moreover Nup50, Nup153, and Nup214
are established ERK targets [130], and their phosphory-
lation changed several interactions that are important for
nuclear transport. Specifically, ERK-dependent modification
of Nup50 interfered with its binding to importin-β and
transportin, which are both carriers of the importin-β family.
Similarly, when Nup153 and Nup214 were phosphorylated
by ERK, their association with importin-β was reduced.
In summary, multiple signaling pathways are activated
by oxidants, MAP kinases reside at the NPC or relocate
upon stress (see below), and several transport factors are
targeted by these kinases. Hence, it is reasonable to propose
a simplified chain of events: oxidative stress → signaling →
transport factor modification and/or relocation → changes
in nuclear trafficking → altered distribution of cargos. This
is by no means a one-way street, as nuclear transport factors
also play a critical role in modifying signaling events.
An example for the interdependence of signaling and
nuclear transport is provided by RanBP3. This transport
factor is not only regulated by multiple kinase modules,
it also controls signaling [131, 132]. RanBP3 is predom-
inantly located in the nucleus and a binding partner for
Ran, RCC1, and Crm1. Aside from participating in Ran
translocation to the cytoplasm, RanBP3 may also sequester
Ran in the nucleus [131]. Phosphorylation by RSK and
Akt can modulate RanBP3 function. In particular, RanBP3
modification is believed to stimulate nuclear import by
regulating its interaction with RCC1. In support of this
model, nonphosphorylatable mutants of RanBP3 displayed
a reduced ability to stimulate RCC1 in vitro and caused
a partial dissipation of the Ran gradient in growing cells
[131]. The emerging scenario is that signaling through
Ras → MEK1/2 → ERK1/2 → RSK and PI3 kinase → Akt
leads to RanBP3 phosphorylation, thereby maintaining the
Ran gradient. Since both signaling pathways are modulated
by ROS, it is tempting to speculate that their activation by
oxidants will help to preserve or re-establish the Ran gradient
in stressed cells.
Besides being a downstream target of several signaling
pathways, RanBP3 has a critical role in controlling TGF-β
signaling [132]. Signaling through TGF-β and its receptors
have multiple links to oxidative stress [133–136], and many
effects of TGF-β-like ligands are exerted by the downstream
transcriptional regulators Smad2/3. Smad2/3 are shuttling
proteins, and their transport to the nucleus relies on direct
binding to importin-β, without involvement of the adaptor
importin-α [137]. Following activation of TGF-β, Smad2/3
are phosphorylated and accumulate in nuclei, where they
regulate the expression of target genes. The termination of
TGF-β signaling involves the dephosphorylation of Smad2/3
and their export to the cytoplasm. Notably, Smad2/3 nuclear
export is not sensitive to leptomycin B, suggesting that Crm1
is not required for exit from the nucleus. Indeed, RanBP3 was
identified as a possible carrier that helps to move Smad2/3 to
the cytoplasm [132]. Several lines of evidence support this
idea; RanBP3 bound nonphosphorylated Smad2/3, inter-
acted with Smad2/3 in the nucleus and promoted Smad2/3
nuclear export in a Ran-dependent fashion. Together, these
studies established an essential role for RanBP3 as a negative
regulator of Smad2/3 signaling, which relies on its ability to
transport Smad2/3 to the cytoplasm.
The impact of ROS on nuclear transport is not limited
to signaling-dependent effects, since ROS can directly induce
the modification of nuclear transport components. Protein
carbonylation is one of the consequences of oxidative stress,
and it occurs in an age-dependent fashion for nucleoporins
Nup153 and Nup93. Nucleoporin carbonylation correlated
with the “leakiness” of NPCs [138], and could be particularly
harmful to postmitotic cells, in which some nucleoporins
are replaced only slowly. In the context of signaling, it
will be interesting to determine whether the age-dependent
nucleoporin carbonylation alters the NPC association of
MAP kinases or nucleoporin phosphorylation.
In summary, experiments described above suggest that
the stress-induced modulation of nuclear trafficking is
caused by changes in the concentration, distribution, and
posttranslational modification of transport factors [72, 82].
This process is further complicated by the fact that oxidant-
dependent relocation of transport factors can be compart-
mentalized even within the nucleus or cytoplasm, as shown
by the formation of cytoplasmic stress granules.
2.5. Oxidative Stress, Stress Granule Assembly, and Nuclear
Transport. One of the possible consequences of oxidative
stress is the formation of cytoplasmic stress granules (SGs).
SGs are generated in response to stress that leads to the accu-
mulation of stalled translation initiation complexes [139,
140]. SG assembly is part of a stress defense mechanism that
helps to retain and protect mRNAs from degradation. One
of the signaling events crucial for the formation of most SGs
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Table 1: Redox-sensitive cellular targets in eukaryotic cells. Components that alter their activity and/or nucleocytoplasmic distribution when
ROS concentrations increase are listed. See text for details.
Component or process Effect of ROS
Signaling proteins, transcriptional regulators
JNK, MAPK Activation
p38, MAPK Activation, nuclear translocation
ERK1/2, MAPK Activation, nuclear accumulation
PI3 kinase (some isoforms) Activation, changes in nucleocytoplasmic distribution
5′-AMP activated kinase
Inhibition, nuclear accumulation; possibly by reduced nuclear export
via Crm1
Human insulin receptor kinase activity Activation
Src family kinases Activation
EGFR Nuclear translocation; DNA repair
Protein tyrosine phosphatases Inactivation
PTEN Nuclear accumulation; association with p53
STAT3 Nuclear translocation
NF-κB, transcription factor Nuclear accumulation; transcription
FoxO transcription factors Nuclear translocation (i.e., FOXO1, FOXO3a, and FOXO4)
yAP-1, yeast transcription factor Nuclear translocation
Msn2p, Msn4p, yeast transcription factors Nuclear translocation, transcription
CREB Phosphorylation, nuclear translocation
Nrf2 Nuclear accumulation
HMGB1 Cytoplasmic translocation
HuR, RNA-binding protein Relocation to cytoplasm, accumulation in stress granules
Nuclear transport apparatus
Classical nuclear import Inhibition
Crm1-dependent nuclear export Inhibition
Ran, small GTPase; Gsp1 in S. cerevisiae Relocation to cytoplasm upon severe oxidative stress
Importin-α1, adaptor for classical nuclear import Accumulation in nuclei, accumulation in cytoplasmic stress granules
Crm1, nuclear exporter Accumulation at nuclear envelope
CAS, exporter for importin-α Nuclear accumulation
Multiple nucleoporins located at different positions
within the nuclear pore complex: Nup358, Nup214,
Nup88, Nup62, Nup153, Nup50, Nup98, and others
Changes in the association with nuclear envelope; altered
nucleocytoplasmic distribution; degradation upon severe stress, in
some cases mediated by caspases.
is Ser51 phosphorylation on eIF2α (eukaryotic translation
initiation factor 2) [139–141]. Ser51 can be modified by
four different upstream kinases, PKR, PERK, GCN2, and
HRI (heme-regulated initiation factor 2 kinase), which are
activated by various stressors, including the oxidant arsenite.
Other signaling events are relevant to SG biogenesis and dis-
assembly; for instance, arsenite promotes the sequestration
of Rho and ROCK1 in SGs, possibly to limit the activation of
the downstream target JNK [142]. Moreover, focal adhesion
kinase (FAK) controls the disassembly of SGs and can be
stimulated with H2O2 [143, 144].
In addition to components of the small ribosomal
subunit and RNA-binding proteins, arsenite-induced SGs
contain importin-α1 [145]. Notably, importin-α1 knock-
down delays SG formation, suggesting a role in the dynamics
of SG assembly. These are important data which further
substantiate the contribution of nuclear protein transport
factors to the stress response. At present, we do not fully
understand these events; however, it is conceivable that
SGs are one of the “hubs”, where ROS-mediated signaling
and nuclear transport components come together in the
cytoplasm. Results for the mRNA-binding protein HuR
support this idea. HuR shuttles between the nucleus and
cytoplasm and relies on importin-α1 for nuclear import.
Under normal growth conditions, HuR is predominantly
in the nucleus, but a 4-hour DEM treatment concentrated
HuR in SGs (Figures 3 and 4). At the same time, importin-
α1 accumulated in nuclei, but it was still detectable in
the cytoplasm [69, 117]. It should be emphasized that the
association of macromolecules with SGs is dynamic. Proteins
as well as RNA can shuttle between SGs and the surrounding
cytoplasm [141, 146], and this may also apply to importin-
α1.
What are the possible mechanisms that promote the
ROS-dependent changes in importin-α1 and HuR distri-
bution and how are these events linked to SG assembly?
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The DEM-induced relocation of HuR is likely driven by
the combination of importin-α1 nuclear accumulation and
HuR association with SGs. In particular, concentrating
importin-α1 in nuclei of stressed cells could diminish nuclear
import of HuR. At the same time, importin-α1 has a role
in SG biogenesis. Although details of this process have
yet to be defined, importin-α1 may recruit components
to cytoplasmic foci that are destined to form SGs. Given
that importin-α1 binds and transports a variety of cargos,
importin-α1 shuttling between SG foci and the cytoplasm
could accomplish this task. If our model is correct, it could
help explain the lack of SG formation in cells incubated with
H2O2 [147, 148]. As shown in Figure 4, H2O2 did not induce
SGs, and importin-α1 became highly concentrated in the
nucleus, with little of the protein remaining in the cytoplasm.
Moreover, stress can also increase nuclear retention and
import of importin-α1 [113]. As a result of these events, the
concentration of importin-α1 in the cytoplasm will be low
when cells are treated with H2O2, which in turn could limit
the formation of SGs.
The potential contribution of nuclear transport factors
to SG assembly or function is not restricted to importin-
α1. Support for this notion comes from importin-β family
members importin 8 and transportin which localize to
SGs upon arsenite treatment [149, 150]. At this point,
we have only few examples that connect nuclear transport
components with SGs, and future studies will have to unravel
how nuclear trafficking, SG assembly, and ROS-dependent
signaling are integrated.
2.6. Oxidative Stress and the Subcellular Distribution of
Key Signaling Molecules. Elevated levels of ROS modify the
activity of redox sensitive components that participate in
signaling or other essential biological processes [1, 6, 9,
39, 69, 79, 87, 88, 114, 116, 151–153]. Notably, such ROS-
dependent changes in activity are frequently accompanied
by the intracellular relocation of the redox-sensitive factors.
This scenario applies to a growing list of protein kinases,
phosphatases, transcription factors, and components of the
nuclear transport apparatus (Table 1). Several of the kinases
and phosphatases that redistribute under oxidative stress
conditions are key players in signaling circuits, where they
control cell survival, growth, proliferation, or death. The
interdependence of the activation status and intracellular
distribution is crucial for these enzymes, as it determines
the specificity and duration of signaling events [152, 154–
156]. In the following, we discuss some of the kinases and
phosphatases for which oxidant-dependent relocation has
been established.
The activity and location of several members of the
MAPK and PI3 kinase families are modulated by ROS.
Such spatiotemporal control is particularly important for the
response to stress, where the repair of stress-induced damage
and cell survival relies on the outcome of compartment-
specific signaling events. Multiple signaling modules that
respond to ROS, both by activation and relocation, have been
analyzed in our group [114, 116]. We focused on Akt and
ERK1/2, kinases that are essential for signal transduction
through PI3 → Akt and MEK → ERK1/2 modules. The
stressor DEM elevated the phosphorylation of Akt on Thr308
and Ser473, which leads to Akt activation. At the same time,
DEM induced the dual phosphorylation of ERK1/2, thereby
activating the MAP kinases. Importantly, DEM not only
activates Akt and ERK1/2, but also increased significantly
the nuclear/cytoplasmic ratio of phospho-Akt(Ser473) and
dually phosphorylated-ERK1/2 [114]. A possible outcome
of this shift is a change in the phosphorylation profiles of
nuclear and cytoplasmic targets. Notably, the compartmen-
talization of Akt and ERK1/2-dependent signaling events
is even more complex [114], as we demonstrated in the
nucleus a direct correlation between the levels of phospho-
Akt(Ser473) and phospho-ERK1/2. Our studies suggested
that the nuclear concentration of phospho-Akt(Ser473) is
dependent on nuclear phospho-ERK1/2 and vice versa.
Accordingly, crosstalk occurs between phospho-Akt(Ser473)
and ERK1/2 in response to oxidative stress; this crosstalk is
specific for the nuclear compartment.
More recent work on PI3 kinase by others further empha-
sizes the importance of the localized action of signaling
molecules. The PI3 kinase catalytic subunit p110β carries a
nuclear localization signal in its C-terminal domain, while
the regulatory subunit p85β harbors a nuclear export signal.
The analysis of a p110β transport mutant showed that the
ability of the p85β/p110β complex to regulate cell survival
was strictly dependent on its nuclear localization [157].
Although the effect of oxidative stress on the distribution of
this kinase has yet to be determined, these findings provide
compelling evidence for the control of cell signaling by
nuclear transport.
Another example that illustrates the ROS-dependent
activation and distribution of protein kinases is the het-
erotrimeric enzyme 5′-AMP activated kinase (AMPK).
AMPK is an energy sensor which plays a pivotal role in
the regulation of metabolic homeostasis by phosphorylating
targets that are involved in glucose, carbohydrate, lipid,
and protein metabolism [158–161]. In unstressed cells,
AMPK shuttles between the nucleus and cytoplasm and
this shuttling relies on the nuclear exporter Crm1 [116,
162]. However, in response to oxidative stress, AMPK α-
and β-subunits concentrated in the nucleus. This could be
accomplished—at least in part—by ROS-induced changes
to the nuclear export apparatus, as Crm1 is one of the
transport components that are affected by ROS (see above).
Interestingly, the link between AMPK activity, subcellular
distribution, and nuclear trafficking is even more intricate,
as importin-α1, a component of the nuclear transport
apparatus, is also modified by AMPK [163].
Epidermal growth factor receptor (EGFR) is a receptor
tyrosine kinase that is especially important to human health,
because signaling through EGFR is linked to tumorige-
nesis, metastasis and radioresistance. EGFR is located in
the plasma membrane, but it also entered the nucleus in
response to oxidative stress, heat, or radiation [164]. More-
over, incubation of cultured cells with hydroxy-nonenal, a
compound generated by lipid peroxidation, promoted the
nuclear accumulation of EGFR [19]. When in the nucleus,
EGFR stimulated DNA repair, a process that contributes
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to radioresistance and potentially limits the success of
radiotherapy. Since EGFR is membrane bound, details of
its nuclear transport are likely to differ from soluble cargos.
Nevertheless, importin-β1 and Crm1 (Figure 1) were identi-
fied as nuclear carriers that participate in EGFR trafficking
[165, 166].
The link between oxidative stress and the localization of
key signaling components is not limited to protein kinases.
For instance, the lipid and protein phosphatase PTEN has
functions in the nucleus and cytoplasm, and oxidative stress
promotes PTEN nuclear accumulation [167]. In cells treated
with H2O2, PTEN concentrated in nuclei, where it stabilizes
the tumor suppressor p53. Under normal conditions, PTEN
is exported from the nucleus by the carrier Crm1 in a
cell-cycle dependent fashion, and this export relied on
signaling through PI3 kinase [168]. However, incubation
with H2O2 induced PTEN phosphorylation on Ser380, which
inhibited its nuclear export [167]. The control of PTEN
shuttling upon oxidative stress probably goes beyond the
oxidant-induced phosphorylation of the enzyme. As such,
the exporter Crm1 is one of the cellular targets that are
sensitive to ROS, and signaling through the PI3 kinase →
Akt module regulates several components of the nuclear
transport apparatus [79, 117]. This interdependence of
nuclear transport and signaling is further complicated by
the fact that the enzymatic activity of PTEN is regulated by
oxidants (see below).
For the examples discussed here, ROS-mediated changes
in the nucleocytoplasmic distribution of kinases and phos-
phatases could reflect the requirement to modify selected
substrates in specific subcellular compartments. To this end,
the ROS-induced nuclear accumulation of ERK1/2, PI3
kinase, AMPK, EGFR, or PTEN will alter the phosphoryla-
tion and activity of nuclear substrates such as transcription
factors and other regulators of gene expression. However,
such redistribution will also impact other compartments,
because the sequestration of kinases or phosphatases in the
nucleus can change the phosphoproteome in the cytoplasm
as well.
2.7. What Is the Interface between the Initial Oxidant Ex-
posure and Changes in the Nuclear Transport Apparatus?
As discussed in previous sections, oxidative stress targets
components of the nuclear transport machinery. Moreover,
different signaling cascades are implicated in the control
of trafficking across the NPC, in part by regulating the
posttranslational modification of nuclear transport factors. A
complete mechanistic understanding of these events requires
that the initial impact of the oxidant can be connected
to functional changes of the nuclear transport apparatus.
For many of the processes described here, the interface
between the primary oxidant-induced event and changes in
the posttranslational modification or function of transport
factors is not fully defined. In the following, we will,
therefore, speculate on some of the possible links.
In principle, two distinct mechanisms can underlie the
effect of ROS on nuclear transport factors. First, ROS might
react directly with the nuclear transport apparatus, leading
to the covalent modification of individual components.
Second, oxidative stress could activate signaling cascades that
ultimately trigger the phosphorylation and/or O-GlcNAc
glycosylation of the transport machinery. In the second
scenario, signaling begins with a redox-sensitive target that
induces a chain of events which conclude with the post-
translational modification of one or more nuclear transport
factors.
Direct Modification of the Nuclear Transport Apparatus by
ROS. In line with what is known about redox-sensitive
residues in proteins, we expect that for nuclear transport
components cysteine, methionine, lysine, arginine, and histi-
dine residues are among the side chains that are particularly
prone to direct oxidation or other ROS-dependent modifi-
cations [169]. This idea is supported by a study describing
the S-nitrosylation of Crm1 on two cysteine residues and the
concomitant inhibition of Crm1-mediated nuclear export
[170]. Besides Crm1, nucleoporins are other candidates for
a direct modification by ROS or compounds generated upon
oxidative stress. Our hypothesis is supported by the increase
in nucleoporin carbonylation when cells encounter oxidative
stress [138].
Signaling as Possible Interface between Oxidant Exposure
and Nuclear Transport Modification. Although many of the
enzymes that mediate the posttranslational modification of
transport factors are known, upstream events regulating
these enzymes are less well understood. This applies in
particular to the first step of the process, that is, the impact of
ROS on its primary target. We propose that protein kinases,
phosphatases, or small GTPases that are redox-sensitive
[171–174] could fill this gap, as they activate signaling
pathways that culminate in transport factor modification.
A particularly interesting candidate in this respect is the
protein kinase Src, which contains a cysteine switch that is
oxidized in order to achieve full kinase activation. Moreover,
the redox-dependent stimulation of Src promotes the ligand-
independent transphosphorylation of EGFR and subsequent
activation of PI3 and ERK kinases [175]. In line with this
order of events, it is possible that the ROS-induced formation
of disulfide bonds in Src will stimulate the PI3 and ERK-
dependent effects on nuclear transport factors as they are
discussed here.
The same reasoning applies to several phosphatases
[174], including PTEN and low molecular weight pro-
tein tyrosine phosphatase (LMW-PTP). PTEN is crucial
for the downregulation of PI3 kinase signaling. However,
oxidant-induced thiol modification of PTEN inactivates the
phosphatase, and thereby promotes signaling through the
PI3 kinase → Akt module [174]. With respect to nuclear
transport, ROS-induced PTEN inactivation would increase
the impact of PI3 kinase on trafficking. In a similar fashion,
the redox-dependent inactivation of LMW-PTP leads to
sustained ERK activation [176]. This could elevate the ERK-
dependent phosphorylation of soluble transport factors and
nucleoporins, thus altering their function.
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Aside from phosphorylation, O-GlcNAc glycosylation of
nucleoporins is induced by oxidative stress. The oxidant-
dependent increase in O-GlcNAc modification is possibly
achieved by the complex regulation of O-GlcNAc transferase
and β-N-acetylglucosaminidase. At present, these events are
not fully understood [177].
Taken together, we propose that changes in the cellular
redox homeostasis impact nucleocytoplasmic trafficking by
two general mechanisms that are likely to operate in parallel.
First, ROS or ROS-generated compounds directly modify
redox-sensitive transport factors, this can alter their func-
tion. Second, the impact of ROS on redox-sensitive signaling
proteins will ultimately modulate the posttranslational mod-
ification and activity of nuclear transport components.
2.8. Antioxidant Defenses Occur in a Compartmentalized
Fashion. In addition to the compartmentalized activation
and action of kinases and phosphatases, components of the
antioxidant defense apparatus are also unequally distributed
within the cell [63, 178]. This is illustrated by catalase,
an enzyme concentrated in peroxisomes, and the different
forms of superoxide dismutase (SOD) [64, 65, 179, 180].
While manganese-containing SOD (MnSOD) is in the
mitochondrial matrix, copper- and zinc-containing SOD
(Cu,ZnSOD) can be found preferentially in the cytoplasm
and extracellular SOD (EC-SOD) on the cell surface. More-
over, the unequal distribution of GSH and enzymes involved
in GSH metabolism will also contribute to subcellular
differences in the response to ROS [59, 181–183]. Aside
from these enzymes and antioxidants, the localized action of
chaperones, critical factors for the repair of stress-induced
damage, is well established [115, 184–186]. Since chaperone
function is essential for proper signaling and also required
for nuclear transport, the nucleocytoplasmic localization
and function of heat shock proteins and other chaperones
will have significant impact when cells experience ROS
imbalances.
We propose that the unequal distribution of antioxidant
defense and repair components will impact both cargos and
transport factors in a compartment-specific fashion. Accord-
ingly, the prevention and repair of oxidant-induced damage
will be different in the nucleus and cytoplasm. Depending
on its subcellular location, this could have differential effects
on the movement and function of a shuttling protein. For
example, nuclear cargos that encounter higher levels of ROS
in the cytoplasm could be immobilized in this compartment.
The same model can be applied to nuclear transport factors.
Thus, nucleoporins on the nuclear and cytoplasmic side
of the NPC could be exposed to different levels of ROS
and repair. Since nuclear and cytoplasmic nucleoporins
participate in different steps of trafficking, damage on either
side of the nuclear pore could have unique consequences for
nuclear transport.
3. Conclusions
The impact of ROS on human health is well established,
and links between oxidative stress, nuclear transport, and
Oxidative
stress
Signaling:
protein kinases
protein and lipid
phosphatases
Cell survival
or death
?
Nuclear transport:
soluble factors
nucleoporins
Chaperones
C
Figure 5: Simplified model for the crosstalk between signaling
and nuclear transport in response to oxidative stress. Oxidative
stress impinges on signaling molecules and the nuclear transport
apparatus, with chaperones modulating both processes. Different
scenarios can explain the communication between nuclear trans-
port and signaling pathways in oxidant-treated cells. In one case,
oxidative stress alters the localization and activity of transport
factors. This will change the subcellular distribution of key signaling
molecules, which in turn affects the modification of downstream
targets. Alternatively, the signaling pathways activated by oxidative
stress cause the modification and redistribution of transport factors.
Both scenarios are likely to take place side-by-side, and the balance
of these events will ultimately determine cell fate.
disease have been defined. For instance, oxidative stress
plays a pivotal role in the hyperglycemia-induced damage
of multiple tissues and organs [47, 49, 51–53, 55, 187].
GAPDH nucleocytoplasmic shuttling not only participates
in these processes, but has also been connected to cancer
and neurodegenerative disorders, such as ALS, Alzheimer,
or Parkinson disease [88]. Hence, it is conceivable that
the oxidant-induced relocation of GAPDH is common to
diabetes, cancer, and some forms of neurodegeneration. This
shared feature can be extended to the stress-induced nuclear
trafficking of the transcriptional regulators NF-κB and Nrf2
and may include other diseases, such as Friedreich ataxia
[56, 188, 189].
The examples highlight how the compartment-specific
action of signaling molecules, defense and repair reactions
provide sophisticated tools to regulate cell physiology. Thus,
confining these processes to specific locations will limit the
access to downstream targets and clients. In the context of
this review, the nucleocytoplasmic distribution of kinases,
phosphatases, and other factors involved in posttranslational
modification or folding can be expected to directly affect
the communication between cytoplasmic and nuclear
compartments. This is emphasized by the fact that many
of the nuclear transport components and their cargos are
modified in an ROS-dependent fashion by phosphorylation,
O-GlcNAc glycosylation, acetylation, or sumoylation.
Our current understanding of ROS, signaling, and
nucleocytoplasmic transport supports the notion that these
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processes are intricately connected. Although many of
the details are still to be discovered, the findings from
different fields can be merged into a simplified model.
Here, we propose that crosstalk and feedback between
different components of this signaling circuit will determine
how cells respond to oxidative stress (Figure 5). In one
scenario, the activation of signaling pathways promotes
the posttranslational modification of nuclear transport fac-
tors. This triggers the redistribution of transport factors
and alters the movement of cargo across the nuclear
envelope. Alternatively, oxidant-induced damage to the
transport apparatus could modulate the nucleocytoplasmic
localization of kinases or phosphatases, thereby changing
the spatiotemporal pattern of signaling. We believe that
the two scenarios will take place side by side, affecting
different signaling modules and targets in the nucleus and
cytoplasm. Both scenarios are further shaped by the localized
action of chaperones, which impact both signaling and
nuclear transport. The input from signaling, trafficking, and
repair will culminate in the decision on cell survival or
death.
As outlined in this review, the dynamic organization
of signaling cascades and the nuclear transport apparatus
are ideal to respond to internal and external cues. In this
context, nucleocytoplasmic trafficking provides the switch
to direct events to the nucleus or cytoplasm. The inter-
dependence of signaling and transport pathways provides
the flexibility to adjust to a wide variety of changes in cell
physiology.
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The formation of reactive oxygen species (ROS) is a result of incomplete reduction of molecular oxygen during cellular metabolism.
Although ROS has been shown to act as signaling molecules, it is known that these reactive molecules can act as prooxidants causing
damage to DNA, proteins, and lipids, which over time can lead to disease propagation and ultimately cell death. Thus, restoring
the protective antioxidant capacity of the cell has become an important target in therapeutic intervention. In addition, a clearer
understanding of the disease stage and molecular events that contribute to ROS generation during tumor promotion can lead to
novel approaches to enhance target specificity in cancer progression. This paper will focus on not only the traditional routes of
ROS generation, but also on new mechanisms via the tumor suppressor p53 and the interaction between p53 and MnSOD, the
primary antioxidant enzyme in mitochondria. In addition, the potential consequences of the p53-MnSOD interaction have also
been discussed. Lastly, we have highlighted clinical implications of targeting the p53-MnSOD interaction and discussed recent
therapeutic mechanisms utilized to modulate both p53 and MnSOD as a method of tumor suppression.
1. Introduction
Oxidative stress has been defined as the cellular imbalance
of prooxidants versus antioxidants that overwhelms the cell’s
capacity to scavenge the oxidative load and contributes to
the pathogenesis of various diseases. Reactive oxygen species
(ROS) are free radicals derived from molecular oxygen that
play a key role in promoting oxidative stress. These radicals
result from the incomplete reduction of oxygen mainly dur-
ing mitochondrial respiration. There are several products
of oxygen metabolism, both nonradicals and radicals that
form ROS such as hydrogen peroxide (H2O2) and super-
oxide anions (O2
.−). Contributors of ROS can modify the
intracellular redox status through unfavorable interactions
with endogenous regulators of oxidative stress. Superoxide
radicals can interact with mitochondrial nitric oxide to form
peroxynitrite which can alter antioxidant enzymes such as
aconitase and the mitochondrial complexes of the electron
transport chain [1]. On the other hand, the presence of
oxidative stress can alter normal cellular homeostasis by
modifying proteins involved in DNA repair; activating signal
transduction pathways involved in cell survival and inflam-
mation; as well as, inducing cellular apoptotic pathways that
are detrimental to the cell. For many years, scientists have
tried to combat free radical generation and superoxide pro-
duction through the utilization of the exogenous antioxidant
supplementation, such as ascorbate, vitamin E, as well as
linoleic acid. However, many of these trials have failed show-
ing no significant decrease in cancer incidence, death, or
major cardiovascular events [2]. Herein, we will focus on sev-
eral novel signaling pathways affecting ROS generation, such
as p53 signaling and the interaction between p53 and manga-
nese superoxide dismutase (MnSOD) and how to potentially
target these pathways for cancer therapy.
2. Oxidative Stress
Oxidative stress has been repeatedly shown to contribute
to the progression of multiple diseases, such as cancer [3],
diabetes [4], ulcerative colitis [5], cardiovascular disease [6],
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pulmonary disease [7] as well as neurodegenerative diseases
[8]. Nevertheless, the biological significance of oxidative
stress can be beneficial or detrimental depending on certain
parameters such as concentration, duration of action, cell
type exposed, the type of free radicals and reactive metabo-
lites involved, and the activities of the associated signal
transduction pathways.
The mitochondrial electron transport chain remains
to be one of the main sources of intracellular oxidative
stress [9]. During mitochondrial respiration, electrons flow
through four integral membrane protein complexes to fi-
nally reduce molecular oxygen to water. However, approx-
imately 1-2% of molecular oxygen undergoes incomplete
reduction, resulting in the formation of superoxide anions
and mitochondria-mediated ROS generation [10]. Though
mainly produced from mitochondrial respiration, superox-
ide anions can be detoxified via endogenous antioxidant
enzymes such as manganese superoxide dismutase (MnSOD)
to hydrogen peroxide, which is further converted to water
via the enzymatic actions of various antioxidant enzymes
including glutathione reductases, peroxiredoxins, glutathio-
ne transferases, as well as catalase which all function in the
removal of hydrogen peroxide.
Nevertheless, it is common for cells in response to stress
to enhance ROS generation. Oxidoreductases are enzymes
that are often activated during the cellular stress response
and catalyze the transfer of electrons from the electron donor
(reductant) to the electron acceptor (oxidant) [11] with asso-
ciated formation of superoxide anions and ROS as byprod-
ucts. There are several enzymes that act as oxidoreductases
and contribute to intracellular ROS generation, such as cy-
clooxygenase [12], lipoxygenase [12, 13], cytochrome P450
enzymes [14], nitric-oxide synthase [15], xanthine oxidase
[16], and mitochondrial NADH: ubiquinone oxidoreductase
(complex I) [17]. NAPDH oxidases of the Nox family are also
oxidoreductases that produce superoxide anions as a primary
product and one of the key sources of intracellular ROS
formation. NADPH oxidases (Nox) are endogenous enzy-
matic heterogenic complexes that reduce molecular oxygen
to superoxide, in conjunction with NADPH oxidation, which
can be converted to various ROS. Nox can be activated by a
myriad of cellular stress stimuli such as heavy metals [18, 19],
organic solvents [20], UV and ionizing irradiation [21, 22].
Once the cellular stress response is initiated two cytosolic
regulatory units of Nox, p47phox, p67phox, and the small
G protein Rac translocate to the membrane and associate
with cytochrome b558 (consisting of two subunits gp91phox
(Nox2) and p22phox), which acts as a central docking site for
complex formation [23]. Emerging evidence has linked Nox
enzymes to oxidative stress that may contribute to disease
progression [11, 17, 24, 25]. The radicals generated from Nox
activation are capable of modulating various redox-sensitive
signaling pathways involved in the activation of mitogen-
activated protein kinases (MAPKs) and transcription factors
(NF-κB) [26–28] causing regulation of Nox activation to be
complex.
Oxidative stress can be generated endogenously, as well
as promoted exogenously by multiple environmental factors.
Ultraviolet irradiation (UV) is an environmental promoter
of oxidative stress. UV is known to damage DNA and other
intracellular proteins through direct and indirect mecha-
nisms. UV exists in three forms UVA (400–320 nm), UVB
(320–290 nm), and UVC (290–100 nm). UVA and UVB are
the most biologically significant, with UVC being most
absorbed by ozone [29]. UV is known to directly induce the
cross-linking of neighboring pyrimidines to form pyrimidine
dimers in DNA that result in mutagenic DNA lesions [30–
35]. However, UV is known to promote ROS generation that
can damage a large number of intracellular proteins and can
indirectly damage DNA.
Associated with oxidative damage is lipid peroxidation.
High levels of ROS are detrimental and can cause damage to
various biomolecules, which include the fatty acid side chains
of membrane lipids that form reactive organic products such
as malondialdehyde and 4-hydroxynonenal, both of which
can generate DNA adducts and point mutations [36]. Lipid
peroxidation not only affects DNA stability, but can also alter
lipid membrane proteins that are involved in signal trans-
duction pathways to promote constitutive activation and
downstream cellular proliferation. Furthermore, previous
studies have shown that products of lipid peroxidation served
as intermediates in the activation of signaling pathways that
involved phospholipase A2 and the MAPK pathway, both
associated with UV-induced carcinogenesis [37–39].
Although there are various sources of endogenous oxida-
tive stress, mitochondria are the major cellular organelles
that contribute to intracellular ROS generation. Mitochon-
dria consume approximately 80–90% of the cell’s oxygen for
ATP synthesis via oxidative phosphorylation. In the early
1920s Otto Warburg and colleagues theorized that defective
oxidative phosphorylation during cancer progression caused
tumor cells to undergo a metabolic shift requiring high rates
of glycolysis that promoted lactate production in the pres-
ence of oxygen. This phenomenon became known as aerobic
glycolysis and later coined “The Warburg Effect.” Some of the
metabolic enzymes that are altered during cancer progression
are involved in the mitochondrial electron transport chain
[40, 41]. The electron transport chain consists of a constant
flow of electrons through mitochondrial intermembrane
complexes with molecular oxygen being the ultimate electron
acceptor. The process of the electron transport chain is used
to pump protons into the mitochondrial inner membrane
creating an electrochemical gradient. The gradient that is cre-
ated is coupled to ATP synthesis. However, leaking electrons
contribute to the incomplete reduction of molecular oxygen,
resulting in superoxide anion formation. Mitochondria are
readily susceptible to oxidative damage for various reasons:
(1) lack of effective base excision repair mechanisms; (2) the
close proximity of mitochondrial DNA to ROS generation;
(3) lack of mitochondrial DNA protective histones [42].
Therefore, alterations in mitochondrial ROS generation
and protection via antioxidant expression are key in the
detrimental effects of disease progression.
3. Manganese Superoxide Dismutase (MnSOD)
Maintaining a balance between free radicals and antioxidants
is required for cellular homeostasis. However, when this
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balance is altered in favor of free radical generation, normal
physiology is altered and the pathogenesis of disease is
promoted. Antioxidants are endogenous defense mecha-
nisms utilized by the cell to fight against fluctuations in
free radical generation, which include both enzymatic and
nonenzymatic contributors. Ascorbic acid (Vitamin C) and
α-tocopherol (Vitamin E) are nonenzymatic antioxidants
that have been previously shown to effectively scavenge free
radicals. On the other hand, antioxidants such as glutathione
peroxidase and superoxide dismutase are enzymatic antiox-
idants that catalyze the neutralization of free radicals into
products that are nontoxic to the cell. Superoxide dismutase
catalyzes the dismutation of superoxide anions leading to
the formation of hydrogen peroxide and molecular oxygen.
Hydrogen peroxide is further detoxified to water via catalase
and other endogenous antioxidant enzymes. The superoxide
dismutase family consists of metalloenzymes. Currently,
there are three major superoxide dismutase enzymes within
the human cell: manganese superoxide dismutase (MnSOD),
copper-zinc superoxide dismutase (Cu, ZnSOD), and extra-
cellular superoxide dismutase (ECSOD). MnSOD is localized
in the mitochondrial matrix [43], Cu, ZnSOD is found
primarily in the cytosol [44] and can be detected in the mi-
tochondrial intermembrane space [45], and ECSOD is a
homotetrameric glycosylated form of Cu, ZnSOD found in
the extracellular space [46].
MnSOD is ubiquitously found in both prokaryotes and
eukaryotes, and its increased activity is often associated with
cytoprotection against oxidants. MnSOD can be induced by
various mediators of oxidative stress such as tumor necro-
sis factor, lipopolysaccharide, and interleukin-1 [47]. This
antioxidant enzyme is nuclear encoded by a gene localized
to chromosome 6q25 [48], a region often lost in cancers
such as melanoma [49]. MnSOD is synthesized in the cytosol
as a larger precursor with a transit peptide on the N-
terminus and imported to the mitochondrial matrix via
proteolytic processing to the mature form [50]. Most cancer
cells and in vitro transformed cell lines have diminished
MnSOD activity compared to normal counterparts [51]. In
addition, deficiencies in MnSOD may contribute to oxidative
stress generation that promotes neoplastic transformation
and/or maintenance of the malignant phenotype. In looking
at the correlation between MnSOD expression and cancer
progression, mutations within the MnSOD gene and its
regulatory sequence have been observed in several types of
human cancers [52, 53]. However, antioxidants can suppress
carcinogenesis, particularly during the promotion phase.
In addition, our laboratory as well as others has shown
that overexpression of MnSOD reduces tumor multiplicity,
incidence, and metastatic ability in various in vitro and in
vivo models [54–57].
4. The Tumor Suppressor p53
p53 is a well-characterized transcription factor known to
induce its tumor suppressor activity by activating genes
known to play a role in cell cycle arrest, such as p21CIP1
and GADD45. These genes, once activated, arrest the cell
cycle to allow for adequate DNA repair to restore normal
cell proliferation. However, if the cell becomes overwhelmed
by the stressor or the DNA damage cannot be repaired, p53
can ultimately induce apoptosis. The tumor suppressive
activities of p53 can also be defined by the induction senes-
cence. Senescence is characterized by irreversible loss of pro-
liferative potential, acquisition of characteristic morphology,
and expression of specific biomarkers such as senescence-
associated β-galactosidase [58]. Nevertheless, how p53 reg-
ulates senescence is often contradictory and dependent on
ROS generation. p53 can mediate cellular senescence via the
transactivation of p21CIP1. Nonetheless, emerging evidence
suggests ROS as a common mediator of senescence with
the involvement of superoxide dismutase and p53. Blander
et al. reported that RNAi-mediated knockdown of SOD1 in
primary human fibroblasts induced cellular senescence me-
diated by p53. However, senescence was not induced in
p53-deficient human fibroblasts [59]. Furthermore overex-
pression of MnSOD induced growth arrest in the human
colorectal cancer cell line HCT116 and increased senescence
which required the induction of p53 [60]. On the contrary,
p53 can suppress senescence through the inhibition of the
mTOR pathway via multiple mechanisms [61–63]. Never-
theless, this diverse biological spectrum of p53 regulation of
cellular function remains complex and is dependent on the
source of activation and cell type.
There are various sources of p53 activators, which
include nucleotide depletion, hypoxia, ultraviolet radiation,
ionizing radiation, as well as many chemotherapeutic drugs
can act as activators of p53 (i.e., Doxorubicin). In normal
cells, p53 remains at a low level and is under strict control
by its negative regulator Mdm2. p53 induces autoregulation
via Mdm2. As a transcription factor, p53 can bind to the
promoter region of the mdm2 gene to promote transcription
of Mdm2 mRNA [64, 65]. Following proper translation into
a functional protein, Mdm2 acts as an E3 ligase during
p53 activation. Mdm2 can polyubiquitinate p53 leading to
proteasomal degradation [66]. However, Mdm2 can also
monoubiquinate p53 leading to intracellular trafficking [67].
The decisive role of p53 to induce cell cycle arrest, se-
nescence, or apoptosis involves intricate posttranslational,
as well as, transcription-dependent and transcription-inde-
pendent mechanisms. The tumor suppressor p53 is a well-
characterized transcription factor known to induce the trans-
activation of proapoptotic genes such as Bax, Puma, Noxa,
Bid and represses the transcription of anti-apoptotic genes
such as Bcl-2, Bcl-xL, and survivin [68, 69]. Nevertheless,
p53 can induce apoptosis independent of its transcriptional
activity. Many of the transcription-independent mechanisms
of p53 were discovered through the use of inhibitors of
transcription/translation, as well as p53 truncated mutants
with altered subcellular localization, DNA binding, and co-
factor recruitment. The p53 monomer consists of various
multifunctional domains including the N-terminal trans-
activation domain (residues 1–73), a proline-rich region
(residues 63–97), the highly conserved DNA-binding core
domain (residues 94–312), a tetramerization domain located
within the C-terminus (residues 324–355), and an unstruc-
tured basic domain (residues 360–393) [70] (Figure 1). There
are multiple polymorphisms that occur within the TP3
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Figure 1: p53 Multifunctional domains. The p53 monomer consists
of various multifunctional domains including the N-terminal trans-
activation domain (residues 1–73), a proline-rich region (residues
63–97), the highly conserved DNA-binding core domain (residues
94–312), a tetramerization domain located within the C-terminus
(residues 324–355), and an unstructured basic domain (residues
360–393).
gene that may enhance or alter p53 functionality. Dumont
et al. discovered functional differences in polymorphic
variants that enhanced p53-mediated apoptosis independent
of its transactivation abilities [71]. A common sequence
polymorphism that occurs within the proline-rich domain
encoding arginine at position 72 exhibited a fivefold increase
in inducing apoptosis compared to the common proline
(Pro72) variant. These results suggested two mechanisms of
Arg 72 apoptotic enhancement: (1) increased mitochondrial
localization; (2) enhanced binding of the Arg 72 variant
to the negative p53 regulator E3 ligase, Mdm2. Although
increased binding to Mdm2 did not augment p53 degrada-
tion, it was suggested that the altered confirmation of the
p53 Arg 72 variant enhanced the binding ability and facili-
tated greater nuclear export [71]. This suggests the impor-
tance of understanding the regulation of structure-activity
relationships in polymorphic forms of p53 in transcription-
independent apoptosis.
During p53-mediated apoptosis, a distinct cytoplasmic
pool of p53 translocates to the mitochondria. To promote
mitochondrial translocation, the E3 ligase, Mdm2 monou-
biquitinates p53 [72]. Since the p53 protein lacks a mito-
chondrial localization sequence, p53 interacts with Bcl-2
family proteins via Bcl-2 homology (BH) domains. The
presence of the BH domain allows proteins to regulate and
interact with other Bcl-2 members that consist of multiple
BH domains [73]. Once p53 arrives at the mitochondrial
outer membrane, p53 binds to Bak inducing a conforma-
tional change and Bak homo-oligomerization that results in
mitochondrial outer membrane permeabilization (MOMP).
MOMP allows for the release of pro-apoptotic signaling mol-
ecules from the outer and inner mitochondrial membranes
into the cytosol triggering the intrinsic apoptotic signaling
cascade. ROS generation has been suggested as an alternative
p53 apoptotic target independent of cytochrome c release. Li
et al. found that ROS generation regulated the mitochondrial
membrane potential (Δψ), which was found to be a key
constituent in the induction of p53-mediated apoptosis [74].
Interestingly, during ROS generation, apoptosis occurred
in the absence of Bax mitochondrial translocation, Bid
activation, as well as cytochrome c release. Several studies
have suggested that the downstream effects of p53-mediated
apoptosis are regulated by Bax expression. It has been
shown that the introduction of recombinant Bax protein
into isolated mitochondria induced cytochrome c release.
The ability of Bax to initiate pore formation in synthetic
membranes has been shown to regulate cytochrome c release
resulting in the induction of apoptosis [75, 76]. However,
discrepancies exist with in vivo studies showing Bax being
localized in the cytosol, rather than within the mitochondrial
membrane at physiological conditions [77].
Herein, we show how p53 has been shown to play
a dual role in early-versus late-stage cancer progression.
During the process of carcinogenesis, mutations can occur
both upstream and downstream of p53 activation. For ex-
ample, loss of upstream activators of p53, for example,
ATM and Chk2, can prevent p53 activation, contributing
to unregulated cell cycling and promoting tumorigenesis
[78]. In addition, mutations within the p53 protein can
alter necessary structure conformational changes and DNA
binding properties needed for efficient p53 activation. Lastly,
many of these mutations lead to loss of downstream genes
such as Bax or NOXA which are pro-apoptotic and necessary
for regulation of cellular proliferation and death signaling.
The process of tumor formation is a multistage process
that involves both the activation of protooncogenes, and the
inactivation of tumor suppressor genes, such as PTEN and
p53. The multistage carcinogenesis paradigm consists of
three well-characterized stages: initiation, promotion, and
progression. During the initiation stage, there is the induc-
tion of mutations within critical target genes of stem cells, for
example, H-ras; however in the skin carcinogenesis model,
the epidermal layer remains phenotypically normal. During
the tumor promotion stage, a noncarcinogenic agent such as
a phorbol ester can be used to induce the clonal expansion
of the initiated stem cells through epigenetic mechanisms.
This stage is often used by investigators to identify potential
therapeutic targets due to its reversibility. During the tumor
progression stage, malignancy takes place, being character-
ized by enhanced invasiveness via the activation of proteases,
and metastasizes via tumor cells entering into the lymphatics
and loss of tumor suppressor activity (e.g., p53).
The two-stage skin carcinogenesis mouse model has been
well characterized and used in numerous studies to screen
anti cancer agents. An initiator, such as dimethylbenz[a]an-
thracene (DMBA), is applied to the skin to initiate DNA
damage within skin cells. Following DMBA treatment, a
tumor promoter such as 12-O-tetradecanoylphorbol-13-ace-
tate (TPA) is applied topically to the same area repeatedly for
the duration of the study to promote the clonal expansion
of mutated cells during the promotion stage. Interestingly,
during the early stages of DMBA/TPA-mediated tumor pro-
motion both oncogenes and tumor suppressor genes are ac-
tivated, resulting in increased cell proliferation being accom-
panied by increased cell death [79] (Figure 2). Both processes
exist throughout skin tumor formation. Not surprising, these
two opposing events are closely related.
Many of the tumor-promoting mechanisms utilized by
phorbol esters are directly linked to the involvement of cell
surface membranes [80, 81]. TPA can mediate its pleiotropic
Journal of Signal Transduction 5
Carcinogens
Tumor formation
Tumor suppressor
gene activation
Oncogene
activation
stress
p53 activation Ras-Rac1-NADPH oxidase
pathway
Apoptosis
reduced MnSOD activity
Oxidative
Figure 2: Mechanisms of carcinogens in early stage carcinogenesis. During the early stages of tumor promotion both oncogenes and tumor
suppressor genes are activated, resulting in increased cell proliferation being accompanied by increased cell death.
actions through intercalating into the cellular membrane and
inducing the activation of the Ca2+-activated phospholipid-
dependent protein kinase, protein kinase C (PKC) both in
vitro and in vivo. TPA can directly activate PKC via molecular
mimicry by substituting for diacylglycerol, the endogenous
substrate, increasing the affinity of PKC for Ca2+ which
leads to the activation of numerous downstream signaling
pathways involved in a variety of cellular functions including
proliferation and neoplastic transformation [82]. In addi-
tion, it is known that a direct correlation exists between
phorbol ester-mediated tumor promotion and enzymatic
activation of PKC [82, 83]. The PKC family consists of var-
ious highly conserved serine/threonine kinases. PKCs are
involved in numerous cellular processes including cell dif-
ferentiation, tumorigenesis, cell death, aging, and neurode-
generation [84]; however the induction of the signaling
pathway is determined by the intracellular redox status and
the isoform that is activated. The PKC family consists of a
myriad of isoforms that have been divided into three classes:
(a) classical or conventional PKCs (cPKC: α, βI, βII, and γ);
(b) novel PKCs (nPKC: δ, ε, η, and θ); (c) the atypical PKCs
(aPKC: λ, ι, and ζ) which are classified based on sensitivity
to Ca2+ and diacylglycerol (DAG) [84]. In various types of
cancers PKCε has been shown to be upregulated while PKCα
and PKCδ are downregulated. Interestingly, TPA activates
the PKCε isoform in mouse skin tissues [85]. Furthermore,
overexpression of PKCε has been shown to enhance the
formation of skin carcinomas [86]. Moreover, TPA treatment
leads to the concomitant activation of the redox-sensitive
transcription factor activator protein-1 (AP-1) [85]. The
AP-1 complex consists of both Jun and Fos oncoproteins.
There are 3 jun isoforms (c-jun, jun-B, and jun-D) and 4 fos
family members (c-fos, fra-1, fra-2, and fos-B) [87] whose
activation is modulated by oxidants such as superoxide and
hydrogen peroxide, while DNA binding activities are mod-
ulated by the intracellular redox status [88–90]. Kiningham
and Clair reported a reduction in tumorigenicity and AP-1
DNA binding activity following overexpression of MnSOD in
transfected fibrosarcoma cells [91]. Furthermore, the protein
expression of Bcl-xl, an antiapoptotic AP-1 target gene, was
decreased, as well. In addition, PKCε activation was reduced
in MnSOD transgenic mice treated with DMBA/TPA com-
pared to their nontransgenic counterparts [85]. These results
suggest a mechanistic linkage between MnSOD expression,
mitogenic activation, and AP-1 binding activity.
5. MnSOD-p53 Mitochondrial Interaction
Another activated signaling pathway that has been defined
following DMBA/TPA treatment is the Ras-Rac1-NADPH
oxidase pathway, which leads to p53 mitochondrial translo-
cation and apoptosis [92]. NADPH oxidase forms a stable
heterodimer with the membrane protein p22phox, which
serves as a docking site for the SH3 domain-containing
regulatory proteins p47phox, p67phox, and p40phox. Upon TPA
treatment, Rac, a small GTPase, binds to p67phox which
induces NADPH oxidase activation [11] and superoxide
production. Mitochondrial p53 has been shown to interact
with MnSOD, resulting in decreased enzymatic activity and
promoting oxidative stress propagation [93].
The primary role of MnSOD is to protect mitochondria
from oxidative damage. In 2005, Zhao et al. found that
TPA treatment, both in vitro and in vivo, can induce p53
mitochondrial translocation [93]. In addition, p53 not only
came in contact with the outer mitochondrial membrane
but was able to localize to the mitochondrial matrix.
Interestingly, following p53 mitochondrial translocation and
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matrix localization, p53 interacted with the mitochondrial
antioxidant enzyme MnSOD that resulted in a reduction in
MnSOD activity and propagation of oxidative stress [93].
However, the question remains: does mitochondrial p53
contribute to or suppress tumor promotion during the early
stages of skin carcinogenesis? We addressed this question by
utilizing the JB6 mouse skin epidermal cells. JB6 cells were
originally derived from primary BALB/c mouse epidermal
cell culture [94]. Through nonselective cloning, it was dis-
covered that clonal variants existed within the JB6 cell lineage
that were either stably sensitive (P+) or resistant (P−) to tu-
mor promoter-induced neoplastic transformation [95–97].
In addition, JB6 cells remain the only well-characterized skin
keratinocytes for studying tumor promotion and screening
anti-cancer agents. In 2010, we utilized the JB6 P+ and P−
clonal variants to determine if a relationship existed be-
tween tumor promotion and early-stage TPA-induced p53
activation [98]. Surprisingly, we found that p53 was only
induced in promotion-sensitive P+ cells and not promotion
resistant (P−) cells, therefore suggesting that p53 expression
is highly associated with early stage tumor promotion. We
then assessed Bax protein expression levels, as a marker for
p53 transcriptional activity, and found that Bax expression is
only induced in JB6 P+ cells and not P− cells, suggesting that
p53 expression, as well as transcriptional activity, is highly as-
sociated with early-stage tumor promotion following TPA
treatment. MnSOD expression was also measured in both
JB6 P+ and P− cells and was found to be highly expressed
in promotion-resistant P− cells compared to promotable P+
cells. TPA-mediated ROS generation was measured in P+ and
P− cells (unpublished data), and promotion resistant cells
contained significantly lower levels of ROS following TPA
treatment when compared to their promotable counterparts.
It is known that reduced MnSOD expression contributes to
increased DNA damage, cancer incidence, and radical-
caused diseases [99, 100]. Consistent with that, an increase
of several markers of oxidative damage such as 4-HNE, 8-
oxoDG, and lipid peroxidation has been seen in both in vitro
and in vivo studies following TPA treatment [57, 85, 101,
102], suggesting the involvement of oxidative stress in the
promotion of tumorigenesis. These results imply the impor-
tance of redox regulation in modulating cellular functions
during the early stage of tumor promotion. We questioned
whether the ROS generated from the MnSOD-p53 mito-
chondrial interaction was sufficient to promote tumorigen-
icity. Therefore, we utilized promotion-resistant JB6 P− cells
that exhibited no p53 protein expression or transactivation
following TPA treatment to address this question. Inter-
estingly, we found that when JB6 promotion-resistant cells
were transfected with wild-type p53, these cells were able
to transform and form colonies in soft agar, in comparison
to their control counterparts [98]. These results suggest a
dual role of p53-mediated ROS generation during the early
stages of skin carcinogenesis and how the presence of p53 is
necessary for tumor promotion in skin (Figure 3).
The contradictory role of p53 in promoting cell survival
or death is the result of the ability to regulate the expression
of both pro- and antioxidant genes. For example, p53 can
promote the generation of ROS through the induction of
genes involved in mitochondrial injury and cell death
which include Bax, Puma, and p66SHC and ROS-generating
enzymes such as quinine oxidoreductase (NQO1) and pro-
line oxidase [103]. However, p53 can upregulate the expres-
sion of various antioxidant enzymes to modulate ROS levels
and promote cell survival such as aldehyde dehydrogenase 4
and mammalian sestrin homologues that encode peroxire-
doxins and GPX1, which are major enzymatic removers of
peroxide [103].
Dhar et al. suggested that p53 possessed “bidirectional”
regulation of the antioxidant MnSOD gene. Previous reports
suggest the presence of a p53 binding region at 328 bp and
2032 bp upstream of the transcriptional start site of the
MnSOD gene [104, 105]. Others suggest that p53 represses
MnSOD gene expression by interfering with transcription
initiation [106], inhibiting gene activators at the promoter
level by forming an inhibitory complex suppressing gene
transcription [107] and protein-protein interactions [108].
Nevertheless, p53 can induce the gene expression of MnSOD
[104]. p53-mediated MnSOD expression is regulated in
conjunction with other cell proliferative transcription factors
such as NF-κB. Kiningham and Clair demonstrated the
presence of an NF-κB binding site within the intronic
enhancer element of the MnSOD gene [91]. It was later
shown that mutation of the NF-κB site within the enhancer
element abrogated p53 induced MnSOD gene transcription.
In addition, knockdown of p65 via siRNA reduced MnSOD
gene transcription via p53 as well. Overall the effects of
p53 on MnSOD gene expression have been suggested to
be concentration dependent, with low concentrations of
p53 increasing MnSOD expression via corroborative NF-
κB binding promoting cell survival and high concentrations
of p53 suppressing MnSOD expression by interfering with
important transcriptional binding elements such as SP1.
6. Clinical Implications of the
MnSOD-p53 Interaction
p53 is mutated in 50% of human cancers. However, the
remaining human tumors contain wild-type p53 with defects
in the downstream mediated p53-signaling pathways. This,
in turn, provides novel areas of discovery in stabilization
and restoration of wild-type p53 activity. Currently, many
drug companies are focused on utilizing p53 interactions as
targets for pharmacological intervention [78]. There are var-
ious protein-protein interactions that occur within the cell
that positively or negatively regulate p53 expression and
function. For example, Mdm2 is an E3 ligase of p53 that
polyubiquitinates p53, priming the tumor suppressor for
proteasomal degradation. Many have found that, by blocking
this interaction through peptides or transcriptional inhibi-
tors, longer durations of p53 activation have resulted. Some
of the therapeutic strategies that are currently being utilized
are peptides that increase p53 activation through inhibition
of Mdm2 function [109]. Three-dimensional structural
models [110] of the hdm2-p53 interaction along with bi-
ochemical data [111, 112] have identified three residues that
are important to this interaction, Phe19, Trp23, and Leu26
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Figure 3: Mechanism involving the p53-MnSOD interaction during the early stage of tumor promotion. Following exposure to a carcinogen
the Ras-Rac1-NADPH oxidase pathway is activated, which leads to p53 mitochondrial translocation. Mitochondrial p53 has been shown to
interact with MnSOD, resulting in decreased enzymatic activity and promoting oxidative stress propagation contributing to the early stage
of skin tumorigenicity. Elevated levels of MnSOD reduced oxidative stress propagation, suppressed p53 mitochondrial translocation, and
decreased downstream skin tumor formation. Reduced levels of MnSOD have been shown to contribute to oxidative stress propagation and
promote early-stage skin tumorigenicity.
[111, 112]. From this data, an 8-mer peptide was generated
[113] and showed promising results in inducing apopto-
sis in tumor cells that overexpressed hdm2 [112]. How-
ever, these conditions were difficult to optimize with a
smaller molecule therefore causing this peptide to be ther-
apeutically inefficient. Also nutlins have been utilized to dis-
rupt the mdm2-p53 interaction resulting in reactivation of
the p53 response [114, 115]. Others have used antisense and
transcription inhibitors to prevent the expression of Mdm2
[116].
Gene replacement therapy is another therapeutic modal-
ity that has been explored in treating tumors lacking or
containing mutant p53. This technique utilizes adenoviruses,
as well as retroviruses to achieve high expression of p53 in
tumor cells. Promising results have been seen with retroviral
vectors in patients with nonsmall cell lung cancers [117]. On
the contrary, although we have seen the enhancement of
tumorigenicity in our in vitro p53 transfection studies [98],
we have not tested stably transfected cells in in vivo xenograft
mouse models, nor have we tried other tissue types. There-
fore, the reintroduction of the p53 gene into tumors may
have contradictory outcomes depending on the cell type and
tissue microenvironment. This concern has echoed through
various studies, persuading investigators to opt to combine
gene therapy with chemotherapy and radiotherapy [118–
121].
For decades, it has been shown that p53 functions only
as a tumor suppressor. In addition, p53-mediated ROS
generation has been limited to the induction of apoptosis.
Currently, the ability of wild-type p53 to contribute to tu-
mor promotion has received considerable attention. We have
shown that the p53-MnSOD interaction contributes to the
early stage of tumor promotion. In addition, it has been
consistently shown that MnSOD activity is altered in human
tumors. Therefore, designing diagnostic tools to assess
MnSOD activity, as well as p53 activation, can be used to
effectively design individualized treatments for cancer pa-
tients. For example, following chemotherapeutic treatment,
patients that have higher levels of p53 expression and exhibit
lower levels of MnSOD can receive an SOD mimetic that can
upregulate MnSOD or synthetic compounds that can down-
regulate p53 activity to decrease ROS-mediated apoptosis
and potential relapse within these patients.
Gene therapy has also been utilized to modulate MnSOD
activity during cancer progression. Overexpression of
MnSOD through gene therapy introducing genetically
engineered DNA/liposomes containing the human MnSOD
transgene into preclinical and clinical models has been
shown to be protective in normal tissues against ionizing
irradiation. The final product (VLTS-582) is a DNA/lipo-
some formulation that consists of a double-stranded DNA
bacterial plasmid containing human MnSOD cDNA in con-
junction with two lipids {cholesterol and DOTIM (1-[2-
[9-(2)-octadecenoyloxy]]-2-[8-(2)-heptadecenyl]-3-[hydrox-
yethyl] imidazolinium chloride)} [122]. Recent studies
suggest that this formulation has been successful in murine
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models and has been administered orally to patients concur-
rently with a weekly chemotherapy regime exhibiting no
dose-limiting toxicities. Although proven therapeutically
efficacious, more studies are needed to improve (1) delivery
of the transgene to the targeted tissue; (2) reducing rapid
elimination of the transgene; (3) control of the expression of
the transgene within targeted tissues.
On the other hand, a topical application of an SOD
mimetic has also been described [123]. The Mn (III)
porphyrin MnIII TE-2-Pyp5+ possesses highly potent SOD
activity as facilitated by the redox properties of the metal
center and the positive charge to the ortho-N-ethylpyridyl
nitrogens [124]. MnIII TE-2-Pyp5+ has been proven effective
in vitro and in various human diseases such as stroke [125,
126], diabetes [127, 128], and cancer and radiation-related
treatment [129–132]. In preclinical animal models, topical
application of MnIII TE-2-Pyp5+ was shown to reduce levels
of oxidative damage and reduced cell proliferation without
interfering with p53-mediated apoptosis when applied prior
to TPA treatment [129]. These data support the concept that
overexpression of MnSOD when applied in conjunction with
standard chemotherapeutics or during the tumor promotion
stage is protective in both preclinical and clinical models.
Nevertheless, both p53 and MnSOD have been shown
to posses reduced activity and/or mutated in most human
diseases including cancer. Therefore, more therapeutic quests
are needed to detect and restore both MnSOD and wild-
type p53 activity. However, future therapeutic optimization
strategies should have minimal nonspecific drug-related tox-
icities and be based on the stage of cancer progression which
may reveal a therapeutic window for treatment intervention.
7. Concluding Remarks
In summary, reactive oxygen species have been implicated in
the pathogenesis of various hyperproliferative and inflam-
matory diseases [133]. In addition, the tumor suppressor
p53 has been shown to be activated during the early stage
of skin carcinogenesis and contributed to the propagation
of oxidative stress. Recent studies demonstrate a novel role
of mitochondrial p53 activation. Once in the mitochondria,
p53 physically interacts with MnSOD. As a result, this in-
teraction reduces the free radical scavenging abilities of
MnSOD, promoting enhanced ROS generation which has
been shown to act as a tumorigenic stimulus during cancer
progression. This suggests that wild-type p53 may play a
direct role in promoting oxidative stress and contributing to
the ROS-mediated tumor-proliferative stimuli. In addition,
others have shown that mutant p53 can, in fact, translocate
to the mitochondria and interact with MnSOD [134]. How-
ever, Lontz et al. observed following doxorubicin treatment
of lymphoma cell lines with varying wt or mutant p53
levels, mitochondrial function, as evidenced by Complex
I/II activities, was only compromised in lymphoma cells
expressing wild-type and not mutant p53 [134]. Therefore,
the continuation of deciphering mechanistic differences in
tumors containing wild-type or mutant p53 can lead to the
development of therapeutic p53-mediated interventions and
a clearer understanding of chemoresistance in both wild-type
and mutant p53 human tumors.
Several studies have suggested that MnSOD may play a
primary protective role against tissue injury. MnSOD has
been found to be depleted in a variety of tumor cells,
as well as in vitro transformed cell lines, suggesting that
MnSOD may act as a novel tumor suppressor, protecting cells
from oxidant-induced carcinogenesis [135]. Nevertheless,
overexpression of MnSOD decreases the pathogenesis of
human diseases such as cancer. Consistent with that, accu-
mulating evidence suggests that a number of antioxidants
or drugs with antioxidant properties can reduce mediators
of tumor promotion [136]. Clair et al. showed that trans-
fecting mouse 10T 1/2 cells with human MnSOD cDNA
promoted differentiation with 5-azacytidine treatment and
protected against neoplastic transformation [137]. In addi-
tion, transfecting human MnSOD cDNA into MCF-7 breast
cancer cells and UACC-903melanoma cells suppressed their
malignant phenotype and suppressed growth in nude mice
[54, 138]. We have shown that the cumulative induction of
endogenous antioxidant enzymes (i.e., catalase, total SOD
and MnSOD) is efficient in reducing tumor incidence and
multiplicity [57]. In addition, the induction of endogenous
antioxidant enzymes via dietary administration can suppress
p53 mitochondrial translocation [98]. TPA can induce p53
mitochondrial translocation; however, this phorbol ester also
decreases the mitochondrial membrane potential, as well
as mitochondrial complex activities and respiration. Other
studies have shown that MnSOD overexpression in mice
protects complex I from adriamycin-induced deactivation in
cardiac tissue [139]. These results suggest that antioxidant
expression protects against fluctuations in mitochondrial
functions which suppress p53 mitochondrial translocation,
p53-mediated ROS, and both downstream apoptotic and cell
proliferation signaling pathways. On the contrary, Connor
et al. suggest that overexpression of MnSOD in HT-1080
fibrosarcoma cells and 253J bladder tumor cells enhanced the
migatory ability and invasiveness of tumor cells, through the
upregulation of matrix metalloproteinases [140]. Although
some tumors express higher levels of MnSOD, the down-
stream effects of enhanced antioxidant expression are depen-
dent on the tumor type and susceptibility to oxidative dam-
age, underlying oncogenic mutations and the stage of disease
progression [140]. Nevertheless, these investigators stressed
the need of refined regulation of H2O2 production. Therefore
the question remains, are the effects of the p53-MnSOD
interaction protumorigenic or anti-tumorigenic? To defini-
tively answer this question further investigation of this inter-
action is needed. However, there are several factors that must
be considered in determining the fate of the p53-MnSOD
interaction, which include the stage of disease progression
as well as tumor microenvironment. It has been shown that
p53 activation is required in tumor promotion and can
mediate ROS generation. However, the duration of enhanced
ROS generation, severity of oxidative damage, and the status
of the cellular antioxidant capacity can all contribute to
the proliferative/apoptotic switch that occurs during the
response to cellular stress. Overall, further studies are needed
to clearly assess the status of MnSOD during the various
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stages of carcinogenesis to enhance the efficacy of standard
treatment regimens currently being used.
Consistent with that, defining the downstream effects
of the p53-MnSOD complex formation can expand our
knowledge of the molecular mechanisms that contribute to
the early stage of tumorigenesis and how they may be altered
during cancer progression. With further knowledge, modu-
lators of MnSOD, p53 and their associated regulators can be
therapeutically useful in the treatment of cancer and various
stages of tumor progression.
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Aging is an intricate phenomenon characterized by progressive decline in physiological functions and increase in mortality that
is often accompanied by many pathological diseases. Although aging is almost universally conserved among all organisms, the
underlying molecular mechanisms of aging remain largely elusive. Many theories of aging have been proposed, including the free-
radical and mitochondrial theories of aging. Both theories speculate that cumulative damage to mitochondria and mitochondrial
DNA (mtDNA) caused by reactive oxygen species (ROS) is one of the causes of aging. Oxidative damage affects replication and
transcription of mtDNA and results in a decline in mitochondrial function which in turn leads to enhanced ROS production
and further damage to mtDNA. In this paper, we will present the current understanding of the interplay between ROS and
mitochondria and will discuss their potential impact on aging and age-related diseases.
1. Introduction
The fundamental manifestation of the aging process is a
progressive decline in the functional maintenance of tissue
homeostasis and an increasing propensity to degenerative
diseases and death [1]. It has attracted significant interest
to study the underlying mechanisms of aging, and many
theories have been put forward to explain the phenomenon
of aging. There is an emerging consensus that aging is a
multifactorial process, which is genetically determined and
influenced epigenetically by environment [2]. Most aging
theories postulate a single physiological cause of aging, and
likely these theories are correct to a certain degree and in
certain aspects of aging.
Reactive oxygen species (ROS) are highly reactive mol-
ecules that consist of a number of diverse chemical species
including superoxide anion (O2
−), hydroxyl radical (·OH),
and hydrogen peroxide (H2O2). Because of their potential
to cause oxidative deterioration of DNA, protein, and
lipid, ROS have been implicated as one of the causative
factors of aging [3]. As ROS are generated mainly as by-
products of mitochondrial respiration, mitochondria are
thought to be the primary target of oxidative damage and
play an important role in aging. Emerging evidence has
linked mitochondrial dysfunction to a variety of age-related
diseases, including neurodegenerative diseases and cancer.
Details of the precise relationship between ROS-induced
damage, mitochondrial dysfunction, and aging remain to be
elucidated.
2. ROS and Aging
2.1. ROS, Oxidative Damage, and Cellular Signaling. There
are several sources of ROS within a cell. ROS are generated
as by-products of aerobic respiration and various other
catabolic and anabolic processes [4]. Mitochondria are
the major producer of ROS in cells, and the bulk of
mitochondrial ROS is generated at the electron transport
chain [5, 6]. Electrons leak from the electron transport chain
directly to oxygen, producing short-lived free radicals such as
superoxide anion (O2
−) [7, 8]. O2− can be converted to non-
radical derivatives such as hydrogen peroxide (H2O2) either
spontaneously or catalyzed by superoxide dismutase (SOD)
[9–13]. H2O2 is relatively stable and membrane permeable.
It can be diffused within the cell and be removed by cytosolic
antioxidant systems such as catalase, glutathione peroxidase,
and thioredoxin peroxidase [14, 15]. In addition to being
generated during cellular metabolism in mitochondria, ROS
can be produced in response to different environmental
stimuli such as growth factors, inflammatory cytokines, ion-
izing radiation, UV, chemical oxidants, chemotherapeutics,
2 Journal of Signal Transduction
hyperoxia, toxins, and transition metals [16–26]. Other than
mitochondrial respiration, a number of cytosolic enzymes
are able to generate ROS [27]. The nicotinamide adenine
dinucleotide phosphate (NADPH) oxidases are a group of
plasma membrane-associated enzymes found in a variety
of cell types [28]. The function of NADPH oxidases is
to produce superoxide from oxygen using electrons from
NADPH [29].
Once they are produced, ROS react with lipids, pro-
teins, and nucleic acids causing oxidative damage to these
macromolecules [30–34]. ROS readily attack DNA and
generate a variety of DNA lesions, such as oxidized DNA
bases, abasic sites, and DNA strand breaks, which ulti-
mately lead to genomic instability [35]. 7,8-dihydro-8-oxo-
deoxyguanosine (8-oxo-dG) is one of the most abundant
and well-characterized DNA lesions caused by ROS [36].
It is a highly mutagenic lesion that results in G : C to T : A
transversions [37]. To limit the cellular damage caused by
ROS, mammalian cells have evolved a number of sophis-
ticated defense mechanisms. ROS-generated DNA lesions
are repaired mainly by base excision repair as well as other
DNA repair pathways including nucleotide excision repair,
double-strand break repair, and mismatch repair [38–40].
In addition, the damaging effects of ROS can be neutralized
via elevated antioxidant defense, which includes superoxide
dismutase, catalase, and glutathione peroxidase to scavenge
ROS to nontoxic forms [41].
Intracellular ROS are normally maintained at low but
measurable level within a narrow range, which is regulated
by the balance between the rate of production and the
rate of scavenging by various antioxidants [42]. ROS, at
low level under normal conditions, is found to act as
signaling molecules in many physiological processes, includ-
ing redox homeostasis and cellular signal transduction [7].
By activating proteins such as tyrosine kinases, mitogen-
activated protein kinases, or Ras proteins, ROS are important
mediators of signal transduction pathways [7]. Dependent
on cell types, ROS have been found to function as signaling
molecules in cell proliferation [43], cellular senescence [44],
or cell death [45, 46]. The divergent effects of ROS on
many cellular processes suggest that ROS are not merely
detrimental byproducts, but also generated purposefully to
mediate a variety of signaling pathways.
2.2. The Free Radical Theory of Aging. The free radical theory
of aging proposed by Denham Harman more than fifty years
ago postulates that aging results from the accumulation of
deleterious effects caused by free radicals, and the ability
of an organism to cope with cellular damage induced by
ROS plays an important role in determining organismal
lifespan [3]. In agreement with this theory, increased ROS
production by mitochondria and increased 8-oxo-dG con-
tent in the mtDNA are frequently detected in aged tissues
[40, 47–50], suggesting that progressive accumulation of
oxidative DNA damage is a contributory factor to the aging
process. Consistently, many studies have found that increased
oxidative damage in cells is associated with aging [51–53].
Furthermore, genetic studies in worm, fly, and mouse have
linked enhanced stress resistance or reduced free radical
production with increased lifespan [27]. Mutant strains of
C. elegans that are resistant to oxidative stress have extended
lifespan, whereas those more susceptible to free radicals have
shortened lifespan [54, 55]. Mice lacking the antioxidant
enzyme superoxide dismutase 1 (SOD1) exhibit a 30%
decrease in life expectancy [56]. Conversely, simultaneous
overexpression of SOD1 and catalase extends lifespan in
Drosophila [57]. Small synthetic mimetics of SOD/catalase
increase lifespan in C. elegans [58], while treatment of
antioxidant drugs in mice increases the median lifespan
up to 25% [59, 60]. Further supporting this hypothesis,
mice lacking Ogg1 and Myh, two enzymes of the base
excision repair pathway that repairs oxidative DNA damage,
show a 50% reduction in life expectancy [61]. Collectively,
these studies demonstrate that interplay between ROS and
protective antioxidant responses is an important factor in
determining aging and lifespan.
Despite a large body of evidence supporting the role of
ROS in aging, the free radical theory of aging faces some
challenges [62]. Mice heterozygous for superoxide dismu-
tase 2 (Sod2+/−) have reduced manganese SOD (MnSOD)
activity, increased oxidative damage, but normal lifespan
[63]. Overexpression of antioxidant enzymes in mice, such
as SOD1 or catalase, does not extend lifespan [64, 65].
The median lifespan of mice heterozygous of glutathione
peroxidase 4 (Gpx4+/−), an antioxidant defense enzyme
that plays an important role in detoxification of oxidative
damage to membrane lipids, is significantly longer than
that of wild-type mice, even though Gpx4+/− mice show
increased sensitivity to oxidative stress-induced apoptosis
[66]. Studies of long-lived rodents also do not find a
convincing correlation between level of oxidative damage
and aging [67]. Furthermore, pharmacologic intervention
with antioxidants in humans and mice has little effect on
prolonging lifespan [68–70]. More investigations are clearly
needed to clarify the discrepancy in the role of ROS and
antioxidant enzymes in aging among different species and to
understand the precise role that free radicals play in aging.
2.3. ROS and Senescence. Senescence, a process in which
normal somatic cells enter an irreversible growth arrest
after a finite number of cell divisions [71], is thought
to contribute to organismal aging [72–74]. Senescent cells
are associated with high level of intracellular ROS and
accumulated oxidative damage to DNA and protein [75–
77]. In contrast, immortal cells suffer less oxidative damage
and are more resistant to the deleterious effects of H2O2
than primary cells [78]. Increasing intracellular oxidants
by altering ambient oxygen concentrations or lowering
antioxidant levels accelerates the onset of senescence, while
lowering ambient oxygen or increasing ROS scavenging
delays senescence [76, 78–81].
Telomere shortening is considered as the major cause of
replicative senescence [82, 83]. It has been reported that the
rate of telomere shortening is directly related to the cellular
level of oxidative stress [84]. Telomere shortening is signifi-
cantly increased under mild oxidative stress as compared to
Journal of Signal Transduction 3
that observed under normal conditions, whereas overexpres-
sion of the extracellular SOD in human fibroblasts decreases
the peroxide content and the rate of telomere shortening
[79]. ROS can affect telomere maintenance at multiple
levels. The presence of 8-oxoguanine (8-oxoG), an oxidative
derivative of guanine, in telomeric repeat-containing DNA
oligonucleotides has been shown to impair the formation
of intramolecular G quadruplexes and reduces the affinity
of telomeric DNA for telomerase, thereby interfering with
telomerase-mediated extension of single-stranded telomeric
DNA [85]. ROS also affect telomeres indirectly through
their interaction with the catalytic subunit of telomerase,
telomerase reverse transcriptase (TERT). Increased intra-
cellular ROS lead to loss of TERT activity, whereas ROS
scavengers such as N-acetylcysteine (NAC) block ROS-
mediated reduction of TERT activity and delay the onset
of cellular senescence [86]. Furthermore, the presence of 8-
oxoG in the telomeric sequence reduces the binding affinity
of TRF1 and TRF2 to telomeres [87]. TRF1 and TRF2
are components of the telomere-capping shelterin complex
that protects the integrity of telomeres [88]. In addition,
ROS-induced DNA damage elicits a DNA damage response,
leading to the activation of p53 [89], a critical regulator of
senescence. It has been shown that p53 transactivates E3
ubiquitin ligase Siah1, which in turn mediates ubiquitination
and degradation of TRF2. Consequently, knockdown of
Siah1 expression stabilizes TRF2 and delays the onset of
replicative senescence [90]. The p53-Siah1-TRF2 regulatory
axis places p53 both downstream and upstream of DNA
damage signaling initiated by telomere dysfunction. By
regulating telomere maintenance or integrity directly or
indirectly, ROS plays a critical role in senescence.
2.4. ROS and Stem Cell Aging. Tissue-specific or adult stem
cells, which are capable of self-renewal and differentiation,
are essential for the normal homeostatic maintenance and
regenerative repair of tissues throughout the lifetime of an
organism. The self-renewal ability of stem cells is known to
decline with advancing age [91–94], suggesting that decline
in stem cell function plays a central role in aging. Increasing
evidence suggests that dysregulated formation of ROS may
drive stem and progenitor cells into premature senescence
and therefore impede normal tissue homeostasis.
Genetic studies of mice deficient in genes implicated in
ROS regulation indicate that elevated level of ROS within
the stem cell compartments leads to a rapid decline in stem
cell self-renewal [95–98]. Deletion of Ataxia telangiectasia
mutated (ATM) kinase results in increased ROS level in
hematopoietic stem cell (HSC) population in aged mice,
which correlates with a rapid decline in HSC number
and function [95]. When Atm−/− mice are treated with
antioxidants, the defect in stem cell self-renewal is rescued
[95], suggesting that high level of ROS causes the decline
in stem cell function. Furthermore, deficiency in telomerase
reverse transcriptase (TERT) accelerates the progression
of aging, resulting in an even shorter lifespan in Atm−/−
mice accompanied by increased senescence in hematopoietic
tissues and decreased stem cell activity [99]. These TERT-
deficient HSCs are also sensitive to ROS-induced apoptosis,
suggesting another possible cause of stem cell impairment
during aging [99]. Similarly, defect in HSC number and
activity accompanied by increased accumulation of ROS
is observed in mice lacking three members of Forkhead
box O-class (FoxO) [96–98]. Increased level of ROS in
FoxO3-null myeloid progenitors leads to hyperproliferation
through activation of the AKT/mTOR signaling pathway,
and ultimately premature exhaustion of progenitors [100].
Mice carrying a mutation in inner mitochondrial membrane
peptidase 2-like (Immp2l) gene, which is required to process
signal peptide of mitochondrial cytochrome c1 and glycerol
phosphate dehydrogenase 2, exhibit an early onset of aging
phenotypes, including premature loss of fat [101]. Elevated
mitochondrial ROS level in the Immp2l mutant mice leads to
impaired self-renewal of adipose progenitor cells, suggesting
that ROS-induced damage to adult stem cells is the driving
force of accelerated aging in these mice [101]. Further
supporting this notion, intracellular level of ROS is found
to correlate with the long-term self-renewal ability of HSCs
in mouse [102]. HSCs with high level of ROS show a
decreased ability of long-term self-renewal, and treatment
of antioxidant NAC is able to restore the functional activity
of HSCs with high level of ROS [102]. Taken together, these
studies suggest that ROS play an important role in stem cell
aging.
ROS-generated DNA lesions are repaired by several DNA
repair pathways including base excision repair, nucleotide
excision repair, double-strand break repair, and mismatch
repair [38–40]. Endogenous DNA damage accumulates
with age in HSCs in mouse. HSCs in mice deficient in
DNA repair pathways, including nucleotide excision repair,
telomere maintenance, and nonhomologous end-joining,
exhibit increased sensitivity to the detrimental effect of ROS,
diminished self-renewal and functional exhaustion with age
[103]. These data support the notion that accumulated DNA
damage is one of the principal mechanisms underlying age-
dependent stem cell decline.
3. Mitochondria and Aging
3.1. The Mitochondrial Theory of Aging. Because mitochon-
dria are the major producer of ROS in mammalian cells,
the close proximity to ROS places mitochondrial DNA
(mtDNA) prone to oxidative damage [104]. Consistently,
many studies have shown that 8-oxo-dG, one of the common
oxidative lesions, is detected at higher level in mtDNA than
nuclear DNA, suggesting that mtDNA is more susceptible to
oxidative damage [52, 105–113]. As both the major producer
and primary target of ROS, mitochondria are thought to
play an important role in aging. The mitochondrial theory
of aging, extended from the free radical theory, proposes
that oxidative damage generated during oxidative phospho-
rylation of mitochondrial macromolecules such as mtDNA,
proteins, or lipids is responsible for aging [114]. As mtDNA
encodes essential components of oxidative phosphorylation
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and protein synthesis machinery [115], oxidative damage-
induced mtDNA mutations that impair either the assembly
or the function of the respiratory chain will in turn trigger
further accumulation of ROS, which results in a vicious cycle
leading to energy depletion in the cell and ultimately cell
death [104, 114, 116–118].
As mitochondria play a critical role in regulation of
apoptosis, which is implicated in the aging process [119],
age-related mitochondrial oxidative stress may contribute
to apoptosis upon aging. The activation of the perme-
ability transition pore in mitochondria, which is believed
to play a critical role in cell necrosis and apoptosis, is
enhanced in spleen, brain, and liver of aged mice [120, 121].
Moreover, mitochondrial adenine nucleotide translocase, a
component of the permeability transition pore, exhibits an
age-associated increase of oxidative modification in male
houseflies [122]. Such selective oxidative modification may
cause the cells more vulnerable to apoptotic inducers [123].
Thus, mitochondria appear to influence the aging process via
modifying the regulatory machinery of apoptosis.
Mice expressing proof reading-deficient mitochondrial
DNA polymerase show a consistent increase in mtDNA
mutations, premature onset of the aging phenotypes and
reduced lifespan [124, 125], suggesting a critical link between
mitochondria and aging. Interestingly, ROS production in
these mice is not increased [124, 125]. Similarly, mice
expressing proof reading-deficient mitochondrial DNA poly-
merase specifically in heart show accumulation of mutations
in mtDNA and develop cardiomyopathy, but oxidative stress
in the transgenic heart is not increased, indicating that
oxidative stress is not an obligate mediator of diseases
provoked by mtDNA mutations [126]. More studies are
required to further clarify the consequence of oxidative stress
and mitochondrial dysfunction in aging.
3.2. Age-Associated Changes of Mitochondria. Mitochondrial
genome encodes proteins required for oxidative phospho-
rylation and ATP synthesis, and RNAs needed for mito-
chondrial protein translation [115]. The mtDNA is densely
packed with genes and only contains one noncoding region
called the displacement loop (D-loop) [127]. The D-loop
is important for mtDNA replication and transcription and
has been extensively studied for the presence of age-related
mutations [115]. Age-dependent accumulation of point
mutations within the D-loop has been reported in various
types of cells and tissues, including skin and muscle [128–
132]. In addition to point mutations, deletions of mtDNA
are detected at higher frequency in aged human and animal
tissues [133–145]. Replication is thought to be the likely
mechanism leading to the formation of mtDNA deletions
[146–148], but recent studies suggest that mtDNA deletions
may be generated during repair of damaged mtDNA rather
than during replication [149]. It is thought that repair
of oxidative damage to mtDNA accumulated during aging
leads to generation of double-strand breaks [149], with
single-strand regions free to anneal with microhomolo-
gous sequences on other single-stranded mtDNA or within
the noncoding region [150]. Subsequent repair, ligation
and degradation of the remaining exposed single strands
would result in the formation of an intact mitochondrial
genome harboring a deletion [149]. Whether and how
exactly mutations and deletions of mtDNA cause the aging
phenotypes are not clear. Among mtDNA deletions during
aging, especially in postmitotic tissues like muscle and brain,
the most common one is a 4977-bp deletion [151–153].
The frequency of this deletion increases in brain, heart, and
skeletal muscle with age, although the increase varies in
different tissues of the same individual [154], or even in
different regions of the same tissue [134, 136, 137]. This
deletion occurs in a region encoding subunits of the NADH
dehydrogenase, cytochrome c oxidase, and ATP synthase
[155]. Whether deletion of these genes plays a causative
role in the development of aging phenotypes remains to be
determined.
In addition to age-associated increase of mtDNA muta-
tions and deletions, the abundance of mtDNA also declines
with age in various tissues of human and rodent [156–
158]. For instance, in a large group of healthy men and
women aged from 18 to 89 years, mtDNA and mRNA
abundance is found to decline with advancing age in the
vastus lateralis muscle. Furthermore, abundance of mtDNA
correlates with the rate of mitochondrial ATP production
[158], suggesting that age-related mitochondrial dysfunction
in muscle is related to reduced mtDNA abundance. However,
age-associated change in mtDNA abundance seems to be
tissue specific, as several studies have reported no change
in mtDNA abundance with age in other tissues in human
and mouse [159–161]. It is possible that tissue-specific effect
of aging on mtDNA abundance is related to the status of
aerobic activity [156, 158], as aerobic exercise has been
shown to enhance muscle mtDNA abundance in both human
and mouse [162–164]. Increased prevalence of mtDNA
mutations/deletions and decreased mtDNA abundance offer
attractive underlying causes of mitochondrial dysfunction in
aging, which warrants further investigation.
3.3. Mitochondria Malfunction in Age-Associated Human
Diseases. A heterogeneous class of disorders with a broad
spectrum of complex clinical phenotypes has been linked
to mitochondrial defect and oxidative stress [165, 166].
Particularly, mitochondria are thought to play an important
role in the pathogenesis of age-associated neurodegenerative
diseases, such as Alzheimer’s disease, Parkinson’s disease,
and Huntington’s disease. This is not surprising as neurons
are especially sensitive and vulnerable to any abnormality
in mitochondrial function because of their high energy
demand.
Alzheimer’s disease (AD) is the most common form of
dementia and often diagnosed in people over 65 years of age.
AD is characterized by severe neurodegenerative changes,
such as cerebral atrophy, loss of neurons and synapses, and
selective depletion of neurotransmitter systems in cerebral
cortex and certain subcortical region [167]. Mitochondria
are significantly reduced in various types of cells obtained
from patients with AD [168–170]. Dysfunction of mitochon-
drial electron transport chain has also been associated with
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the pathophysiology of AD [170]. The most consistent defect
in mitochondrial electron transport enzymes in AD is a
deficiency in cytochrome c oxidase [171, 172], which leads to
an increase in ROS production, a reduction in energy stores,
and disturbance in energy metabolism [173].
Parkinson’s disease (PD) is the second most common
progressive disorder of the central nervous system, which is
characterized prominently by loss of dopaminergic neurons
in the substantia nigra and formation of intraneuronal
protein aggregates [174]. The finding that exposure to envi-
ronmental toxins, which inhibit mitochondrial respiration
and increase production of ROS, causes loss of dopaminergic
neurons in human and animal models leads to a hypothesis
that oxidative stress and mitochondrial dysfunction are
involved in PD pathogenesis [175]. Consistent with this
notion, a significant decrease in the activity of complex I
of the electron transport chain is observed in the substantia
nigra from PD patients [176]. Furthermore, neurotoxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine, which acts as
an inhibitor of complex I, can induce parkinsonism in
human, monkey, and rodent [177, 178]. Genetic studies
of PINK1 and PARKIN further support the role of mito-
chondrial dysfunction in pathogenesis of PD [179, 180].
Autosomal recessive mutations in PINK1 and PARKIN are
associated with juvenile Parkinsonism [181–183]. Studies in
Drosophila have provided strong evidence that PINK1 and
PARKIN act in the same genetic pathway to control mito-
chondrial morphology in tissues with high energy demand
and requirement of proper mitochondrial function, such as
indirect flight muscle and dopaminergic neurons [184–186].
Consistent with the finding in Drosophila, primary fibrob-
lasts derived from patients with PINK1 mutations show
similar abnormalities in mitochondrial morphology [187].
The morphologic changes of mitochondria can be rescued
by expression of wild-type PARKIN but not pathogenic
PARKIN mutants [187], suggesting that mitochondrial
dynamics plays an important role in PD pathogenesis.
Huntington’s disease (HD) is another hereditary neu-
rodegenerative disorder that affects muscle coordination
and leads to cognitive decline and dementia. HD is caused
by an autosomal dominant mutation in the Huntingtin
(HTT) gene [188]. Morphologic defects of mitochondria,
such as reduced mitochondrial movement and alterations
in mitochondrial ultrastructures, have been observed in
patients with HD or transgenic HD mouse models [189,
190]. In addition, expression of mutant HTT leads to
impaired energy metabolism, abnormal Ca2+ signaling and
mitochondrial membrane potential, and drastic changes
in mitochondrial ultrastructures [191, 192]. Although the
underlying molecular mechanism remains to be determined,
it is recently proposed that mutant HTT conveys its neu-
rotoxicity by evoking defects in mitochondrial dynamics,
mitochondrial fission and fusion, and organelle trafficking,
which in turn result in bioenergetic failure and HD-
associated neuronal dysfunction [189].
Mitochondrial dysfunction and increased oxidative dam-
age are often associated with AD, PD, and HD, suggesting
that oxidative stress may play an important role in the
pathophysiology of these diseases [193]. Increased produc-
tion of cellular ROS and oxidative stress have been reported
to induce autophagy, a homeostatic process that enables
cells to degrade cytoplasmic proteins and organelles [194–
197]. The observation of increased autophagy in the brains
of patients with AD, PD, and HD suggests that autophagy
contributes to the pathogenesis of these neurodegenerative
diseases, possibly by causing cell death [170, 198–202].
Consistently, oxidative stress-induced autophagy of accu-
mulated amyloid β-protein in AD causes permeabilization
of lysosomal membrane and leads to neuronal cell death
[203]. Mitochondria damaged by significantly increased
oxidative stress in pyramidal neurons of AD are subjected
to autophagic degradation, ultimately leading to neurode-
generation [204]. Furthermore, overexpression of wild-
type PINK1 increases mitochondrial interconnectivity and
suppresses toxin-induced autophagy, whereas knockdown of
PINK1 expression potentiates mitochondrial fragmentation
and induces autophagy [197], suggesting that induced
autophagy as a consequence of loss of function of PINK1 may
contribute to the pathogenesis of PD.
Interestingly, autophagy also serves as a protective mech-
anism in age-related neurodegenerative diseases. Several
studies demonstrate that basal level of autophagy clears the
deleterious protein aggregates that are associated with AD,
PD, and HD [205–207], therefore playing a protective role
in the maintenance of neural cells. For instance, autophagy
is involved in degradation of HTT aggregates [198]. Admin-
istration of rapamycin induces autophagy and enhances the
clearance of mutant HTT, improving cell viability and ame-
liorating HD phenotypes in cell and animal models [208].
Furthermore, PARKIN, whose loss of function mutation
causes early onset PD, has been found to promote autophagy
of depolarized mitochondria [209], suggesting that a failure
to eliminate damaged mitochondria by mutant PARKIN is
responsible for the pathogenesis of PD. It is not entirely clear
why autophagy can exert protective or deleterious effects on
pathogenesis of these neurodegenerative diseases. A better
understanding of autophagy, mitochondrial dysfunction,
and oxidative stress is necessary in order to dissect the
pathogenesis of AD, PD, and HD.
Cancer is considered an age-associated disease, as the
incidence of cancer increases exponentially with age. War-
burg first discovered that cancer cells constitutively metabo-
lize glucose and produce excessive lactic acid even in the pres-
ence of abundant oxygen, a phenomenon named “aerobic
glycolysis” [210]. In contrast, normal cells generate energy
mainly from oxidative breakdown of pyruvate, which is an
end product of glycolysis and is oxidized in mitochondria.
Conversion of glucose to lactate only takes place in the
absence of oxygen (termed “Pasteur effect”) in normal cells.
He hypothesized that defect in mitochondrial respiration in
tumor cells is the cause of cancer, and cancer should be
interpreted as mitochondrial dysfunction [210]. A growing
body of evidence has demonstrated the presence of both
somatic and germline mutations in mtDNA in various types
of human cancers [211–213]. The most direct evidence that
mtDNA mutations may play an important role in neoplas-
tic transformation comes from the study by introducing
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a known pathogenic mtDNA mutation T8993G into the
prostate cancer cell line PC3 through transmitochondrial
cybrids [214]. The T8993G mutation derived from a mito-
chondrial disease patient causes a 70% reduction in ATP
synthase activity and a significant increase in mitochondrial
ROS production [215]. Tumor growth in the T8993G mutant
cybrids is much faster than that in the wild-type control
cybrids [214]. Moreover, staining of tumor sections confirms
a dramatic increase in ROS production in T8993G mutant
tumors, suggesting that mitochondrial dysfunction and ROS
elevation contribute to tumor progression. Consistent with
this notion, the Sod2+/− mice exhibit increased oxidative
damage and enhanced susceptibility to cancer as compared
to wild-type mice [63]. Collectively, these studies suggest that
mtDNA mutations could contribute to cancer progression
by increasing mitochondrial oxidative damage and changing
cellular energy capacities.
3.4. Mouse Models of Oxidative Stress and Mitochondrial
Dysfunction in Aging. Genetically engineered mouse models
provide great systems to directly dissect the complex relation-
ship between oxidative damage, mitochondrial dysfunction,
and aging. Although it is difficult to manipulate mitochon-
drial genome, genetic engineering of nuclear genes that
are involved in oxidative stress response and mitochondrial
function has been utilized to study mitochondrial biology
and aging.
Mammalian cells scavenge ROS to nontoxic forms
through a sophisticated antioxidant defense that includes su-
peroxide dismutase (SOD), catalase, and glutathione peroxi-
dase. Genetic ablation of SOD2, which encodes a mitochon-
drial manganese SOD (MnSOD), leads to early postnatal
death in mice accompanied by a dilated cardiomyopathy,
metabolic acidosis, accumulation of lipid in liver and
skeletal muscle, increased oxidative damage, and enzymatic
abnormalities in mitochondria [216, 217]. Treatment of
Sod2−/− mice with a synthetic SOD mimetic not only rescues
their mitochondrial defects in the liver, but also dramati-
cally prolongs their survival [218]. Furthermore, heterozy-
gous Sod2+/− mice show evidence of decreased membrane
potential, inhibition of respiration, and rapid accumulation
of mitochondrial oxidative damage [219]. Mitochondrial
oxidative stress induced by partial loss of SOD2 leads to an
increase in proton leak, sensitization of the mitochondrial
permeability transition pore and premature induction of
apoptosis [219]. These studies clearly demonstrate that ROS
generated in mitochondria play an important role in cell
homeostasis and aging.
Conflicting results of the effect of increased SOD2
expression on aging are obtained using different SOD2
transgenic mouse strains [220–222]. A transgenic line car-
rying a human SOD2 transgene under the control of a
human β-actin promoter shows protection against hyperoxic
lung injury [220], reduction in mitochondrial superoxide in
hippocampal neurons, and extended lifespan as the result of
increased activity of MnSOD [221]. Another transgenic line
carrying a 13-kb mouse genomic fragment containing SOD2
[223] has a twofold increase in the activity of MnSOD [222].
Such level of SOD2 overexpression does not alter either
lifespan or age-related pathology, even though these mice
exhibit decreased lipid peroxidation, increased resistance
against paraquat-induced oxidative stress, and decreased age-
related decline in mitochondrial ATP production [222]. The
reason behind the different outcomes of these two SOD2
transgenic mice on lifespan is not clear, but may be related to
different levels of SOD2 expression. The precise role of SOD2
in aging needs further investigation.
An important function of mitochondria is to produce
ATP. Targeting genes involved in ATP production offers a
great opportunity to study the role of mitochondrial function
in aging. An example is a mouse model with targeted
inactivation of adenine nucleotide translocator (ANT), a
transporter protein that imports ADP and exports ATP from
the mitochondria. Ant1−/− mice exhibit classical physiolog-
ical features of mitochondrial myopathy and hypertrophic
cardiomyopathy in human, as evident of cardiac hypertro-
phy, an increase in succinate dehydrogenase and cytochrome
c oxidase activities, a degeneration of the contractile muscle
fibers, and a massive proliferation of abnormal mitochondria
in skeletal muscle [224]. The increase in mitochondrial
abundance and volume in muscle of Ant1−/− mice is
accompanied by upregulation of genes that are known to
be involved in oxidative phosphorylation [225]. Consistently,
mitochondrial H2O2 production increases in skeletal muscle
and heart of Ant1−/− mice [226]. The Ant1-deficient mouse
model provides strong evidence that a defect in mitochon-
drial energy metabolism can result in pathological disease
[224].
IMMP2L protein is a subunit of a heterodimer complex
of inner mitochondrial membrane peptidase that cleaves
signal peptide from precursor or intermediate polypeptides
after they reach the inner membrane of mitochondria
[227, 228]. Mammalian IMMP2L has two known substrates,
cytochrome c1 and glycerol phosphate dehydrogenase 2,
both of which are involved in superoxide generation [229].
The Immp2l mutant mice have impaired processing of
signal peptide of cytochrome c1 and glycerol phosphate
dehydrogenase 2 [230], and consequently show elevated level
of superoxide ion, hyperpolarization of mitochondria, and
increased oxidative stress in multiple organs. Furthermore,
these Immp2l mutant mice exhibit multiple aging-related
phenotypes, including wasting, sarcopenia, loss of subcuta-
neous fat, kyphosis, and ataxia [101]. These data provide a
strong evidence that mitochondrial dysfunction is a driving
force of accelerated aging.
4. Conclusion
Aging is a complex process involving a multitude of fac-
tors. Many studies have demonstrated that oxidative stress
and mitochondrial dysfunction are two important factors
contributing to the aging process. The importance of mito-
chondrial dynamics in aging is illustrated by its association
with a growing number of age-associated pathogenesis.
A better understanding of response to oxidative stress
and mitochondrial dynamics will lead to new therapeutic
Journal of Signal Transduction 7
approaches for the prevention or amelioration of age-asso-
ciated degenerative diseases.
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Bacteria are permanently in contact with reactive oxygen species (ROS), both over the course of their life cycle as well that present
in their environment. These species cause damage to proteins, lipids, and nucleotides, negatively impacting the organism. To detect
these ROS molecules and to stimulate the expression of proteins involved in antioxidative stress response, bacteria use a number
of different protein-based regulatory and sensory systems. ROS-based stress detection mechanisms induce posttranslational mod-
ifications, resulting in overall conformational and structural changes within sensory proteins. The subsequent structural rear-
rangements result in changes of protein activity, which lead to regulated and appropriate response on the transcriptional level.
Many bacterial enzymes and regulatory proteins possess a conserved signature, the zinc-containing redox centre Cys-X-X-Cys in
which a disulfide bridge is formed upon oxidative stress. Other metal-dependent oxidative modifications of amino acid side-chains
(dityrosines, 2-oxo-histidines, or carbonylation) also modulate the activity of redox-sensitive proteins. Using molecular biology,
biochemistry, biophysical, and structure biology tools, molecular mechanisms involved in sensing and response to oxidative stress
have been elucidated in detail. In this review, we analyze some examples of bacterial redox-sensing proteins involved in antioxi-
dative stress response and focus further on the currently known molecular mechanism of function.
1. Introduction
Interference in the balance between the environmental pro-
duction of reactive oxygen species (ROS), including hydrox-
yl radicals (•OH) and hydrogen peroxide (H2O2), and the
ability of biological systems to readily detect and detoxify
them, or repair the resulting damage, are defined as oxidative
stress. Highly reactive radicals cause the oxidative damage
of different macromolecules—proteins, DNA, and lipids—
leading to loss of function, an increased rate of mutagenesis,
and ultimately cell death. In humans, for example, oxidative
stress is involved in many diseases, such as rheumatoid ar-
thritis, autoinflammatory diseases, neurodegenerative dis-
eases, and cancer [1, 2]. However, the production of some
ROS (e.g., •OH) can also be beneficial, as they are used by the
human immune system to attack and kill pathogens, such as
the production of ROS by macrophages. Additionally, H2O2
is an important signalling molecule that participates in redox
signalling [3].
Sensing of ROS-mediated signals also plays a cru-
cial role in the biology of microorganisms. Bacteria, for
example, are in continuous contact with ROS generated
both endogenously, as a product of aerobic metabolism,
or exogenously during ionizing (γ) and nonionizing (UV)
irradiation leading to the production of a number of radical
and peroxide species through the ionization of intracellular
water. Industrial contaminants that are widespread in soils
and on the surfaces of plants are also sources of ROS.
Iron is earth’s fourth most abundant metal, after oxygen,
silicon, and aluminium. Its relevance for bacterial cells is
emphasized by the fact that it is involved in a wide range of
biological processes, including photosynthesis, N2 fixation,
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H2 production and consumption, respiration, oxygen trans-
port, and gene regulation [4, 5]. However, in the presence
of oxygen, ferrous ions frequently result in oxidative stress
through the generation of hydroxyl radicals via the Fenton
reaction (Fe2+ + H2O2 −→ Fe3+ + •OH +−OH). Therefore,
bacteria have developed a variety of different mechanisms
to ensure that iron is sufficiently accessible as well as being
maintained in a nontoxic form [4]. They possess high-
affinity iron transport systems (i.e., siderophores and mem-
brane iron transporters) that enable iron to be scavenged. In-
tracellular iron can be stored in protein complexes (i.e., in
Dps and ferritins). Thus, the homeostasis of these ions is
tightly regulated so that their intracellular concentrations do
not reach toxic levels. Previously, it has also been suggested
that the production of hydroxyl radicals is induced by bacte-
ricidal antibiotics to kill bacteria, in which iron ions and the
Fenton reaction play a role [6], or during a wide range of
plant or human pathogen interactions. Moreover, ROS can
also be produced during the degradation of natural existing
biopolymers (cellulose, chitin, or xylan) by microorganisms
[7]. To reduce the hazardous effects of iron-based production
of •OH, bacteria produce proteins with an enzymatic activity
to degrade ROS (i.e., superoxide dismutases, catalases,
peroxidases, and alkylhydroperoxide reductases), other small
redox proteins (thioredoxins and glutaredoxins) as well as
low molecular-weight thiols (glutathione and mycothiol)
[8, 9]. All these cell components contribute in maintaining
a reducing environment both in the cell and in controlling
the extent of the oxidative burst.
In analogy to Fe(II) ions, other transition metals ions
[i.e., Cu(I), Co(II), Mn(II), Ti(III), or Cr(V)] are closely link-
ed with the production of free radicals in cells [10]. Although
these metal ions can be hazardous for living organisms, they
also serve as signal mediators in signalling cascades. Another
metal with high biological relevance is zinc. It is an essential
trace element that is localized in the active center or in a
structurally important site of many bacterial proteins [11].
Zinc is a cofactor for more than 300 enzymes (i.e., super-
oxide dismutase and alcohol dehydrogenase). It is also a
structural element of at least 40 protein classes (i.e., RNA
polymerase and tRNA synthetases). Additionally, zinc can
protect sulfhydryl groups from free radicals and inhibits free
radical formation by competing with redox-active metals
such as iron [12, 13]. Binding of zinc as well as metal-cata-
lyzed oxidation in proteins is closely related with the pre-
sence of redox-active cysteine residues (e.g., within Cys-X-X-
Cys motifs) and other metal-sensing amino acids. Moreover,
bacterial redox sensory proteins can act either as single tran-
scription regulators (e.g., FurS or Irr) displaying a sensory
and response domain within itself [14, 15], or as a part of
multicomponent systems (e.g., HbpS or ChrS) in which
sensing and response are distributed among each protein
component [16–18].
In bacteria, there are a high number of redox sensory pro-
teins that show different mechanism of function. Here, we
will give an overview of them and focus further on signalling
pathways in which redox-active cysteines as well as iron ions
are involved.
2. Zinc-Containing Cys-X-X-Cys Motifs as
Sensor Centres
Cysteine residues (Cys) in proteins are prominent targets for
protein oxidation, as they easily react with H2O2 and free
radicals. Oxidation of Cys by H2O2 involves nucleophilic
attack of the cysteinyl thiol group on the electrophilic center
of H2O2. Deprotonation of the Cys thiol group to generate
the thiolate anion increases its nucleophilicity, and hence
reactivity towards H2O2. These reactions are chemically
highly complex and can lead to different sulfur oxidation
states, including thiols, sulfenic and sulfinic acids, thiyl rad-
icals, disulfide S-oxides, or disulfides [19]. Disulfides can be
generated between two Cys either intra- or intermolecularly
(Figure 1). The sensitivity of Cys thiol groups to oxidation
provides them with redox sensitivity, and hence the ability to
sense redox status. The molecular environment of the redox
sensitive Cys also modulates the sensing mechanism. For
example, the thiolate anion can be stabilised by proximity to
hydrogen bond donors, basic residues, and metal ions [20].
In this review, we will focus on intramolecular disulfides
that are formed within Cys-X-X-Cys motifs—(X: any amino
acid)—a motif that is widespread in bacterial sensor proteins
(Table 1). In addition to redox-sensing properties, these
motifs are often involved in zinc binding (i.e., in FurS,
Hsp33, RsrA, RslA, Trx2, and SbcC) (Table 1), and in the
stabilization of protein domains that are crucial for function.
It can be expected that the molecular environment of Cys is
in this case also important for zinc binding.
Table 1 comprises two different types of Cys-X-X-Cys-
containing proteins. Proteins belonging to the first group
exhibit enzymatic function (Hsp33, ResA, DsbA, SbcC,
cytochrome c, Trx2, AhpF/AhpC, CopA, and HypA). For
example, under reducing conditions, the chaperone Hsp33
binds a single zinc ion through its C-terminal Cys-X-Cys-
X6-Cys-X-X-Cys motif. Upon oxidative stress, the four Cys
residues form intramolecular disulfide bridges resulting in
release of zinc accompanied by considerable conformational
changes that lead to destabilization of its C-terminus [22]. As
a consequence, Hsp33 dimerises and acquires a chaperone
function to prevent protein aggregation [23]. Similarly, in
the DNA repair protein SbcC, two monomers are linked via
Cys-X-X-Cys motifs and a zinc ion, forming a functional
zinc bridge that is important for SbcC exonuclease activity
[24]. ResA—an extracellular low potential thiol-disulfide
oxidoreductase—was shown to maintain Cys residues of
cytochrome c in their reduced form. The thiolate species
within the heme-binding motif (Cys-X-X-Cys-His) of apo-
cytochrome c are required for covalent attachment of heme
[25]. Contrary to the other Cys-X-X-Cys-containing proteins
described here, ResA does not bind zinc through this motif.
Other proteins with this signature and lacking zinc are listed
in Table 1 but are not within the focus of this review.
The second group of Cys-X-X-Cys-containing proteins is
involved in transcriptional regulation and can be subdivided
into two subtypes: proteins that either directly control
transcription (i.e., WhiB3, FurS, CatR, SoxR, and SurR) or
require further regulatory components (i.e., Spx, RsrA, RslA,
and RshA).
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Figure 1: Formation of intramolecular disulfide bonds (S–S). Oxi-
dation of a cysteine thiol by H2O2 yields a sulfenic acid residue
that can undergo reaction with a neighbouring “back door” cysteine
thiol to generate a disulfide linkage (S–S). S–S bonds can overtime
be returned to the native SH state by reactions with biological thiols
(RSH). This picture was adapted from [21].
The redox-dependent Cys-X-X-Cys-containing transcrip-
tional regulator WhiB3, from Mycobacterium tuberculosis,
has been shown to sense the intracellular redox state in the
cell, and to be required for the production of virulence pol-
yketides, including polyacyltrehaloses (PAT), sulfolipids (SL-
1), di-o-acyl-trehaloses (DATs) and trehalose dimycolates
(TDMs). WhiB3 directly regulates the expression of the fol-
lowing genes in a redox-dependent manner: pks3 (encoding
a polyketide beta-ketoacyl synthase involved in PAT and DAT
anabolism), pks2 (encoding a polyketide synthase involved in
SL-1 anabolism), and fbpA (encoding a fibronectin-binding
protein for TDMs production) [26]. WhiB3 contains an iron-
sulfur cluster [4Fe-4S]+ that under aerobic conditions is
oxidized to [4Fe-4S]2+. Further oxidative conversions result
in complete loss of this cluster [27]. Unlike the superoxide
stress sensor SoxR, the redox state of the WhiB3 iron-sulfur
cluster does not modify the DNA binding affinity to target
gene promoters, but rather the redox state of the cysteine
residues is critical for DNA binding. It was shown that, while
the reduction of Cys in WhiB3 abolishes its DNA binding
activity, oxidation induces it. It is noteworthy to mention that
reduction and oxidation in WhiB3 are reversible processes.
In the case of the zinc-containing transcriptional repres-
sor FurS from Streptomyces reticuli, it was biochemically and
spectrophotometrically shown that H2O2-mediated disulfide
bond formation between Cys93 and Cys96 in FurS is accom-
panied by the release of the bound zinc ion. This leads to
conformational changes in FurS, resulting in a loss of FurS
binding to its own DNA operator sequence within the regu-
latory region of the target operon, furS-cpeB. As a result, the
expression of this operon is no longer repressed, leading to an
increase in production of FurS and the mycelium-associated
catalase-peroxidase CpeB. This enhanced expression in turn
detoxifies the surrounding environment of hazardous H2O2
[9, 14].
Proteins with Cys-X-X-Cys motifs are also indirectly
involved in transcriptional regulation, by interacting with
additional components. Reversible disulfide formation can
regulate the activity of the sigma factor R (σR) of Strep-
Cys57
Cys54
Figure 2: An image showing the redox-sensing cysteine residues
(Cys54 and Cys57) within the crystal structure of RslA from
Mycobacterium tuberculosis (PDB: 3HUG). The coordinated zinc
ion (shown as a violet ball) strongly contributes to the overall fold
stability.
tomyces coelicolor A3(2). Here, the thiol-specific oxidant di-
amide induces σR-mediated transcription of >30 genes,
including those encoding thioredoxins and thioredoxin re-
ductases that are involved in antioxidative stress response.
However, σR does not contain any Cys and in vitro studies
have demonstrated that its transcriptional activity is not
dependent on oxidative stress. This strongly suggests that an
additional component must act as the oxidative stress sensor
[28]. Indeed, researchers have characterised the protein RsrA,
which interacts with σR and regulates its transcriptional
activity in a oxidative stress-dependet manner [29]. RsrA is
a zinc-containing and redox-sensitive antisigma factor that
possesses seven Cys, two of which (Cys41 and Cys44) are
located within a Cys-X-X-Cys motif that is important for
activity. Under oxidising conditions, a disulfide bond is
formed in RsrA, and this oxidized state cannot bind σR or
inhibit its transcriptional activity. Oxidised RsrA can be re-
reduced by thioredoxin and in the thiol-reduced state RsrA
reassociates with σR and blocks its transcriptional activity.
The redox sensing Cys in RsrA also coordinate zinc ions
that provide the protein with a higher structural stability,
strengthening its interaction with σR. Upon redox stress
and induction of disulfide bond formation, zinc is released
and RsrA undergoes conformational changes, generating a
structure that does not bind σR[30]. Structural studies of
an RsrA homolog, RslA (Table 1) from Mycobacterium tuber-
culosis revealed that the redox sensing and zinc binding Cys
(Cys54 and Cys57) are closely located (∼3, A˚; Figure 2) to
each other and are solvent exposed in the complex, thus,
providing a structural basis for the redox sensitivity of RslA
[31]. The solvent exposed state of Cys within the Cys-X-X-
Cys motif is also an essential feature in redox sensing by
the heat-shock protein Hsp33 (Table 1; PDB: 1VQ0) from
Escherichia coli [22].
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Figure 3: Metal-catalyzed oxidation of histidine. The exact chemi-
cal mechanism of the iron-mediated formation of 2-Oxo-histidine
remains unclear. This picture was adapted from [34].
3. Iron-Based Oxidative Stress
To assure that iron is sufficiently accessible as well as being
maintained in a nontoxic form, bacteria have developed a
variety of protein-based protection mechanism. They em-
ploy iron-sensing regulatory proteins (i.e., PerR and HbpS-
SenS-SenR; see also Table 2) that control the expression of
proteins (i.e., H2O2-degrading enzymes such as catalases)
blocking iron-dependent damage. Upon sensing of iron-
based stress, these proteins undergo different oxidative mod-
ifications, including oxidation of histidines (Figure 3), dity-
rosine formation, or carbonylation.
Table 2 lists different iron-sensing proteins that mostly
control redox stress resistance systems. They can directly reg-
ulate the transcription of target genes by DNA binding to
regulatory regions (i.e., Fur, DtxR, RirA, Irr, PerR, DmdR1,
IdeR, SirR, FNR, and TroR) or utilize further regulatory
elements (HbpS-SenS-SenR; PmrA-PmrB, ChrS-ChrA, and
FecA-FecR-FecI) that mediate the adaptive response.
Iron-dependent gene regulation has been demonstrated
for the diphtheria toxin repressor (DtxR) from Corynebac-
terium diphtheriae and Corynebacterium glutamicum [35].
Binding of divalent iron ions to the global regulator DtxR
results in the transcriptional repression of a number of genes
required for iron uptake (i.e., htaA coding for a secreted
iron acquisition and transport protein), as well as for usage
and storage (i.e., hmuO coding for a heme oxygenase and
ftn coding for a ferritin-like protein). Mutational analyses
have additionally demonstrated that DtxR is also involved in
the iron-dependent expression of DNA-protecting proteins,
including Dps-like proteins that bind iron and DNA.
In Bacillus subtilis, the peroxide resistance regulator PerR
has been shown to sense metal dependent as well as H2O2-
based oxidative stress, and to regulate the corresponding
adaptive response [36]. The metalloprotein PerR is a small
dimeric protein that coordinates two metal ions per mono-
mer. One binding site binds a zinc ion, whereas the second
one a regulatory metal, either iron or manganese [37, 38].
In vivo, the regulatory metal is required for repression of the
transcription of target genes, including those ones encoding
a catalase, alkylhydroperoxide reductase, and the Dps-like
DNA-binding protein MrgA. Under H2O2-based oxidative
stress conditions, Fe2+ catalyzes the oxidation of histidines
(either His37 or His91) in the regulatory binding site of PerR.
This results in Fe2+ release and subsequent derepression
of PerR target genes. Analysis of electron maps density in
the crystal structure of the oxidised PerR protein (PerR-
Zn-ox) showed the presence of a 2-oxo-histidine residue
at position 37. Further, MALDI-TOF and tandem ESI-MS
studies additionally revealed the oxidation of His91 within
Per-Zn-ox [36, 38, 39]. It was concluded that the structural
conformation of PerR is dependent on the oxidation state of
the regulatory site.
Oxidative modifications have also been shown to regulate
the activity of the redox sensor and heme-binding protein
HbpS from Streptomyces reticuli. HbpS is extracellularly lo-
cated and interacts with the membrane-embedded histidine
autokinase SenS from the two-component system SenS SenR
[40, 41]. Analyses of the crystal structure of HbpS com-
bined with size exclusion chromatography and static light
scattering [42–44] allowed the identification of HbpS as an
octamer. Further studies demonstrated that the octameric
assembly in HbpS is required for an efficient interaction with
SenS [43]. Phosphorylation analyses also revealed that under
nonoxidative stress conditions HbpS inhibits the autophos-
phorylation of SenS, whereas oxidative stress induces the
HbpS-mediated activation of SenS [16]. After autophos-
phorylation at a conserved histidine, SenS transfers the phos-
phate group to its cognate response regulator SenR, resulting
in SenR∼P. SenS acts also as a phosphatase of SenR∼
P. The unphosphorylated form of SenR binds to specific
sites upstream of the furS-cpeB operon (encoding for the
redox regulator FurS and the mycelia-associated catalase-
peroxidase CpeB), leading to its transcriptional repression.
Once SenR has been phosphorylated, it loses the ability to
bind to this operator, leading to a de-repression of the furS-
cpeB transcription. In addition, SenR∼P has been shown to
activate the transcription of hbpS. Comparative physiological
analyses have demonstrated that the presence of HbpS and
SenS-SenR provides S. reticuli with a defence system against
redox-stressing conditions [40, 41].
It was proposed that the switching of HbpS from its
inhibitor to activator state of SenS autophosphorylation
under oxidative stress conditions is controlled by conforma-
tional changes in HbpS. Indeed, CD spectroscopy as well as
FRET analyses revealed that after iron-mediated oxidative
stress HbpS undergoes secondary structure and overall in-
trinsic conformational changes, which are accompanied by
oxidative modifications (i.e., carbonylation and dityrosine
formation). While the sites of carbonylation have not yet
been determined, the tyrosine residues participating in di-
tyrosine formation have been identified as Tyr77. These
residues are localized in the interface of HbpS subunits
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Table 1: Examples of proteins containing the redox-sensing motif Cys-X-X-Cys. (∗) The references given are for the protein from the strain
listed. Sequence alignments demonstrate that highly homologous proteins are found across many different bacterial species.
Name Strain∗ Function
Zn2+-
binding
Enzymatic
function
Hsp33 Escherichia coli
The redox-regulated heat shock protein Hsp33 is a dual stress sensor
responding to peroxide stress and increased temperature.
Stress-mediated conformational changes result in zinc release and
activation of Hsp33 chaperone function leading to suppression of
protein aggregation [18].
Yes
Trx2 Escherichia coli
Trx2 reductase activity is controlled by a redox switch within two CXXC
motifs involved in zinc binding. Release of the bound zinc ion results in
a conformational change leading to the reductase activity [23].
Yes
ResA Bacillus subtilis
Substrate selection of the membrane-bound thiol-disulfide
oxidoreductase ResA is regulated by conformational changes
determined by CXXC reduction or oxidation [24].
No
DsbA Escherichia coli
DsbA is a periplasmic protein oxidant for disulfide formation of
extracellular proteins belonging to the Dsb family [25].
No
SbcC Bacillus subtilis SbcC is a DNA repair protein with exonuclease activity [27]. Yes
Cytochrome c Bacillus subtilis
The covalent coordination of heme to apo-cytochrome c requires a
reduced CXXC motif within the heme-binding motif [28].
No
AhpF/AhpC
Salmonella
typhimurium
AhpC and flavoprotein AhpF catalyze the pyridine
nucleotide-dependent reduction of hydroperoxide substrates. AhpC, the
peroxide-reducing component, is a scavenger of hydrogen peroxide in
bacteria, whereas the disulfide reductase protein AhpF regenerates AhpC
[29].
No
CopA
Thermotoga
maritima
CopA, a copper transport ATPase, sustains important roles in
homeostasis of heavy metals and delivery of copper to metalloenzymes
[30].
No
HypA Escherichia coli
HypA is required for nickel insertion into the hydrogenase precursor
proteins [31].
No
Transcriptional
regulator
FurS
Streptomyces
reticuli
Oxidation of the transcriptional repressor FurS leads to derepression of
the transcription of the gene cpeB coding for a catalase peroxidase [6].
Yes
CatR
Streptomyces
coelicolor A3 (2)
During peroxide stress, the Fur-like regulator CatR activates
transcription of catA coding for catalase A [21].
No
WhiB3
Mycobacterium
tuberculosis
WhiB3 DNA binding to control the expression of genes coding for
polyketide synthases is reversibly regulated by a thiol-disulfide redox
switch. Reduction of the apo-WhiB3 Cys thiols of the CXXC motif
suppresses genes regulating the synthesis of complex lipids, whereas
oxidation stimulates it [22].
No
SoxR Escherichia coli
SoxR senses superoxide stress through a CXXC-coordinated
[2Fe-2S]-cluster that results in transcriptional activation of a superoxide
response regulon [32].
No
SurR
Pyrococcus
furiosus
(Archaea)
A redox switch regulates the transcriptional regulator SurR. Oxidation
with S0 inhibits DNA binding by SurR, leading to repression of genes
related to H2 production and activation of genes involved in S0
metabolism [33].
No
Regulatory
element
Spx Bacillus subtilis
Global oxidative stress regulator interacting with the α-subunit of RNA
polymerase for transcriptional induction of genes involved in thiol
homeostasis (mrsA-mrsB operon) [19].
No
RsrA
Streptomyces
coelicolor A3 (2)
Antisigma factor RsrA negatively regulates expression of the thioredoxin
system in response to cytoplasmatic oxidative stress. Under reducing
conditions, RsrA binds to σR resulting in inhibition of transcription
[20].
Yes
RslA
Mycobacterium
tuberculosis
Membrane-associated RslA oxidation results in the release of bound
Zn2+ through disulfide bond formation within the CXXC motif. The
resulting conformational change leads to decreased σL binding. The
released sigma factor regulates the expression of genes involved in
cell-wall and polyketide synthesis [17].
Yes
RshA
Mycobacterium
tuberculosis
RshA is an antisigma factor of the central regulator SigH that responds
to oxidative and heat stress; it functions as a negative regulator of the
alternative sigma factor SigH activity under reducing conditions [26].
No
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Table 2: Examples of iron-dependent redox sensor proteins in bacteria. (∗) The references given are for the protein from the strain listed.
Sequence alignments demonstrate that highly homologous proteins are found across many different bacterial species.
Name Strain∗ Function
Transcriptional
regulator
Fur Escherichia coli
Regulator with iron-dependent DNA-binding affinity negatively
regulates genes involved in ferric iron uptake [38].
DtxR
Corynebacterium
glutamicum
DtxR acts as a global iron-mediated regulator, activating genes
involved in iron storage and DNA protection and repressing
genes involved in iron uptake and utilization [39].
RirA
Rhizobium
leguminosarum
Transcriptional regulator RirA is involved in ferric uptake
regulation by regulating genes coding for iron transport,
siderophore biosynthesis, and iron-sulfur cluster assembly [40].
Irr
Bradyrhizobium
japonicum
Iron response regulator (Irr) senses iron through the status of
heme biosynthesis to regulate gene expression involved in iron
homeostasis [42].
PerR Bacillus subtilis
DNA binding by the regulator PerR in response to peroxide stress
is iron dependent [51].
DmdR1
Streptomyces
coelicolor
The transcriptional regulator DmdR1 regulates genes involved in
desferrioxamine production in response to iron availability [43].
IdeR
Mycobacterium
smegmatis
IdeR negatively regulates siderophore biosynthesis involved in
iron acquisition [44].
SirR
Staphylococcus
epidermidis
SirR is a Fe2+or Mn2+-dependent transcriptional repressor
regulating the sitABC operon encoding an ATPase, a cytoplasmic
membrane protein, and the 32-kDa lipoprotein involved in
siderophore-mediated iron uptake [45].
FNR Escherichia coli
Transcription factor FNR regulates gene expression in response
to oxygen deficiency by its redox-sensitive bound iron. Binding of
an iron-sulfur cluster is required for a conformational change to
enhance DNA binding [46].
IscR Escherichia coli
[2Fe-2S]-cluster assembly regulates activity in transcription
factor IscR of genes coding for proteins involved in iron-sulfur
cluster assembly [47].
TroR
Treponema
denticola
TroR is a Mn2+ and Fe2+-dependent repressor of the ATP-binding
cassette cation transport system (troABCD) regulating
manganese and iron homeostasis [50].
Regulatory
element
HbpS/SenS/SenR
Streptomyces
reticuli
Iron-dependent activation/inhibition of the two-component
system SenS-SenR involved in oxidative stress response through
heme degradation and associated secondary structural changes
[8].
PmrA/PmrB Salmonella enterica
The PmrA/PmrB two-component system senses iron and
regulates the transcription of genes involved in iron resistance
[41].
ChrS/ChrA
Corynebacterium
diphteriae
ChrS, the heme-sensing sensor kinase of the two-component
system ChrS/ChrA, regulates genes involved in utilization of host
heme as an iron source and in protecting the bacteria against the
toxic effects of heme [48].
FecA/FecR/FecI Escherichia coli
The periplasmic protein FecR senses periplasmic iron dicitrate by
the outer membrane protein FecA which is loaded with ferric
citrate. FecR transmits the signal to the sigma factor FecI which
results in transcriptional activation of the fec-operon for ferric
citrate transport [52].
AcnA/AcnB Escherichia coli
The aconitases AcnA (induced by iron and oxidative stress) and
AcnB posttranscriptionally regulate gene expression (i.e., sodA)
by an iron-sulfur cluster-dependent switch [49].
and are located in close proximity to each other, over the
monomer-monomer interface. Interestingly, Tyr77 is situ-
ated near to a postulated iron-binding site, containing Glu78
and Glu81 within an E-X-X-E motif (Figure 4) that has been
previously characterized as an iron-binding motif [45–47].
The reported oxidative modifications in HbpS result in
the degradation, either autonomously or protease depen-
dent, of the oxidized protein [45]. A metal-catalyzed protein
oxidation accompanied by cross-linking and degradation
has been reported for the Bradyrhizobium japonicum iron
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Figure 4: An image showing the arrangement of the internal EXXE
motif between two subunits (red and turquoise chain, respectively)
in the octameric HbpS (PDB: 3FPV). The amino acids Tyr77 (Y77),
Glu78 (E78), Glu81 (E81), and Arg82 (R82) are indicated.
response regulator (Irr) protein, which is involved in the reg-
ulation of iron transport as well as of heme biosynthesis
genes [15]. It is proposed that the iron-catalyzed oxidation
with subsequent degradation of Irr is the molecular basis for
the modulation of the activity of this regulator.
The membrane-embedded sensor kinase PmrB from the
two-component system PmrA-PmrB of the pathogen Salmo-
nella enterica serovar typhimurium exhibits two copies of the
EXXE iron-binding motif. These are periplasmically locat-
ed and have been proposed to be involved in sensing of extra-
cellular ferric iron. Upon iron sensing and autophosphoryla-
tion, PmrB transfers the signal to its cognate response regu-
lator PmrA, which in turn regulates Fe3+ resistance genes:
pbgP and ugd both coding for enzymes that modify the
lipid A region of lipopolysaccharide (LPS) with 4-aminoar-
abinose. The gene product of pmrC catalyzes the addition of
phosphoethanolamine to lipid A, whereas the phosphatase
encoded by pmrG targets the phosphate located in the core
region of the LPS. These modifications result in a less-
charged cell surface and diminished binding of ferric iron to
the membrane [48]. In contrast to other iron-sensing systems
(i.e., PerR and HbpS-SenS-SenR), PmrA-PmrB seems to pro-
tect the cell against iron toxicity independent of the simul-
taneous presence of oxygen.
Beside the posttranslational modifications (i.e., oxidation
of histidines, carbonylation, dityrosine formation, or S–S
bonding) that regulate iron-sensing proteins, posttranscrip-
tional regulation of gene expression in response to oxidative
stress has been reported for the aconitases AcnA and AcnB of
Escherichia coli [49, 50]. In their holo form, both AcnA and
AcnB contain an iron-sulfur cluster, [4Fe-4S], and exhibit
enzymatic function. Under reducing conditions, they cat-
alyze the isomerisation of citrate to isocitrate. Upon oxidative
stress and iron depletion, the iron-sulfur cluster is released.
The resulting apo-AcnA and apo-AcnB proteins act as RNA-
binding proteins that stabilize acnA- and acnB-mRNA trans-
cripts, leading to increased amount of the respective aconi-
tases that subsequently complex iron-sulfur clusters [49].
Moreover, mutational analyses have revealed that the pres-
ence of AcnA provides E. coli with enhanced resistance
against superoxide-mediated oxidative stress. Additionally,
proteomics studies demonstrated that the expression of anti-
oxidative stress-working proteins (i.e., SodA and TrxB) is
dependent on AcnA.
4. Summary
As in humans, the exposure of bacteria to ROS causes dam-
age to a variety of macromolecules, resulting in mutations
and often in cell death. However, ROS may also be considered
to be beneficial compounds, as they function as signalling
molecules that lead to a coordinated response of bacteria
under redox-stress conditions. These signals can be sensed by
redox-active and zinc-coordinating Cys-X-X-Cys centres in
proteins. Under reducing conditions, zinc stabilizes protein
structure, but the presence of H2O2 provokes the release of
zinc and the formation of S–S bridges that significantly alter
the conformation and structure of the protein (i.e., FurS or
RsrA). As a result, transcriptional activity is altered (by FurS),
or the ability to interact with the partner DNA-binding
protein is lost (by RsrA). In both cases, the transcription of
genes involved in the anti-oxidative stress response is ulti-
mately activated. The structural basis for the redox sensitivity
is given by the location of S–S-forming cysteines in the pro-
tein, namely, their solvent exposition within the three-di-
mensional structure. Importantly, reduction and oxidation
processes within Cys-X-X-Cys redox centres are reversible
and provide bacteria with an elegant switch on/off mecha-
nism.
Iron-dependent oxidative modifications (i.e., 2-oxo-his-
tidine or dityrosine formation) are also involved in ROS-
based signalling. Under H2O2-based stress, iron catalyzes the
oxidation of histidines in the peroxide resistance regulator
PerR, leading to release of iron and subsequently to de-
repression, and expression of target genes. In analogy, iron-
based stress activates the HbpS-SenS-SenR-mediated sig-
nalling cascade. HbpS is a redox sensor that upon oxida-
tive modifications undergoes conformational and structural
changes, inducing the phosphorylation cascade between the
sensor kinase SenS and the response regulator SenR. As
known for other regulators, oxidative modifications lead to
the building of covalent bonds within proteins. Such pro-
cesses are irreversible and lead ultimately to degradation of
oxidized proteins. Therefore, de novo protein biosynthesis is
required to switch off the corresponding signal cascade.
The diversity of responsive protein elements among bac-
teria correlates with the diversity in: ecological niches, life
cycles, pathogenic, and nonpathogenic character. Future ef-
forts will undoubtedly demonstrate that additional further
specialized systems exist.
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